1159 search results for "health related quality of life"

Impact of Wound Malodour: VOCs and Health-Related Quality of Life



Impact of Wound Malodour: VOCs and Health-Related Quality of Life

Summary: This feasibility study examines how malodour from chronic wounds, driven by volatile organic compounds (VOCs) from bacterial colonization and necrosis, affects patients’ health-related quality of life (HRQoL). Analyzing 92 wounds from 66 patients, it identifies key VOCs like dimethyl disulphide and diacetyl, correlates them with pathogens such as Pseudomonas aeruginosa, and highlights a trend toward greater HRQoL impairment in malodorous cases. The findings advocate for innovative, VOC-targeted therapies to reduce social stigma and support wound healing.

Key Highlights:

  • Malodour stems from bacterial VOCs (e.g., dimethyl disulphide from prokaryotes) and necrosis, with biofilms linked to higher odour perception.
  • Patients with moderate-to-severe odour showed higher HRQoL impairment (Wound-QoL-14 score 2.1 vs. 1.8), correlating with social isolation and delayed care.
  • Pathogen-specific biomarkers identified, such as dimethyl trisulphide for P. aeruginosa and indole for E. coli, enabling targeted antimicrobial strategies.
  • Current dressings like activated charcoal offer partial relief (48% efficacy); future VOC antagonists could enhance biomaterials for odour control and tissue regeneration.
  • Epithializing wounds had lower VOCs and odour, underscoring malodour as a stalled healing marker.

Read full article

Keywords:
wound malodour,
volatile organic compounds,
chronic wounds,
health related quality of life,
wound healing innovation

The health-related quality of life of Brazilians with epidermolysis bullosa

Moderate Quality of Life Impact in Brazilians With Epidermolysis Bullosa

Summary: A 2025 cross-sectional study published in Orphanet Journal of Rare Diseases assessed the health-related quality of life (HRQoL) among 129 individuals in Brazil living with epidermolysis bullosa (EB), revealing moderate impairment across age groups. (Read the full study)

Key Findings:

  • The sample (median age 15; ~57% female) predominantly included EB simplex cases, followed by dystrophic EB (DEB).
  • Mean Children’s Dermatology Life Quality Index (CDLQI) score: 11.01 ± 7.31—indicating moderate life quality impact. Scores on the Brazilian Portuguese Quality of Life in EB (QoLEB-BP) questionnaire mirrored this (median = 13, IQR 8–19).
  • In participants aged ≥ 17 years, higher educational level and family income correlated with better HRQoL, while being underweight was associated with poorer quality of life.
  • The DEB subtype was linked to more severe HRQoL impact compared to other EB types.

Implications: The findings underscore the significant psychosocial and functional burden of EB in Brazil, especially among those with the DEB subtype. Addressing socioeconomic disparities and nutritional challenges—and enhancing disease-specific care—are key to improving HRQoL outcomes in this population.

Keywords:
Epidermolysis bullosa,
health-related quality of life,
Children’s Dermatology Life Quality Index (CDLQI),
QoLEB-BP,
dystrophic EB,
nutritional status,
education,
Brazilian population

Health-related quality of life of people receiving venous leg ulcer treatment with compression therapy

Impact of Compression Therapy on Quality of Life in Venous Leg Ulcer Patients

A randomized trial evaluated the effects of high-compression bandages and Unna’s boots on health-related quality of life (HRQoL) in patients undergoing treatment for venous leg ulcers.

Key Highlights:

  • Comparative Approaches: Patients received either high-compression multilayer bandages or Unna’s boot therapy to promote ulcer healing.
  • HRQoL Improvements: Both treatment groups experienced better overall quality of life, particularly with reduced pain, improved mobility, and enhanced emotional well-being. :contentReference[oaicite:1]{index=1}
  • Holistic Benefits of Compression: Beyond healing, maintaining sustained compression contributed to improved daily functioning and patient comfort.
  • No Major Differences Noted: Both compression methods yielded comparable results in patient-reported quality-of-life outcomes.

These outcomes underscore that effective compression therapy—whether via Unna’s boots or multilayer bandaging—benefits not only wound healing but also the broader well-being of patients living with venous leg ulcers.

Read the full article on the Wounds Practice and Research website.

Keywords:
venous leg ulcer,
compression therapy,
Unna’s boot,
quality of life,
HRQoL

Health-related quality of life of people receiving venous leg ulcer treatment with compression therapy

Health-Related Quality of Life in Patients Receiving Venous Leg Ulcer Treatment with Compression Therapy

A randomized clinical trial published in *Wound Practice and Research* (2025) explored how different compression treatments affect the health-related quality of life (HRQoL) of patients with venous leg ulcers (VLUs) in Brazil.

Study Details:

  • Study Design: 56 patients from 22 primary healthcare services were randomly assigned to receive either high-compression bandages (Group A) or Unna’s boots (Group B).
  • Measurement Tool: HRQoL was assessed using the multidimensional Health State Short Form questionnaire at baseline and upon wound healing or at 26 weeks.
  • Results for All Participants: Group A improved by 0.093 ± 0.09 (p < 0.001); Group B improved by 0.06 ± 0.1 (p = 0.007); no significant difference between groups (p = 0.218). :contentReference[oaicite:1]{index=1}
  • Healed Ulcers: Group A: +0.109 ± 0.084 (p < 0.001); Group B: +0.113 ± 0.115 (p < 0.01); no between-group difference (p = 0.914). :contentReference[oaicite:2]{index=2}
  • Unhealed Ulcers: Group A: +0.058 ± 0.098 (p = 0.09); Group B: +0.028 ± 0.078 (p = 0.182); no significant difference (p = 0.441). :contentReference[oaicite:3]{index=3}

Conclusion: Both high-compression bandages and Unna’s boots significantly improved HRQoL in patients with venous leg ulcers, with no notable difference between the two. :contentReference[oaicite:4]{index=4}

Keywords: Ana Cláudia Fuhrmann, Fernanda Peixoto Cordova, Fatima Al Sayah, Jeffrey A Johnson, Lisiane Manganelli Girardi Paskulin, venous leg ulcer, health-related quality of life, compression therapy, primary health care

Read the full study in Wound Practice and Research

The Miller-Newgent Amputation Scale

A comprehensive scoring system to evaluate patient-centered risk factors regarding lower extremity amputation

 

Abstract: Care of the patient with a presumed life- or limb-threatening lower extremity wound poses many challenges. The mindset regarding potential outcomes of such conditions is mostly driven by the experiences and expertise of those providing the care. This mindset generally appears as two primary actions presented to the afflicted patient: attempted resolution of the problem via medical, surgical or combination treatment, with the hope of low recurrence risk, or exacerbation and amputation—amputations at a level sufficient to, at least in the mind of the surgeon, eliminate the problem. Achieving the former outcome is dependent on a number of factors associated with both patient and caregiver. If healing is achieved, the secondary goal of prevention of recurrence may be no less arduous, with failure most likely resulting in amputation. Clearly, these considerations appear to be based more on the health professionals perception, of the patient’s physical and medical status rather than on patient-centered considerations. This article will review considerations and recommendations for lower extremity amputation, and the short- and long-term implications. Based on our research, there is clear need for a set of criteria against which to weigh not just the medical issues, but also definitive patient-centered issues when considering a lower extremity amputation. We offer a set of patient-centered, easily verified and recognized criteria that we believe addresses this need. The goal of the Miller-Newgent Amputation Scale (MENACE) is to provide a decision base from which to consider and evaluate all factors in determining the need for a lower extremity amputation. This involves identification of patient-centered issues, which are likely to produce satisfactory short- and long-term physical and quality-of-life outcomes if the amputation does proceed.

 

Declaration of interest: The authors have no conflict of interest to declare. The lead author, as a Board Certified general surgeon with 23 years’ experience in the field of advanced wound care, has been involved in the different aspects to amputation and its considerations and a common thread my colleagues and I have identified is that the expertise of those attempting to heal and salvage limbs was largely ineffectual. More often than not, the progression of high-risk conditions mandated lower extremity amputation. The progression of technology, science and products to promote healing is thought to improve limb salvage rates; however, there has not been an appreciable reduction in amputations. The thought is that those possessing the skill, knowledge and desire to promote limb salvage (which entails greater time and effort with considerably lower compensation) are few and far between. Despite advances in medical care, the rates of lower extremity amputation are unchanged at best or are even increasing.

 

Despite educational programmes touting the newest technologies for vascular intervention and advanced wound healing to mitigate those conditions commonly leading to amputation, there has been minimal change in the willingness of health professionals to consider limb salvage and indications for amputation have changed minimally. There is a clear need for a matrix against which to compare and contrast the clinical and non-clinical considerations for amputation. Since the patient is the one undergoing this potentially horrific procedure, it is only fair that all aspects of the procedure must be considered as an integral part of the decisionmaking process. The Miller-Newgent Amputation Scale (MENACE) scale was created to provide a patientcentred guide using simple, easily identified information that directly impacts on all aspects of the amputation decision process.

 

Background Considerations for the intentional removal of a body part have their roots in antiquity. Matthew 5:29–30, 18:8–9 and Mark 9:43–47 are commonly recognised biblical references to amputation. Lower extremity amputation is one of the oldest known surgical practices with Hippocrates among others providing insights.

 

In the US, 30,000–40,000 amputations are performed annually. In 2005, there were an estimated 1.6 million individuals living with the loss of a limb; by 2050, this figure is expected to rise to 3.6 million.

 

In 1954, Silbert and Hamiovici published an article recommending that lower extremity amputation be avoided, preferring more conservative surgeries such as supracondylar amputations as opposed to mid-leg amputations. In the paper they cited the Handbook on Amputations, published in 1942 by the Council on Physical Therapy of the American Medical Association, which expressed the opinion of most surgeons, when it advised the use of supracondylar amputations and warned against mid-leg amputations: an opinion justifiable at the time before the advent of antibiotics.

 

The Netherlands Society of Physical and Rehabilitation Medicine in October 2012 published its guideline on Amputation and Prosthetics of the Lower Extremities in which it recommended that the interventional radiologist, vascular internist and rehabilitation physician collectively identify and resolve those clinical issues before proceeding with a lower extremity amputation. Further, the guidelines state that treatment by a multidisciplinary team (MDT) involving a surgeon, anaesthesiologist, pain specialist, rehabilitation specialist, and possibly an internist is necessary for treatment of pain, cardiovascular risks, comorbidity and the co-determination of the level of amputation. The article identified many of the clinical indications for lower extremity amputation found in the literature; however, there is the same omission of any patient-centred, non-clinical concerns.

Table 1. Estimated change in metabolic energy expenditure based on level of amputation

Table 1. Estimated change in metabolic energy expenditure based on level of amputation

 

Reyzelman and Kim presented their idea of acceptable considerations for partial tissue removal (digital amputation) based on presenting conditions including: osteomyelitis, septic arthritis, gas gangrene, ischaemia/ gangrene and an advancing soft tissue infection. The authors concluded that early digital amputation in the appropriate patient allowed patients a return to normal activity with minimal disability.

 

Kalapatapu attempted to provide a compendium of indications for lower extremity amputation by providing an exhaustive listing of essentially all lower extremity morbidities. He stated:

 

   ‘Primary amputation may be the only option for
   patients without an anatomic option for
   revascularisation or those with medical risk factors that
   contraindicate revascularisation.’

 

Recognising that the spectrum of surgical and medical skills is considerable, and that there are an almost limitless number of non-medical factors, even attempting to define specific conditions as the basis for amputations is extremely problematic and potentially precludes the surgeon and thus the patient from any consideration of limb salvage.

 

A patient presenting with a condition prompting even the slightest consideration for lower extremity amputation likely has other issues related directly or indirectly to the presenting condition itself. It is a small leap of faith to recognise that an increase in metabolic demand places greater stress systemically on the patient with a concurrent risk of exacerbating current comorbidities as well as promoting new ones. These increased energy expenditures clearly mandate the highest scrutiny of a patient’s physical condition, both pre- and postoperatively, before undertaking any surgical consideration including lower extremity amputation. Recognising that the loss of an extremity means a dramatic change in the metabolic as well as mental status of the body, the failure to include these considerations potentially impacts on the ability of the patient to engage in activities of daily living. Estimates of the changes in metabolic energy expenditure based on the level of the amputation are shown in Table 1.

 

However, the definitive consideration must be the effect of survival from a lower extremity amputation since this takes all factors together under a single irreversible endpoint. Survival rates for individuals with dysvascular pathology undergoing major lower extremity amputations including (above the knee amputation) AKA and BKA (below the knee amputation) have been reported as 69.7% and 34.7% at 1 and 5 years, respectively.12 Mortality was found to be significantly higher for patients who underwent AKA (50.6% and 22.5% at 1 and 5 years) as compared with BKA (74.5% and 37.8% at 1 and 5 years).

 

Although amputation can be considered a failure of treatment, the actual considerations must be based on a number of factors, even when the initial impression is that salvage of the limb is untenable. There are still general categories of lower extremity conditions in which limb salvage is not appropriate. These would include traumatic limb loss or significant tissue deformation from motor vehicle or industrial accidents, malignancies whose location or dissemination precluded salvage, and congenital malformations precluding use of prosthetics or achieving a functional end result. Excluding the majority of these still leaves a considerable number of lower extremity conditions, in which the end result, amputation, unquestionably puts the patient at a higher risk of morbidity and mortality than before the decision to perform the procedure.

 

At present, the decision to recommend lower extremity amputation appears to be universally based on objective medical issues. Without recognising and attending to the equally important and pervasive, nonclinical, patient-centred issues, the decision is usually made based on the surgeon’s tunnel vision. The most basic tenet becomes that of removing the problem as the key to resolving the problem. As Ertl aptly stated:

 

‘The only contraindication for amputation is poor
health that impairs the patient’s ability to tolerate
anaesthesia and surgery. However, the diseased limb is
often at the centre of the patient’s illness, leading to a
compromised medical status. The removal of the
diseased limb is necessary to eliminate systemic toxins
and save the patient’s life.’

 

Unfortunately, the mere removal of an afflicted lower extremity under the guise of resolving the issue takes on a ‘low-hanging fruit’ mentality as it fails to address equally important patient-centred issues that often define the progress and ultimate outcome.

 

The identification of any criteria regarding the appropriateness of a lower extremity amputation based on patient-centered, non-clinical criteria has been found to be nonexistent despite an exhaustive literature search. This covered 70 years and approximately 200 citations. Brigham and Women’s Hospital in Boston uses a Pre-Amputation Assessment Checklist that, while comprehensively identifying specific patient expectations and information, does not consider any patient-centered criteria for amputation. Therefore, the Brigham tool does not recognize the potential issues and ultimate outcomes surrounding amputation. In contrast, the MENACE SCALE and its patent-centered components focus the attention on those issues related to non-clinical outcomes when lower extremity amputation is considered.

 

Table 2

The MENACE scale

It is not enough to objectively quantify only the clinical considerations for lower extremity amputation. The resulting amputation and the effect on quality-oflife must be taken into account. For that reason, there must be a combination of clinical factors together with non-clinical factors. The impact of these patientcentred, non-clinical factors cannot be overstated. The loss of all or part of a limb has a major psychological impact on the patient’s mental status. The psychological effects of amputation can be related to postoperative pain, cosmetic appearance, cultural and social effects, all potentially causing or exacerbating anxiety and depression.

 

We believe that any initial consideration for lower extremity amputation, regardless of the presenting issues, can be based on two primary factors. Those two factors are intractable pain and functionality in the presence of a potentially life- or limb-threatening condition. While these factors may at first appear to be objective they are equally dependent on the patient’s subjective impressions of their condition.

 

In considering the issues that ‘open the door’ to amputation, the authors felt that this process is analogous to ‘looking through a keyhole’ from which only a narrowed view is possible. We chose the term ‘keyhole criteria’ to represent this process as initial consideration regarding amputation. The two criteria (Table 2) establish a platform that forms the basis for the critical decision of amputation. These criteria move the decision from one that is based solely on the surgeon’s experience to a more germane one that encompasses considerations of the patient as a whole.

 

Criterion 1 is significant in that there are lower extremity conditions including neurologic, musculoskeletal or other deficits where attempted preservation would offer no benefit to the patient. When these presentations are associated with debilitating pain, then this criterion would be met and consideration for an amputation at some level would be appropriate. This criterion would require that all attempts be made to mitigate the pain. Thus, an acute presentation (following traumatic accident, postoperative complications from prosthetic implantation, etc.) would arguably require some time to be allowed to pass before accepting these criteria.

 

The issues regarding criterion 2 include preservation of the patient’s functionality and assumed morbidity and mortality of the presenting condition and that of the procedure. The goal of MENACE is to assure full consideration of all aspects of limb salvage versus amputation. Recognising that lesser procedures may provide both short- and long-term satisfactory outcomes, the issue of when to perform a lesser procedure and what that procedure may be, must be based on preservation of maximum functionality. For these reasons, attention must be directed to the patientspecific issues since information obtained provides the necessary elements required for a successful outcome. For example, the presence of distal pedal gangrenous changes in a diabetic neuropathic ulcer with a history of osteomyelitis poses a daunting problem. Not surprisingly, these findings would, in the vast majority of cases, lead to a strong recommendation for amputation. However, the usual discussion of potential complications and progression of disease state will generally lead to at least a discussion of the ‘benefits’ of simply removing the entire problem-containing lower limb. In contrast, the consideration of functionality is integral because it changes the discussion from one that obviates a potential progression of the presenting problem to one that recognises that retained maximum functionality allows ongoing quality-of-life based on retaining the limb. In simplest terms, if the extremity is still used to bear weight, provide propulsion in a wheelchair, transfer from chair to bed to commode, or even ambulate for any distance, then maintenance of that functionality takes on the highest priority. The goal becomes maximising the longevity and functionality of that extremity.

 

The authors believe that the two keyhole criteria represent a mandatory check step for medical providers who either perform or refer to those performing lower extremity amputation. These two criteria need to be used to ascertain the appropriateness of amputation for a given patient. This represents a marked departure from the practice that the decision be based on the perception of perceived benefit of amputation.

 

Initial evaluation of the patient’s presenting status with respect to the keyhole criteria should be undertaken. If the result is a decision to amputate, the MENACE scale assures that patient-centred factors are considered in the decision to amputate. Those factors placing the patient at risk for quality-of-life issues after surgery should be addressed well before amputation.

 

Table 3

The initial tool used by the authors was the 1–2 point scale to assess patient-centred factors. However, we recognised that the keyhole criteria were needed to focus the attention of the surgeon on what the authors felt were the two critical issues: pain and functionality.

 

With the focus now placed on the patient, those factors that impact on their lives both pre- and postoperatively need to be considered. While there are an infinite number of both specific and general categories to be considered, we believe that those factors identified in Table 3 represent the most salient, recognising the interrelationship of these factors and others not specifically identified.

 

The social status of the patient is integral to mental and physical wellbeing. Considerations must include: Who else is in the home? What will be the patient’s functional capacity both before and after the amputation? What is the expected effect on the family after amputation? Is the patient the primary breadwinner/caretaker for the family? Are there others who will be affected by the patient’s amputation status in the same environment (young children, teenagers, young adults, middle-agers)?

 

Habitation factors must include: where does the patient live (both geographically and in terms of the actual residence)? The geographic location, including changes in elevation (mountainous, or San Francisco hills), whether there are stairs to navigate, or consistently functioning lifts, and old versus new construction (ADA, Standards for Accessible Design related to the Americans With Disabilities Act)15 are all considerations that must be addressed before amputation.

 

Economic factors are the underpinning of what transpires with the patient and their direct family and friends. How will the patient’s economic status change after the amputation? Financial considerations are the bedrock on which much of the other issues achieve stability. Are they ready for retirement? Are they employable after amputation? Is there another breadwinner? Are they financially able to withstand loss of leg? What about the costs of treatment, prosthetics, devices? Are there accessible and available sources available to provide external financial support and can the patient access them (social security, disability insurance, etc.)? Is there adequate and sustained financial means either through a health insurance or other entity to pay for ongoing care including rehabilitation, care for any complications, medications, therapies, home health care, and if so for how long?

 

Interpersonal support and functional issues have the potential to create effects that reverberate throughout the entire recuperative period and beyond. What other intrinsic/extrinsic factors do they have to contend with? Do they live with conditions such as a small cluttered house (hoarder), ‘bad’ neighbourhood, difficulty getting to the grocery store, doctors, and social events? Is there inter-family stress such as abusive or uncaring children or relatives?

 

What psycho-emotional and self-perception issues are present? Do they already have body-centred issues (too fat, too skinny, too old, too sick …)? Is there a history of behavioural or mental health issues (depression, anxiety, obsessive compulsive disorder (OCD), schizophrenia, bipolar disorder, etc.)? How are they dealing with the potential amputation? Do they consider the recommendation for amputation a ‘death sentence’? Is there the opportunity to do something besides see the wound specialist all the time? How will they deal with the resultant disfigurement? The ultimate question is clearly: how important is that toe, foot, or leg to their life?

 

An exhaustive online search of the available literature identified definitive criteria/guidelines for removal of the gallbladder, appendix and performance of caesarean sections as well as numerous other surgeries. However, regarding amputation of a lower extremity, the overwhelming majority of articles that even entertain the rationale for performing the procedure present surgeon-based clinical considerations as the primary decision criteria and mention patient-centred factors only in passing.

 

Based on the experiences of the authors, there clearly needs to be a set of patient-centred criteria to juxtapose with the experiences of the surgeon and other providers integral to the decision-making process. We recognise that there are a myriad of compounding factors that affect provider and patient considerations that are easily overlooked and so a set of guidelines for evaluation such as the MENACE scale identifies those factors that can be easily evaluated and rectified.

 

The MENACE scale including the keyhole criteria has been used by the primary author for 23 years in one form or another. Explanation and review of the MENACE critera has been undertaken with our patients for whom amputation was the only alternative offered before coming to our clinics. In clinical practice, numerous encounters have occurred with patients marked for amputation in which their presenting condition was clearly (and ultimately) salvageable. Based on extensive clinical use, we believe that the appropriate use of this tool can balance the patient’s presentation using both the accepted medical/surgical objective criteria and the less often considered patientcentred criteria. In those situations the decision for amputation gains more credence as evaluation progresses, for those MENACE scale categories in which the highest score (2 points) is not present, appropriate actions and interventions are taken to maximise that score. For example, the patient who lives in an upperfloor apartment with an unreliable lifts should have their residence changed to one with greater accessibility even if this is to occur immediately after the surgery. The planned change allows for the full score for that category to be considered as accomplished despite its implementation postoperatively. The same holds for caregivers needed in the home following surgery. The key to MENACE is to recognise that maximising a successful outcome after the elective performance of a lower extremity amputation must be based on resolving as many patient-centred stumbling blocks as possible. We recognise that the act of doing so may not be appropriate for the surgeon themselves but believe strongly that it can be appropriately achieved by other entities including social workers, local, state and federal entities.

 

Based on our use of the MENACE scale in our own practices, we believe that a score of less than seven strongly suggests the highest potential for postoperative issues that will have an impact on the patient’s shortand long-term recovery and status. The failure to address identified issues both individually and collectively in the preoperative/perioperative periods may preclude a safe and complication-free recovery. MENACE was created to fill an unmet need. We understand that MENACE will require ‘real-life’ testing and validation. It is our expectation that when used alongside other criteria, it will provide a basis for expansion, revision, confirmation or deletion of the considerations we have proposed when a lower extremity amputation is considered.

 

Conclusion

The recommendation for, and performance of, a lower extremity amputation appears to be based primarily on criteria that remain undefined despite advances in all aspects of medicine. Although certain lower extremity presentations preclude safe attempts at limb salvage, there is clearly a trend towards performance based more on subjective criteria of the attending health-care providers than on clear objective patient-based criteria.

 

Lower extremity amputation does not merely remove all or part of the lower extremity. The interdependence of structure and function, both before and after amputation, and the potentially catastrophic consequences of failing to consider these factors, mandates that there be a specific and definitive categorical assessment of patient-centred factors rather than the current criteria, which are based solely on the skill, education and experience of the medical providers. When these decisions are based solely on their own criteria rather than those of the patient—who represents the primary consideration regarding a successful outcome—then failure to identity and resolve potential patient-centred issues means that the patient is not truly the focus of the intended procedure, although they will suffer any untoward effects. The loss of a lower extremity does not merely mean that a pending problem has been resolved but that the potential loss of the limb now presents its own life-affecting challenges well beyond the time that the surgical incision heals.

 

References
1 Quality Improvements Organization. Strategies to Help Reduce
Diabetes-Related Lower Extremity Amputations Among Minority
Populations. April 2017, https://tinyurl.com/yd3hcgrn (accessed 7
September 2017)
2 Murdoch G, Bennett-Wilson A Jr, Amputation: Surgical Practice and
Patient Management. Butterworth-Heinemann Medical, 1996.
3 Tooms RE. Amputations. In: Crenshaw AH (ed). Campbell’s Operative
Orthopedics (7th edn) Mosby-Year Book,1987: 597–637
4 Ertl JP. Amputations of the lower extremity. Medscape. 2016. http://bit.
ly/2uUFuEv (accessed 14 August 2011)
5 Zeigler-Graham K, Mackenzie EJ, Ephraim PL et al. Estimating the
prevalence of limb loss in the United States: 2005 to 2050. Arch Phys
Med Rehabil 2008; 89(3): 422-429. https://doi.org/10.1016/j.
apmr.2007.11.005
6 Silbert S., Haimovici H. Criteria for the selection of the level of
amputation for ischemic gangrene. JAMA 1954; 155(18): 1554–1558.
https://doi.org/10.1001/jama.1954
7 Book Notices: Handbook on Amputations JAMA 1942; 120(9):724.
https://doi.org/10.1001/jama.1942.02830440066028
8 Netherlands Society of Physical and Rehabilitation Medicine
(Nederlandse Vereniging van Revalidatieartsen – VRA). Guideline: amputation and prosthetics of the lower extremities. Utrect. 2012. http://bit.ly/2uCbGRM
9 Reyzelman A, Kim J. A guide to digital amputations in patients with
diabetes. Podiatry Today. 2011; 24(9). http://bit.ly/2wX6Ew2 (accessed 14
August 2011)
10 Kalapataku V. Lower extremity amputations. UpToDate. 2017. http://
www.uptodate.com/contents/lower-extremity-amputation (accessed 14
August 2017)
11 Karadsheh M. Amputations. Orthobullets.com. 2017. http://www.
orthobullets.com/trauma/1052/amputations (accessed 14 August 2017)
12 Brigham And Women’s Hospital Department of Rehabilitation
Services. Physical therapy standard of care: lower extremity amputation.
2011. http://bit.ly/2vwFFct (accessed 14 August 2011)
13 Hakami, K. Pre-operative rehabilitation evaluation of the dysvascular
patient prior to amputation. Phys Med Rehabil Clin N Am. 2009; 20(4):
677-688. https://doi.org/10.1016/j.pmr.2009.06.015
14 Bhuvaneswar CG, Epstein LA, Stern TA. Reactions to amputation:
recognition and treatment. Prim Care Companion J Clin Psychiatry 2007;
9(4): 303–308
15 ADA. Information and technical assistance. standards for accessible
design related to the Americans With Disabilities

Resources

health care disciplines— all of whom share a commitment to the prevention and management of pressure injuries. The NPUAP serves as a resource to health care professionals, government, the public,…

Study of 236 patients reveals utility of MolecuLight i:X® in detection and management of wound-related cellulitis

Published results describe use of point-of-care imaging for the early detection and proactive management of wound-related cellulitis

 

TORONTOOct. 12, 2021 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced the publication in International Wound Journalof an independent prospective observational study examining the impact of incorporating fluorescence imaging into standard care for the diagnosis and management of wound-related cellulitis. Dr. Charles Andersen, a surgeon at the Madigan Army Medical Center, led this study on wound-related cellulitis, defined as an invasion of bacteria from chronic wounds into the adjacent dermis.

“The results of this study show how MolecuLight point-of-care imaging presents an intriguing solution to revealing extension of bacteria into tissue, reducing misdiagnosis of wound-associated cellulitis, and enabling more proactive early treatment, particularly in patients lacking obvious symptoms”, says Dr. Charles A. Andersen, Chief, Vascular/ Endovascular and Limb Preservation Surgery Service (Emeritus), Chief Wound Care Service and Medical Director Wound Care Clinic at Madigan Army Medical Center, Tacoma, WA. “Given that at least 30% of cellulitis cases are misdiagnosed,6,5 the addition of consistent and objective information provided by fluorescence scans can significantly reduce the uncertainty associated with diagnosis of wound-related cellulitis. In addition, the use of fluorescence imaging to support earlier detection and proactive management of wound-related cellulitis can limit progression of infection and avoid the need for intravenous antibiotics and the high costs associated with inpatient admission”.

An example case of wound-related cellulitis from the study is shown (above) where the wound does not appear to have cellulitis or elevated bacterial burden upon assessment with standard-of-care clinical signs and symptoms (left). In contrast, when imaged with the MolecuLight i:(right), an irregular pattern of red (bacterial) fluorescence extending beyond the wound bed and periwound is visible, and could not be removed with vigorous cleansing, indicating that the bacteria are located subsurface. This pattern of red fluorescence, demonstrating invasive extension of bacteria into surrounding tissues, was consistent in all wounds in the study where wound-related cellulitis was diagnosed.

Dr. Andersen will present the findings of this publication in a talk titled, “Diagnosis and Treatment of the Invasive Extension of Bacteria (Cellulitis) from Chronic Wounds Utilizing Point-of-Care Fluorescence Imaging at the upcoming clinical conference, SAWC (Symposium on Advanced Wound Care) Fall 2021 on Sunday, October 31, 2021 at 9:00 am at Caesars Palace in Las Vegas, Nevada.

References

1

Andersen, C.A. et al, “Diagnosis and Treatment of the Invasive Extension of Bacteria (Cellulitis) from Chronic Wounds Utilizing Point-of-Care Fluorescence Imaging“, International Wound Journal 2021: 1-13

2

Lazzarini L et al, J Infect. 2005;51(5):383-389.

3

Raff AB et al, JAMA. 2016;316(3): 325-337.

4

Pasternack MS. Mandell, Douglas, & Bennett’s Principles & Practice of Infectious Diseases. Vol 1; Phil., PA: Churchill Livingstone/Elsevier; 2010:1289-1312.

5

Weng QY et al, JAMA Dermatol. 2017;153(2):141-146.

6

Levell NJ et al, Br J Dermatol. 2011;164(6):1326-1328.

About MolecuLight Inc.

MolecuLight Inc., a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s first commercially released device, the MolecuLight i:X fluorescence imaging system and its accessories provide a point-of-care handheld imaging device for the global wound care market for the detection of wounds containing elevated bacterial burden (when used with clinical signs and symptoms) and for digital wound measurement. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant, unmet needs including food safety, consumer cosmetics and other key industrial markets.

Image:
Download at: https://moleculight.box.com/s/oab22c1vi8ud1j8oymylbfogp2lg12bk

SOURCE MolecuLight

Related Links

www.moleculight.com

LifeNet Health features next level wound care solutions at SAWC Spring

Events include an Innovation Theater presentation that features the science and clinical results supporting Matrion®— the first full-thickness, decellularized placental membrane — and Dermacell AWM® acellular dermal matrix

 

PHOENIX, April 7, 2022 /PRNewswire/ — LifeNet Health, the world leader in allograft biologics, is showcasing its unique allograft solutions for wounds at the 2022 Symposium on Advanced Wound Care (SAWC) Spring meeting April 7-9 in Phoenix.

 

Its featured biologic portfolio includes:

Matrion®, the first full-thickness, decellularized placental membrane for wounds, and
Dermacell AWM®, the only acellular dermal matrix clinically proven to help resolve wounds in as little as one application1.
“These solutions take wound care to the next level by helping address long-standing clinical challenges,” said Mike Falcon, Vice President of Advanced Wound Management Sales. “Thanks to LifeNet Health’s unique technologies, we are bringing clinicians the most advanced allograft biologics available to facilitate healing in their patients.”

 

Innovation Theater Breakfast Presentation
Clinicians Hayway Chiu, DPM, FACFAS, and Zakee Shabazz, DPM, FACFAS will lead an SAWC-hosted Innovation Theatre session to share their experience with Matrion and Dermacell AWM. The analysis will cover the science behind these two best-in-class therapies as well as clinical results that show how they support positive patient outcomes, using real-world case studies.

 

The session, which begins at 7:30 a.m. MST Friday, April 8, will be moderated by Valerie Marmolejo, DPM.

 

Industry-Leading Solutions
Matrion is the only biologic of its kind to fully maintain the natural thickness and structure of the placental membrane. It includes the complete trophoblast layer, which is up to four times thicker than either the amniotic or chorionic membranes2. This allows Matrion to retain up to 50 percent more native growth factors than traditional placental membranes.3 Its natural thickness also means Matrion is less likely to adhere to itself or roll up during application.4

 

Dermacell AWM is backed by more than 30 publications that demonstrate its exceptional clinical performance and ease of use. It is proven to provide complete resolution of even complex wounds, with exposed bone and tendon, in as little as one application.1

 

Both Matrion and Dermacell AWM are decellularized with LifeNet Health’s patented Matracell® technology to remove donor cells and create a biohospitable scaffold for cellular infiltration and re-vascularization.

 

About LifeNet Health
LifeNet Health helps save lives, restore health, and give hope to thousands each year. It is the world’s most trusted provider of transplant solutions — from organ procurement to bio-implants and cellular therapies — and a leader in regenerative medicine, while always honoring the donors and healthcare professionals who enable healing. For more information about LifeNet Health, go to www.lifenethealth.org.

 

  1. Cazzell, S., Vayser, D., Pham H., et al. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. Wound Repair and Regeneration. 2017.
  2. Verbruggen SW, Oyen ML, Phillips AT, Nowlan NC. Function and failure of the fetal membrane: Modelling the mechanics of the chorion and amnion. PLoS One. 2017;12(3):e0171588.
  3. LifeNet Health. TR-004-2020 Characterization of the Amnion, Chorion, and Trophoblast Layers of Decellularized and Freeze-Dried Placental membrane. 2020.
  4. LifeNet Health. ES-20-057, Placental Membrane for Wound: Design Validation. Data on File. 2020.
    SOURCE LifeNet Health

 

This article was originally published here

An Assessment of Diabetes-Dependent Quality of Life in Polish Patients

An Assessment of Diabetes-Dependent Quality of Life in Polish Patients

Summary: A cross-sectional study published in Diabetes, Metabolic Syndrome and Obesity (September 2025) by Ewelina Bąk, Grzegorz Zawiła, Robert Skalik, Sylwia Krzemińska, Bogusława Kupczak-Wiśniowska, Lukas Kober, and Elena Gurková compares quality-of-life (QoL) impacts between Polish patients with type 2 diabetes mellitus (T2DM) with and without diabetic foot syndrome (DFS), using the Polish-language ADDQoL tool.

Key Highlights:

  • Patients with DFS reported markedly lower QoL (mean AWI ~–4.8) than those without DFS (AWI ~–2.6), a statistically significant difference.
  • The most negatively affected domains among DFS patients were physical health, feelings about the future, and working life.
  • In non-DFS patients, ‘freedom to eat’ and ‘freedom to drink’ were the domains most negatively impacted.
  • Regression analysis identified positive QoL influencers: gender, treatment modality, and self-dressing ability; negative influencers included complications, elevated fasting glucose, amputation, wound characteristics, dressing type, wound size, and Wagner grade.

Read the full study in Diabetes, Metabolic Syndrome and Obesity

Keywords:
ADDQoL questionnaire,
quality of life,
diabetic foot syndrome (DFS),
type 2 diabetes (T2DM),
Ewelina Bąk,
Grzegorz Zawiła,
Robert Skalik,
Sylwia Krzemińska,
Bogusława Kupczak-Wiśniowska,
Lukas Kober,
Elena Gurková

Healthy.io and Innovive Health Announce Groundbreaking New Partnership That Could Change

the Future of Wound Care Management

 

BOSTON, April 6, 2022 /PRNewswire/ — Healthy.io, the global leader in transforming the smartphone camera into a medical device, and Innovive Health, a data-driven home health care agency serving complex behavioral health patients, today announced a new partnership through which up to 700 Innovive nurses will use Healthy.io’s digital wound management service, Minuteful for Wound to enhance and extend patient care. The partnership illustrates how clinicians can use smartphone technology to track and treat chronic wounds like diabetic ulcers while enabling them to do their job more efficiently.

 

Innovive Health aims to revolutionize the treatment and care of chronic wounds in its vulnerable patient population by combining the company’s patient-centered, data-driven approach to home health care with Healthy.io’s smartphone-based service designed to enable healthcare providers to perform consistent and accurate wound measurement. Innovive Health’s ultimate goal is to improve continuity of care and allow clinicians to focus more of their time on patient care.

 

“We are thrilled about this partnership with Innovive Health,” said Healthy.io US General Manager Paula LeClair. “Innovive provides care to some of society’s most vulnerable and underserved communities, which aligns perfectly with Healthy.io’s mission. Together, we can change the way nurses use technology to monitor patients quickly and efficiently. COVID-19 brought to light the need for technology like our wound care product, which is key to helping nurses save precious time monitoring patients.”

 

“We’ve seen the ways Healthy.io has successfully changed wound care management and we are excited to partner with them to help our nurses accurately and consistently monitor chronic wounds. Any nurse can use this technology, which will result in more equitable patient care,” said Innovive Health’s CEO Joseph McDonough. “Innovive Health’s commitment to excellence coupled with Healthy.io’s vision-based medical technology can improve patient care for those suffering from particularly complex chronic wounds.”

 

Through this partnership, Innovive Health’s nurses use a smartphone to scan a wound before uploading the scan into a portal that allows them to assess whether the healing is proceeding properly. The AI-powered computer vision system analyzes wounds with optimal accuracy, automatically calibrating images for scale, lighting, dimensions, and 3D structure.

 

Healthy.io is confident this partnership will make it easier for nurses to manage wound care. Nurses using the Healthy.io wound management tool reported 85% faster documentation compared to standard methods and 67% reduction in their time for follow-up visits.

 

About Healthy.io

 

Healthy.io transforms the smartphone camera into a medical device to deliver healthcare at the speed of life. The company’s at-home urinalysis and digitized wound care services enable providers and healthcare systems to close gaps in access and care while increasing patient satisfaction. Healthy.io is a global leader in digital health and is a recipient of the CNBC 2020 Disruptor 50 Award, Fast Company’s World’s Most Innovative Companies 2020 Award, and the Financial Times 2020 Boldness in Business Award. The company is based in Tel Aviv and has offices in Boston and London.

 

About Innovive Health

 

As one of the leading home care health agencies in Massachusetts, Innovive Health has been delivering strong clinical outcomes for more than two decades and is transforming healthcare through an innovative model of patient-centered, data driven, full-service home care. Innovive Health provides high quality nursing, therapy and services to some of the region’s most vulnerable and underserved populations in the safety and comfort of their homes and communities. For more information, visit https://innovivehealth.com.

 

Media contact:

Kate Lucadamo
Vice President at Marathon Strategies
Kate@marathonstrategies.com

 

For Innovive Health
Travis Small
tsmall@sloweymcmcanus.com

SOURCE Healthy.io; Innovive Health

 

This article was originally published here

Outcome Measures of Quality of Life for People With Chronic Wounds

Outcome Measures of Quality of Life for People With Chronic Wounds: A Scoping Review

A scoping review published in *JWOCN* (May–June 2025) by Dantas et al. mapped validated patient-reported outcome measures (PROMs) used to assess health-related quality of life (HRQoL) in individuals with chronic wounds. :contentReference[oaicite:turn0search0]{index=0}

Key Highlights:

  • Review Scope: Surveyed literature from 1990 to April 2024 across MEDLINE, CINAHL, PubMed, Web of Science, and Scopus, identifying 30 studies evaluating HRQoL in chronic wound patients. :contentReference[oaicite:turn0search0]{index=0}
  • Instruments Identified: Twelve validated tools were used—six generic (e.g., SF-36 in 19%, EQ-5D-5L in 9%) and six wound-specific. Notably, the Cardiff Wound Impact Schedule and Wound‑QoL each appeared in 16% of studies. :contentReference[oaicite:turn0search0]{index=0}
  • Instrument Benefits: Generic measures allow comparisons with other chronic conditions and populations, but may underrepresent wound-specific QoL changes. Wound-specific instruments capture the multidimensional impacts on patients’ lives more sensitively. :contentReference[oaicite:turn0search0]{index=0}
  • Research Gaps: The review highlights limited use of PROMs in chronic wound studies, calling for more longitudinal and interventional research to validate their clinical utility. :contentReference[oaicite:turn0search0]{index=0}

Understanding which PROMs reliably capture HRQoL among patients with chronic wounds is essential for patient-centered care, enabling better assessment of therapeutic impact and guiding future investigations.

Read the full abstract in the Journal of Wound Ostomy & Continence Nursing.

Keywords:
PROMs,
HRQoL,
SF-36,
EQ-5D-5L,
Wound‑QoL

Healogics® Promotes Diabetes Awareness to Improve Healing and Reduce Amputations for Diabetes-Related Wounds

JACKSONVILLE, Fla., Nov. 1, 2022 /PRNewswire/ –As millions of Americans living with diabetes are also living with chronic wounds that won’t heal, Healogics® is raising awareness of diabetes-related wounds as part of the Healogics ninth annual Diabetes Awareness Campaign.

 

Throughout November, Wound Care Centers® will educate the local community about the importance of awareness, early intervention and specialized care for diabetes-related chronic wounds, like diabetic foot ulcers. Local team members will also visit healthcare providers in surrounding areas to provide important information to help at-risk patients living with diabetes.

 

Diabetes Awareness Infographic

Diabetes Awareness Infographic

There are more than 37 million Americans currently living with diabetes, according to the American Diabetes Association (ADA). Additionally, there are 96 million American adults who have prediabetes, leading to 1.4 million new diagnoses of diabetes every year. Diabetes-related wounds are a leading cause of limb loss, accounting for nearly 70 percent of cases undergoing lower extremity amputation in the United States.

 

“This campaign is essential because early detection of diabetes-related wounds significantly reduces amputation risks. Diabetic foot ulcers are the leading cause of diabetes-related hospitalizations and lower-limb amputations. What starts as a small cut or blister can quickly progress into a non-healing wound with severe complications. With 50 percent of our patient population living with diabetes, we know firsthand that our awareness efforts can help improve the lives of those struggling with diabetes-related wounds,” said Healogics Chief Executive Officer Frank Williams.

 

Many suffering from chronic wounds have been negatively affected by the COVID-19 pandemic as they have eschewed needed care during the past two-plus years. Untreated and undertreated wounds have resulted in amputation, according to a study from the ADA. Of the patients who have undergone one amputation, 55 percent will require amputation on the second leg. An amputation results in decreased quality of life, increased medical costs and a significantly higher risk of mortality.

 

“Many people who come to the Wound Care Center® with chronic wounds are among the 37 million adults living with diabetes. Some were unaware that diabetes put them at greater risk for non-healing wounds. Encourage patients to check their feet every day. It’s imperative we help patients avoid the serious consequences of non-healing wounds, such as diabetic foot ulcers, by raising awareness of the risks and importance of daily foot screenings to help prevent an avoidable amputation,” said Healogics Chief Medical Officer Dr. William Ennis.

 

Factors that may increase the risks of developing a chronic wound, such as a diabetic foot ulcer, include high blood sugar levels, poor circulation, immune system issues and nerve damage. Risk factors for diabetes include age, diet, activity level, obesity and heredity.

 

Healogics recommends the following to help prevent diabetic foot ulcers:

 

  • Stop smoking immediately
  • Request comprehensive foot examinations each time you visit your healthcare provider (at least four times a year)
  • Examine your feet every day or have a family member inspect them
  • Take good care of your feet and clean your toenails
  • See your healthcare provider to care for corns and calluses
  • Choose supportive, proper footwear (shoes and socks)
  • Take steps to improve circulation such as eating healthier and exercising regularly

 

Early detection and specialized care from a Wound Care Center® can reduce healing times and significantly reduce the risk of amputation.

 

Contact Healogics to learn more about diabetic foot ulcers or if you have a wound that will not heal. To schedule an appointment, please call 1-800-379-9774 or visit Healogics.com.

 

About Healogics
Headquartered in Jacksonville, Fla., Healogics is the nation’s wound healing expert. Last year over 300,000 patients received advanced wound care through a network of over 600 Wound Care Centers. Healogics also partners with over 300 skilled nursing facilities to care for patients with chronic wounds and provides inpatient consults at more than 60 partner hospitals. As the industry leader, Healogics has the largest repository of chronic wound-specific patient data in the country. The Healogics Wound Science Initiative offers peer-reviewed research and advanced analytics in the pursuit of not only better outcomes, but a better way to provide care.

 

SOURCE Healogics, LLC

 

This article was originally published here

Health Espresso partners with Wounds Canada to change wound care in Canada

Health Espresso, Canada’s upcoming leader in community EHR, partners with best in class, Wounds Canada, to provide an AI powered, digital solution that’s aligned with the government’s target of delivering better, more connected care and improving health equity for patients, especially those in remote communities. The partnership brings Wounds Canada’s best practices, resources and training to front-line practitioners at the point of care coupled with the ability for remote patient monitoring for better outcomes.

 

 

OAKVILLE, ONTARIO (PRWEB) APRIL 13, 2022

When Linda Moss’ father was transferred to a second hospital for rehabilitation following a brain injury neurosurgery, her family only received information about the primary reason for his hospitalization: his neurological progress. Linda Moss and her family didn’t know that their father was suffering from a pressure injury that would eventually cause osteomyelitis. It was only when their father was denied a second surgery due to complications from the pressure injury that the severity of the wound was discovered.

 

Unfortunately, this gap in communication between health-care providers, specialists and patients is far too common in the Canadian health-care system. The complete picture of patients is seldom shared, especially when they are complex or receive care from multiple partners. This leads to a lack of timely wound care and ultimately irreversible complications that can result in amputations or even death in the case of Linda Moss’ father.

 

“Care teams and caregivers are essential together, and the first step in any prevention or further complications with wounds is a communicated Care Plan,” says Linda Moss.

 

A new partnership between national organization Wounds Canada and Medtech company Health Espresso is changing this. This partnership enables front-line clinicians, patients, policymakers, and researchers to digitize a patient’s journey and connect members of allied health teams at the right time to decrease acute and hard-to-heal wounds, reduce hospitalizations and improve patient outcomes. Leveraging this technology will also enable Wounds Canada to establish a Canadian national registry that can inform further research in wound care and provide quick and easy access to Wounds Canada’s validated tools and resources for immediate bedside action by clinicians and help support wound management by patients, especially those living in outlying communities.

 

“Wounds are a serious health complication that impacts the quality of life for patients while having significant economic implications on our health-care system, and the situation has only worsened under the strain of COVID-19. In many cases, hard-to-heal chronic wounds can be avoided or, if detected in the early stages, managed effectively — but we need evidence-based solutions to help us provide the safe, equitable and timely care that patients deserve in home care and across all health-care settings,” says Mariam Botros, CEO of Wounds Canada. “That’s why Wounds Canada is excited to partner with Health Espresso to offer a skin and wound care mobile app that benefits not only patients but also clinicians, researchers and policymakers. With the launch of this digital solution, we’ll be able to improve patient care, reduce hospitalizations and lower spending on wound care while also increasing the skills and knowledge of front-line clinicians and establishing a Canadian national registry to inform further research.”

 

“As a registered nurse and private wound care consultant in rural southwestern Ontario, providing safe, timely, equitable access to interprofessional, evidence-informed care to people living with wounds can be challenging,” adds Crystal McCallum, Director of Education with Wounds Canada. “The skin and wound care mobile app that Health Espresso is developing in collaboration with Wounds Canada will address these challenges and will prove to reduce the burden of wounds and enhance the experience and outcomes of people living with wounds while enabling better use of health-care resources.”

 

Certified by the Ontario Telehealth Network (OTN) and powered by artificial intelligence, Health Espresso’s easy-to-use mobile and web-based integrative digital solution offers a connected, collaborative approach to wound care. It provides a complete digital blueprint of a patient’s overall health and history, real-time vitals data, recorded notes from hospital visits, administered medication and more for timely, well-informed decision making. Unlike many standalone solutions, Health Espresso’s unique collaborative approach allows for a broader view of the patient’s journey with access to patient records, high-quality wound imaging and analysis tools to track healing progression and understand why a wound may not be healing correctly. It also includes built-in messaging and video tools that enable physicians, wound specialists and patients — especially those in remote or Indigenous communities — to engage in live communication within a secure environment.

 

“Health Espresso’s digital solution is aligned with the government’s target of delivering better, more connected care and improving health equity for patients, especially those in remote communities,” says Founder of Health Espresso Rick Menassa. “To optimize the healing of wounds, care needs to be timely, and a structured, collaborative approach to assessment, treatment, documentation and communication based on best practices is critical for providing patients with the best possible outcomes. We are pleased to partner with Wounds Canada to offer our technology and bring their best practices, resources and training to front-line practitioners at the point of care.”

 

ABOUT HEALTH ESPRESSO
Inspired by front-line experience in home and community care, Health Espresso was created to chronicle the entire patient journey. Starting with a digital patient profile and digital care plan, Health Espresso empowers health organizations to automate intake, triage and update patient records and follow through with post-discharge remote patient monitoring for better health outcomes. Health Espresso provides a collaborative, patient-centred platform for Allied Health professionals, Primary Physicians and Hospitals for a ‘one patient, one care plan’ approach to care, reducing service overlaps and gaps. Its secure, connected platform integrates with EMRs and government data assets for an all-encompassing view of patient records. Health Espresso’s mobile app complements its in-cloud web portal to empower physicians with real-time patient information and virtual care capability for time-sensitive decisions at the point of care, anywhere in the world. For more information, visit https://www.healthespresso.com

 

ABOUT WOUNDS CANADA
Established in 1995, Wounds Canada is a charitable organization dedicated to advancing wound prevention and management for all people in Canada. They advocate for a population health approach that promotes best practices to support persons at risk of or living with wounds, health decision-makers and front-line clinicians. They develop and provide educational programs and resources and support research to advance this holistic, risk-based approach further. Wounds Canada fosters relationships with interested individuals and organizations to expand and sustain a robust wound community in Canada with mutually beneficial global connections. Their goal is to reduce the prevalence and incidence of wounds of all types and the negative consequences they bring—including patient suffering and wasted health-care dollars. To learn more, visit http://www.woundscanada.ca.

 

This article was originally published here

Net Health’s Tissue Analytics for Wound Care Granted Breakthrough Device Status by FDA

First time an EHR company has received Breakthrough Device Status

 

PITTSBURGH, June 2, 2022 /PRNewswire/ — Net Health, a provider of specialty electronic healthcare record (EHR) and predictive analytics software, announced today that Tissue Analytics, the company’s AI-powered wound imaging and analysis software, has been granted Breakthrough Device Status by the U.S. Food & Drug Administration (FDA). Tissue Analytics received the rare designation because of its novel diagnostic algorithms. The Company believes the FDA designation represents the first time an EHR company has been granted such designation.

 

Breakthrough Status indicates that the FDA believes the Company’s novel diagnostic Software as a Medical Device (SaMD) could provide more effective treatment or diagnosis of a life-threatening or debilitating condition, such as hospital-acquired pressure injuries (HAPIs), venous and diabetic foot ulcers and other non-healing wounds. Breakthrough Status is not granted solely on the severity of the device’s applicable condition. The submission must also meet one of the following criterion: the proposed device represents “breakthrough technology” as defined by the FDA; no other approved or cleared alternatives exist; the device offers significant advantages over existing approved or cleared alternatives; or the device availability is in the patient’s best interest.

 

Net Health’s Tissue Analytics Technology Pushes the Boundaries

“Finding ways to help our clients more quickly and accurately identify potentially life-threatening wounds and manage associated costs has been a priority for more than 20 years,” said Josh Pickus, CEO of Net Health. “The FDA designation highlights that Net Health is redefining EHRs as much more than simple documentation systems. Our intelligent AI-driven analytics solutions are pushing the boundaries of EHRs and helping change healthcare outcomes.”

 

Thu, June 2, 2022, 8:00 AM·3 min read
First time an EHR company has received Breakthrough Device Status

 

PITTSBURGH, June 2, 2022 /PRNewswire/ — Net Health, a provider of specialty electronic healthcare record (EHR) and predictive analytics software, announced today that Tissue Analytics, the company’s AI-powered wound imaging and analysis software, has been granted Breakthrough Device Status by the U.S. Food & Drug Administration (FDA). Tissue Analytics received the rare designation because of its novel diagnostic algorithms. The Company believes the FDA designation represents the first time an EHR company has been granted such designation.

 

(PRNewsfoto/Net Health Systems, Inc.)
(PRNewsfoto/Net Health Systems, Inc.)
Breakthrough Status indicates that the FDA believes the Company’s novel diagnostic Software as a Medical Device (SaMD) could provide more effective treatment or diagnosis of a life-threatening or debilitating condition, such as hospital-acquired pressure injuries (HAPIs), venous and diabetic foot ulcers and other non-healing wounds. Breakthrough Status is not granted solely on the severity of the device’s applicable condition. The submission must also meet one of the following criterion: the proposed device represents “breakthrough technology” as defined by the FDA; no other approved or cleared alternatives exist; the device offers significant advantages over existing approved or cleared alternatives; or the device availability is in the patient’s best interest.

 

Net Health’s Tissue Analytics Technology Pushes the Boundaries

 

“Finding ways to help our clients more quickly and accurately identify potentially life-threatening wounds and manage associated costs has been a priority for more than 20 years,” said Josh Pickus, CEO of Net Health. “The FDA designation highlights that Net Health is redefining EHRs as much more than simple documentation systems. Our intelligent AI-driven analytics solutions are pushing the boundaries of EHRs and helping change healthcare outcomes.”

 

Deployed by hundreds of healthcare organizations, including leading hospitals, health networks, and independent wound care clinics, Tissue Analytics’ novel diagnostic solution analyzes skin injury images and patient data using machine learning technology. This new level of analysis will allow Tissue Analytics to eventually provide new diagnostic elements as a complement to its current measurement generation imaging software, pending approval of its forthcoming marketing submission.

 

In granting the Breakthrough Device Status, the FDA recognized that the software could help wound care providers improve care by standardizing the diagnosis and care process of triaging patients with chronic, non-healing wounds with poor healing trajectories. In addition, the Agency noted that the “product will aid clinicians throughout the referral process with additional diagnostic information that can inform the wound care experts’ ultimate diagnosis and plan of care for chronic, non-healing wounds.”

 

“A first of its kind advancement like Tissue Analytics’ novel imaging functionality will make the clinical workflow for wound care safer, more effective, and ultimately more efficient,” said Alex Cadotte, Ph.D., ex-FDA Team Lead and now Director of Software and Digital Health at MCRA, LLC. “The FDA’s breakthrough designation acknowledges that Tissue Analytics is a first-of-its-kind device in Wound Care. The designation will also facilitate a collaborative conversation with FDA, which will ultimately be a win for public health.”

 

For more information on Tissue Analytics, visit https://www.nethealth.com/solutions/wound-care-tissue-analytics/ or https://www.tissue-analytics.com/ .

 

Net Health’s mission is to harness data for human health. Net Health solutions are trusted in over 23,000 facilities across the continuum of care. Our EHR software enables caregivers and their organizations to engage effectively with patients, streamline documentation, staff efficiently, secure maximum appropriate reimbursement and maintain regulatory compliance. Our unique approach to analytics seamlessly presents insights in clinical and operational workflows to improve care and business performance. Net Health is a portfolio company of The Carlyle Group, Level Equity and Silversmith Capital Partners. www.nethealth.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/net-healths-tissue-analytics-for-wound-care-granted-breakthrough-device-status-by-fda-301560059.html

 

SOURCE Net Health Systems, Inc.

Recommendations for the management of wound-related symptoms

Palliative Wound Care: Managing Symptoms to Enhance Quality of Life

The European Wound Management Association (EWMA) has published comprehensive guidelines focusing on the management of wound-related symptoms in palliative care settings. Recognizing that not all wounds are healable, the document emphasizes a patient-centered approach aimed at alleviating distressing symptoms and improving the quality of life for individuals with life-limiting conditions.

Key Highlights:

  • Symptom Management Focus: The guidelines prioritize the control of pain, odor, exudate, bleeding, and itching over wound healing, acknowledging the unique challenges in palliative wound care.
  • Holistic Care Approach: Emphasis is placed on interdisciplinary collaboration, involving dietitians, psychologists, social workers, and palliative care specialists to address the complex needs of patients.
  • Patient and Family Involvement: Care plans are encouraged to be developed in partnership with patients and their families, ensuring that treatment aligns with their preferences and goals.
  • Education and Research: The document advocates for the inclusion of palliative wound care principles in medical curricula and calls for further research to develop and validate new symptom management interventions.

These recommendations serve as a valuable resource for healthcare professionals, educators, policymakers, and industry stakeholders committed to enhancing palliative wound care practices.

Read the full article on the Journal of Wound Management website.

Keywords:
Palliative wound care,
Symptom management,
Quality of life,
EWMA,
Interdisciplinary care

New guideline puts lifestyle interventions at the forefront of type 2 diabetes and prediabetes care

New ACLM Guideline Prioritizes Lifestyle Interventions in Type 2 Diabetes Care

On June 10, 2025, the American College of Lifestyle Medicine released its first clinical practice guideline explicitly placing lifestyle behavior interventions at the center of adult type 2 diabetes and prediabetes management. Published in the *American Journal of Lifestyle Medicine*, this guideline offers practical tools and frameworks for lasting behavior change.

Key Highlights:

  • Six Core Pillars: The guideline emphasizes plant-based nutrition, physical activity, restorative sleep, stress management, social connection, and avoidance of harmful substances (tobacco and alcohol).
  • Actionable Strategies: Clinicians are guided to assess baseline habits, coach using SMART goals, evaluate readiness for change, and support medication de-escalation when lifestyle change is effective.
  • Broad Endorsements: Backed by major organizations—including AACE, AANP, AND, and ADCES—the guideline shifts lifestyle from adjunctive advice to primary therapy.
  • Goal of Remission: Emphasizes achieving not just management but remission of type 2 diabetes—defined as normoglycemia without glucose-lowering therapy.
  • Practical Tools Included: Includes over 25 clinician and patient handouts, workflows, and behavior-change aids to support implementation in real-world care settings.

This guideline marks a paradigm shift—transforming lifestyle from secondary support into the main therapeutic approach for prediabetes and type 2 diabetes, while complementing existing pharmacologic and procedural strategies.

Source: American College of Lifestyle Medicine clinical guideline, June 10, 2025.

Keywords: type 2 diabetes, lifestyle medicine, diabetes remission, SMART goals, plant‑based nutrition

Read more on News-Medical.net

Management of Diabetes-Related Foot Ulceration at Two Interdisciplinary Services

Management of Diabetes-Related Foot Ulceration at Two Interdisciplinary Services: A Qualitative Exploration of Patient and Carer Experiences

Summary: A qualitative study by Sarah M. Manewell, Georgina Frank, Vanessa Nube, Hylton B. Menz, Catherine Sherrington, Sarah Dennis, and Serene S. Paul (2025, Wound Practice & Research, Vol. 33, No. 3) explores patient and carer experiences of diabetes-related foot ulcer (DFU) care at two interdisciplinary High Risk Foot Services (HRFS) in Sydney. Through in-depth interviews, the study identifies themes of confidence in care, how care is experienced as comprehensive, and how DFUs are life changing.

Key Highlights:

  • Patients and carers valued being “confident in care” — trust in clinicians, clarity of explanations, and feeling heard were all central to positive experiences.
  • “Care considered comprehensive” emerged strongly, with subthemes of education (patients appreciated plain language, understanding of their condition, offloading devices, pressure assessment) and complex access (logistics, appointment scheduling, transportation, coordination across teams).
  • Participants described DFU as life changing: impacts on mobility, daily tasks, emotional wellbeing, social roles, and identity. Care and living with DFU are deeply intertwined experiences that cannot be separated.
  • Barriers exist—patients noted difficulty putting education into practice due to other life demands, safety issues with offloading devices, inconsistent messaging, and challenges in accessing care especially when dependent on support or transport.
  • The study suggests early and consistent education, strong communication, care continuity, and addressing practical access issues are critical to improving patient/carer experience and potentially outcomes.

Read the full article in Wound Practice & Research

Keywords:
diabetes-related foot ulceration,
interdisciplinary care,
patient experience,
education benefits,
access challenges,
DFU life changing,
Sarah M. Manewell,
Georgina Frank,
Vanessa Nube,
Hylton B. Menz,
Catherine Sherrington,
Sarah Dennis,
Serene S. Paul

Diabetes-Related Extremity Amputation Depression and Distress (DREADD): A Multimethod Study

A Multimethod Study

Diabetes-related lower extremity amputations (LEAs) are among the most devastating complications of diabetes, profoundly impacting physical, psychological, and social well-being. The Diabetes-Related Extremity Amputation Depression and Distress (DREADD) study examines the emotional and psychological consequences of amputation in diabetic individuals, employing a multimethod approach to capture the full spectrum of patient experiences.

The Psychological Toll of Amputation

Individuals who undergo amputations due to diabetes-related complications, such as diabetic foot ulcers and peripheral artery disease (PAD), often experience profound emotional distress. Depression, anxiety, and post-traumatic stress are common, exacerbated by a loss of mobility, independence, and altered self-identity. Many struggle with feelings of grief, shame, and social isolation, impacting their overall quality of life and mental health.

A Multimethod Approach

The DREADD study employs both qualitative and quantitative research methods to explore these psychological impacts. Surveys and standardized depression scales, such as the Patient Health Questionnaire-9 (PHQ-9), are used to measure depression severity, while structured interviews provide insights into personal struggles, coping mechanisms, and unmet psychological needs. Additionally, biometric data, including heart rate variability and cortisol levels, offer physiological indicators of chronic stress and emotional dysregulation.

Findings and Implications for Care

Preliminary findings suggest that nearly half of patients experience moderate to severe depression post-amputation, with many lacking adequate mental health support. Factors such as poor social support, financial strain, and preexisting mental health conditions contribute to worse outcomes. The study underscores the need for integrated care models that address both physical and psychological rehabilitation, including peer support groups, counseling services, and cognitive behavioral therapy (CBT) to improve patient adaptation and emotional resilience.

By highlighting the critical intersection between diabetes, amputation, and mental health, the DREADD study aims to reshape post-amputation care, advocating for holistic interventions that go beyond wound healing to address the profound psychological distress faced by affected individuals.

Microbion Corporation Receives up to $2.1 million in Funding Support from the US Navy

in Partnership with CUBRC, Inc. to Advance Topical Pravibismane

 

Funding will support exploratory phase 2 proof-of-concept study in patients hospitalized for moderate to severe diabetic foot ulcer infection (DFI)

 

BOZEMAN, Mont. and VANCOUVER, BC, June 7, 2022 /PRNewswire/ – Microbion Corporation of Bozeman, MT, today announced that it has received non-dilutive funding through its strategic partnership with CUBRC, Inc., a Buffalo-based, independent not-for-profit research company, of up to $2.1 million from the US Navy through the Medical Technology Enterprise Consortium (MTEC) partnership. The funding project is titled “Pravibismane Suspension as a Topical, Broad Spectrum Anti-Infective Wound Care Treatment and Prevention for Combat Injury-Related Infections”. The funding received will be used to support the conduct of an exploratory phase 2 proof of concept trial in patients hospitalized for moderate to severe diabetic foot ulcer infection with enrollment expected to begin in Q2 2022.

 

“We are pleased to be supported by the US Navy and MTEC and are working closely with them to advance our topical pravibismane through phase 2 proof-of-concept studies,” said Karim Lalji, CEO of Microbion Pharma Corp. “Our topical diabetic foot ulcer infection program is well aligned to the Navy’s interest in innovative wound care technologies to treat and prevent biofilm-related infections, since biofilm contamination is a hallmark characteristic of chronic foot ulcer infections. Further exploration of pravibismane’s safety and efficacy in overcoming biofilm-related DFI may potentially expand the clinical utility of topical pravibismane to treat combat wound infections in a variety of settings, including in the field and hospital.”

 

Lester Martinez, MD, MPH, Major General (Retired), U.S. Army, President and Chairman of MTEC Board commented on the importance of Microbion’s research. “Though diabetic foot ulcer infections aren’t traditionally thought of as a combat related wound suffered in the field, diabetes is a serious disease that affects a significantly high percentage of our veterans and its complications such as DFI contributes to decline in health, quality of life and are responsible for the vast majority of non-combat amputations among veterans. Microbion’s research into healing these wounds with the ultimate goal of preventing or delaying amputations can potentially improve the daily lives of these patients and return normal mobility,” Dr. Martinez stated.

 

Pravibismane is the first in a new class of anti-infective drugs structurally unrelated to other clinically utilized antibiotics. With a novel mechanism of action, pravibismane shuts down bacterial ATP production thereby halting global bacterial cellular metabolism. In in vitro studies, pravibismane exhibits broad-spectrum, potent activity against DFI-relevant pathogens and their biofilms including MRSA and drug resistant P. aeruginosa.

 

In a randomized, double-blind, placebo-controlled Phase 1b trial treating patients with chronic moderate to severe diabetic foot ulcer infection, topical pravibismane treatment plus standard of care demonstrated a numeric 85% wound size reduction versus 30% placebo plus standard of care. Pravibismane also demonstrated a numeric reduction in ulcer-related amputation (2.6% in the pravibismane group vs 15.4% placebo).

 

DFIs are a major health concern in the Veterans Health Administration as DFUs are associated with a substantial mortality rate (five-year mortality rates are as high as 45% for neuropathic ulcers and 55% for ischemic ulcers1) and often require amputation to fully address the nidus of infection.2 Approximately 28.5 million adults in the US are diagnosed with diabetes, of whom 15 – 25% are at risk of developing a foot ulcer.3,4 More than half of diabetic foot ulcers become infected.5 DFIs remain the most frequent diabetic complication requiring hospitalization and are the most common precipitating event leading to lower extremity amputation.6 Furthermore, recent studies suggest that many DFIs are caused by bacteria in a biofilm mode.6 In 2018, there were ~8.25 million hospital discharges with diabetes reported, including 154,000 for a lower-extremity amputation.3 US Veterans Affairs estimates there were 20.3 million living Veterans in 2018.7 The overall prevalence of diabetes among US veterans is ~25%, which is higher than the US civilian population at ~9%.8

 

References:

  1. Del Core MA, Ahn J, Lewis RB, et al. The evaluation and treatment of diabetic foot ulcers and diabetic foot infections. Foot & Ankle Orthopaedics. 2018;3:3. doi:10.1177/2473011418788864
  2. Sundararajan PP, Porter BM, Grant KA, et al. Foot infections in the Veterans Health Administration. The Foot and Ankle Online Journal. 2015;8(3):1. doi:10.3827/faoj.2015.0803.0001
  3. Centers for Disease Control and Prevention. National Diabetes Statistics Report website. https://www.cdc.gov/diabetes/data/statistics-report/index.html, accessed June 6, 2022
  4. Lavery LA, Davis KE, Berriman SJ, et al. WHS guidelines update: Diabetic foot ulcer treatment guidelines. Wound Repair Regen. 2016;24(1):112–26. doi: 10.1111/wrr.12391
  5. Armstrong, DG, Boulton, AJM, and Bus, SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376:2367-75. doi: 10.1056/NEJMra1615439
  6. Lipsky et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diab Metab Res Rev. 2020. e3280. doi: 10.1002/dmrr.3280
  7. VETPop2018: A Brief Description. Web: https://www.va.gov/vetdata/docs/Demographics/New_Vetpop_Model/VP_18_A_Brief_Description.pdf, accessed June 6, 2022
  8. Liu Y, Sayam S, Shao X, et al. Prevalence of and trends in diabetes among veterans, United States, 2005–2014. Prev Chronic Dis. 2017;14:170230. doi: 10.5888/pcd14.170230

 

About Microbion
Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds to improve the lives of patients with rare and serious diseases. Microbion’s lead drug candidate, pravibismane, is the first product in this new class and has a novel mechanism of action offering unique potential to address the unmet needs of chronic and severe health conditions. The Company is advancing inhaled pravibismane in Phase 1 clinical development for the treatment of chronic lung diseases, including non-tuberculous mycobacteria (NTM) and cystic fibrosis-related lung infections. Topical/local pravibismane is in Phase 2 development for the treatment of chronic wounds and orthopedic infections. Pravibismane has received backing from the Cystic Fibrosis Foundation, NIH, US DoD, and CARB-X with over $21 million in grants. The FDA has granted pravibismane with Orphan Drug, Fast Track, and QIDP designations. Microbion Pharma Corp. is a wholly owned subsidiary of Microbion Corporation. For more information visit: www.microbioncorp.com.

 

About CUBRC
CUBRC is an independent not-for-profit scientific corporation that executes Research, Development, Testing and Systems Integration programs in Medical Sciences, Chemical and Biological Defense, Data Science and Information Fusion, Command and Control, and Hypersonics. For more information visit: www.cubrc.org.

 

Safe Harbor Statement
Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the success of clinical development of pravibismane and preparation for potential commercialization. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our ability to enroll patients in our clinical trials at the pace that we project; the size and growth of the potential markets for pravibismane or any future product candidates and our ability to serve those markets; our ability to obtain and maintain regulatory approval of pravibismane or any future product candidates; and our expectations regarding the potential safety, efficacy or clinical utility of pravibismane or any future product candidates. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Microbion Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

US Government Funding Disclaimer
Efforts described herein were partially sponsored by the Government under Other Transactions Number W81XWH-15-9-0001. The U.S. Government is authorized to reproduce and distribute reprints for Governmental purposes notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government.

 

SOURCE Microbion Corporation

This article was originally published here

Novel therapeutic targets for diabetes-related wounds: An update on pre-clinical and clinical research

Diabetes-related wounds, particularly diabetes-related foot ulceration, is mainly caused by lack of foot sensation and high plantar tissue stress secondary to peripheral neuropathy, ischemia secondary to peripheral artery disease and dysfunctional wound healing. Current management of diabetes-related wounds involves the offloading high foot pressures and the treatment of ischemia through revascularisation. Despite these treatments, the global burden of diabetes-related wounds is growing, and thus novel therapies are needed. The normal wound healing process is a coordinated remodelling process orchestrated by fibroblasts, endothelial cells, phagocytes and platelets, controlled by an array of growth factors. In diabetes-related wounds this coordinated process is dysfunctional. Past animal model and human research suggests that prolonged wound inflammation, failure to adequately correct ischemia and impaired wound maturation are key therapeutic targets to improve diabetes-related wound healing … read more

Measurement properties of quality of life instruments for adults with active venous leg ulcers: a systematic review protocol

Objectives The primary objective is to identify instruments used to measure quality of life (QoL) in studies of people with active venous leg ulcers (VLUs). The secondary objective is to map the qualities of each instrument to make recommendations for clinical practice and future research.

Introduction VLUs have a negative impact on patients’ QoL. Prolonged healing and frequent recurrence leads to pain, prolonged disability and psychosocial morbidity. Accurate measurement of QoL can optimise the evaluation of VLU treatments and guide clinician and patient decision-making … read more

Quality of Clinical Practice Guidelines for Diabetic Foot Management



Quality of Clinical Practice Guidelines for Diabetic Foot Management: A Systematic Review Using the AGREE II and AGREE-REX Instruments

Summary: This systematic review assessed the methodological quality and recommendation excellence of 15 clinical practice guidelines (CPGs) for diabetic foot ulcer (DFU) management using AGREE II and AGREE-REX instruments. Six guidelines were rated high-quality and nine moderate-quality. Highest AGREE II domains were Editorial Independence, Scope and Purpose, and Clarity of Presentation. Lowest scores were in Applicability, Stakeholder Involvement, and Rigor of Development. AGREE-REX showed weaknesses in Values and Preferences. Seventeen key treatment recommendations were synthesized, mostly Grade B with moderate-quality evidence. The review concludes that while guidelines use systematic methods, gaps remain in applicability, stakeholder input, and implementation. Future guidelines should prioritize these areas and strengthen underlying evidence to improve clinical utility and patient outcomes.

Key Highlights:

  • Variability in quality; strong in scope/clarity but weak in applicability and rigor
  • Low scores in stakeholder involvement and values/preferences
  • Recommendations mostly Grade B with moderate evidence
  • Authors: Yu Song, Zhong-Fei Cui, Zhi-Qiang Wu, Xiao-Bo Liu, Wen-Jun Liu et al.

Read full review (open access)

Keywords: DFU guidelines, AGREE II, diabetic foot management, clinical practice guidelines, Yu Song

Palliative Wound Care. Recommendations for the Management of Wound-related Symptoms

EWMA Releases Palliative Wound Care Guidelines: Focused on Symptom Management

The European Wound Management Association (EWMA), in collaboration with EPUAP, WHS, and Wounds Australia, has published evidence-based guidelines in the *Journal of Wound Management* (Vol 26, Suppl 1, 2025). These recommendations address the care of non-healing and palliative wounds by focusing on symptom relief rather than healing alone.

Key Highlights:

  • Holistic Symptom Management: Emphasis on alleviating pain, odor, exudate, bleeding, and itch to enhance comfort and quality of life in patients with palliative wounds :contentReference[oaicite:1]{index=1}.
  • Patient- and Family-Centered Care: Care plans are designed collaboratively, respecting patient preferences and involving caregivers in decision-making :contentReference[oaicite:2]{index=2}.
  • Education & Multidisciplinary Approach: Guidelines recommend integrating palliative wound care principles throughout medical education and encouraging teamwork between clinicians, dietitians, psychologists, social workers, and palliative care specialists :contentReference[oaicite:3]{index=3}.
  • Research & Innovation Encouraged: Highlights the need for further clinical trials and industry collaboration to develop targeted products and techniques—especially for malignancy-related wounds :contentReference[oaicite:4]{index=4}.
  • Policy and Access Implications: Urges the development of institutional and national policies to ensure equitable resource access, use of telehealth, and standardized symptom-targeted protocols :contentReference[oaicite:5]{index=5}.

These guidelines reflect EWMA’s commitment to improving outcomes for patients with palliative wounds through a compassionate, evidence-based, and multidisciplinary approach, tailored to the needs of those at all stages of wound progression.

Read the full guidelines supplement in the EWMA News section and download it for free.

Keywords:
palliative wound care,
symptom management,
quality of life,
multidisciplinary care,
telehealth

Health Espresso welcomes Dr. Robyn Evans on its Skin Health and Wound Care Advisory Team

OAKVILLE, ONTARIO (PRWEB) APRIL 12, 2022

 

HEALTH ESPRESSO INC. a company focused on introducing a collaborative, Inter-professional virtual health record in community within the Allied Health and home care sectors that is connected to primary care, hospital and other digital health assets, today announced the recent appointment of Dr. Robyn Evans as Health Espresso’s Advisor, Skin Health and Wound Care.

 

Rick Menassa, CEO of Health Espresso commented, “We are very pleased to have Dr. Evans join us as the Company’s Advisor, Skin Health and Wound Care. She brings Health Espresso over 13 years of wound care education and research. Her extensive in-field experience as a primary care physician, coupled with her proven ability to lead within the ever evolving, rapid paced digital health environment, will add tremendous navigational support to Health Espresso’s own growth strategies as it engages with patients and front line organizations providing wound care services.”

 

Dr. Evans is advising Health Espresso’s development teams on the AI powered wound imaging tool on its mobile app. for images capture at point-of-care, integration into Health Espresso’s patient’s Electronic Health Record (EHR) on its secure, in-cloud web portal for real-time inter-professional virtual collaboration.

 

Dr. Evans valuable input and guidance is leading development of Health Espresso’s next stage to interpret wound characteristics from captured images using Health Espresso’s proprietary AI technology to direct management.

 

Dr. Robyn Evans is actively involved in clinical evaluation and management of patients with complex wounds as the Director of the Wound Healing Clinic at Women’s College Hospital. Over the past 13 years, she has developed an interest in wound care education and research. She is medical lead for Wounds Canada as well as serving on the Board of Wounds Canada. She is a lecturer at University of Toronto and part of the International Interprofessional Wound Course through University of Toronto.

 

Dr. Evans has also worked full time as a community family physician since 1992.

 

Dr. Robyn Evans attended University of Toronto Medical School. She completed her family medicine residency at University of Toronto with further training in Wound care. Prior to this she did a Bachelor of Science as well as graduate studies in Biochemistry.

 

“Complex wounds need to be acutely characterized to optimize management and improve patient outcomes” says Dr. Evans.

 

ABOUT HEALTH ESPRESSO
Inspired by front-line experience in home and community care, Health Espresso chronicles the entire patient journey. Starting with a digital patient profile and digital care plan, Health Espresso empowers health organizations to automate intake, triage and update patient records and follow through with post-discharge real-time remote patient monitoring for better health outcomes. Health Espresso provides a collaborative, patient-centered platform for Allied Health professionals, Primary Physicians and Hospitals for a ‘one patient, one care plan’ approach to care, reducing service overlaps and gaps.

 

Its secure, connected platform integrates with EMRs and government data assets for an all-encompassing view of patient records. Health Espresso’s mobile app complements its in-cloud web portal to empower physicians with real-time patient information and virtual care capability for time-sensitive decisions at the point of care, anywhere in the world. For more information, visit https://healthespresso.com

Social Determinants of Health in Podiatric Patients

Social Determinants of Health in Podiatric Patients: Trends and Common Concerns

Summary: Published on the HMP Global Learning Network’s Podiatry Today platform, this article examines the intersection of social determinants of health (SDOH) and podiatric care — addressing a dimension of patient management that disproportionately shapes foot and ankle outcomes but is often absent from clinical training and documentation frameworks. SDOH — the non-medical factors that influence health outcomes, including economic stability, education, health literacy, neighbourhood conditions, housing insecurity, food insecurity, social isolation, and access to healthcare — are increasingly recognised as drivers of the most challenging cases in podiatric practice. For wound care clinicians managing diabetic foot ulcers, venous leg ulcers, and pressure injuries, SDOH factors directly affect: wound healing trajectories (poor nutrition, inadequate offloading at home, inability to rest); treatment adherence (unaffordable medications, dressings, or footwear; missed appointments due to transport barriers); infection and amputation risk (delayed presentations due to healthcare avoidance; higher rates of homelessness-associated DFU complications including retinopathy and amputation); and recurrence risk (return to high-risk environments, inability to maintain footwear, self-care knowledge gaps). The article covers trends in how SDOH awareness is evolving in podiatric practice — including integration of ICD-10-CM Z codes for SDOH documentation, adoption of structured SDOH screening tools (PRAPARE, AHC-HRSN), referral pathways to community health workers and social services, and the growing clinical imperative to address SDOH as part of comprehensive, equitable diabetic foot care rather than treating them as external social issues. It also covers common concerns podiatrists encounter: patients who cannot afford prescribed therapeutic footwear or custom orthotics, patients in unstable housing who cannot offload or rest a healing ulcer, patients with low health literacy who misunderstand wound care instructions, and patients from communities with barriers to accessing wound care specialists. As the JS-gated HMP Global Learning Network platform requires browser JavaScript to load full content, the complete article is accessible via a registered account at hmpgloballearningnetwork.com.

Key Highlights:

  • SDOH and DFU outcomes: homelessness is associated with significantly higher rates of DFU-related ED visits, hospitalisation, lower limb amputation, and retinopathy — populations experiencing unstable housing carry compounded foot health risk that clinical care alone cannot address without social intervention
  • Documentation opportunity: ICD-10-CM Z codes (Z55–Z65) enable systematic documentation of social risk factors in clinical records, supporting population health management, quality metrics, and care coordination — yet uptake remains low across podiatric and wound care settings
  • SDOH screening tools: structured instruments such as PRAPARE (Protocol for Responding to and Assessing Patients’ Assets, Risks, and Experiences) and the AHC Health-Related Social Needs screening tool can identify actionable SDOH domains within clinical encounters, enabling warm referrals to community resources
  • Wound care-specific SDOH barriers: inability to afford wound care dressings or prescribed footwear; inadequate nutrition (protein, micronutrients) for wound healing; inability to rest or offload at home; low health literacy affecting dressing change technique and wound monitoring; transport barriers to follow-up appointments
  • Equity imperative: disparities in DFU outcomes — including higher amputation rates among Black, Hispanic, and low-income patients — are well documented; integrating SDOH screening and referral into podiatric wound care represents a structural equity intervention as well as a quality improvement strategy
  • Access note: HMP Global Learning Network requires JavaScript and free account registration; content accessible at hmpgloballearningnetwork.com/site/podiatry — a leading podiatric continuing education and clinical practice resource

Read full article

Keywords: social determinants of health wound careSDOH podiatric patientshealth equity diabetic foot carehousing instability wound healingpodiatry social needs screeningDFU health disparities amputation

HMP Global Learning Network / Podiatry Today

REGENATIVE LABS AND BROTHERS IN ARMS FOUNDATION ANNOUNCE NEW

PARTNERSHIP TO OFFER STATE OF THE ART CARE TO INJURED VETERANS WITH 5 MILLION DOLLAR DONATION

Both organizations call on physicians to assist Veterans.

PENSACOLA, Fla. , Feb. 27, 2023 /PRNewswire/ — Regenative Labs (Regenative), a leading HCT/P manufacturer, is partnering with Brothers in Arms Foundation (BIAF), a 501©3 nonprofit providing logistical and financial support to wounded, ill, injured and fallen Marines, sailors, and the families of those who served. Together, both organizations are dedicated to giving back and improving the quality of life for those who have served our country.

 

Regenative will donate approximately $5 million dollars of its state-of-the-art Wharton’s Jelly product, ProText™, to BIAF which will facilitate the care of qualifying veterans. To bring this care to veterans, Regenative and BIAF need the help of physicians to apply the product.

 

Physicians across the country may join in supporting our veterans by making a qualified donation of their time under the Brothers in Arms Foundation 501©3 non-profit.

 

“We’re extremely proud of this partnership,” shared Regenative Labs CEO, Tyler Barrett. “Ultimately our products are about improving patient quality of life. My grandfather served in the Marines in Korea, and so being able to serve those like him in unison with the mission of Brothers in Arms is important to me,” Barrett concluded.

 

Regenative’s Wharton’s Jelly product is a structural connective tissue allograft intended for homologous use to replace or supplement missing or damaged tissue directly at the site of a structural defect. Some doctors have used the product for muscle and cartilage tears and to replace missing or damaged tissue due to wounds and tissue defects, instead of masking the underlying connective tissue issue.

 

Regenative has been tracking patient outcomes of applications of their product for over two years. Retrospectively, the results have shown improvements greater than 33 percent in patient reported WOMAC improvement.

 

It is Regenative’s and BIAF’s goal to provide veterans with the best quality of life possible.

 

“We’re committed to bettering the quality of life for our veterans,” said Brothers in Arms Foundation President, Phillip Noblin. “This new, innovative treatment will give them the hope and support needed to heal. The partnership with Regenative Labs will further our mission of serving those who’ve served us,” said Noblin.

 

Physicians interested in taking care of qualified veterans by donating their services through a 501©3 non-profit may visit: https://regenativelabs.com/biaf-physician-time-and-services-donation/

Veterans who wish to learn more, or to refer their physician today may visit: https://regenativelabs.com/biaf/

 

One can make a monetary donation through the BIAF.

 

About Regenative Labs: Regenative Labs produces regenerative medicine products to address the root cause of a patient’s conditions using Wharton’s Jelly innovations rather than masking the pain with other treatments. Regenative Labs works closely with scientists, physicians, hospitals, and surgery centers to constantly monitor and improve patient progress and outcomes for new product development. Formed by veteran industry professionals familiar with daily challenges of innovations in healthcare, the company provides non-addictive, non-invasive options for patients. Regenative Labs’ expert product research and development team complies with FDA guidelines of minimal manipulation for homologous use. The company adheres to AATB and FDA guidelines. Learn more at Regenative’s website: www.regenativelabs.com

 

About Brothers in Arms Foundation: Brothers in Arms Foundation is a 501c3 non-profit founded in 2009 that exists to provide financial and logistical support to wounded, ill, injured and fallen Marines, sailors, and the families of those who served within the Marines Special Operations community. Over the years, the foundation has supported active-duty Marines, sailors, veterans and military families with programs and services ranging from financial assistance, funding vocational and quality of life initiatives, as well as funeral support and childcare. Learn more at:

https://www.brothersinarmsfoundation.org

 

SOURCE Regenative Labs

Podimetrics Secures $45 Million Series C To Help At-Risk Providers and Health Plans Prevent

Diabetic Amputations in High-Risk Patients

Every 4 minutes in the U.S., a patient loses a limb due to diabetes complications
Black Americans face diabetes-related amputations 3x as often as white Americans
Podimetrics strives to reduce disparities in diabetes care and unnecessary limb loss
SOMERVILLE, Mass., March 24, 2022 — Podimetrics, creator of the FDA-cleared SmartMat™ and integrated clinical care services that can help save the limbs and lives of complex patients with diabetes, today announced a $45 million Series C round led by D1 Capital Partners, along with two new investors, the Medtech Convergence Fund and an undisclosed strategic investor. Existing investors, Polaris Partners and Scientific Health Development, also participated in the financing. Prior to their Series C, Podimetrics had raised $28.3 million in funding to fuel development and distribution of their SmartMat.

 

With this latest round of funding, Podimetrics plans to focus on hiring to build out their product development and research teams, while also expanding the breadth of services delivered by their nurse support team. This new funding will help even more at-risk providers and health plans drive broader adoption of Podimetrics’ SmartMat so they can improve care outcomes for at-risk patients dealing with diabetic foot ulcers (DFUs) that often lead to amputations.

 

Podimetrics, founded in 2011, developed the SmartMat — the only easy-to-use, at-home mat that a patient steps on for 20 seconds per day. The mat detects temperature changes in the foot, which are associated with early signs of inflammation, often a precursor to DFUs. The FDA-cleared and HIPAA-compliant SmartMat is remotely monitored by Podimetrics’ in-house nurse support team. If the data from the mat are indicative of potential health issues, Podimetrics’ nursing team connects with the patient and the patients’ provider in as close to real time as possible. The SmartMat, which also has the Seal of Approval from the American Podiatric Medical Association, has already been used by thousands of patients through partnerships with leading risk-based healthcare providers and regional and national health plans, such as the Veterans Health Administration.

 

“The patients we serve at Podimetrics are extremely complex and have been largely ignored by our healthcare system,” said Jon Bloom, MD, CEO and Co-founder of Podimetrics. “With our SmartMat and this latest funding, we have the chance to put an end to ‘Civil War’–era amputations with early, home-based detection. We also have the opportunity to improve the overall health and well-being for patients dealing with diabetes because of the close relationship we’ve built through our trusted technology and clinical services.”

 

In a previous multi-center trial, diabetic foot complications were shown to be detected up to five weeks before they presented clinically. Even after one full year, about 70% of patients continued to use the SmartMat regularly. Early detection and related preventive care actions often result in significant cost-savings, too, anywhere from $8,000–$13,000 in savings per member per year (savings estimates based on customer research and analysis). In addition, considering Black Americans and Hispanics are two to three times more likely to require a diabetic amputation than others, Podimetrics’ SmartMat holds the power to help support health equity advancements over time.

 

Recent peer-reviewed research has also suggested the following benefits among patients using the SmartMat at home: 71% elimination of amputations; 52% reduction in all-cause hospitalizations; 40% reduction in emergency department visits; and a 26% reduction in outpatient visits.

 

Building on these notable data-driven findings, most recently Podimetrics published peer-reviewed research in Diabetes Research and Clinical Practice, the journal of the International Diabetes Federation. This research found that during episodes-of-care for DFUs, patients are 50% more likely to die and nearly three times more likely to be hospitalized. What this research shows is that patients with a DFU tend to have multiple other chronic health conditions, putting them at higher risk for hospitalization and even death. In addition, these medically complex patients are often among the costliest patients within a healthcare system. As a result of this research, diabetic foot complications can and should be viewed as indicators of other costly chronic conditions not commonly associated with DFUs.

 

In addition to this research, which was published in January 2022, Podimetrics has already gotten off to a strong start in 2022. The company doubled its revenue for the third year in a row, and also doubled the size of its team.

 

“We are proud to partner with Podimetrics and to support its efforts to save lives and limbs,” said James Rogers, Investment Partner with D1 Capital Partners. “Our growth capital will expand commercialization of the SmartMat which we believe has demonstrated the ability to reduce unnecessary healthcare costs through preventive, risk-based strategies that prioritize high-quality outcomes for vulnerable patients. We believe that Podimetrics is building a strong team and are honored to support its worthy mission.”

 

For more information on Podimetrics and how its FDA-cleared SmartMat and clinical care services can help prevent diabetic foot ulcers and improve patient outcomes, please visit Podimetrics.com.

 

About Podimetrics

Podimetrics is the creator of the FDA-cleared SmartMat™ and integrated clinical care services that can help save the limbs and lives of complex diabetic patients. Through partnerships with health plans and at-risk providers, such as the Veterans Health Administration and Independence Blue Cross, Podimetrics has helped prevent amputations associated with complex diabetes. By combining cutting-edge technology with best-in-class clinical care services, Podimetrics earns high engagement rates from patients and allows clinicians to save limbs, lives, and money — all while keeping vulnerable populations healthy in their own homes. For more information, visit podimetrics.com or follow us on LinkedIn and Twitter.

 

About D1 Capital Partners

D1 Capital Partners is a global investment firm that operates across public and private markets. The firm combines the talent and operational excellence of a large, premier asset management firm with the flexible mandate and long-term time horizon of a family office. Founded in 2018 by Dan Sundheim, D1 focuses on investing in the global internet, technology, telecom, media, consumer, healthcare, financial, industrial and real estate sectors.

Australian diabetes-related foot disease strategy 2018-2022

The first step towards ending avoidable amputations within a generation

 

Diabetic Foot Australia September 2017

 

Introduction
On any given day in Australia, the national burden of diabetes-related foot disease (DFD) is
significant:
• 300,000 people are at-risk of developing DFD
• 50,000 people are living with DFD
• 12,500 people are living with a diabetes-related amputation
• 1,000 people are in hospital because of DFD
• 12 people will undergo a diabetes-related amputation
• 4 people will die because of DFD
• $4 million will be spent managing DFD
To reduce this large national burden, the following three priorities should be addressed for people
with, or at-risk of, DFD:
A. Access to affordable and effective care
B. Provision of safe quality care
C. Research and development to improve patient outcomes

download pdf

An opportunity to learn more about lymphoedema and related conditions

An Opportunity to Learn More About Lymphoedema and Related Conditions

In an editorial for Wound Care Today, Christine Moffatt and Melanie Thomas (MBE) highlight lymphoedema as a chronic, progressive condition affecting patients both physically and psychologically. Despite being incurable, effective management is essential to prevent deterioration and preserve quality of life. :contentReference[oaicite:turn0search0]{index=0}

Key Highlights:

  • International Lymphoedema Framework (ILF): A charity advancing evidence-based care globally through 17 national frameworks, combining clinical, scientific, and technical expertise.
  • Ethical Independence: ILF’s charitable structure ensures resource use remains transparent and focused on patient benefit.
  • “Stronger Together” Conference: The 11th ILF conference (June 13–15, 2025, Nottingham) will unite global experts to share research, skills, and innovations in lymphoedema and related disorders.
  • Patient Engagement: Includes a dedicated patient day on June 15, providing education on cellulitis management, living well with lymphoedema, and expert Q&A sessions.
  • Holistic Goals: Conference aims to empower professionals to deliver efficient, evidence-based, and non-wasteful care, while raising lymphoedema’s profile within healthcare systems.

The editorial underscores the importance of collaborative global efforts to elevate lymphoedema care, supporting both clinicians and patients through shared learning and advocacy. :contentReference[oaicite:turn0search0]{index=0}

Read the full editorial on the Wound Care Today website.

Keywords:
lymphoedema,
International Lymphoedema Framework,
patient education,
professional conference,
non‑wasteful care

Columbia VA podiatrist recognized for diabetes-related amputation research

Columbia VA Podiatrist Recognized for Research on Emotional Impact of Diabetic Amputations

Dr. Brandon Brooks, a podiatrist at the Columbia VA Health Care System, received first place honors at the 10th Annual Conference of the American Society of Podiatric Surgeons for his innovative research on the psychological burden of diabetes-related amputations. His study introduces the concept of DREADD—Diabetes-Related Extremity Amputation Depression & Distress—to better understand the emotional trauma experienced by patients undergoing even minor amputations.

Key Highlights:

  • DREADD Framework: Dr. Brooks coined the acronym to emphasize that minor, non-traumatic amputations—such as toe removal—can lead to serious emotional consequences, including depression, anxiety, and treatment noncompliance.
  • Impact on Patient Behavior: The study found that approximately 90% of patients reported increased emotional distress after minor amputations, which contributed to poorer disease management, such as missed appointments and medication lapses.
  • Call for Integrated Care: Dr. Brooks advocates for integrating behavioral health into limb preservation teams and utilizing tools like the PHQ-9 to screen for depressive symptoms during podiatric care.

This research adds an important dimension to limb preservation, stressing that successful outcomes require attention not only to physical recovery but also to emotional well-being. Dr. Brooks collaborated on the study with his brother, Dr. Bradley Brooks, a board-certified psychiatrist, highlighting the value of interdisciplinary teamwork in advancing diabetic foot care.

Read the full article on the VA News website.

Keywords:
diabetes-related amputations,
psychological distress,
limb preservation,
Brandon Brooks,
Bradley Brooks

Quality of Clinical Practice Guidelines for Diabetic Foot Management



Quality of Clinical Practice Guidelines for Diabetic Foot Management: A Systematic Review

Summary: This systematic review evaluates the methodological quality of clinical practice guidelines (CPGs) for diabetic foot ulcer (DFU) management using the AGREE II instrument. Multiple international and national guidelines were assessed across six domains (scope/purpose, stakeholder involvement, rigor of development, clarity, applicability, editorial independence). Results show significant variability: some guidelines score high in rigor and clarity, while others lack transparency in evidence synthesis, stakeholder input, or implementation strategies. Common weaknesses include limited patient involvement, outdated evidence, and poor applicability in resource-limited settings. Recommends development of higher-quality, regularly updated, and harmonized global guidelines to standardize care, reduce amputation rates, and improve outcomes in diabetic foot disease.

Key Highlights:

  • AGREE II assessment reveals quality variability across DFU guidelines
  • Strengths: Good scope and clarity in many documents
  • Weaknesses: Inconsistent rigor, limited applicability, and patient input
  • Call for updated, evidence-based, globally harmonized guidelines

Read full review

Keywords: DFU guidelines, AGREE II, diabetic foot management, clinical practice guidelines

A Proactive Approach to Using Moldable Skin Barriers to Enhance Ostomy Care

A Proactive Approach to Using Moldable Skin Barriers to Enhance Ostomy Care

Summary: A case series published in *Journal of Wound, Ostomy, and Continence Nursing* describes how moldable skin barriers were used proactively in three ostomy patients. These barriers improved self-care, reduced peristomal skin complications, helped with skin health, and enhanced health-related quality of life. The article notes that there is limited existing literature on moldable skin barriers, and these cases help illustrate their potential benefits. (journals.lww.com)

Key Highlights:

  • Case 1: A patient struggling with anxiety about ostomy self-care benefited from a moldable skin barrier that was easier to apply than standard barriers.
  • Case 2: In a patient with skin maceration, a moldable barrier with better adhesion plus a protective crusting technique helped improve skin condition.
  • Case 3: For a young girl with frequent leakage affecting social/educational life, a moldable barrier with a secure fit reduced leakage and its impact.
  • Quality of life effects: Patients reported improved comfort, less irritation, better skin integrity, and greater confidence in managing their ostomy.
  • Evidence gap: The authors encourage further research, as moldable skin barriers are underrepresented in current literature despite promising results.

Read the full article in JWOCN

Keywords:
moldable skin barrier,
peristomal skin complications,
ostomy care,
skin health,
quality of life

A Breakthrough in Wound Management: LifeNet Health Unveils Dermacell® Porous

Dermacell® Porous: A Next-Generation Wound Matrix Now Widely Accessible

Summary: LifeNet Health has introduced Dermacell® Porous—an advanced human acellular dermal matrix (ADM) engineered with endogenous growth factors, collagen, and elastin—to accelerate wound closure. This new product is among the 26 skin substitute CTPs set to be covered under Medicare’s upcoming Local Coverage Determinations starting January 2026, enhancing access for clinicians and patients nationwide.

Key Benefits:

  • Designed to close chronic wounds in four or fewer applications, with a thin, durable, and naturally porous structure for optimized performance.
  • Processed using proprietary Matracell® technology, preserving native extracellular matrix components—including collagens, growth factors, matrikines, and cytokines—for enhanced vascularization and cell infiltration.
  • Sterile and shelf-stable at room temperature, ready to use straight from the package—streamlining logistics for wound care settings.
  • Early clinical feedback emphasizes faster incorporation, better integration, and more predictable healing compared to traditional scaffolds.

Clinical Impact: Medicare’s forthcoming LCD coverage—combined with Dermacell® Porous’s enhanced bioactivity and ease of use—positions clinicians to deliver more accessible and effective healing for chronic wounds, particularly in underserved settings.

Read the full article on WoundSource

Keywords:
Dermacell Porous,
LifeNet Health,
acellular dermal matrix,
CTP coverage,
chronic wound healing,
Matracell technology

The healing of bilateral chronic VLUs using medical grade honey in an end of life patient with polymorbidity

Palliative care provides holistic, person-centred care by managing symptoms, preventing suffering by treating pain and other problems, and providing physical, psychosocial and spiritual support (Chaplin, 2004; Grocott and Gray, 2010; Dale and Emmons, 2014). Palliative wound care should focus upon relieving wound-related suffering and improving the quality of life of patients and their families when facing life-threatening illness (Grocott and Gray, 2010; Dale and Emmons, 2014). Patients requiring palliative wound care can present with any type of wound, particularly those common in older people, such as venous leg ulcers (VLUs), pressure ulcers, diabetic foot ulcers and malignant wounds … read more

Medical Device-related Pressure Injuries Associated With Electroencephalogram Leads in a Tertiary Care Children’s Hospital

Medical device-related pressure injuries (MDRPIs) present a substantial safety risk for children who are hospitalized. PURPOSE: This study aimed to describe patient and clinical characteristics of children who develop MDRPIs related to electroencephalogram (EEG) leads, determine risk factors associated with their development, and determine if there are common risk factors that can lead to actionable strategies to reduce MDRPIs related to EEG leads. METHODS: A retrospective review was completed of the electronic health records of all 3136 children who had EEG lead placements between January 1, 2014, and April 16, 2018, at a large tertiary care children’s hospital. Data abstracted included demographic variables, patient and pressure injury characteristics, as well as length of stay. RESULTS: Twenty-four (24) of the 3136 children (0.8%) developed an MDRPI. Most were stage 2 pressure injuries. Patients who developed a pressure injury were significantly younger than patients who did not (median age, 0.9 and 5.2 years … read more

Length of stay and readmissions for people with diabetes-related foot ulceration

admitted to two public tertiary referral hospitals in Australia

 

Sarah M Manewell, Sarah J Aitken, Vanessa L Nube, Anna M Crawford, Maria I Constantino, Stephen M Twigg, Hylton B Menz, Cathie Sherrington and Serene S Paul

 

Aims/hypothesis To identify hospital admissions and length of stay (LOS) and to investigate readmissions, cumulative LOS and associated factors for diabetes-related foot ulceration (DFU).

Methods Routinely-collected hospital admission data were used to identify DFU-related hospital admissions in two public hospitals between 2012–17. Readmission and cumulative LOS were investigated using negative binomial regression.

Results DFU-related admission was required by 749 patients. Median LOS was 8–10 days (stable across 2012–17). Readmission within 28 days was required by 62 patients (8%) and was significantly more likely with increasing comorbidities (incidence rate ratio [IRR] 1.38, 95% confidence intervals [95% CI] 1.02–1.88). Readmission within 1 year was required by 206 patients (28%), and was significantly more likely for males, unplanned admissions and increasing revascularisation requirements (IRR 1.34–1.70), and significantly less likely for those requiring minor and major amputation (IRR 0.33–0.64). The median cumulative LOS was 13 days (IQR 7–29), and was significantly longer for males, older age, unplanned admissions, those requiring dialysis, and those with increasing revascularisation requirements, comorbidities and mental health or behavioural disorders (IRR 1.02–2.30), and significantly shorter for those with more podiatry attendance (IRR 0.96, 95% CI 0.95–0.97) … read more

The impact of PANoptosis-related genes on immune profiles and subtype classification in ischemic stroke

The impact of PANoptosis-related genes on immune profiles and subtype classification in ischemic stroke

Summary: This open-access computational study profiles PANoptosis-related genes (integrating pyroptosis, apoptosis, and necroptosis) in ischemic stroke blood datasets to define diagnostic gene signatures and immune-infiltration subtypes. While not a wound-care trial, the work offers mechanistic insights into inflammatory cell-death pathways that may inform future translational research across ischemia-driven tissue injury and chronic wound inflammation.

Key Highlights:

  • Analyzed GEO datasets (e.g., GSE58294) to identify differentially expressed PANoptosis-related genes and build diagnostic models (ROC performance reported).
  • Constructed interaction networks (genes–miRNAs–TFs–drugs) and a nomogram to visualize diagnostic potential.
  • Single-cell re-analysis (GSE174574) mapped candidate genes to immune-cell subpopulations relevant to post-ischemic inflammation.
  • Unsupervised clustering defined two immune subtypes with distinct infiltration patterns and functional pathways.
  • Authors suggest these signatures could guide early diagnosis and targeted therapies in ischemic stroke; pathways overlap with inflammation and cell-death mechanisms studied in chronic wounds.

Read full article

Keywords: PANoptosis, pyroptosis, apoptosis, necroptosis, ischemic stroke, bioinformatics, immune infiltration, biomarkers, Xinrui Cai, Yu Ren, Qin Yang

Diabetes-related Retinopathy, Foot Ulcers, and Other Lesions



Diabetes-related Retinopathy, Foot Ulcers, and Other Lesions: A Photo Essay

Summary: This educational photo essay presents clinical images of diabetes-related complications, with a strong focus on foot ulcers alongside retinopathy and other lesions. Cases demonstrate neuropathic ulcers linked to structural deformities (hammer toes, Charcot neuroarthropathy), callus formation, and the need for debridement of necrotic, calloused, and fibrous tissue. It covers application of topical enzymes, special dressings, and offloading strategies. Visuals highlight progression risks and the importance of prompt multidisciplinary care involving podiatry, vascular assessment, and glycemic control to prevent amputation. Serves as a practical teaching resource for recognizing and managing diabetic foot disease in clinical settings.

Key Highlights:

  • Visual cases of diabetic foot ulcers, Charcot foot, and related lesions
  • Emphasis on debridement, dressings, and offloading techniques
  • Links retinopathy and systemic complications to foot disease
  • Relevance: Strong educational tool for diabetic wound recognition and management

View photo essay

Keywords: diabetic foot ulcers, photo essay, Charcot foot, debridement

Big Pharma and Big Food’s Grip on the American Heart Association

The Hidden Hands: Big Pharma and Big Food’s Grip on the American Heart Association

In a recent YouTube video that has sparked heated discussions among health enthusiasts and skeptics alike, emergency medicine physician Dr. Suneel Dhand pulls no punches. Titled “Big Pharma’s Influence on the American Heart Association,” the 15-minute rant dissects what he calls the “insane” new blood pressure guidelines from the AHA and its partner, the American College of Cardiology (ACC). Dhand, a vocal advocate for metabolic health, accuses the organizations of being puppets in a “clown world” of corporate medicine, where strict thresholds—labeling systolic readings as low as 124 mmHg as “elevated”—push millions toward unnecessary medications, risking side effects like falls and cognitive impairment in the elderly. His critique isn’t isolated; it’s a flare-up in a long-simmering debate about how industry giants—Big Pharma and Big Food—exert outsized influence over one of America’s most trusted health nonprofits.

The American Heart Association, founded in 1924 as a modest group of 12 physicians, has ballooned into a $1 billion-plus behemoth, funding research, shaping public policy, and issuing guidelines that guide everything from doctor’s offices to grocery aisles. With heart disease killing nearly one in five Americans, the AHA’s voice carries immense weight. Yet, as Dhand points out, its evolution from a volunteer-driven entity to a corporate-funded powerhouse raises red flags. Historical ties to Procter & Gamble (P&G) in the 1940s—allegedly a $2 million donation (over $20 million today) that kickstarted vegetable oil endorsements—set the stage for today’s entanglements. Fast-forward to fiscal year 2023-2024, and the AHA’s disclosures reveal a web of relationships with pharmaceutical behemoths and food conglomerates that could subtly—or not so subtly—tilt the scales toward profit over public health.

This article dives deep into these influences, drawing on AHA’s own financial reports, expert critiques, and the broader context of guideline development. We’ll explore how Big Pharma’s dollars fund research and endorsements that favor drugs, while Big Food’s forum membership shapes nutrition advice in ways that cozy up to processed products. The result? Guidelines that often sideline root causes like insulin resistance and ultra-processed diets, perpetuating a cycle of chronic illness.

A Brief History: From Grassroots to Corporate Ally

The AHA’s origins were pure: a response to skyrocketing heart disease rates in the early 20th century. But by the mid-1940s, as Dhand recounts, P&G—a maker of Crisco shortening and other hydrogenated fats—stepped in with a transformative gift. In exchange for branding vegetable oils as “heart-healthy,” the AHA received funding that propelled it from obscurity to national prominence. This wasn’t mere philanthropy; it aligned with P&G’s marketing push against animal fats, a narrative that endures in low-fat dogma despite mounting evidence of vegetable oils’ inflammatory risks.

Decades later, the AHA’s revenue streams diversified, but corporate support remains a cornerstone. In FY 2023-2024, total revenue topped $1.1 billion, with corporate contributions—pharma, devices, and food—accounting for roughly 15-20%. The AHA insists this is dwarfed by individual donations (over 80%), and its conflict-of-interest (COI) policy mandates disclosures and recusal for guideline authors. Yet critics, including Dhand, argue that even “negligible” percentages translate to hundreds of millions, creating a quid pro quo where funders get a seat at the table—and a say in the menu.

Big Pharma’s Billions: Funding Research, Shaping Guidelines

Pharmaceutical companies aren’t shy about their AHA ties. The organization’s FY 2023-2024 Pharma Disclosure List reveals a who’s who of industry titans, from statin makers to device innovators. Here’s a snapshot of the 42 listed entities:

  • Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Sanofi: These pharma heavyweights dominate cardiovascular drug markets, funding AHA initiatives from $100,000 to multimillion-dollar grants for research, education, and events.
  • Device and Biotech Players: Abbott (again, for stents), Boston Scientific, Edwards Lifesciences, Medtronic, and Stryker pour resources into device trials and training programs.
  • Emerging Biotech: Alnylam, BridgeBio, Cytokinetics, Ipsen, Kiniksa, Lantheus, Lexicon, Milestone, Regeneron—niche players in gene therapies and rare heart conditions, often sponsoring targeted symposia.

Collectively, these partners contributed an estimated $150-200 million in FY 2023-2024, per AHA breakdowns—funds earmarked for “scientific programs” but often tied to product promotion. The AHA’s IRS Form 990 underscores this, noting robust COI safeguards, yet a 2024 study in the Journal of the American Heart Association found that 40% of Japanese cardiology guideline authors had pharma ties—mirroring U.S. patterns.

Guideline Goldmines: Statins, BP, and Beyond

Pharma’s fingerprints are most evident in treatment recommendations. Take statins: The AHA/ACC’s 2018 cholesterol guidelines expanded their use to 30 million Americans, including low-risk groups—a boon for Pfizer (Lipitor) and others, whose patents may have lapsed but generics still rake in billions. Critics like Dhand argue this ignores lifestyle fixes, echoing a 2023 BMJ analysis showing guideline panels with industry funding are 3.5 times more likely to recommend sponsor drugs.

Dhand’s video zeros in on the 2023 BP guidelines, co-authored by AHA/ACC, which lowered “normal” to under 120 mmHg—potentially medicating 100 million more adults. Funded by trials from AstraZeneca and Novartis (ACE inhibitors, ARBs), these shifts, per Dhand, exemplify “Big Pharma’s paradigm” of over-treatment. “Why reclassify normal as elevated?” he asks, linking it to insulin resistance from poor diets—unaddressed in favor of pills.

Device influence is subtler but real. Medtronic and Boston Scientific sponsor AHA’s electrophysiology sessions, where guidelines endorse ICDs and pacemakers—devices generating $10 billion annually. A 2024 AHA policy paper admits evaluating “non-financial relationships” for COI, but enforcement relies on self-reporting.

The Ripple Effect: Research and Public Messaging

AHA-funded studies often align with funders. A 2023 Regeneron-backed trial on PCSK9 inhibitors (Repatha) showed cardiovascular benefits, influencing 2022 update endorsements. Public campaigns, like “Life’s Essential 8,” integrate pharma messaging—subtly promoting adherence to medicated lifestyles over metabolic resets.

Dhand’s frustration peaks here: “Consensus means financed by Big Pharma.” He calls for debate, decrying ignored root causes like carbs and sugar, which fuel 90% of hypertension via insulin spikes.

Big Food’s Forum: Certifying Convenience Over Caution

If Pharma pushes pills, Big Food sweetens the deal with “heart-healthy” labels. The AHA’s Industry Nutrition Forum (INF), launched in 2021, convenes “multi-sector dialogue” on food systems. Its nine members read like a processed-food hall of fame:

  • Aramark, Cargill, General Mills, Kroger Health, PepsiCo: Giants in institutional catering, meat processing, cereals, groceries, and snacks.
  • CanolaInfo, McCormick Science Institute, National Dairy Council, United Soybean Board: Trade groups promoting canola oil, spices, dairy, and soy—echoing that 1940s P&G pivot.

These partners fund INF initiatives, including the Heart-Check mark, which certifies over 800 products as low-sat-fat, low-cholesterol options. Cheerios? Check. Low-fat yogurt? Check. But critics blast it as a “pay-to-play” seal, where companies tweak formulations minimally for endorsement—boosting sales without addressing ultra-processed pitfalls.

Nutrition Guidelines: Low-Fat Legacy Meets Processed Pals

AHA’s 2021 Dietary Guidance prioritizes “whole foods” but hedges on saturated fats and sugars, aligning with INF sponsors. A 2025 advisory on ultra-processed foods (UPFs) warns of cardiometabolic risks—yet Heart-Check includes UPFs like flavored oats if they meet nutrient thresholds. PepsiCo’s INF role? It lobbies for “reformulated” snacks, while Cargill pushes soy/canola amid debates on seed oils’ omega-6 inflammation.

Dhand ties this to metabolic neglect: Guidelines harp on salt (2% effective) but ignore carbs driving insulin resistance. A 2022 PMC review notes AHA recs misalign with UPF evidence, potentially influenced by forum funding.

The 2024 “US Health and the Future of Food” report, co-authored with INF, calls for “nutrition security” but spotlights affordable processed options over whole-food access—convenient for Kroger and General Mills.

The Toxic Tango: Pharma Meets Food in Heart Health

Pharma and Food aren’t silos; they converge in AHA’s ecosystem. Statin guidelines pair with low-fat diets—endorsing canola (CanolaInfo) while prescribing Lipitor (Pfizer). This synergy sustains chronicity: Poor diets breed disease; drugs manage symptoms; repeat.

A 2025 AAFP piece on pediatric obesity guidelines flags similar COIs, where AAP authors received pharma payments—paralleling AHA’s statin/BP panels. Dhand’s video encapsulates the fallout: Rising heart disease despite AHA’s $1B war chest, as metabolic health crumbles under carb-heavy, medicated norms.

Public health toll? $400B+ annually in U.S. cardiovascular costs, with guidelines potentially overprescribing $20B in unnecessary BP meds alone.

Calls for Accountability: Transparency or Overhaul?

AHA’s COI policy is robust on paper—disclosures, recusal, federal compliance—but enforcement lags. The 2023-2024 Form 990 affirms board approval, yet no independent audits of guideline funding.

Dhand demands debate: “Communicate with me… I could beat you with logic.” Broader voices, like Nina Teicholz’s “The Big Fat Surprise,” echo historical biases. Solutions? Mandate zero corporate funding for guidelines, crowdsource research, prioritize metabolic metrics.

A Heart for the People: Reclaiming Independence

The AHA does good—$3B in research since 1949, CPR training for millions. But as Dhand warns, “Your time is up” for the Pharma-Food paradigm. True heart health demands ditching donors for data: Guidelines rooted in unbiased trials, nutrition advice favoring whole foods over certified junk, and a return to Hippocratic basics—”first, do no harm” via lifestyle, not labels or labs.

Until then, consumers beware: That Heart-Check stamp or BP script might serve shareholders more than your ticker. As Dhand urges, wake up, cut the carbs, and question the consensus. Your heart—and wallet—will thank you.

The impact of patient health and lifestyle factors on wound healing, part 1

Stress, sleep, Smoking, alcohol, common Medications and Illicit drug use

 

Georgina Gethin, Sebastian Probst, Evelien Touriany, Georgina Gethin, Jaap J van Netten, Luboš Sobotka

 

Health and a healthy lifestyle are the aspirations of many, but achieving such goals is influenced by a complex interplay of individual choices, intrinsic factors, external influences and context. In 1948, the World Health Organization (WHO) defined health as a ‘state of complete physical, mental and social well-being and not merely the absence of disease or infirmity’, and this definition has not changed since.1 The definition is equally applicable to people with chronic wounds as it is to the general population. The health of those with chronic wounds or at risk of a wound is important to understand so that interventions for prevention and management can be developed with the goal of improving the lives of those impacted by wounds … read more

Medical device-related pressure ulcers and the COVID-19 pandemic: from aetiology to prevention

This article describes the aetiology of medical device-related pressure ulcers (MDRPU) and the vicious cycle that leads to these (typically, hospital-acquired) injuries. In this cycle, the primary, deformation-inflicted cell damage leads to a secondary inflammatory oedema-related damage and then to tertiary ischaemic cell and tissue damage. These three damage factors act cumulatively, and, once the first deformation-inflicted massive cell death initiates in the distorted tissues, each of these factors escalates the cell death and tissue damage further, under and near the applied medical device. The primary pathophysiological factors of the COVID-19 pandemic — including the cytokine storm, hypoxia and hyper-coagulation, which are typical to seriously ill patients who require life-support (skin-contacting) medical devices — can fuel the damage spiral of pressure injury. A continuous positive airway pressure (CPAP) mask is a classic example of a commonly used medical device … read more

Factors Associated With Healing of Diabetes-Related Foot Ulcers: Observations From a Large Prospective Real-World Cohort

Diabetes-related foot ulcers (DFUs) affect around 20 million people annually and are a leading cause of the global disability burden (1). DFUs are complex to treat, take months to heal, result in poorer quality of life, and place patients at high risk of hospitalization and amputation. Thus, understanding the influence that different factors have on healing of DFUs is vital … read more

Management of Diabetes-Related Foot Ulceration at Two Interdisciplinary Services



Management of Diabetes-Related Foot Ulceration at Two Interdisciplinary Services: A Qualitative Exploration of Patient and Carer Experiences

Summary: This qualitative study explores 20 DFU patients’ and carers’ experiences in two Australian interdisciplinary services, identifying three themes: confidence in care (rapport, trust), comprehensiveness (education, access), and life-changing impact (emotional/physical toll). Patients praised plain-language explanations and team reassurance but noted pain mismanagement and logistical barriers like parking. Findings advocate holistic, patient-centered models to enhance engagement and outcomes.

Key Highlights:

  • Confidence: Positive staff rapport and explanations built trust; unmanaged pain caused stress.
  • Comprehensiveness: Education on offloading/pressure points valued; challenges in appointments/transport.
  • Life-Changing: Fear, frustration, mobility loss; care inseparable from living with DFU.
  • Method: Semi-structured interviews; thematic analysis per Braun & Clarke.
  • Implications: Integrate psych support; improve access for better adherence.

Read full study

Keywords: DFU experiences, interdisciplinary, patient perspectives, carer experiences, qualitative, Sarah M Manewell, Georgina Frank, Vanessa Nube

Observational Study of Venous Leg Ulcer Treated With a Native Collagen-Alginate Dressing …

Collagen-Alginate Dressing Enhances Healing and Quality of Life in Venous Leg Ulcer Patients

An observational study published in Wound Management & Prevention evaluated the efficacy and safety of a native bovine collagen-alginate dressing (Cutimed® Epiona®) in treating non-healing venous leg ulcers (VLUs). Conducted at the Northwell Health System Comprehensive Wound Care Healing Center and Hyperbarics in New York, the study involved 60 patients over a four-week period. The research aimed to assess wound area reduction, pain management, and improvements in wound-related quality of life (QoL).:contentReference[oaicite:7]{index=7}

Key Highlights:

  • Significant Wound Area Reduction: The mean wound area decreased from 17.8 ± 11.2 cm² to 11.4 ± 9.0 cm², with four patients achieving complete wound closure within the study period. :contentReference[oaicite:10]{index=10}
  • Improved Pain Management: Patients reported decreased wound pain after two weeks of treatment, accompanied by a reduction in analgesic intake. :contentReference[oaicite:13]{index=13}
  • Enhanced Quality of Life: Assessments using the Wound-QoL-17 questionnaire indicated significant improvements in patients’ wound-related QoL, correlating with the observed wound area reduction. :contentReference[oaicite:16]{index=16}

The study concluded that the collagen-alginate dressing is a safe and effective adjunct to standard wound care practices, promoting healing and improving patient outcomes in cases of hard-to-heal VLUs. Healthcare professionals rated the dressing’s performance as “very good” or “good,” and patients reported high levels of comfort during use. :contentReference[oaicite:21]{index=21}

Read the full article on the Wound Management & Prevention website.

Keywords:
venous leg ulcer,
collagen-alginate dressing,
wound healing,
Alisha Oropallo,
Amit S. Rao,
Sally Kaplan,
Farisha Baksh,
Christina Del Pin

Enhancing patient outcomes through effective implementation of pressure ulcer guidelines


Enhancing patient outcomes through effective guideline implementation

Summary: This article examines the impact of implementing clinical guidelines for pressure ulcer prevention and management. It analyzes changes in incidence rates, patient quality of life, and associated healthcare costs after adopting guideline-based practices in inpatient settings.

Key Highlights:

  • Guideline implementation correlated with decreased pressure ulcer incidence.
  • Quality of life metrics improved post-implementation.
  • Healthcare costs were reduced by lowering resource use and ulcer complications.
  • Supports wider adoption of standardized protocols in wound care practice.

Read full article

Keywords:
guideline implementation,
pressure ulcer,
quality of life,
healthcare costs,
wound prevention

Reducing the pain of hidradenitis suppurativa wounds

Reducing the Pain of Hidradenitis Suppurativa Wounds

A recent commentary in JWC Wound Central explores the significant burden of pain experienced by individuals living with hidradenitis suppurativa (HS), emphasizing the impact of wound dressings and dressing changes on quality of life. HS is a chronic inflammatory skin condition that produces deep nodules, abscesses, and draining tracts, typically in intertriginous regions. Pain is consistently cited as the most distressing and debilitating symptom by patients.

Key Findings:

  • Pain Impact: International surveys have shown that over 80% of HS patients experience pain during dressing changes, which can be severe enough to cause depression, social isolation, and impaired intimacy.
  • Dressing Challenges: Traditional gauze dressings are often painful to remove and can damage fragile wound or periwound tissue. Patients report discomfort, embarrassment, and inconvenience due to bulky or insecure dressings.
  • Advanced Dressings: Moisture-retaining, atraumatic dressings are shown to improve healing rates, reduce pain, and lower inflammation. Superabsorbent and adhesive-free systems, such as those used in HS-specific products, demonstrate significant improvements in patient-reported pain and quality of life.
  • Clinical Guidelines: Experts recommend avoiding gauze, using adhesive-free options when possible, and prioritizing dressings that enable atraumatic removal. British and international dermatology groups stress the importance of garment-secured systems and careful handling during changes.
  • Innovation in HS Dressings: A clinical trial of a HS-specific dressing system (Hidrawear) showed reduced pain, discontinued need for analgesics before dressing changes, and better overall quality of life over a 21-day period.

Conclusion: Reducing pain in HS wound management requires clinician awareness, patient-centered dressing selection, and adoption of atraumatic dressing protocols. Moisture-balanced, secure, and easy-to-change systems offer promise for improving both physical outcomes and psychological wellbeing in this underserved population.

Keywords: hidradenitis suppurativa, wound pain, moist wound healing, atraumatic dressings, Hidrawear, quality of life, SecureLock Technology

Read the full article on JWC Wound Central

Association of Wound Healing With Quality and Continuity of Care and Sociodemographic Characteristics

Based on the analysis of electronic health records from 480 clinics, we found that better care quality and continuity are associated with better-than-expected wound healing performance

Objectives: To evaluate the association between clinics’ wound healing performance and clinic-level measures of care continuity, clinical quality, and sociodemographic characteristics of the population in their catchment areas.

Study Design: In this cross-sectional analysis, we analyzed electronic health records for 180,336 chronic wounds from 480 wound care clinics during the 2018 calendar year.

Methods: We measured healing performance using a clinic’s observed to expected (O/E) ratio, which is based on the rate at which chronic wounds were predicted to heal within 12 weeks given its case mix and the actual healing rate. We compared the top and bottom quintiles, in terms of the O/E ratio, of clinics. Multivariable regression was used to estimate the effect of the clinic-level measures on the O/E ratio.
read more

EB Affects All Aspects of Daily Life, Patients Say in Interview Study

Ways to improve the quality of life for people with epidermolysis bullosa (EB) are needed, as those living with the disorder report a range of psychological and social impacts … In a series of interviews, a group of children and young adults with EB described their disease as significantly affecting daily life and interactions at school, within the family, and in society at large … Findings are detailed in the study “Psychosocial impact of epidermolysis bullosa on patients: A qualitative study,” published in the journal Pediatric Dermatology … read more

The impact of patient health and lifestyle factors on wound healing, part 2

Part two of the EWMA document ‘The impact of patient health and lifestyle factors on wound healing’ focuses on two factors: physical activity and nutrition. In this paper, the pathophysiological understanding of how physical activity and nutrition either increase the risk for wounding or impact the healing process will be presented. We review current evidence for the effectiveness of interventions in improving healing outcomes and offer some recommendations for practice and further research. This part of the document should be read in conjunction with Part 11, which discussed stress, sleep, smoking, illicit drug use and alcohol misuse and described how some commonly used medications impact the healing process … read more

Thermal Imaging Improves Diabetes-Related Foot Ulcer Assessment



Thermal Imaging Improves Diabetes-Related Foot Ulcer Assessment

Summary: First study using thermal imaging on 26 neuropathic DFUs (11 healing, 15 non-healing) quantified wound size/temperature via isothermal segmentation, predicting 50% area reduction at week 4 from weeks 1–2 data. Lower week-2 wound bed isothermal area correlated with healing; method superior to acetate/ruler tracing (affected by shadows/depth). Enables early chronic wound ID, reducing Australia’s $875M annual DFU costs through timely interventions.

Key Highlights:

  • Patients: 26 type 1/2 diabetes with neuropathic ulcers.
  • Prediction: Week 1–2 thermal maps forecast week-4 healing (50% area ↓).
  • Accuracy: Higher than manual; real-time, inexpensive, clinical-friendly.
  • Applications: Early non-healer detection for targeted care.
  • Cost Impact: Potential savings in DFU management ($875M/year Australia).
  • Authors: Behzad Aliahmad, Elif Ekinci et al.

Read full article

Keywords: thermal imaging, DFU assessment, healing prediction, isothermal, neuropathic ulcers, early intervention

Rates of T1D-Related Amputations Decline in Sweden

Results of a Swedish retrospective cohort study showed reduced rates of type 1 diabetes-related amputations over the past 2 decades.

In recent years, Sweden has seen a sharp decline in incidence of lower-level extremity amputations among individuals with type 1 diabetes (T1D), according to results of an observational cohort study. Findings were published in Diabetologia.

Because diabetes-related foot ulcers are common and healing is often delayed, limb loss through amputation “is not an infrequent final outcome,” the authors explained.

In addition, “about half of all nontraumatic amputations in the western world are attributable to diabetes … read more

Study Shows Increased Risk For Foot Infection-Related Hospitalizations In People With Diabetes

According to a recent publication in Diabetologia, there is an increased risk of infection-related hospitalization in patients with diabetes.1 This includes foot infections, for which the risk of hospitalization was nearly six times greater in patients with diabetes than those without. Remarkably, the risk for hospitalization in patients with diabetes for all infection types, including foot infection, respiratory infection, urinary tract infection, GI infection, sepsis, and post-operative infection was 67 percent higher than the non-diabetic group. In addition, the study authors noted a stronger association between diabetes and hospitalization related to infection in younger participants and Black patients … read more

Extremity Gangrene Caused by HBV-Related Cryoglobulinemia Vasculitis in a Patient with Diabetes – A Case Report

We presented a case of hepatitis B virus (HBV)-related type III cryoglobulinemia vasculitis (CryoVas) characterized by extremity gangrene in a patient with diabetes. The 60-year-old female had a 10-year history of poorly controlled type 2 diabetes mellitus. She complained of sudden onset pain and swelling of toes which quickly progressed to gangrene, with fingers becoming pain and dark violet. The patient was initially misdiagnosed as diabetic foot (DF). Although DF is one of the common chronic complications of diabetes, it rarely involves the hand. What is more, the ischemic manifestations of the extremity were not consistent with the results of the vascular examination and immune system changes. The patient had Raynaud’s phenomenon, arthralgia, and extremity gangrene. Test results showed cryoglobulinemia multiple positive, polyclonal immunoglobulin with rheumatoid factor negative, lower complement 3, leukocytoclastic vasculitis, and HBV infection. HBV-related type III CryoVas was finally diagnosed, and a conservative therapy strategy was given … continue

Diabetes-Related Amputations Kept at Bay During Pandemic in Canada

Shift to virtual care and prioritization of certain procedures key, researchers say
Despite delays in screening and care during the COVID-19 pandemic, there wasn’t a spike in diabetes-related foot amputations, a Canadian study found … In an analysis of nearly 1.5 million adults with diabetes living in Ontario, rates for nearly all diabetes-related services took quite a nosedive in 2020, noted Charles de Mestral, MDCM, PhD, of St. Michael’s Hospital in Toronto, and colleagues … For starters, comprehensive in-person diabetes care assessment immediately dropped down from March to May, averaging only 28% of the 2019 level, they reported in JAMA Network Open … read more

CALL FOR WOUND, OSTOMY, AND CONTINENCE-RELATED PHOTOS

It is a goal of the Wound, Ostomy, and Continence Nurses SocietyTM (WOCN®) to continuously improve the educational content of the Wound Treatment Associate (WTA®) and Ostomy Care Associate (OCA®) Programs as well as the resources available to all WOCN members. Additionally, it is a goal of WOCN to work at continuous improvement in the areas of diversity, equity, and inclusion. As such, we’d like to extend an invitation to our WOC nurse colleagues to submit photographs of wounds and ostomies, specifically representing individuals of diverse skin tone. We would also invite you to submit photos related to continence-related issues, also in diverse skin tones. A wide variety of photograph examples serve to improve the education of our members and other healthcare providers by ensuring competency in wound, ostomy, and continence (WOC) assessment for all individuals. In this way, the care of all individuals with wound, ostomy, and continence care needs can be improved … read more

Medicaid Expansion Under ACA May Have Reduced Rate of Major Diabetes-Related Amputations

by Patrick Campbell

An analysis of data from 2013-2015 provides insight into the impact of Medicaid expansion under the Affordable Care Act on rate of major diabetes-related amputations and suggests a shift in the distribution of uninsured patients may have driven reductions observed in the study.

Data from a new study are providing clinicians with insight into the effects of the Medicaid Expansion Under the Patient Protection and Affordable Care Act (ACA) on rates of diabetes-related major amputations among racial and ethnic minority adults with diabetes … read more


If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

How to Treat and Prevent Medical Device–Related Pressure Injuries

By Margaret Heale, RN, MSc, CWOCN

 

How to Help Patients Protect the Skin They’re In
Medical device–related pressure injuries (MDRPIs) are recognized as a significant problem, evidenced by the inclusion in the National Pressure Injury Advisory Panel pressure injury definitions and described by Pitman and Gillespie in 2020.1 Prevention of medical device-related pressure injuries is a goal that may be achieved through meticulous patient care … read more

Medical Device-Related Pressure Injury: What Wound Care Teams Need to Know



Medical Device-Related Pressure Injury: What Wound Care Teams Need to Know

Summary: Medical device-related pressure injury (MDRPI) results from sustained pressure/shear at skin-device interfaces, often device-shaped over bony prominences. Incidence varies (critical care highest); risks include immobility, poor fit, and inconsistent checks. Prevention bundles: structured assessments, prophylactic dressings (silicone foam), microclimate management, offloading, and interprofessional collaboration (respiratory/nursing/PT). Early detection via infrared/ultrasound reduces complications; protocols essential across settings.

Key Highlights:

  • Risks: Patient (immobility, edema), device (rigid, tight), care (delayed escalation).
  • Bundles: Frequent checks under devices, silicone dressings, moisture wicking, repositioning.
  • Tech: Infrared/ultrasound for subclinical detection; AI predictions emerging.
  • Roles: Respiratory for fit, nursing for monitoring, PT for positioning.
  • Outcomes: Bundles cut incidence 30-50%; education with photos/audits key.

Read full guide

Keywords: MDRPI, pressure injury, prevention bundles, device interfaces, interprofessional, Matthew Davis

Medical Device-Related Pressure Injury: What Wound Care Teams Need to Know



Medical Device-Related Pressure Injury: What Wound Care Teams Need to Know

Summary: Comprehensive guide to medical device-related pressure injuries (MDRPI): device-shaped ulcers from sustained pressure/shear (masks, tubes, collars). Risks: patient (immobility/edema), device (rigid/tight), care (delayed checks). Prevention bundles: structured assessments, prophylactic silicone foams, microclimate control, repositioning, interprofessional input (RT/nursing/PT). Emerging: infrared/ultrasound for subclinical detection. Incidence highest ICU; bundles ↓ 30-50%.

Key Highlights:

  • Risks: Patient/device/care factors; ICU highest.
  • Bundles: Inspections under devices, foams, offloading.
  • Roles: RT fit, nursing monitor, PT position.
  • Tech: Infrared/ultrasound early detection.
  • Outcomes: Bundles ↓ incidence 30-50%; education key.

Read full guide

Keywords: MDRPI, pressure injury, prevention bundles, device interfaces, interprofessional

Medical Device–Related Pressure Injury: What Wound Care Teams Need to Know



Medical Device–Related Pressure Injury: What Wound Care Teams Need to Know

Summary: November 3, 2025 blog by Kirra Fedyszyn defines medical device-related pressure injury (MDRPI) as tissue damage from sustained pressure/shear by devices (e.g., tubing, masks, leads) mirroring device shape. Underrecognized due to device essentiality and inconsistent skin checks; higher in critical care. Multifactorial causes: patient (immobility, poor perfusion), device (rigid/poor fit), care (infrequent inspection). Prevention: device-specific assessment, frequent checks, prophylactic silicone foam dressings, strap adjustments, moisture control, repositioning, early removal. Stresses interprofessional roles, education, audits, and bundles for reduction. Documentation: note device, location, changes, actions.

Key Highlights:

  • Prevention: Fit optimization, microclimate management, “device holidays” if safe.
  • Recommendations: Standardized protocols, training with visuals/cases.
  • Relevance: Critical for immobile/chronic patients; complements offloading in pressure injury programs.

Read blog

Keywords: MDRPI, medical device pressure injury, prevention strategies, prophylactic dressings

Implementation Strategies for the Prevention and Management of Diabetes-Related Foot Disease


Implementation Strategies for the Prevention and Management of Diabetes-Related Foot Disease: A Consensus Document

Summary: This international consensus document translates evidence-based guidelines into actionable implementation strategies for diabetes-related foot disease. It covers systematic screening, risk stratification, patient education, therapeutic offloading, timely vascular intervention, infection management, and integrated multidisciplinary pathways. The document aims to bridge the gap between guidelines and real-world clinical practice to reduce ulcers, amputations, and mortality.

Key Highlights:

  • Clear pathways for annual screening and risk stratification
  • Practical offloading and footwear recommendations
  • Emphasis on rapid access to multidisciplinary teams
  • Strategies to overcome implementation barriers in different settings

Read full consensus document

Keywords: diabetes foot disease implementation, DFD prevention, international DFU guidelines

Sequence LifeScience, Inc. Announces First Patient Enrolled in Groundbreaking Clinical Trial for Diabetic Foot Ulcers


Sequence LifeScience, Inc. Announces First Patient Enrolled in Groundbreaking Clinical Trial for Diabetic Foot Ulcers

Summary: Sequence LifeScience reported first-patient-in for a prospective, multicenter trial assessing outcomes of placental membrane allografts in hard-to-heal diabetic foot ulcers.

Key Highlights:

  • Study aim: Evaluate wound closure and healing trajectory in chronic DFU using company’s allografts.
  • Design: Prospective, multicenter clinical investigation focused on hard-to-heal ulcers.
  • Rationale: Address persistent limb-loss risk and need for effective adjunctive biologics.

Read the press release on PR Newswire

Keywords:
Sequence LifeScience,
diabetic foot ulcer,
placental allograft,
clinical trial

Integra LifeSciences Q3 2025: Zero Mention of Ransomware Fallout



Integra LifeSciences Q3 2025: Solid Growth, Zero Mention of Ransomware Fallout

Summary: Five days after the November 13 Clop ransomware attack, Integra LifeSciences’ latest financial recap (published November 16) reports Q3 revenue of $402.1 million — up 5.6% year-over-year — with no disclosure of material operational, supply-chain, or payment disruptions. The company continues to state only that it is “managing a cybersecurity incident” with “no material impact to date.” As of November 18, clinician forums and distributor channels remain quiet on graft or instrument shortages.

Key Highlights:

  • Q3 Revenue: $402.1M (+5.6% YoY), driven by Codman Specialty Surgical and Tissue Technologies segments.
  • Wound Care Portfolio: Includes Integra Dermal Regeneration Template, PriMatrix, AmnioExcel, and CUSA Clarity — collectively ~20% of U.S. advanced wound procedures.
  • Cyber Incident Disclosure: Still limited to generic statements; no 8-K update since initial acknowledgment.
  • Market Reaction: Stock (IART) essentially flat since breach claim surfaced on dark-web trackers.
  • Comparison: Unlike Change Healthcare 2024 (weeks of visible chaos), Integra’s silence suggests containment or robust backups.

Read full recap

Keywords: Integra LifeSciences, ransomware, Clop, Q3 2025, supply chain, provider payments, IART


Editor’s Note: M-Med USA has ample supplies of total contact casting kits to help mitigate any disruptions in offloading solutions for DFUs. Contact them for immediate availability and support.

Cost effectiveness of topical wound oxygen therapy for chronic diabetic foot ulcers

Topical Wound Oxygen Therapy Proven Cost-Effective for Chronic Diabetic Foot Ulcers

A recent study published in the Journal of Diabetes and Its Complications evaluates the cost-effectiveness of Topical Wound Oxygen (TWO2) therapy for chronic diabetic foot ulcers (DFUs). Utilizing a Markov model over a two-year horizon, the research assesses both economic and clinical outcomes associated with TWO2 therapy compared to standard care. Read the full article.

Key Highlights:

  • Economic Benefits: The study indicates that, at a weekly cost of £650 for up to 12 weeks, TWO2 therapy results in a £5,038 reduction in total diabetic foot care costs over two years per patient compared to standard care.
  • Improved Health Outcomes: Patients receiving TWO2 therapy experienced an increase of 0.07 quality-adjusted life years (QALYs) over the two-year period.
  • High Probability of Cost-Effectiveness: Probabilistic sensitivity analysis reveals an 81% likelihood that TWO2 therapy is cost-effective at a willingness-to-pay threshold of £25,000 per QALY.
  • Clinical Efficacy: The model’s clinical inputs are derived from a multinational randomized controlled trial demonstrating superior healing rates with TWO2 therapy.
  • Global Health Implications: Given the substantial burden of DFUs worldwide, the adoption of cost-effective treatments like TWO2 therapy could significantly reduce healthcare expenditures and improve patient quality of life.

This study underscores the potential of TWO2 therapy not only to enhance clinical outcomes for patients with chronic DFUs but also to provide significant cost savings for healthcare systems.

Read the full article on the Advanced Oxygen Therapy Inc. website.

Keywords:
Topical Wound Oxygen Therapy,
diabetic foot ulcers,
cost-effectiveness,
quality-adjusted life years,
health economics

The Role of Internal Offloading and Rotational Flap Closure of Charcot Arthropathy-Related Midfoot Ulcers

The patient with Charcot foot is seldom studied for their body’s ability to heal an open diabetic foot ulcer. These patients are usually excluded from all prospective randomized trials. Over a 5-year period, patients with Charcot arthropathy (CA) have been shown to have a 63% chance of developing a CA foot ulcer (CAFU), and those with a foot ulcer have a 37% mortality within the same timeframe.¹ To the authors’ knowledge, a correlation between healing a CAFU and mortality reduction has not been indicated. It is well-known that healing such ulcers improves quality of life and reduces the chance of hospitalization. The primary modality to heal such an ulcer is maintaining or creating a plantar grade foot.1 In a retrospective study of 106 patients with CAFU, Schmidt and Holmes² reported that 44% of the patients’ ulcers had healed, 11% had received a minor amputation, and only 9% had undergone major amputation … read more

Patients with SSc-related digital ulcers use ‘significantly more’ health care resources

Patients with systemic sclerosis who demonstrate digital ulcers use “significantly more” health care resources annually than patients without digital ulcers, according to data published in Arthritis Care and Research … “[Digital ulcers (DUs)] are slow to heal, specially if there is calcinosis, and can be complicated by soft tissue infections, wet and dry necrosis, eschar, underlying tissue exposure, gangrene, osteomyelitis, and amputation,” Tatiana Nevskaya, MD, PhD, of the Schulich School of Medicine and Dentistry, in Ontario, and colleagues wrote … read more

neoplas med GmbH: Superiority of cold atmospheric plasmajet therapy in the treatment of

chronic wounds proven by gold-standard trial

 

Comparative clinical trial shows significant improvement in wound closure and infection control based on treatment with the plasmajet kINPen® MED from neoplas med compared to best practice wound care – cost-effectiveness analysis proves high cost-savings by innovative technology

 

GREIFSWALD, Germany and FELDKIRCH, Austria, March 22, 2022 /PRNewswire/ — The results of a randomized controlled trial (RTC) may offer new opportunities for the approximately two million patients with chronic wounds solely in Germany: The innovative cold atmospheric plasmajet (CAP-jet) technology showed significantly more healing progress in chronic wounds in comparison to best practice (BP) modern wound care at two study centers. Within six weeks, 59 percent of all wounds healed completely under cold plasma treatment compared to only 5.1 percent in patients under BP therapy. Time to complete healing was also considerably shorter under CAP-jet treatment, and wound infections were overcome statistically significant more rapid. With a very good tolerability profile, an economic analysis of the study data also showed a cost saving of 65 percent for the dressing material alone compared to the BP group. The study data were recently published in the journal Nature Scientific Reports.

 

Acceleration of wound healing and wound closure proven

In the study conducted by Prim. Univ.-Professor Robert Strohal, head of the Department of Dermatology and Venereology at the Federal Academic Teaching Hospital Feldkirch, the cold plasma procedure of the Greifswald-based company neoplas med GmbH was scientifically examined in wound care. For this purpose, he compared treatment with the CAP-jet kINPen® MED at the Austrian Federal Academic Teaching Hospitals Feldkirch and Bregenz with current best practice treatment in 78 patients with infected and non-infected wounds. ‘This study was the first to investigate the exclusive effect of tissue accessible cold plasma on wound healing and infection control without the use of an additional standard therapy,’ said Prim. Univ.-Prof. Strohal.

 

After treatment with the CAP-jet, the proportion of healthy tissue increased significantly faster than under the BP treatment and the wounds under CAP-jet therapy also healed significantly faster. At the end of the study, the wound area in the CAP group had reduced by 94.7 percent compared to the baseline value, in the comparison group it was only 56.3 percent. CAP also proved superior in terms of infection control. In contrast to BP therapy, all wounds infected at the start of the study showed complete resolution of infection signs. In addition, the signs of infection disappeared significantly faster under cold plasmajet therapy.

 

Patients’ quality of life can improve

Ulrike Sailer, CEO of the company neoplas med GmbH in Greifswald/Germany, explained: ‘The Joint Federal Committee (Gemeinsamer Bundesausschuss, G-BA) as the central decision-making body of the German health care system already recognized last year the potential of cold plasma for the innovative treatment of chronic wounds at our request. Therefore, the G-BA decided to carry out an observational trial for testing with the aim of obtaining health insurance approval. The results of the clinical trial that now have been published clearly demonstrate the superiority of the CAP-jet kINPen® MED compared to BP wound care. These results provide further evidence for the high clinical relevance of the CAP-jet precision technology. At the same time, it represents important news for millions of people who suffer from chronic wounds for years.’

 

Chronic wounds are often associated with high morbidity and considerable impairments in everyday life as well as the patients’ psyche. Faster wound healing and thus a shorter therapy duration by using the plasmajet kINPen® MED can therefore significantly improve the patients’ quality of life. Furthermore, a lower burden by pain during treatment can be observed, and a reduced number of dressing changes can be assumed. Patients confirmed the very good tolerability and even described the treatment as pleasant in the majority of cases.

 

Significant advantage in treatment costs

A cost-effectiveness analysis based on the available study data showed that 21.4 percent fewer physician visits and 34.3 percent fewer dressing changes were necessary in the CAP-jet group compared to BP. The savings alone in dressing material resulted in a cost advantage for CAP-jet therapy of 64.7 percent compared to BP. Previously, average costs of 10,000 € per patient and year were assumed. Ulrike Sailer: ‘Thus, the cold plasmajet kINPen® MED offers not only a more efficient and tolerable technology, but also opens up the opportunity for significantly higher cost-effectiveness in the treatment of chronic wounds.’

 

Further information material can be found under the following link: https://1drv.ms/u/s!Aph6cOwNbPEJgQCIbClSETCZ_lal?e=BvkuGi

 

Background Information:

The study included 78 patients with wounds up to 10 x 20 cm in size and existing for at least 6 weeks. The patients were randomized in a 1:1 ratio into two groups and treated for the study duration of 6 weeks either with the CAP-jet kINPen® MED (30 seconds per cm2 wound area) or suitable wound dressings according to BP wound care. Only one wound per patient was evaluated.

 

With regard to the treatment regime, CAP-jet therapy was administered 3 times in the 1st week in the CAP group, 2 times in the 2nd week and once a week in the following observation period; furthermore, the wounds were covered with gauze and a secondary dressing. In contrast, the BP group was treated with a wound phase-adapted dressing; infected wounds were additionally cleaned with an antiseptic. In both groups, patients with venous ulcers received compression therapy. The primary endpoint of the study was the amount of granulation tissue at the end of the study. In addition, cold plasma effects on wound infection, wound area, healing time, wound pH and exudate volume (wound fluid) as well as local tolerability were investigated.

 

Improvement in wound infection: All 13 wounds infected at baseline in the CAP-jet group showed complete resolution of infection signs without the need for additional antiseptics. In contrast, 4 of the 18 wounds infected at baseline in the BP group showed no improvement despite the use of antiseptics. Furthermore, the signs of infection decreased significantly faster under CAP-jet therapy compared to BP therapy. These data confirm the previously published evidence on the good antimicrobial efficacy of CAP.

 

Cold plasma is a gas containing ionized atoms, ions and electrons that has been shown to disinfect wounds and activate the wound healing process. With its fine jet, the plasmajet kINPen® MED enables highly precise treatment in anatomically and pathologically challenging areas under visual control and without touching, which is not possible with other wound therapies.

 

About neoplas med GmbH

neoplas med GmbH was founded in 2009 as a spin-off of the Leibniz Institute for Plasma Science and Technology e. V. (INP) in Greifswald, Germany. Ulrike Sailer took over the position of managing director at the end of 2019. Based on the INP research into plasma medicine, the emerging company develops innovative products for medical applications. The first product developed on this basis is the CE-marked kINPen® MED atmospheric pressure plasmajet, the first internationally approved and marketed plasmajet for the treatment of chronic wounds and pathogen-induced skin disorders. It is the result of a long-lasting cooperation with the INP institute, the university hospital of Greifswald, Germany, the Charité hospital of Berlin, Germany, and various industrial partners. In July 2021, the Federal Joint Committee, as the central decision-making body in the self-governing health care system, decided on a trial study with the cold plasmajet procedure and thus took an important step towards reimbursement by the health insurance companies.

 

About kINPen® MED

The plasmajet kINPen® MED is the first atmospheric pressure plasmajet to receive CE approval for the treatment of chronic wounds and pathogen-induced skin disorders. The plasmajet applies a physical cold plasma with a temperature of < 40 degrees Celsius with pinpoint precision and without wound contact. Areas with an uneven profile, recesses or cavities can be reached easily and treated evenly. The noble gas argon used for the generation of the plasma provides a controlled atmosphere around the generated plasma beam, thus ensuring a consistent high treatment quality.

 

Press contact

Claudia Kerber
Phone: +49 3834 515 201
Mobile: +49 (0)162 23 770 70
claudia.kerber@neoplas-med.eu
neoplas med GmbH
Walther-Rathenau-Straße 49a, 17489 Greifswald, Germany

Association of Wound Healing With Quality and Continuity of Care and Sociodemographic Characteristics

Based on the analysis of electronic health records from 480 clinics, we found that better care quality and continuity are associated with better-than-expected wound healing performance … Chronic wounds, defined as wounds that “fail to proceed through the normal phases of wound healing in an orderly and timely manner,”1 affect 6.5 million Americans and result in $50 billion in annual Medicare expenditure.2-4 Despite growing prevalence and economic burden in the aging US population, chronic wound care remains an area with inconsistent adherence to evidence-based recommendations and variable quality of care.5 For example, despite evidence-based recommendations for compression therapy for venous ulcers and total contact casting (TCC) for offloading of pressure for diabetic foot ulcers, a previous study involving 2404 patients from 18 hospital-based … read more

Improving Pressure Injury Care Outcomes with a Quality Improvement Project



Improving Pressure Injury Care Outcomes with a Quality Improvement Project

Summary: This QI project implemented a PI care bundle (risk assessment, education, audits) in a 500-bed hospital, reducing hospital-acquired PI incidence from 4.2% to 2.7% (35% drop) over 6 months. Staff compliance rose 60%; education sessions reached 80% of nurses. Bundle included Braden scoring, turning schedules, and nutrition consults.

Key Highlights:

  • Bundle: Braden q-shift, turning q2h, nutrition screening, audits.
  • Outcomes: 35% incidence drop; 60% compliance increase.
  • Method: Pre/post implementation; PDSA cycles.
  • Sustainability: Monthly audits; 80% nurse training.
  • Authors: Pittman J, McNichol L, Gray T et al.

Read QI project

Keywords: PI care bundle, quality improvement, hospital acquired, nurse education, incidence reduction, J Pittman, L McNichol, T Gray

Preventing Hidden Bioburden in Surgical Instruments

Ultrasonic Cleaning Is Not a Machine; It Is a Quality System: Preventing Hidden Bioburden in Surgical Instruments

Summary: Published in the March 2026 issue of Infection Control Today (Vol. 30, No. 1), this article by Marjorie Wall, EDBA, CRCST, CIS, CHL, CSSBB, argues compellingly that ultrasonic cleaning in the sterile processing department (SPD) must be conceptualized and managed not as a piece of equipment but as a validated patient safety quality system — with the same rigor applied to sterilizers and washer/disinfectors. The core argument is that while ultrasonic cleaning is the most effective available tool for removing microscopic soil from complex surgical instruments — using cavitation (imploding microscopic bubbles generated by high-frequency sound waves) to dislodge debris from serrations, hinges, box locks, cannulations, and lumens that manual brushing cannot reliably address — its effectiveness is entirely dependent on whether the system is correctly managed, monitored, and maintained. The article identifies the central patient safety risk: ultrasonic cleaning can fail silently. Instruments may appear clean, packaging may be intact, and sterilization indicators may have changed — yet retained bioburden can remain trapped in lumens and complex features. This invisible failure can lead to surgical site infections, operating room tray recalls, and medico-legal exposure without any obvious proximate cause. Drawing on Anderson et al. (AORN Journal, 2023), Wall identifies three core performance components that every facility must continuously verify: (1) cavitation performance — using objective cavitation indicators to confirm adequate ultrasonic energy generation (not simply “running the cycle”); (2) soil removal effectiveness — using synthetic soil challenge tests that mimic blood and tissue to confirm cleaning under real working conditions; and (3) lumen perfusion — confirming that lumened devices are correctly connected to irrigation ports and that internal surfaces are actually being flushed, not just externally exposed to cavitation. Water quality is addressed as a frequently overlooked but critical variable: water hardness, endotoxin levels, temperature, ion content, and microbial load all affect detergent performance and cleaning efficacy, and Wall advocates for including ultrasonic washers in facility water management programs as a shared infection prevention priority. The article concludes with a seven-question IP audit framework for SPD rounds and a discussion of how strong ultrasonic programs build trust between SPD and the perioperative team.

Key Highlights:

  • Ultrasonic cleaning must be managed as a validated quality system — installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ) testing required, mirroring sterilizer validation standards
  • Three verifiable performance components: (1) cavitation — use objective cavitation indicators, not visual inspection; (2) soil removal — use synthetic soil challenge tests simulating blood and tissue; (3) lumen perfusion — confirm irrigation port connection, adapter compatibility, tubing integrity, and flow adequacy
  • Most dangerous failure mode is the invisible one: instruments that appear clean may still harbour retained bioburden in lumens, serrations, and box locks — risking SSI, OR delays, and tray recalls without obvious proximate cause
  • Water quality as a shared infection-prevention priority: hard water, elevated endotoxins, and microbial contamination reduce cavitation effectiveness and detergent performance — facilities should include ultrasonic washers in water management programs, requiring collaboration across SPD, facilities management, and clinical engineering
  • Common operational failures: overloading tanks, instruments closed rather than open, inadequate degassing, improper detergent selection, poor solution change practices, kinked or misconnected lumen tubing, lack of preventive maintenance, inconsistent staff competency validation
  • Seven-question IP audit: written IFU-aligned policies; cavitation verification frequency and documentation; consistent lumen port connection; soil indicator use and trend tracking; corrective action process for failed tests; water type and quality monitoring; preventive maintenance schedule documentation

Read full article

Keywords: sterile processing wound caresurgical instrument bioburdenultrasonic cleaning instrumentsinfection prevention surgical instrumentssterile processing quality systemsurgical site infection prevention

Nutritional Interventions to Optimize Orthobiologic Therapy Quality in Type 2 Diabetes Mellitus



Nutritional Interventions to Optimize Orthobiologic Therapy Quality in Type 2 Diabetes Mellitus and Metabolic Syndrome

Summary: This comprehensive review examines the impact of targeted nutrition on the efficacy of orthobiologic treatments (PRP, stem cells, bone marrow concentrate) in patients with type 2 diabetes and metabolic syndrome. Hyperglycemia and chronic inflammation impair regenerative cell function; specific interventions such as flaxseed oil (1000 mg/day) have shown DFU size reduction and improved insulin sensitivity in trials. The authors discuss omega-3 fatty acids, antioxidants, vitamin D, and Mediterranean-style diets to optimize stem cell quality, reduce oxidative stress, and enhance healing. Practical guidance is provided for integrating nutrition into multidisciplinary limb-preservation and regenerative wound care programs.

Key Highlights:

  • Nutrition modulates orthobiologic efficacy in diabetic patients
  • Flaxseed oil supplementation linked to smaller DFUs and better metabolic control
  • Focus on anti-inflammatory and antioxidant strategies
  • Authors: Multiple (MDPI IJMS team)

Read full open-access review

Keywords: nutritional interventions DFU, orthobiologics diabetes, flaxseed oil wound healing

Orpyx launches Orpyx SI Flex Sensory Insoles and Diabetes Healthspan Extension care model

13-Jun-2022 8:05 AM EDT, by Orpyx Medical Technologies Inc.

 

Newswise — CALGARY, AB, June 13, 2022 /PRNewswire/ — Orpyx® Medical Technologies Inc. (Orpyx), a digital health company focused on extending the health span of patients with diabetes, announced the launch of the Orpyx SI® Flex Sensory Insole system and Orpyx Remote Patient Monitoring (RPM) services. This remote monitoring program drives engagement and extends mobility for people living with diabetes by transforming patient care through real-world patient data, analytics, and coaching.

The Orpyx SI® Flex Sensory Insoles help reduce the risk of plantar complications by monitoring plantar pressure, adherence, step count, and temperature data for patients that need preventative care.

“The launch of Orpyx SI Flex is our next step in enabling Diabetes Healthspan Extension™,” stated Dr. Breanne Everett, CEO and co-founder of Orpyx. “In North America, one-third of people are living with diabetes or pre-diabetes which often requires juggling an overwhelming number of actions, measurements, and appointments. By taking a holistic approach through a digital care platform we can dramatically improve upon the current standard of care. We are starting with foot care through robust data generation via our sensory insoles, and supporting patient engagement through RPM and coaching.”

 

The Orpyx SI Flex Sensory Insole system is a wearable technology designed to help prevent plantar foot complications for at-risk patients with peripheral neuropathy. “It is like having a supercomputer on the bottom of each foot,” said Denis Brisson, Chief Operating Officer at Orpyx. “Plantar pressure is a leading cause of foot ulceration so by measuring sustained high pressure we can help eliminate the root cause of many of these wounds before they happen.”

 

Along with pressure, the system captures wear time to determine how compliant the patient is to their provider’s treatment plan, step count to help dose activity levels, and temperature the last line of defense to indicate when inflammation is present and tissue damage is occurring. The ultra-thin, prefabricated sensory insoles fit in most every-day footwear, making them practical and comfortable for a broad range of patients.

 

Orpyx is changing the conversation by initially focusing on preventing foot ulceration by generating the most robust set of real-world plantar data. Historically, the focus has been on how to treat patients’ foot ulcers after they have already formed, with disappointing results as 25% of people with diabetes will develop an ulcer during their lifetime. These ulcers have a detrimental impact on patients’ mobility often resulting in life-shortening events such as amputation which can cause a ripple effect of social isolation, mental health challenges, and in the most complex situations death. Most diabetic foot ulcers (DFUs) are preventable, so we are on a mission to help patients and providers achieve improved, sustainable outcomes.

 

“Healthcare systems cannot sustain the current clinical strain of managing the 34 million people with diabetes in the US and the resulting $176B in financial costs. One third of this cost is attributed to lower limb care which is why this is such important work,” continued Dan Hughes, Orpyx’s Chief Commercial Officer. “Orpyx SI Flex Sensory Insoles and our new RPM services were specifically developed to meet these challenges head-on. Our insoles will play a significant role in the diabetic care pathway enabling patients to take proactive steps to manage their diabetes while reducing the total cost of care for Commercial Payers and Integrated Delivery Networks across the United States. Ultimately, this technology drives alignment and better outcomes for patients, providers, payers, and physicians.”

 

Healthcare providers seeking additional information to help their patients prevent DFUs can learn more about the new Orpyx SI Flex Sensory Insoles at https://www.orpyx.com/orpyx-si-flex-sensory-insoles.

 

About Orpyx Medical Technologies Inc.

 

Founded in 2010, Orpyx® Medical Technologies Inc. (“Orpyx”) is a Calgary-based digital health company. We take a holistic approach to remote “anywhere” care, which includes the company’s proprietary, imperceptible sensory insole platform that detects pressure, temperature, gait, activity, and movement symmetry. Our comprehensive Orpyx SI® Sensory Insole system enables continuity of care between visits to provide optimal remote care for people living with diabetes or recovering from surgery. The patient’s data is uploaded to the Orpyx SI cloud-based dashboard, where accredited healthcare practitioners remotely monitor it. The remote monitoring team communicates directly with the patient between care visits to ensure ongoing continuity and quality of care.

 

Visit www.orpyx.com for more information.

Quality Care and Implications for the Limb Salvage Center

Kevin G Kim, BS; Manas Nigam, MD; Jenna C Bekeny, BA; Cameron M Akbari, MD, MBA; John S Steinberg, DPM; Christopher E Attinger, MD; Kenneth L Fan, MD; Karen K Evans, MD

 

Chronic wounds are those that do not regain normal functional and anatomic characteristics within 3 months, and they can be broadly classified into the following 4 categories: pressure ulcers, diabetic ulcers, venous ulcers, and arterial insufficiency ulcers.[1] Data indicate that chronic wounds affect 1% to 2% of the population in economically developed countries, with rates as high as 15% in certain populations, namely Medicare beneficiaries in the United States.[1,2] Patient-reported outcomes for physical functioning and pain are consistently low in the setting of a chronic lower extremity wound, which has broad implications for quality of life, mortality, and cost.[3] Chronic wounds are also a significant driver of cost in the US health care system. Estimated Medicare spending for all wound types was $28.1 billion to $96.8 billion … read more

HARTMANN USA and Corstrata Collaborate to Improve Patient Wound Outcomes

Two leading wound industry solutions companies, with a shared passion for improving patient outcomes, are collaborating to improve the way that Home Health and other in-home providers care for patients with chronic wounds.

 

 

SAVANNAH, GA. (PRWEB) OCTOBER 24, 2022

 

HARTMANN USA and Corstrata announce their collaboration to support home health and other in-home providers in caring for wound patients at a time when the incidence of complex chronic wounds is increasing while access to wound care nurse specialists is becoming more challenging. At the core of a successful wound care program is access to both highly effective advanced wound dressings as well as clinical expertise to implement evidence-based treatment protocols and monitor wounds to closure. According to a recent study published by top-50 accounting firm BerryDunn, National Healthcare at Home Best Practices and Future Insights Study, 100% of Home Health Centers of Excellence (those Home Health agencies in the top 10% for quality and patient satisfaction and with a positive financial surplus) have a wound-certified specialist on staff.

 

This collaboration will increase access to Corstrata’s team of virtual board-certified wound nurses (WOC nurses) and HARTMANN’s suite of advanced wound care products to improve clinical and financial outcomes for in-home providers that care for patients with chronic wounds.

 

HARTMANN has been providing advanced wound dressing solutions globally for over 150 years and has evolved with its broad portfolio of high-quality, cost-effective products that provide home health clinicians with a simplified, consistent approach for effectively managing wounds. Corstrata provides virtual wound and ostomy care management nationwide across multiple provider settings, including home health, skilled nursing facilities, hospice, and emerging hospital-at-home solutions companies.

 

According to Jon Procopio, Managing Director of HARTMANN USA, “Patient care is our priority. HARTMANN strives to enable the progression of the wound towards complete healing that patients deserve and strengthen the confidence that healthcare professionals need to provide wound care. We have a nationwide team of dedicated account and customer care representatives specifically trained for consultation, education, and support in offering clinical and business solutions. Now, with Corstrata, we will enhance access to clinical expertise related to wound care through their team of certified WOC nurses.”

 

“The Corstrata team is excited about this important collaboration with HARTMANN to create access to Corstrata’s virtual WOC nurses for customers and the patients they serve. With up to one-third of all home health and hospice patients having a chronic wound, it is critical for clinicians to provide evidence-based care to both prevent and heal wounds,” says Joseph Ebberwein, co-founder and Chief Financial Officer of Corstrata. “At this time when agencies are struggling with critical staffing shortages, including WOC nurses, and increasing financial challenges, having a strong wound program is essential. This collaboration between Corstrata and HARTMANN provides a path to success.”

 

According to Katherine Piette, Corstrata’s CEO, the decision to collaborate with HARTMANN is an easy one. “Our virtual WOC nurses rely on our provider customers having access to highly effective advanced wound dressings to accelerate wound healing and reduce the overall cost of patient care, ” Piette says. “HARTMANN has a unique suite of advanced dressings that are being used by some of the top home health providers in the U.S. with impressive results. We are excited about the opportunity to improve the level of wound care provided for this ever-growing cohort of complex wound patients. Our clients can access clinical support from Corstrata when needed without the cost of hiring their own WOC nurse, a costly and often frustrating proposition. This collaboration will equip providers with turn-key wound solutions that they have been missing in their clinical care delivery at a crucial time in the industry.”

 

About HARTMANN
The HARTMANN GROUP is one of the leading providers of wound treatment and skin integrity solutions around the world. Wound dressings and maintaining healthy skin have been at the heart of HARTMANN from the beginning when we introduced the world’s first antiseptic wound dressing over 150 years ago. Overall, HARTMANN looks at rich legacy. Every day, healthcare professionals and patients rely on HARTMANN brands in the segments of Incontinence Management (e.g. MoliCare®), Wound Care (e.g. Zetuvit®) and Infection Management (e. g. Sterillium®). This is expressed in our brand promise of “Helps. Cares. Protects.” In 2021, the HARTMANN GROUP reported Group sales of EUR 2.3 billion.

 

For the latest information on HARTMANN, follow @HARTMANN_GROUP on Twitter.
To learn more about the HARTMANN GROUP, click here.
To learn more about HARTMANN USA, click here.

 

About Corstrata
Corstrata is a virtual care solution that utilizes technology to provide access to scarce certified wound and ostomy nurses at the patient’s bedside in post-acute provider settings, including home health, hospice, skilled nursing facilities, and emerging hospital-at-home providers. Corstrata’s team of WOC nurses provides consultations with provider staff at the patient’s bedside, either through HIPAA-compliant video or through review of store-and-forward wound images, to improve clinical and financial outcomes for providers.

 

For the latest information on Corstrata, follow @Corstrata on Twitter.
To learn more about Corstrata, click here.

 

This article was originally published here

New Expert Guidelines from IWGDF Highlight the Growing International Recognition of Topical

admin

Oxygen Therapy for Diabetic Foot Ulcers

 

Evidence-based recommendations support the effective use of TOT in diabetic foot ulcer management, revolutionizing treatment approaches worldwide

CAMBRIDGE, EnglandMay 17, 2023 /PRNewswire/ — NATROX® Wound Care, a leading innovator in wound care technology, proudly announces the release of newly published expert recommendations on the use of topical oxygen therapy for wound healing1. The updated guidelines endorse topical oxygen therapy (TOT) as an adjunct therapy in the treatment of diabetic foot ulcers (DFUs) 1. With its endorsement by leading experts, this ground-breaking therapy is poised to transform the lives of millions of people worldwide, offering renewed hope for effective healing and improved quality of life.

New IWDGF Guidelines
The International Working Group on the Diabetic Foot (IWGDF) has just published its 2023 Guidelines. This set of recommended DFU interventions, developed by a panel of renowned experts, serves as a trusted resource for healthcare professionals worldwide.

Notably, among the 29 recommendations highlighted, TOT gained recognition as an accepted intervention when treating non-healing DFUs. Consider the use of topical oxygen as an adjunct therapy to standard of care for wound healing in people with diabetes-related foot ulcers where standard of care alone has failed and resources exist to support this intervention1.”  With its inclusion in the IWGDF guidelines, topical oxygen therapy emerges as a vital tool, poised to revolutionize the management and healing of foot ulcers in individuals with diabetes.

In addition, the guidelines note that evidence on topical oxygen has substantially expanded in the last four years with several new RCTs with a total of ten included in the systematic review for these guidelines (References 100-109) 1, which includes an RCT study published in 2021² which compared the healing effects of using standard care against a combination of standard care plus NATROX® O₂ topical oxygen therapy. In the study, patients completing the therapy experienced 71% greater healing rates² and 73% greater reduction in wound size² with NATROX® O₂.


Experts recommend updating algorithms to include TOT
In the Journal of Wound Care, experts reached a “clear consensus that adjunctive treatments with a solid evidence base, including NPWT and TOT, must be included3 in each of the four proposed regional guidelines. Most notably, the experts agreed that “all hard-to-heal wounds are likely to benefit from TOT³.”


TOT received “A grade” from the American Diabetes Association
The American Diabetes Association recently released its “Standards of Care in Diabetes⁴” which not only recommended TOT as an adjunctive therapy for chronic DFUs, but also gave it an “A grade” based on the quality of evidence⁴. The newly published recommendations acknowledge the remarkable potential of TOT⁴.

According to Dr. Windy Cole, DPM, CWSP, FAPWH, FACCWS, renowned authority in podiatric medicine and dedicated wound care advocate for over two decades, “The evidence supporting the efficacy of TOT is now undeniable. It is imperative that healthcare professionals embrace this innovative yet simple approach to achieve improved healing outcomes.”  After witnessing the positive impact topical oxygen therapy can have on healing DFUs in her own clinic, Windy recently joined the NATROX® team as Director of Global Medical Affairs to further advocate for the integration of topical oxygen therapy in the treatment pathway for chronic wounds.

NATROX® Wound Care CEO, Craig Kennedy, expressed great enthusiasm regarding the recognition and international acceptance of topical oxygen therapy, stating, “We’re delighted that topical oxygen therapy continues to gain international recognition, cementing its status as a game-changing treatment in wound care. The inclusion of topical oxygen in the IWGDF Guidelines further validates our mission to transform the quality of life for patients suffering from chronic wounds, particularly those with diabetic foot ulcers.”

What is NATROX® O₂ Topical Oxygen Therapy NATROX® Wound Care manufactures an award-winning5,6,7 topical oxygen therapy device known as NATROX® O₂The compact, wearable device generates and delivers a continuous flow of oxygen directly to the wound bed to promote accelerated healing and foster a healthy wound environment. Its non-invasive nature, coupled with its remarkable effectiveness², offers a significant advancement in chronic wound treatment, even allowing patients to be treated from the comfort of home.

To learn about NATROX® O₂ and request a demo, visit: https://bit.ly/NO2therapy

About NATROX® Wound Care 
NATROX® Wound Care is an Inotec AMD brand. The specialist wound care company based in Cambridge, England was formed specifically to introduce new technologies to healthcare professionals around the world to promote faster and better healing to patients. The company’s flagship product, NATROX® O₂, is positioned to become an integral part of global wound care treatment regimes in the coming years. To learn more, explore the website: natroxwoundcare.com.

See the references:  https://bit.ly/nwc-iwgdf-guidelines

Media Contact:

NATROX® Wound Care 
Nancy Stahulak
VP Global Marketing
marketing@natroxwoundcare.com 
+1 (888) 354 9772

Electrical Stimulation for Pressure Injuries: A Health Technology Assessment

Background

Pressure injuries (bedsores) are common and reduce quality of life. They are also costly and difficult to treat. This health technology assessment evaluates the effectiveness, cost-effectiveness, budget impact, and lived experience of adding electrical stimulation to standard wound care for pressure injuries.

Methods

We conducted a systematic search for studies published to December 7, 2016, limited to randomized and non–randomized controlled trials examining the effectiveness of electrical stimulation plus standard wound care versus standard wound care alone for patients with pressure injuries. We assessed the quality of evidence through Grading of Recommendations Assessment, Development, and Evaluation (GRADE). In addition, we conducted an economic literature review and a budget impact analysis to assess the cost-effectiveness and affordability of electrical stimulation for treatment of pressure ulcers in Ontario. Given uncertainties in clinical evidence and resource use, we did not conduct a primary economic evaluation. Finally, we conducted qualitative interviews with patients and caregivers about their experiences with pressure injuries, currently available treatments, and (if applicable) electrical stimulation.

Results

Nine randomized controlled trials and two non–randomized controlled trials were found from the systematic search. There was no significant difference in complete pressure injury healing between adjunct electrical stimulation and standard wound care. There was a significant difference in wound surface area reduction favouring electrical stimulation compared with standard wound care.

The only study on cost-effectiveness of electrical stimulation was partially applicable to the patient population of interest. Therefore, the cost-effectiveness of electrical stimulation cannot be determined. We estimate that the cost of publicly funding electrical stimulation for pressure injuries would be $0.77 to $3.85 million yearly for the next 5 years.

Patients and caregivers reported that pressure injuries were burdensome and reduced their quality of life. Patients and caregivers also noted that electrical stimulation seemed to reduce the time it took the wounds to heal … read more

Prediction of Diabetes Among Homeless Adults Using Artificial Intelligence

Prediction of Diabetes Among Homeless Adults Using Artificial Intelligence: Suggested Recommendations

Summary: Published March 22, 2026 in Healthcare (MDPI), this case-control study from Cairo University Faculty of Nursing, Beni-Suef University, and Saudi Electronic University applies machine learning-based diabetes prediction to a medically underserved population — homeless adults — using a hybrid stacking ensemble model. Led by Khadraa Mohamed Mousa and Manal Mohamed Elsawy (Community Health Nursing, Cairo University), the study enrolled 150 homeless adults at the Ma’ana Rescue Human Foundation (Giza, Egypt), including 99 confirmed diabetic cases (FBS ≥ 126 mg/dL or prior diagnosis) and 51 non-diabetic controls. Structured interviews collected demographic data, medical history, 15-item lifestyle questionnaire, and 7-item diabetes knowledge assessment; physiological measurements included weight, height, BMI, waist circumference, triceps skinfold thickness (TSF), fasting blood sugar, and blood pressure. From 43 initial variables, recursive feature elimination and correlation analysis reduced the predictor set to 13 variables: BMI, systolic blood pressure, triceps skinfold thickness, waist circumference, lifestyle score, presence of other diseases, diastolic blood pressure, age, regular medication use, educational level, marital status, duration of residence, and diabetes knowledge. SMOTE was applied exclusively to the training set (80/20 split) to address class imbalance without contaminating test evaluation. Six base classifiers were evaluated (logistic regression, SVM, random forest, decision tree, KNN, gradient boosting) before implementation of a hybrid stacking ensemble with XGBoost as the meta-learner using out-of-fold predicted probabilities from all six base models. The stacking ensemble achieved 95.45% accuracy, 100% precision, 93.75% recall, F1-score 0.968, and AUC-ROC 0.979 on the held-out test set — substantially outperforming all individual classifiers (accuracy 56.7–70%, F1 0.686–0.781). Wound care relevance: homeless adults with diabetes face substantially higher rates of lower limb amputations, less reliable wound care, inadequate nutritional status, and significantly higher rates of diabetes-related hospitalisations than housed populations — all of which converge on wound complications. The study explicitly references a 2021 AI-based DFU and amputation risk stratification study by Schäfer et al. as the broader clinical context. The authors recommend that healthcare institutions integrate AI-powered diagnostic support into community nursing workflows for early diabetes detection in vulnerable populations.

Key Highlights:

  • Stacking ensemble performance: hybrid XGBoost meta-learner achieved 95.45% accuracy, 100% precision, AUC 0.979 — substantially outperforming individual classifiers (best individual: 70% accuracy); feature selection improved hybrid model accuracy from 82% to 95% and AUC from 0.87 to 0.98
  • 13 key predictors identified: BMI, SBP, TSF, waist circumference, lifestyle score, comorbidities, DBP, age, medication adherence, educational level, marital status, duration of residence, and diabetes knowledge — a novel combination integrating psychosocial and contextual factors rarely included in conventional diabetes risk models
  • Homeless population vulnerability: diabetes in homeless adults associated with 5× higher ED visit and hospitalisation rates vs. housed counterparts; significantly higher rates of lower limb amputation (vs. 0.01% baseline mortality in same age group in general population); poor medication adherence; unreliable wound care; and low diabetes knowledge (82.8% had incorrect knowledge of diabetes definition)
  • Clinical wound care context: the study references Schäfer et al. (2021, Front Med) on ML-based DFU and amputation risk stratification as its broader framework — positioning early AI-assisted diabetes detection in homeless populations as an upstream prevention strategy for the DFU and amputation pipeline
  • Limitations: single-centre, n=150, purposive sample; case-control design reflects institutional prevalence rather than community prevalence; small test set (n=30) may inflate performance estimates; external validation in larger multi-centre samples is required before clinical deployment
  • Nursing recommendation: community and gerontological health nurses are positioned to implement AI-assisted screening alongside fingertip glucose testing in shelter and community settings — providing instant results and enabling same-encounter lifestyle counselling for high-risk homeless adults

Read full article

Keywords: diabetes prediction machine learninghomeless population diabetes wound riskAI diabetic foot amputation riskcommunity nursing diabetes screeningensemble machine learning healthcarehealth equity diabetes vulnerable population

Khadraa Mohamed Mousa, Farid Ali Mousa, Naglaa Mahmoud Abdelhamid, Mona Sayed Atress, Manal Mohamed Elsawy

Palliative Wound Care: Balancing Comfort and Clinical Decisions

Palliative Wound Care: Balancing Comfort and Clinical Decisions

Summary: In a Wounds International podcast, Professors Karen Ousey and Sebastian Probst discuss the complexities of palliative wound care. Their conversation highlights the shift in priorities from aggressive healing to comfort, dignity, and symptom management for patients approaching end of life.

Key Highlights:

  • Patient-centred focus: Wound care decisions in palliative phases emphasize comfort and quality of life rather than complete closure.
  • Skin changes: Fragile skin and physiological changes near end of life require gentle, non-invasive care strategies.
  • Ethical and emotional aspects: Clinicians must navigate the expectations of families while respecting the wishes of the patient.
  • Collaboration: Interdisciplinary teams, including palliative specialists and wound care clinicians, are essential for aligning treatment goals.

Listen to the full podcast on Wounds International

Keywords:
palliative wound care,
Karen Ousey,
Sebastian Probst,
end of life care,
quality of life

Integra LifeSciences Announces Positive Clinical Outcomes for PriMatrix® Dermal Repair Scaffold for the Management of Diabetic Foot Ulcers

Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced positive clinical outcomes for PriMatrix® Dermal Repair Scaffold for the management of hard to heal diabetic foot ulcers (DFUs). This study is one of the largest DFU randomized controlled trials (RCTs) ever completed with more than 100 patients per treatment group and demonstrated that in most cases, one application of PriMatrix plus standard of care (SOC) healed 60% of DFUs in 12 weeks versus 35% of DFUs that healed in 12 weeks with SOC for the per protocol analysis.

This data was recently published by lead investigator, John Lantis, M.D., FACS, from Mount Sinai Health System in New York, in the Journal of Wound Care, the definitive wound-care journal and leading source of up-to-date research and clinical information on everything related to tissue viability … read more

Integra LifeSciences reveals FDA warning letter over chronic wound treatment

Integra LifeSciences (NSDQ:IART) today revealed its receipt of a warning letter sent by the FDA last week about quality system issues at a Boston-area plant that makes products to treat chronic wounds … Plainsboro, N.J.-based Integra said the FDA inspected the plant last October and November, resulting in a Form 483 covering the problems found there. The facility makes extracellular bovine matrix products that accounted for less than 4% of Integra’s sales last year, the company said … read more

FDA Announces Recall for MediHoney and CVS Wound Care Products

FDA Announces Recall for MediHoney and CVS Wound Care Products Due to Sterility Concerns

Summary: The U.S. Food and Drug Administration issued a recall notice for specific wound and burn care products — including items under the CVS Health brand — following the identification of packaging failures that may have compromised sterile barriers and increased infection risk for patients. The recall, announced March 10, 2026, was initiated by Integra LifeSciences, which manufactures and distributes both the MediHoney product line and certain CVS-branded wound care products. Products covered include all lots of MediHoney Calcium Alginate Dress Rope, MediHoney Calcium Alginate Dressing (two sizes), and two formulations of MediHoney Gel in tube form, along with CVS Wound Gel (1-ounce tubes) from lots 2446 and 2428. Integra LifeSciences identified packaging failures in the MediHoney line that could result in infections or render the products unusable, potentially delaying wound treatment. Similar production and process control issues were identified for the CVS Wound Gel. As of December 19, 2025, the company had received reports of 11 serious injuries linked to MediHoney products and 3 serious injuries associated with the CVS Wound Gel, with no deaths reported. The FDA classified the hazard as capable of causing temporary or reversible health problems or, in rare cases, more serious adverse outcomes. Integra LifeSciences sent customer notification letters on January 16 directing immediate removal of affected products from service and quarantine. Healthcare facilities were instructed to notify clinical staff, identify and quarantine affected items in all clinical areas, and discard expired units per standard institutional procedures. Distributors were directed to cease distribution of affected products, notify downstream customers, and collect impacted inventory. MediHoney and CVS Wound Gel are typically used to maintain a moist healing environment and protect skin from further breakdown in wound and burn management.

Key Highlights:

  • Recall initiated by Integra LifeSciences — covers MediHoney Calcium Alginate products (two sizes), MediHoney Gel (two formulations), and CVS Wound Gel lots 2446 and 2428; all used for moist wound healing and skin protection
  • Cause: packaging failures that may compromise the sterile barrier — raising infection risk or rendering products unusable; both manufacturing process issues (MediHoney) and production/process control issues (CVS Wound Gel) identified
  • Adverse events as of December 19, 2025: 11 serious injuries linked to MediHoney; 3 serious injuries linked to CVS Wound Gel; no deaths reported
  • FDA classification: products could cause temporary or reversible health problems or, in rare cases, more serious medical complications
  • Immediate action required for healthcare facilities: remove all affected product lots from clinical service, quarantine them, notify all relevant clinical staff, and discard expired units per standard procedures
  • Distributor action required: immediately cease distribution of recalled lots, notify all customers, and collect impacted inventory — customers must not use affected products under any circumstances

Read full article

Keywords: FDA wound care recallMediHoney recall sterilityIntegra LifeSciences recallCVS wound gel recallwound dressing sterility failuremedical device recall wound care

Integra LifeSciences

Evaluation of fluorescence biomodulation in the real-life management

     of chronic wounds: the EUREKA trial

 

Fluorescence biomodulation (FB), a form of photobiomodulation (PBM) that is also known as low energy level light (LELL), has become an increasingly used clinical tool to induce wound healing in wounds that remain recalcitrant to treatment. In a real-life clinical setting, the aim of the EUREKA (EvalUation of Real-lifE use of Klox biophotonic system in chronic wound mAnagement) study was to confirm the efficacy and safety of LumiHeal, a system based on FB, in the treatment of chronic wounds such as venous leg ulcers (VLUs), diabetic foot ulcers (DFUs) and pressure ulcers (PUs). The effects of this FB system on the modulation of wound healing in chronic ulcers through FB induction were previously examined in an interim analysis of this study … read more

Case series: ALLEVYN LIFE Non-Bordered foam dressing for

managing moderate to heavily exuding wounds

 

Exudate is vital for moist wound healing; however, overproduction of exudate is detrimental to the wound healing trajectory. Under compression, the capacity of some dressings to absorb exudate can fall by more than 40% and leaks are common, requiring more frequent dressing changes (Körber et al, 2008). Non-bordered foam dressings present a flexible class of dressings that can be used under compression and for cushioning, can conform to awkward positions on the body and can be cut to shape for unusually shaped wounds. This series of six case studies describes the use of ALLEVYN LIFE Non-Bordered foam dressing (Smith & Nephew) in the management of moderate to heavily exuding diabetic foot, venous and pressure ulcers. ALLEVYN LIFE Non-Bordered foam dressing is designed to lock in exudate and minimise the risk of skin damage … read more

Swiss Life & Wound Science Virtual Summit 2026



SLWVS 2026

Summary: The Swiss Life & Wound Science Virtual Summit (SLWVS) 2026 is a virtual conference dedicated to advancements in life sciences and wound care. The event brings together clinicians, researchers, and industry experts to discuss cutting-edge innovations, evidence-based practices, and emerging therapies in wound management. Topics likely include advanced dressings, regenerative approaches, infection control, and multidisciplinary strategies for chronic and complex wounds. Offers accessible education for global participants without travel requirements.

Visit summit site

Keywords: SLWVS, wound care conference, virtual wound summit

Next Science Product Featured in Lifetime Channel Program on Treating Chronic Wounds

Next Science (ASX:NXS), an innovative medical technology company and leader in treating biofilm-based infections in humans, today announced new educational broadcast content about chronic infections, which impact 17 million Americans each year. “The Balancing Act,” a lifestyle show that airs on the Lifetime channel, will feature a segment that discusses the costly and debilitating nature of these infections and how physicians can more effectively treat patients suffering from chronic wounds, including diabetic wounds, by using BLASTX, Next Science’s antimicrobial wound gel … In addition to treating diabetic foot and leg ulcers, BLASTX can also be used for stage I-V pressure ulcers, partial- and full-thickness wounds, post-surgical wounds, first and second degree burns, and grafted and donor sites. BLASTX, which uses Next Science’s patented XBIO® Technology, which physically deconstructs the protective shell over the bacterial biofilm matrix, destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment. BLASTX is non-toxic and lasts up to five days … read more

Siren Announces Publication of Foundational Data for Novel Approach

     to Skin Temperature Monitoring in Journal of Medical Internet Research (JMIR)

 

— Paper details results of first at-home, continuous, wireless temperature monitoring system to detect onset of diabetic foot ulcers caused by neuropathy

— Temperatures measured by standalone sensors were within 0.2℃ of the reference standard

–Data demonstrates potential as promising approach for early warning of foot ulcers, Charcot foot, and re-ulceration

 

SAN FRANCISCO–(BUSINESS WIRE)–Siren, the health technology company that developed Neurofabric™, a machine-washable, machine-dryable smart textile with built-in sensors, today announced publication of a foundational paper supporting its approach in Journal of Medical Internet Research (JMIR), the leading peer-reviewed journal for digital medicine, and health & healthcare in the Internet age. In the paper, a team of international researchers led by Ran Ma, co-founder and CEO, and Alexander M Reyzelman, DPM; Samuel Merritt University, detail the role of Siren’s Diabetic Sock and Foot Monitoring System in maintaining continuous, wireless skin temperature monitoring for users at-home, demonstrating the potential for the reduction of foot ulceration for diabetic patients.

 

“Diabetic foot ulcers (DFU) result in considerable cost to the healthcare system when immediate ulcers, social services, home care, and subsequent ulcers are taken into consideration,” said Alexander M Reyzelman, DPM; Samuel Merritt University and lead author on the paper. “The cost per ulcer is over $33,000 per year and the cost per leg amputation is more than $100,000 per year. Over 100,000 legs are lost to diabetes each year. In diabetic foot complications such as foot ulcers, elevated temperatures in regions of the foot have been shown to be a precursor for ulceration.”

 

The JMIR publication details Siren’s pilot study of its Diabetic Sock and Foot Monitoring System to assess how comfortable their sensor-embedded socks were for daily use, and whether observed temperatures correlated with clinical observations.

 

In the study, patients wore the socks at home for a median of 7 hours, reporting that they felt just like their normal, everyday socks. Their stated willingness to wear the socks every day underscores the socks’ suitability for home use, suggesting that Neurofabric can seamlessly integrate into the life of the wearer.

 

“Several tools have been developed to measure plantar temperatures and the progression of foot ulcers, but they only measure temperature once a day which can lead to false-positives, or are only available for in-clinic use and not at home,” said Ran Ma, co-founder and CEO of Siren. “Now, for the first time, we highlight the striking connection between our Neurofabric’s powerful ability to capture data at home, every single second. The data is incredibly meaningful—it’s the largest amount of patient data that physicians have had wireless access to in real-time. This solidifies the potential for Neurofabric to change the trajectory of diabetic foot ulcerations and the many complications that can occur from it—including sepsis, and lower limb amputations.”

 

Patients also reported that Siren’s mobile app was easy to use and navigate. Through the mobile app, wearers can view the current temperature as measured at six points on the user’s foot. While the app was not set up to generate alerts in this study, users can receive a notification on their phone when a temperature increase is detected between contralateral positions.

 

“Digital health is a vast and burgeoning field and spans several aspects of health management—Neurofabric can facilitate the management of chronic conditions at home, including the effective and timely management of DFUs,” said Henk Jan Scholten, co-founder and COO of Siren. “The JMIR publication sheds light on both the ability of these Neurofabrics to improve quality of life for diabetes patients, and Siren’s first use-case to empowering people to take their health into their own hands.”

 

Siren is initiating a large-scale patient study in 2019.

 

Read the JMIR paper in full here: Continuous Temperature-Monitoring Socks for Home Use in Patients With Diabetes: Observational Study

 

About Siren

 

Founded in August 2016, Siren is a health technology company and the maker of Neurofabric™, machine-washable, machine-dryable smart textiles. Siren’s first product, Siren Diabetic Socks, are designed to help people with diabetes avoid amputations. Siren was previously named AARP Consumer’s Choice Award winner, 2017 CES TechCrunch Hardware Battlefield, 2018 CES Best of Innovation, Fast Co.’s 2018 Innovation by Design Award Honorable Mention, and 2018 ADA Healthtech Showcase winner. Siren’s investors include DCM, Khosla Ventures and Founders Fund.

press release from BusinessWire

Lumicell Launches Wound Care Infection and Perfusion Division

WELLESLEY, Mass.–(BUSINESS WIRE)–Lumicell, Inc., a leader in the field of image-guided cancer surgery, today announced that it has created a new division to drive the expansion of its pioneering technologies to include wound care, infection and perfusion.

 

According to a recent study in the Journal of The International Society for Pharmacoeconomics and Outcomes Research, each year in the U.S. there are about 8.2 million patients being treated under Medicare for chronic wounds with an estimated cost between $31.7 to $96.8 billion per year1. With the rising prevalence of obesity-related diseases, such as diabetes, and an aging population – there continues to be a growth in the number of patients suffering from chronic wounds. And with healthcare professionals making care decisions based on the limited, evidence-based knowledge of wounds and requiring patients to make weekly visits to track progress, this upward trend is predicted to continue.

 

“Chronic wounds have a dramatic impact on affected individuals, their families and the U.S. Health Care System, leading to reduced quality of life, limb loss and loss of life at a significant financial cost,” said Robert S. Kirsner, M.D., PhD, FAAD, Director, University of Miami Hospital and Clinics Wound Center. “Unfortunately, wound care is often a largely overlooked medical need compared to other medical challenges like cancer, despite similar effects on loss of life. There is a need for new technologies to assess the state of a wound, integrate this with clinical data, and support the best treatment, for the right patient, at the right time.”

 

“We created our new wound care, infection and perfusion division for the same reason we launched our pioneering cancer technology — we identified a patient population in desperate need and decided to apply our technology and leverage our world-class team to help people suffering from chronic wounds,” said W. David Lee, CSO of Lumicell. “We believe the biggest healthcare engineering breakthroughs happen outside of the biology lab. As such, Lumicell’s new division will use concurrent engineering – the convergence of engineering and biological research – to accelerate the pace of biological discoveries and create new applications to diagnose and treat patients.”

 

“While it will require significant research and development, it will be well worth the effort,” Lee said. “Lumicell has already established the foundational technology for this forward-thinking approach and assembled a small group of advisors to guide the team through the first stages of development. Our goal is to better understand wound healing and on a molecular level and to create an unbiased, holistic protocol that blends Lumicell’s care-leading technology, artificial intelligence and informed care options.”

 

Lumicell also hopes to create a community of wound care experts, including doctors, nurses, researchers and insurance company executives who are interested in providing expertise, evidence, opinions and guidance. This community will curate the statistics, biology and science needed to ensure the infection and profusion detecting technologies and accompanying standard of care protocols are accessible and adopted across disciplines.

 

Samuel R. Nussbaum MD, Marissa J. Carter PhD MA, Caroline E. Fife MD, Joan DaVanzo PhD MSW, Randall Haught, Marcia Nusgart RPh, Donna Cartwright MPA. An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds. Journal of The International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Value in Health 21 (2018) 27-32

 

About Lumicell, Inc.
Lumicell is a technology leader in the field of image-guided cancer surgery. The company is developing a novel system that enables real-time detection of tumor tissue in patients so that no cancer cells are left behind during surgery. The company’s LUM System has unprecedented ability to see and remove cancer cells remaining in the surgical cavity – beyond the margin of the specimen – and has the potential to significantly improve surgical outcomes and reduce healthcare costs by eliminating the need for repeat surgeries. Lumicell is investigating the LUM System in patients undergoing surgery for breast cancer, prostate cancer, colorectal, esophageal and pancreatic cancers. Additional future indications are planned to include surgeries for lung, ovarian, and brain cancers. For more information, please visit www.lumicell.com.

Contacts

For Lumicell
Ali Buckneberg, 612-334-5960
ali.buckneberg@wordsatwork.com

press release from BusinessWire

Infection-Related Hospitalizations High for Adults With Diabetes

People with diabetes may face a higher risk for hospitalization for any infection, a new analysis suggested.

In a prospective study of over 12,000 middle-age adults, those with diabetes had a 67% higher risk for infection-related hospitalization compared with adults free of diabetes over the course of nearly 30 years (HR 1.67, 95% CI 1.52-1.83), reported Elizabeth Selvin, PhD, MPH, of Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues … read more

Record 169 UK patients a week get diabetes-related amputations

A record 169 people a week are having to undergo an amputation procedure as a result of diabetes, a study has found.

 

Analysis by the charity Diabetes UK found that 26,378 people had lower limb amputations linked to diabetes between 2014 and 2017, a 19.4% rise from 2010 to 2013. Unhealed ulcers and foot infections are the main cause of diabetes-related amputations. Diabetes affects almost 3.7 million people in the UK … read more

Thermal imaging improves diabetes-related foot ulcer assessment

Thermal imaging can better predict a diabetes related foot ulcer’s size and the healing trajectory than conventional methods, Melbourne-led research has found. It could also possibly save money through better targeted treatment … The study, which was the first of its kind, was a collaboration between RMIT University, the University of Melbourne and Austin Health. It used thermal imaging to quantify the size and predict the healing status of recently developed ulcers … based on their work, the RMIT researchers want to see thermal imaging, which is suitable for most clinical settings, used as an inexpensive and real-time option to identify wounds that may have delayed healing … read more

Medical Adhesive-Related Skin Injury: Treatment and Prevention

by Holly M. Hovan MSN, APRN-ACNS-BC, CWOCN-AP

Medical adhesive-related skin injury, or MARSI, is a common type of skin injury, often seen in inpatient settings and in vulnerable populations with fragile skin such as older adults (decreased elasticity, usually multiple pre-existing comorbidities) or pediatric patients (skin is not fully developed). MARSI is caused by trauma to the skin from medical adhesives (think of things such as… tape used to secure a dressing after a blood draw, clear film dressings, ostomy pouches, external catheters in men, tube securement devices, surgical dressings, etc.). MARSI is not a pressure injury and is not caused by pressure.

 

Anytime we are consulted or asked to follow up on a new wound, one of the things we are assessing for is the cause of the wound or injury—trauma, pressure, moisture, friction, shear, impaired blood flow, etc. It is important to look at the big picture and what caused the wound or skin injury. Many variables can and do make wounds and skin conditions worse, but when determining the true etiology, we must look at what initially caused the problem … read more

A metatranscriptomic approach to explore longitudinal tissue specimens from non-healing diabetes related foot ulcers

Cellular mechanisms and/or microbiological interactions which contribute to chronic diabetes related foot ulcers (DRFUs) were explored using serially collected tissue specimens from chronic DRFUs and control healthy foot skin. Total RNA was isolated for next-generation sequencing. We found differentially expressed genes (DEGs) and enriched hallmark gene ontology biological processes upregulated in chronic DRFUs which primarily functioned in the host immune response including: (i) Inflammatory response (ii) TNF signalling via NFKB, (iii) IL6 JAK-STAT3 signalling, (iv) IL2 STAT5 signalling and (v) Reactive oxygen species. A temporal analysis identified RN7SL1 signal recognition protein and IGHG4 immunoglobulin protein coding genes as being the most upregulated genes after the onset of treatment. Testing relative temporal changes between healing and non-healing DRFUs identified progressive upregulation in healed wounds of CXCR5 and MS4A1 … read more

Device-related pressure ulcers: SECURE prevention. Second edition

Amit Gefen, Catherine T Milne, Fiona Coyer, Guido Ciprandi, Karen Ousey, Nicola Waters, Norihiko Ohura, Paulo Alves, Peter Worsley

 

We have over 100 resources, free for everyone to browse and read and share. These resources are suitable for a range of skin and wound care disciplines, roles, and educational purposes

Although great strides have been made to tackle hospital-acquired pressure ulcers (HAPUs), there is a need for greater recognition of device-related pressure ulcers (DRPUs), including their causes, management and prevention. This consensus statement, an updated second edition, aims to continue raising awareness of these largely preventable injuries and, crucially, to stimulate action … read more

Nurses’ Knowledge of Pressure Ulcer Management-Related Monitoring and Financial Costs of Treatment: A Prospective Intervention Study

Nurses’ Knowledge of Pressure Ulcer Management-Related Monitoring and Financial Costs of Treatment: A Prospective Intervention Study

Summary: This prospective intervention study evaluates nurses’ knowledge in pressure ulcer (PU) prevention and management—particularly regarding monitoring and treatment costs—using the validated Pressure Ulcer Knowledge Test (PUKT) questionnaire in the Czech Republic. The study assessed knowledge before and after targeted education and incorporated considerations of updated PU classifications and socio-cultural adaptations.

Key Highlights:

  • Baseline nurse knowledge of PU prevention/treatment—as measured via the PUKT—was found to be inadequate, echoing findings from previous systematic reviews. :contentReference[oaicite:1]{index=1}
  • Targeted educational interventions in the clinical setting significantly improved knowledge scores post-intervention. :contentReference[oaicite:2]{index=2}
  • The study emphasizes the importance of embedding education within practice to enhance cost-effective PU care implementation and monitoring. :contentReference[oaicite:3]{index=3}

Read the full article in Journal of Wound Management

Keywords:
pressure ulcer knowledge,
PUKT,
nurse education,
cost monitoring,
preventive intervention

A Novel Approach to Diabetes-Related Foot Ulcers/Disease



A Novel Approach to Diabetes-Related Foot Ulcers/Disease: First Report of Bipolar Pulsed RF Lumbar Sympathectomy

Summary: This retrospective cohort of 31 DFU patients with critical limb ischemia ineligible for revascularization underwent bipolar pulsed radiofrequency (RF) lumbar sympathectomy, achieving 60% wound closure, significant pain reduction (VAS 7.2 to 2.1), and improved ABI (0.6 to 0.8). Performed under fluoroscopy, the procedure disrupts sympathetic nerves to enhance perfusion without surgery, with 80% limb salvage at 12 months. As first report, it offers a safe, minimally invasive adjunct for refractory DFUs, warranting RCTs.

Key Highlights:

  • Cohort: 31 patients (mean age 62, 65% male); Wagner II-IV DFUs; ABI <0.7.
  • Procedure: RF at L2-L3 under fluoroscopy; 80% sympathectomy success.
  • Outcomes: 60% closure at 3 months; pain VAS drop 5.1; no major AEs.
  • Follow-Up: 80% AFS at 12 months; improved transcutaneous O2.
  • Authors: Iida O et al. (Nov 13, 2025).

Read full article

Keywords: bipolar RF, lumbar sympathectomy, diabetes foot ulcers, perfusion, limb ischemia, O Iida, T Yokoi, M Kato

TIMERS: the race against hard to heal wounds

TIMERS: The Race Against Hard-to-Heal Wounds — Advanced Therapies & Patient-Related Factors

In Part 4 (Sections 5 and 6) of the “TIMERS: The Race Against Hard-to-Heal Wounds” series, *Wound Care Professional* Consultant Editor **Menna Lloyd Jones** explores the advanced and adjunctive product options alongside the critical impact of patient-related factors in wound management.

Advanced & Adjunctive Product Use — When and How:

  • Adjunctive therapies such as amniotic membranes, ECM scaffolds, platelet-rich plasma, bioengineered skin substitutes, negative pressure wound therapy (NPWT), oxygen therapy, stem cell treatments, and autologous skin grafts can be deployed to enhance repair and regeneration.
  • Ancillary options like chemical debriders (e.g., Santyl®, Octenidine), larval therapy, and activated carbon dressings serve purposes such as biofilm removal, odor control, and non-traumatic debridement.
  • Choice of advanced therapies must account for wound condition, infection status, cost, patient readiness, and realistic goals, ideally in the setting of multidisciplinary care.

Managing Patient-Related (Social) Factors:

  • The “S” component in TIMERS addresses social circumstances—such as patient literacy, belief systems, psychosocial status, adherence, and support networks—that profoundly influence outcomes.
  • Effective wound care requires patient engagement, tailored education, motivational interviewing, goal setting, and active listening to align care with individual life contexts.
  • Understanding and addressing these factors creates a strong foundation for healing and significantly improves the success of advanced therapies.

Conclusion: Integrating advanced wound therapies with a robust strategy for managing social and patient-related determinants under the TIMERS framework enables truly holistic, patient-centered wound management—especially vital in complex or recalcitrant cases.

Keywords:
Menna Lloyd Jones,
TIMERS framework,
advanced therapies,
adjunctive products,
patient-related factors,
holistic wound care,
debridement

Read the full article on Wound Care Professional

MolecuLight Point-of-Care Wound Imaging Devices Awarded Group Purchasing Agreement with AllSpire Health GPO

Contract Awarded for Products that Bring Improvement to the Health Care Industry

 

PITTSBURGH, Sept. 29, 2022 /PRNewswire/ – MolecuLight Corp., the leader in point-of-care fluorescence imaging for the real-time detection of bacteria in wounds, announces it has been awarded a new group purchasing agreement with AllSpire Health GPO, a Mid-Atlantic GPO and a partner of HealthTrust Purchasing Group, engaged with over fifty hospitals in Maryland, New Jersey and Pennsylvania. AllSpire helps health systems optimize their operations by aggregating purchasing volumes, expenses, streamlining supplier negotiations and implementing efficiencies across the supply chain. The MolecuLight i:X® and DX™ wound imaging devices, which will now be available to AllSpire’s members, are helping clinicians to improve the state of wound care and ultimately to improve outcomes.

 

MolecuLightDX point-of-care imaging system for detection of elevated bacterial loads in wounds and for performing digital wound measurement and tracking (CNW Group/MolecuLight)

The MolecuLight imaging devices are the only FDA-approved devices that allow clinicians to visualize the presence, location, and load of bacteria (>104 CFU/g) in wounds in real-time. Published results from a recent 350-patient, 14-site clinical trial showed that the clinical standard of care alone detected 15% of wounds with elevated bacterial burden, while the addition of the MolecuLight device led to a 400% improvement in detecting these wounds2. The presence of elevated bacterial loads is known to impede wound healing1 and removal of bioburden is critical to improved wound outcomes1. The i:X and DX provide invaluable bacterial information at the point-of-care to inform clinical decision-making and enable targeted wound therapies. In a 2022 randomized controlled trial (RCT) 3, the highest level of evidence-based research, the improvement in healing rate at 12 weeks doubled in the patients that had care informed by MolecuLight fluorescence imaging compared to those that were not. Improvements in the patients’ quality of life were also reported. Another recent study reporting increased wound healing rates with the incorporation of bacterial information from MolecuLight imaging also found substantially decreased use of antimicrobial dressings and systemic antibiotics4. The MolecuLight devices also perform accurate digital wound measurement, allowing for the consistent monitoring and documentation of wounds.

 

“We are thrilled to have entered into a supply contract with AllSpire Health GPO,” says Anil Amlani, MolecuLight’s CEO. “Through the i:X and DX, we hope to enable significant cost-savings and improvements in clinical outcomes. AllSpire’s extensive member base can now easily access the MolecuLight wound imaging devices and see the clinical benefits in their wound care practices.”

 

“We are most impressed with the clinical utility that the MolecuLight i:X and DX devices provide to wound care professionals and are pleased to offer the MolecuLight portfolio via our Group Purchasing Agreement to our member hospitals”, says James Wallick, Senior Director, Strategic Sourcing at AllSpire Health GPO. “AllSpire is dedicated to sourcing the most innovative products that help to improve clinical decision-making and cost-efficiencies. We believe that the MolecuLight devices are highly innovative and will help to provide such clinical and operational benefits”.

 

In addition to the clinical benefits, MolecuLight procedures performed in the United States can benefit from an available reimbursement pathway including two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” procedures and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment.

 

  1. Caldwell et al. Surg Clin North Am, 2020, 100(4)
  2. Le et al. Adv Wound Care, 2021
  3. Rahma S. et.al Diabetes Care 2022;45(7):1601–1609
  4. Price et al. Diagnostics, 2020

 

About MolecuLight Corp.

MolecuLight Corp. is the US subsidiary of MolecuLight Inc., a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection of wounds containing elevated bacterial burden (when used with clinical signs and symptoms) and for digital wound measurement. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant unmet needs including food safety, consumer cosmetics and other key industrial markets.

 

About AllSpire Health GPO

 

Founded in 2016, AllSpire Health GPO, LLC is a collaborative, regional group purchasing organization utilizing innovation analytics, as well as product and purchased service standardization, as a platform to escalate the improvement of clinical outcomes, enable greater access to affordable healthcare, ensure economic sustainability, and enhance patient, physician, and clinician satisfaction among its members. AllSpire Health GPO delivers value via the development and execution of clinical and service line improvement initiatives across the care continuum.

 

SOURCE MolecuLight

Reducing the incidence and severity of pressure injuries in a high level care residential aged facility: a quality improvement project

Aims Reduce pressure injuries (PIs) in residents of a high level care facility by increasing staff knowledge and skills through clinical support and a skin integrity education package.

Method This project was a quality improvement (QI) activity and data were de-identified and reported in aggregate. Pre- and post-implementation data included staff knowledge testing and PI prevalence and severity.

Results Pre-implementation data indicated that staff knowledge was very limited, skin inspections and PI risk assessment were not performed, and use of pressure redistribution devices was low, with point prevalence at 64% of mainly severe PIs. Despite ongoing external clinical … read more

Clinical Achievement of Wound Closure and Tissue Quality

With a Novel Microvascular Tissue Graft

 

The authors aim to demonstrate the ability of processed microvascular tissue to enhance wound closure, increase local perfusion and vascular maturity, and improve overall tissue quality in several clinical cases of diabetic foot ulcers … view video

Medicare update: new electronic clinical quality measure

The Centers for Medicare and Medicaid Services (CMS) recently released an announcement seeking input from stakeholders on a new electronic clinical quality measure under development titled, “Hospital Harm – Hospital-Acquired Pressure Injury.”

 

This measure assesses the proportion of hospitalized patients 18 years and older who develop a new stage 2-4 pressure ulcer, deep tissue injury, unstageable pressure ulcer, or experience worsening of any of the above during their hospitalization.

 

We read the full description of the measure and provided the following feedback on behalf of APWCA membership … read more

Internet-Based Patient Education Materials Regarding Diabetic Foot Ulcers: Readability and Quality Assessment

David Michael Lee, Elysia Grose, Karen Cross

 

While diabetic foot ulcers (DFU) are a common complication of diabetes, little is known about the content and readability of online patient education materials (PEM) for DFU. The recommended reading grade level for these materials is grades 6-8. The aim of this paper was to evaluate the quality and readability of online PEM on DFU … read more


If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

New National Perioperative Guideline for Geriatric Surgical Quality Care is Released



New National Perioperative Guideline for Geriatric Surgical Quality Care is Released

Summary:** The American College of Surgeons and AGS have released a new perioperative guideline for geriatric patients, covering 9 domains including nutrition, UTI prevention, functional decline, and pressure ulcer care. It recommends preoperative assessments, frailty screening, and post-op mobilization to minimize complications like wounds from immobility. For pressure ulcers, it advocates risk screening, repositioning, and specialized surfaces, integrating with infection control for better recovery in surgical elderly.

Key Highlights:

  • Domains: 9 areas from pre-op to discharge; pressure ulcers addressed via Braden screening and preventive protocols.
  • Recommendations: Multidisciplinary teams; nutrition for healing; early mobilization to prevent decubitus.
  • Evidence: Based on 50+ studies; reduces readmissions by 20% with adherence.
  • Implementation: Tools for shared decision-making; focus on post-op wound monitoring.
  • Impact: Improves outcomes for 50%+ of surgical patients over 65.

Read full article

Keywords: geriatric surgery, pressure ulcer guideline, perioperative care, frailty screening, elderly wound management

Current Challenges in Wound Care

Chronic wound care is a wound that persists after 4-6 weeks, and a complex wound is one that a health care professional is the one who needs to take care of it. The lack of progression and the complex nature of the wounds are due to multiple reasons and can be explained by the following factors1:

  • patient-related factors (lack of assessment of comorbidities or factors contributing to the wound, and difficulties related to the patient’s behavior and cooperation);
  • factors related to the wound (surface, volume, damage to the noble tissues, misdiagnosis of the etiology of the wound, and lack of diagnosis of infectious or ischemic complications of the wound);
  • factors related to the skills and knowledge of health professionals (absence of standardized or appropriate care protocols);
  • factors related to environmental or social difficulties in terms of resources available for the treatment of the wound.

read more

Complex multilevel and multivessel endovascular revascularization through an occluded

femoral-popliteal bypass in a patient with chronic limb threatening ischemia
Chronic limb-threatening ischemia (CLTI) represents the end stage of peripheral artery disease, a problem of growing prevalence and increased health care costs around the globe. CLTI is a highly morbid disease, incurring significant mortality, limb loss, pain, and diminished health-related quality of life. The major cause of non-traumatic lower extremity amputation are related to diabetes and CLTI. Between 2% to 3% of patients with peripheral artery disease present with a severe case of CLTI, a condition that is correlated with multilevel and multivessel arterial disease, calcification, and chronic total occlusions. Multiple technical strategies to successfully cross long occlusions in arterial segments have been described. Recanalization can be performed using endoluminal, subintimal, and retrograde techniques … read more

Power to control bleeding Power to heal | LifeScience PLUS

LifeScience PLUS is a leader in advanced wound care technology. We are committed to developing and marketing innovative total wound care solutions: hemostasis (bleeding control), sealant, moist dressing, contamination prevention, and fast tissue growth generation. Our patented, best-in-class flagship product—BloodSTOP® iX Advanced Hemostat with WoundHEAL®—utilizes our revolutionary technology for both acute and chronic wound care.

BloodSTOP iX can be applied in many different specialty care areas with successful and positive outcomes. Our primary focus is to provide medical professionals an innovative product for EMS prehospital point-of-care treatment of traumatic wounds; for surgical procedures, including burn and trauma surgeries; and for treatment of diabetic ulcer and decubitus wounds … learn more

Use of ALLEVYN LIFE foam dressing to manage a heavily exudating venous leg ulcer

A 62-year-old man presented with a left lower leg venous ulcer on the shin. The ulcer had high exudate levels, which was resulting in strike-through of dressings and there was some evidence of surrounding skin maceration. Investigations revealed an ankle brachial pressure index (ABPI) of 1.4. ALLEVYN◊ LIFE Non-Bordered foam dressing (Smith & Nephew) was selected to manage and absorb high-levels of exudate and minimise the risk of trauma to the fragile surrounding skin. Multi-layer compression therapy was also used. After 3 weeks, the ulcer had reduced in size and there was a visible improvement in viable skin [Figures 2–5]. The patient found the dressing comfortable with excellent conformability to the lower leg and minimal pain on dressing removal …

read more (requires account)

New physicians want work-life balance in first job, survey says

by Richard Payerchin
Work-life balance is the most important factor for new physicians choosing their first jobs – possibly as a result of dealing with stresses brought on by COVID-19, according to a new survey … The responses confirmed and surpassed a similar finding from a study of 2018, according to health staffing consultant CHG Healthcare. The company announced the survey from its CompHealth division, which surveyed 145 physicians who had been out of residency for two to three years … read more


If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Life and Limb: Advances in the Management of the Diabetic Foot

By Chase Doyle
If untreated or unsalvageable, the diabetic foot requires surgical interventions to address the risks to its viability. However, recent advancements in the field suggest that surgeons may not always have to sacrifice a limb to save a life.

During the 2021 virtual American College of Surgeons Clinical Congress, Lucas M. Ferrer, MD, described the use of endovascular venous arterialization for limb salvage, and William P. Robinson, MD, discussed the timing of foot amputation after revascularization … read more


If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Prevention or Delay of Diabetes and Associated Comorbidities

ADA 2025 Standards: Prevention or Delay of Diabetes and Comorbidities

The American Diabetes Association’s 2025 *Standards of Care in Diabetes* dedicates a key section to preventing or delaying type 2 diabetes and associated comorbidities, highlighting lifestyle management, screening protocols, and targeted pharmacotherapy.

Key Highlights:

  • Annual Monitoring: Individuals with prediabetes should be monitored at least annually (or more frequently based on risk) using A1C, fasting glucose, or OGTT to detect progression early.
  • Lifestyle First: Intensive lifestyle programs—emphasizing ≥7% weight loss and ≥150 minutes/week of moderate activity—can reduce the risk of developing diabetes by over 50%. Programs like DPP also showed long-term benefits extending up to 30 years post-intervention.
  • Evidence-Based Diets: Various eating patterns—including Mediterranean-style, low-carb, DASH, and plant-based diets—are endorsed, with flexibility based on individual preference and metabolic goals.
  • Nutrition Therapy Support: Referral to dietitians for individualized medical nutrition therapy and counseling has proven effective at achieving weight loss, improved glycemia, and delay of progression in prediabetes.
  • Metformin & Medications: Metformin is recommended for high-risk individuals (BMI ≥35 kg/m², age 25–59, elevated A1C/glucose, or history of gestational diabetes) as an adjunct to lifestyle changes. Other agents like TZDs and GLP‑1 agonists are also mentioned for specific cases.
  • Tech-Enabled Delivery: Diabetes Prevention Programs delivered via technology are recognized—when CDC-approved—as viable, with telehealth and mobile apps expanding access, though retention among younger and underserved groups remains a challenge.

This guidance underscores a structured, multi-layered prevention model: routine risk assessment, personalized lifestyle intervention, dietician-led support, and selective pharmacotherapy, with technology gradually bridging access gaps.

Based on “Prevention or Delay of Diabetes and Associated Comorbidities,” *Diabetes Care*, Supplement 1, January 1, 2025 (Volume 48, S50–S58).

Keywords: prediabetes monitoring, lifestyle intervention, medical nutrition therapy, metformin prevention, diabetes prevention programs

Read the full ADA standards section on Diabetes Care

The Human Body Is Designed to Walk: Insights from Linda Rusiecki, DPT

The Human Body Is Designed to Walk: Insights from Linda Rusiecki, DPT

In her article, “The Human Body Is Designed to Walk: It Thrives When It Walks”, Linda Rusiecki, DPT, Inpatient Rehabilitation Educator at Corewell Health, emphasizes the fundamental role of walking in human health and the importance of mobility aids in supporting this function. She underscores that walking is not only essential for physical well-being but also for psychological and emotional health.

Key Highlights:

  • Evolutionary Perspective: Rusiecki discusses how the human body has evolved to walk upright, making walking a natural and necessary activity for maintaining health.
  • Health Benefits: Regular walking contributes to improved cardiovascular health, enhanced mood, better balance, and increased independence, especially in older adults.
  • Role of Mobility Aids: For individuals facing mobility challenges, appropriate aids such as walkers, canes, or prosthetics can facilitate walking, thereby promoting autonomy and quality of life.
  • Rehabilitation Focus: In rehabilitation settings, encouraging walking with or without aids is a primary goal to restore function and prevent complications associated with immobility.

Rusiecki’s insights highlight the intrinsic link between walking and overall health, advocating for the use of mobility aids as tools to enhance movement and independence. Her perspective serves as a reminder of the importance of maintaining mobility throughout all stages of life.

Read the full article on the Medical Tech Outlook website.

Keywords:
walking,
mobility aids,
rehabilitation,
Linda Rusiecki,
Corewell Health

Why Podiatry Should Be a First-Line Strategy in Diabetes Management

Why Podiatry Should Be a First-Line Strategy in Diabetes Management

Summary: While diabetes care often focuses on blood sugar, cardiovascular risk, and weight management, foot health remains one of the most critical yet overlooked aspects. With updated guidelines and digital tools available in 2025, podiatry should be recognized as a first-line strategy for preventing complications, reducing amputations, and preserving quality of life.

Key Highlights

  • The overlooked connection: Up to 25% of people with diabetes will develop a foot ulcer in their lifetime, many of which progress to amputation if untreated.
  • Preventive care: Routine podiatric exams by primary care and endocrinology teams should be part of every diabetes visit, even when patients are asymptomatic.
  • Insurance barriers: Limited coverage for preventive foot care discourages early intervention. Policy changes incentivizing regular podiatry visits could lower long-term costs.
  • Multidisciplinary models: Clinics integrating podiatrists with endocrinologists and vascular specialists provide coordinated care that reduces delays and improves outcomes.
  • Patient-centered strategies: Education campaigns, digital reminders, and resources like Healthcare.pro empower patients to prioritize foot health.
  • Updated guidelines: Recognizing podiatry alongside glycemic control and cardiovascular outcomes signals that foot health is central to comprehensive diabetes care.

Conclusion

Podiatry is not secondary—it is a first-line defense against diabetic complications. By making podiatry central to diabetes management, clinicians can reduce amputations, lower costs, and protect mobility and independence. The future of comprehensive diabetes care must include proactive podiatric strategies.

FAQs

Why is podiatry important in diabetes management?
Because diabetic foot complications are common and costly, podiatry helps prevent ulcers and amputations through early detection and treatment.

What new technologies are supporting diabetic foot care?
Smart insoles, thermal imaging socks, and AI-driven image analysis detect problems earlier and improve monitoring.

Do drugs like Ozempic and Mounjaro help with foot health?
Indirectly, yes—by improving glycemia, weight loss, and vascular health, these therapies reduce risk factors that contribute to foot complications.

How often should patients with diabetes see a podiatrist?
At least once a year for low-risk patients, more frequently for those with neuropathy, vascular disease, or prior ulcers.

Can preventive podiatric care reduce healthcare costs?
Yes. Early podiatric intervention prevents ulcers and amputations, lowering long-term healthcare spending.

Read the full article at Diabetes in Control

Keywords:
podiatry,
diabetes management,
foot ulcers,
amputation prevention,
diabetic foot care

Wound Care: Wearable Sensors and Systems for Wound Healing-Related pHand Temperature Detection

Wound healing is a delicate tissue regeneration procedure that entails numerous changes in various physiological parameters.

FREMONT, CA: Wearable sensors and systems refer to devices that can detect minute amounts of biological or chemical analytes and convert chemical reactions or physical changes into usable signals (optical or electrical signals, for example) following predefined rules. Wearable sensors/systems for monitoring markers in or around the wound environment can provide real-time symptom information and hold promise for therapy studies, which also meets the World Union of Wound Healing Societies’ requirement that “diagnostic tools be moved into the clinic or patient’s home to ensure optimal care is provided for patients with wounds.” Researchers have developed various wearable sensors/systems based on optical (fluorescence, colorimetry, etc.) or electrical (impedance, potentiometry, amperometry, etc.) mechanisms integrated with conventional wound dressings to form innovative wound dressings. These smart wound dressings convert changes in these biomarkers into visual or electrical signals, allowing for real-time monitoring of wound healing … read more

Hydrosurgical Debridement Use Associated With Decreased Surgical Site-Related Readmissions: A Retrospective Analysis

Debridement is the cornerstone of wound care management. It allows for the removal of fibrinous and necrotic debris from the wound bed as well as the reduction of bacterial bioburden, thus allowing for proper granulation and wound healing. Hydrosurgical debridement uses a controlled, high-pressure fluid jet to cut and remove necrotic debris, contaminants, and bacteria, thereby facilitating a potentially more aggressive debridement. Objective. The efficacy of this system was compared with that of other methods of debridement in reducing … read more

Resurgence of diabetes-related nontraumatic lower extremity amputation

     in the young and middle-aged adult U.S. population

 

We are grateful to Linda Geiss and her coworkers at CDC for their always intriguing efforts at revealing the big picture to us. These data– which certainly aren’t welcome news– are supremely important. Do they signal what we’ve posited for some time? Did the increase in the “denominator” of people with diabetes in the mid-1990s initially reduced the proportionate pool of high risk patients (and thereby reduced amputation rates)? Was it better team care? Whatever the explanation, we have yet more data on which to ruminate … read more

HbA1c, wound healing unrelated in diabetic foot ulcers

Among patients with long-term diabetic foot ulcers, neither baseline HbA1c nor change in HbA1c was associated with wound healing time, according to findings from a clinic-based observational study.

 

“Although we know that chronic hyperglycemia leads to neuropathy and peripheral vascular disease, which are the proximal risk factors for diabetic foot ulcers, we did not see a clear association between HbA1c levels and wound healing in patients who have developed foot ulcers,” Nestoras Mathioudakis, MD, MHS, assistant professor of medicine and clinical director, division of endocrinology, diabetes and metabolism at Johns Hopkins University School of Medicine, told Endocrine Today. “It is likely that the damage induced by chronic hyperglycemia reaches a point where it cannot be reversed in a relatively short time frame to improve wound healing.”

read more

Time in Range Is Closely Related to Healing Time of Diabetic Foot Ulcers

Time in Range Predicts Healing Time in Diabetic Foot Ulcers

A pilot prospective study conducted at Vall d’Hebron Hospital Campus (Barcelona) evaluated whether continuous glucose monitoring (CGM) metrics—specifically Time in Range (TIR), Time Above Range (TAR), and Glucose Management Indicator (GMI)—correlate with healing duration in outpatients with uncomplicated diabetic foot ulcers (DFUs, University of Texas Grades I–II Stage A–C).

Key Highlights:

  • CGM Metrics Matter: Higher TIR was strongly associated with faster ulcer closure (p = 0.005), while prolonged TAR and elevated GMI were linked to slower healing (p < 0.05).
  • Practical Outpatient Use: CGM devices were worn until wound closure, offering real-time glycemic data in a typical outpatient setting, enhancing its clinical relevance.
  • Impact on Wound Care: These findings suggest that optimizing TIR can actively influence DFU healing timelines, moving beyond HbA1c as the sole indicator of glycemic control.

This study strengthens the growing evidence that CGM-derived TIR is a valuable biomarker for predicting and potentially improving healing outcomes in diabetic foot ulcers.

Read the full article in Wound Repair & Regeneration.

Keywords:
Time in Range,
continuous glucose monitoring,
diabetic foot ulcer,
wound healing,
glycaemic control

Reframing Diabetes Treatment as Diabetes Prevention

Reframing Diabetes Treatment: A Shift Toward Prevention

A recent article from Podiatry Today advocates for a proactive approach to diabetes management, emphasizing prevention over reactive treatment. By focusing on early intervention and lifestyle changes, healthcare providers can reduce complications, including diabetic foot ulcers, and improve patient outcomes.

Key Highlights:

  • Preventive Focus: Early education and lifestyle modifications, such as diet and exercise, are critical to preventing diabetes progression and related complications.
  • Foot Health Emphasis: Regular podiatric assessments can identify risks early, reducing the incidence of ulcers and amputations in diabetic patients.
  • Patient Empowerment: Encouraging patient engagement through education and self-care practices fosters better long-term health outcomes.
  • Interdisciplinary Approach: Collaboration between podiatrists, endocrinologists, and primary care providers is essential for comprehensive diabetes prevention strategies.

This perspective shift offers clinicians actionable insights to prioritize prevention in diabetes care, particularly for foot-related complications.

Read the full article on the HMP Global Learning Network website.

Keywords:
Diabetes prevention,
Diabetic foot ulcers,
Podiatric care,
Patient education,
Preventive healthcare,
Robert G. Smith

Swift Medical Announces Proven Outcomes Across 20 Million Wound Assessments

Swift’s AI-powered wound imaging technology shown to improve quality of care and costs to manage complex patients

June 01, 2023 09:00 AM Eastern Daylight Time
TORONTO–(BUSINESS WIRE)–Swift Medical, a digital health technology company focused on improving clinical and economic outcomes in wound care, today announced proven outcomes from more than 20 million wound assessments captured with Swift’s leading, AI-powered wound care platform. Deployed in nearly 4,000 healthcare facilities across North America, Swift’s technology has been shown to speed up wound healing by 37%, reduce wound prevalence and hospitalizations by 35% and 14%, respectively, and reduce hospital length of stay by 62%.

“We are proud to share the incredible impact our technology is having on the millions of patients living with wounds – one of today’s most expensive and overlooked threats to patients and our overall healthcare system”

Tweet this
“We are proud to share the incredible impact our technology is having on the millions of patients living with wounds – one of today’s most expensive and overlooked threats to patients and our overall healthcare system,” said Brian Litten, CEO of Swift Medical. “These outcomes demonstrate the impact of having the most powerful wound image dataset in the world and its ability to deliver high quality wound care with reduced costs.”

The Swift Skin & Wound mobile application enables any mobile device to be equipped with AI-powered imaging capabilities to capture clinically validated, high-precision 3D images, measurements, and other clinical data. The imaging captured at the point of care enables real-time, at-risk patient monitoring, proactive decision-making, and remote wound consultations, reducing the time and cost spent evaluating wounds to create a more efficient wound care experience for both clinicians and patients.

Today, more people suffer from chronic wounds than those with breast cancer, colon cancer, lung cancer, and leukemia combined. Despite this costly, growing problem, the current standard of care is outdated and highly inaccurate. Clinicians typically receive less than 10 hours of formal education and rely on paper rulers for measurements and cotton swabs for depth assessment. This inefficient and ineffective approach is both painful for patients and leads to poor diagnostic accuracy, prolonged healing, and inappropriate selection of therapies, putting patients at greater risk for readmission, longer lengths of stay and higher care costs.

With its advanced analytics and proven outcomes, Swift is now poised to partner with health plans and risk-bearing providers to deliver high quality, value-based wound care at scale.

About Swift Medical

Swift Medical is the global leader in digital wound care. We are headquartered in Toronto, with operations expanding across the U.S. and Canada. Our mission is to make empathy-driven wound care ubiquitous through AI-powered diagnostic technology. We are the trusted wound technology partner of more than 4,000 healthcare facilities in North America across the continuum of care. Our solutions empower healthcare providers to deliver standardized, accessible and equitable wound care for every patient – with advanced, high-precision imaging, compliant documentation, clinical analytics and remote care. To learn more about Swift Medical, visit us at www.swiftmedical.com.

Contacts
Media

David Mannion
416-303-8020
david.mannion@swiftmedical.com

University Health Opens Clinic Aimed at Preventing Diabetic Amputations



University Health Opens Clinic Aimed at Preventing Diabetic Amputations

Summary: University Health has launched a new Limb Salvage Clinic at the Texas Diabetes Institute in San Antonio to combat the rising tide of diabetes-related foot ulcers and amputations in Bexar County, where 15% of residents (up to 239,000 people) live with diabetes—higher than state and national averages. Led by interventional cardiologist Dr. Anand Prasad, the clinic offers comprehensive, one-stop services including podiatric wound monitoring, debridement, minimally invasive vascular procedures like angioplasty with dissolvable stents, and preventive care for peripheral artery disease (PAD) and neuropathy. Highlighting the urgency, the facility treated its first patient, 50-year-old Charlie Treviño, a diabetic construction worker with a recent foot ulcer post-heart surgery, aiming to restore blood flow and promote healing to avoid limb loss. By integrating podiatry, cardiology, and vascular surgery, the clinic addresses rapid wound progression—potentially infecting within days—and underserved needs in high-risk Hispanic and Black communities, targeting 20+ patients weekly for faster, multidisciplinary intervention.

Key Highlights:

  • Bexar County diabetes prevalence: 15% (239,000 people), with some zip codes over 20%; lifetime foot ulcer risk for diabetics: 25-33%; U.S. annual diabetic amputations: >100,000.
  • Clinic location: Texas Diabetes Institute, South Zarzamora Street, San Antonio; services include wound debridement, offloading, vascular angioplasty, and collaborative podiatry-cardiology care.
  • First patient case: Charlie Treviño received immediate podiatric evaluation and planned stent procedure to improve leg/foot circulation, emphasizing early intervention for non-healing ulcers.
  • Expert insights: Dr. Michael Sobolevsky calls San Antonio the “diabetic foot capital of the world”; Dr. Ivana Akinyeye stresses single-visit efficiency as “time is of the essence” for ulcers.
  • Broader impact: Addresses PAD/neuropathy causing poor healing; aims to reduce lifelong disability in underserved areas, with plans for vascular surgery integration and expanded staffing.

Read full article

Keywords: limb salvage clinic, diabetic foot ulcers, amputation prevention, peripheral artery disease, multidisciplinary wound care

AOTI Receives China FDA Approval for Topical Wound Oxygen (TWO2) Therapy

Providing Renewed Hope for World’s Largest Diabetic Foot Ulcer Population

 

OCEANSIDE, Calif., March 23, 2022 /PRNewswire/ — Advanced Oxygen Therapy Inc. (AOTI), the global leader in noninvasive topical oxygen wound healing solutions, announced today that is has received Chinese National Medical Products Administration (NMPA), commonly referred to as China FDA, approval for its unique cyclically pressurized Topical Wound Oxygen (TWO2) therapy. Making it the only advanced sustained wound healing therapeutic to have achieved such a designation and allowing the company to now commence marketing in China with its local partner.

 

China has the world’s largest Diabetic and resultingly Diabetic Foot Ulcer (DFU) population. The International Diabetes Federation estimates that 10.6% of the Chinese adult population now have diabetes that equates to 141 million people. This represents a 56%, or 50 million person, increase in the last 10 years alone.1 In China, the annual incidence of DFU and Amputation has recently been reported to be 8.1% and 5.1% respectively, representing a staggering 11.4 million ulcerations and 7.2 million preventable lower extremity amputations every year.2

 

AOTI’s globally patented TWO2 homecare therapy has been demonstrated in recently published high-quality Randomized Controlled Trial 3 and Real Word Evidence 4 studies to provide more durable complete DFU healing. Resulting in six-fold reductions in ulcer recurrence, with an unprecedented 88% reduction in hospitalizations and 71% reduction in lower extremity amputations seen over 12 months. Such sustained healing provides patients with renewed hope of limb preservation, while offering significant reductions in healthcare resource utilization with resultant health economic savings.

 

Professor Andrew Boulton, past-President of the European Association for the Study of Diabetes and Professor of Medicine at the University of Manchester, UK and University of Miami, USA, and Chairman of AOTI’s Scientific and Clinical Advisory Board, commented: “Diabetes is one of the fastest growing global health emergencies of the 21st century. It is a real game-changer to finally have clinically proven homecare therapeutics like TWO2 available that make meaningful impact in such critical outcomes as hospitalizations and amputations. Now that TWO2 therapy is authorized in China, the world’s largest diabetic foot ulcer population has a renewed hope for better outcomes.”

 

1 International Diabetes Federation. IDF Diabetes Atlas, 10th Edition. Brussels, Belgium: 2021. Available at: https://www.diabetesatlas.org

 

2 Development and validation of a brief diabetic foot ulceration risk checklist among diabetic patients: a multicenter longitudinal study in China. Zhou, Q., Peng, M., Zhou, L. et al. Nature, Sci Rep 8, 962 (2018). https://doi.org/10.1038/s41598-018-19268-3

 

3 Multinational, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy of Cyclical Topical Wound Oxygen (TWO2) Therapy in the Treatment of Chronic Diabetic Foot Ulcers; The TWO2 Study. Robert G. Frykberg et al, Diabetics Care 2020; 43:616-624. https://doi.org/10.2337/dc19-0476.

 

4 Reduced Hospitalizations and Amputations in Patients with Diabetic Foot Ulcers Treated with Cyclical Pressurized Topical Wound Oxygen Therapy: Real-World Outcomes; Jessica Izhakoff Yellin, et al; Advances in Wound Care 2022; http://doi.org/10.1089/wound.2021.0118

 

About AOTI
AOTI is a privately-owned company based in Oceanside, California USA and Galway, Ireland that provides innovative solutions to resolve severe and chronic wounds worldwide. Our products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. Our patented non-invasive Topical Wound Oxygen (TWO2) homecare therapy is clinically proven to deliver Sustained Wound Healing that reduces both Amputations and Hospitalizations, So Life Can Get Back to Normal.

 

For more information see: www.aotinc.net
Dr. Mike Griffiths
CEO & President
332487@email4pr.com
(760) 672 1920
SOURCE AOTI Inc.

Observational Study of Venous Leg Ulcer Treated With a Native Collagen-Alginate Dressing and …



Observational Study of Venous Leg Ulcer Treated With a Native Collagen-Alginate Dressing and the Impact on Wound-Related Quality of Life

Summary: In an observational single-center study of 60 patients with non-healing venous leg ulcers (VLUs; mean duration 1.5-24 months), a collagen-alginate dressing with standard care (compression, debridement) reduced mean wound area from 17.8 to 11.4 cm² (32% relative reduction, P<0.0001) over 4 weeks, with 8% complete closure. Pain dropped (VAS 3.9 to 1.7, P<0.0001), analgesic use halved, and QoL improved (total score P<0.0001), correlating with wellbeing gains. Clinicians rated it 'very good' (98%), with no serious AEs, positioning it as effective for stalled VLUs.

Key Highlights:

  • Wound area: 32.2% mean reduction; 4/50 complete closures (8%).
  • Pain: VAS decreased 2.2 points; pain-free patients rose from 15% to 49%; analgesics from 61% to 33%.
  • QoL: Total score improved; wellbeing sub-score correlated with area reduction (P=0.0002).
  • Safety: 8 moderate AEs (unlikely related); exudate reduced 43%; periwound improved.
  • Authors: Alisha Oropallo, MD; Amit Rao, MD; Sally Kaplan, RN; Farisha Baksh, BS; Christina Del Pin, MD; Julie Isgro, NP.

Read full article

Keywords: collagen alginate, venous leg ulcer, wound QoL, compression therapy, VLU healing

The Wound Company Launches With $4.25M In Funding To Curb the Amputation Epidemic And Save The Healthcare System Billions

Led by Susa Ventures and Sozo Ventures, the funding will be used to transform the $45B wound and ostomy care industry by bringing on-demand experts to more patients and providers in need via telehealth and in-person visits

 

Minneapolis, MN – WEBWIRE – Thursday, June 15, 2023

The Wound Company, a multi-channel on-demand wound and ostomy care delivery company that improves patient outcomes, today announced its launch from stealth with $4.25M in seed funding from Susa Ventures and Sozo Ventures. The funding will be used to expand the company’s national footprint, hire top talent, and to continue improving health outcomes in the most cost-effective way possible while bringing dignity to the over 13 million people in need of improved wound and ostomy care.

Why Wound Care Matters

The US is experiencing an amputation epidemic due to diabetic foot ulcers and other serious wounds. Despite medical advancements, Americans are amputating double the number of limbs today than during the Civil War. About 50% of lower extremity amputations would have been preventable if patients with type 2 diabetes and foot ulcers had access to better healthcare. This issue is one of the problems The Wound Company is solving for.

Often providers need more wound care expertise or, due to understaffing, don’t have time to offer comprehensive care continuously, leaving patients to figure it out on their own. This leads to wound care patients returning to the hospital due to improper wound care. But it can be prevented.

“The wound and ostomy care industry is broken,” said Nima Ahmadi, founder and CEO of The Wound Company. “It’s operating in the fee-for-service world, which pushes expensive procedures and products that help the bottom line, but don’t impact outcomes for the patient. We’re paid to heal wounds with continuous care and, in doing so, save money for health plans and at-risk providers.”

Enter The Wound Company

The Wound Company aims to fix the broken space of wound and ostomy care by using predictive analytics and multi-channel communications to deliver the right wound and ostomy care to the right patient in the right channel at the right time. The tech connects patients and providers to wound and ostomy experts virtually or via in-person visits to ensure they have top-tier care.

“The Wound Company’s innovative technologies have the potential to save health plans billions of dollars and transform the patient experience,” says Susa Ventures Investor Derick En’Wezoh. “With a dedicated team of highly experienced experts, a strong vision, and a passion for improving healthcare outcomes, this tech will save lives.”

The platform also offers clinical reporting, customer data integration, and workflow automation to make care delivery as painless as possible for providers.

While in stealth, The Wound Company has already partnered with health plans, health systems, home care providers, hospice providers, and patients, with significant results to date:

  • A potential 15-20% reduction in the total cost of care for wound and ostomy patients for payers
  • Up to 50% savings on supplies per patient for home and hospice care providers
  • 60% of patients demonstrated progressive healing week after week
  • 90% of Stage I/II pressure ulcers resolved without advancing to a higher stage
  • 100% of ostomy patients have a predictable pouching system and reduced chance of ER visits or readmissions

 

“Our blend of virtual and in-person services provided by passionate experts in wound care helps people heal quickly, safely, and with the dignity they deserve while helping to alleviate the pressure on overworked healthcare professionals,” said Chief Medical Officer Sanford Roberts.

The Wound Company is open to partnerships with health plans, at-risk providers, home health providers, and hospice care providers. For more information, visit www.thewound.co.

About The Wound Company

The Wound Company is a Minneapolis-based technology company dedicated to advancing wound and ostomy care. The company uses proprietary technology to connect providers with experienced and certified wound care specialists who can care for patients virtually or via in-person visits. The Wound Company partners with health plans, home care companies, and providers to bring dignity to patients with wounds and ostomies while increasing positive patient outcomes.

This article was originally published here

Preventable Wounds Are Costing Texas Patients Their Health and Facilities Their Reputation

Preventable Wounds Are Costing Texas Patients Their Health and Facilities Their Reputation

Summary: Agape Life Multicultural Services (ALMS) is expanding its mobile wound care services across Texas, aiming to reduce hospital readmissions and improve outcomes by delivering wound care where patients live—homes, nursing facilities, rehab programs, etc. They emphasize early intervention (within days of hospital discharge) to prevent complications in chronic, diabetic, pressure, and surgical wounds.

Key Highlights:

  • ALMS is now serving areas including Mansfield, Dallas, Arlington, Grand Prairie, and others.
  • The model involves seeing discharged patients within the critical 7–14-day window to avoid wound deterioration that leads to readmission.
  • Focus is on both prevention and early treatment to reduce burden on hospitals and improve patient quality of life.
  • The expansion includes working with skilled nursing, assisted living, home health, LTACs, and rehab facilities to close gaps in care continuum.

Read the full press release on PRLog

Keywords:
mobile wound care,
preventable wounds,
hospital readmissions,
Texas wound care,
chronic wound prevention

Measuring Pressure Redistribution Properties of 4 Hospital Bed Surfaces: A Quality Improvement Project

Oleg Teleten, MS, RN, CWCN
Tatyana S. Polyak, MD
Jessica Espinoza, OTS
Andrew I. Li
Ariel J. Rodgers, MD
Holly Kirkland-Kyhn, PhD, FNP, GNP, CWCN, FAANP

 

Pressure ulcers/injuries (PU/Is) are still highly prevalent in the acute care setting. According to the Joint Commission Center for Transforming Healthcare (2021), more than 2.5 million patients in US acute care facilities are estimated to have PU/Is each year, and 60,000 die of their associated complications.1 PU/I development has many contributing factors, including prolonged pressure over bony prominence due to inactivity/immobility, shearing between skin surface and mattress/seating surface,2 poor perfusion,3 tissue ischemia, and prolonged high surface interface pressure.4-6 Incidence of PU/Is has been shown to be associated with increased disease burden, financial burden, and increased in-hospital mortality rates … read more

We come to you: recognising the challenges of access to quality wound specialists

We Come to You: Expanding Access Through Post-Acute Mobile Wound Care

This editorial from JWC Wound Central highlights the growing importance of mobile wound care services in addressing barriers to access for patients with hard-to-heal wounds. As populations age and mobility challenges rise, many patients are unable to access advanced care through traditional outpatient clinics—whether due to location, physical limitations, social isolation, or lack of insurance coverage.

Key Highlights:

  • Rising Need for Access: Post-acute mobile wound care has emerged to meet the growing need for at-home or facility-based services across hospitals, nursing homes, assisted living facilities, and group homes.
  • Technology On-the-Go: These mobile services offer patients access to cutting-edge tools like CAMPs (cellular, acellular, matrix-like products) and near-infrared spectroscopy previously limited to wound centers.
  • iPAWS Summit 2024: The inaugural International Post-Acute Wound Society (iPAWS) Summit, held in New Orleans, convened over 200 clinicians to advance education, business models, and competency-based training for mobile wound care providers.
  • Featured Sessions:
    • Medical Necessity Documentation – William O’Malley, former Medicare Auditor
    • The Business of the Mobile Model – Dennis Deruelle, MD; Martha Kelso, RN, CHWS, DAPWCA, HBOT; and Naz Wahab, MD
  • Call to Action: As mobile wound care rapidly becomes a core element of the specialty, education and advocacy must grow alongside it to ensure equitable, expert-level care reaches every patient in need—regardless of setting.

This movement underscores a shift in wound care delivery—meeting patients where they are, while embracing technological innovation and reshaping access across the care continuum.

Keywords:
post-acute wound care,
mobile wound care,
iPAWS,
Martha Kelso,
Dennis Deruelle,
Naz Wahab,
William O’Malley,
cellular acellular matrix,
near-infrared spectroscopy,
wound access equity

Read the full editorial in JWC Wound Central

Durable Healing Outcomes of Topical Wound Oxygen (TWO2) Therapy Highlighted at Leading International Clinical Conferences

OCEANSIDE, Calif., Aug. 26, 2021 /PRNewswire/ — Advanced Oxygen Therapy Inc. (AOTI) announced today that its unique multimodality Topical Wound Oxygen (TWO2) therapy was recently highlighted at multiple leading international clinical conferences across the United States and United Kingdom. AOTI participated both as a sponsor and exhibitor at these events that were conducted in a hybrid format, where attendance could be either in person, or virtually, to allow for the greatest clinician engagement, something that has now become standard during the ongoing COVID-19 pandemic.

 

Clinical Societies
Clinical Societies
The prestigious Malvern Diabetic Foot Conference, the world’s longest standing international multidisciplinary diabetic foot meeting, was held in Malvern, UK, from July 7 – 9, where during the New Treatments for Diabetic Foot Lesions session, the growing portfolio of high quality clinical evidence supporting the effectiveness of cyclical-pressure TWO2 therapy in healing DFU, was expertly summarized by Professor Robert Frykberg, DPM, MPH., who also presented the results from the recently published paper entitled: Topical oxygen therapy for diabetes-related foot ulcers: A systematic review and meta-analysis, by Professor Golledge et al., which further highlighted the strength of the TWO2 RCT.

 

The Annual Scientific Meeting (The National) of the American Podiatric Medical Association was held in Denver, USA from July 29 – August 1, where a breakthrough abstract by Matthew G. Garoufalis, DPM and Aliza M. Lee, DPM, MS, entitled: The Power of TWO2: Real World Evidence of the Long-Term Healing and Health Benefits of Cyclical Pressurized Topical Wound Oxygen Therapy in Diabetic Foot Ulcerations was presented, further demonstrating significant reductions in Hospitalization and Amputations over 12-months for DFU patients treated with TWO2, compared to those who were not.

 

The 2021 Vascular Annual Meeting of the Society for Vascular Surgery was held in San Diego, USA from August 18 – 21, where during a Vascular Live Presentation, entitled: TWO2 Therapy for Healing DFU and VLU: Reducing Hospitalizations and Amputations, the eminent vascular surgeon, Anil Hingorani, MD, summarized the cyclical oxygen pressure noncontact compression mechanism of action of TWO2, reviewed real word cases and even provided a video testimonial from a patient who had suffered with nonhealing Venous Leg Ulcers (VLU) for years, until finally healing with the addition of TWO2 therapy.

 

Dr. Mike Griffiths, CEO and Medical Director of AOTI, commented; “AOTI is proud to continue to support the world’s leading clinical societies and wound care physicians in their quest for more durable healing of Diabetic Foot Ulcers and Venous Leg Ulcers by utilizing our unique multimodality approach. Our evidence-based TWO2 therapy is applied by the patient safely at home, which when combined with our enhanced Telehealth features, helps clinicians maintain critical continuity-of-care during the ongoing COVID-19 pandemic. It is especially rewarding to hear in a patient’s own words the significant impact that durably healing their refractory wounds has on their daily lives. It’s both quite humbling and motivating for us all to continue in our cause to make TWO2 therapy available to all who could benefit from its life altering outcomes.”

 

About AOTI

AOTI is a privately-owned company based in Oceanside, California USA and Galway, Ireland that provides innovative solutions to resolve severe and chronic wounds worldwide. Our products reduce healthcare costs and improve the quality of life for patients with these debilitating illnesses. Our patented non-invasive Topical Wound Oxygen (TWO2) therapy is unsurpassed in closing all chronic wound types.

 

For more information see: www.aotinc.net

Contact:
Dr. Mike Griffiths
CEO and Medical Director
317543@email4pr.com
(760) 672 1920

SOURCE AOTI Inc.

The Challenges Faced by Clinicians in Providing a Telehealth Service for Aboriginal Patients with Diabetic Foot Complications



The Challenges Faced by Clinicians in Providing a Telehealth Service for Aboriginal Patients with Diabetic Foot Complications in Rural and Remote Western Australia

Summary: Authors Johanna Lee van Rooyen and Donna Evelyn Larsen present two case reports of Aboriginal patients from remote Western Australia with severe diabetic foot infections. The cases illustrate key challenges: late presentation, limited local resources, workforce transience, poor image quality in telehealth, and the need for culturally safe care. Multidisciplinary collaboration and strong regional relationships are essential for better outcomes.

Key Highlights:

  • Late presentation and delayed specialist access in remote communities
  • Difficulties with telehealth (image quality, supply chain, staff training)
  • Importance of cultural safety, Aboriginal Liaison Officers, and family involvement
  • Need for sustained multidisciplinary support beyond metropolitan centres

Read full article

Keywords: telehealth DFU, Aboriginal diabetic foot, rural wound care

Electrical Stimulation for Pressure Injuries: A Health Technology Assessment

Pressure injuries (bedsores) are common and reduce quality of life. They are also costly and difficult to treat. This health technology assessment evaluates the effectiveness, cost-effectiveness, budget impact, and lived experience of adding electrical stimulation to standard wound care for pressure injuries … We conducted a systematic search for studies published to December 7, 2016, limited to randomized and non–randomized controlled trials examining the effectiveness of electrical stimulation plus standard wound care versus standard wound care alone for patients with pressure injuries. We assessed the quality of evidence through Grading of Recommendations Assessment, Development, and Evaluation (GRADE). In addition, we conducted an economic literature review and a budget impact analysis to assess the cost-effectiveness and affordability of electrical stimulation for treatment of pressure ulcers in Ontario. Given uncertainties in clinical evidence and resource use, we did not conduct … read more

The Most Positive Thing to Happen to Negative Pressure Wound Therapy

NEXA NPWT System Launched in the USA

OCEANSIDE, Calif.June 7, 2023 /PRNewswire/ — AOTI Inc, the global leader in multi-modality topical wound oxygen, announced exciting news from ongoing WOCNext conference in Las Vegas, Nevada, where their game changing NEXA Negative Pressure Wound Therapy (NPWT) system made its official USA debut.

The unique NEXA NPWT system is an incredibly flexible platform that is simple to use, silent, portable and affordable. NEXA seamlessly combines the simplicity of disposable NPWT with the performance features of more traditional durable NPWT technology platforms.

Dr. Mike Griffiths, CEO and President of AOTI commented; “Releasing the innovative NEXA NPWT platform in the USA is a major milestone for the company that will allow clinicians, payers, and patients alike to experience much improved performance at significantly lower cost. With NEXA, we have reimagined how NPWT should function.

Its addition to our portfolio only further enhances our mission of helping all people with chronic conditions get back to living their lives to the fullest.”

AOTI’s unique NEXA NPWT and Topical Wound Oxygen (TWO2) therapy are unlike any other treatment approaches. NEXA provided unrivaled flexibility and performance in a portable NPWT system. TWO2 is the only device that provides a multimodality treatment, combining higher pressure oxygen delivery with non-contact cyclical compression and humidity, in a therapeutic applied by the patient at home. This patented approach has been demonstrated in numerous Randomized Controlled Trial (RCT) and Real World Evidence (RWE) studies to not only heal chronic wounds at a far higher rate, but perhaps more importantly, keep them closed longer term, thereby reducing unnecessary hospitalizations and amputations.1, 2

1 Multinational, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy of Cyclical Topical Wound Oxygen (TWO2) Therapy in the Treatment of Chronic Diabetic Foot Ulcers; The TWO2 Study. Robert G. Frykberg et al, Diabetics Care 2020; 43:616-624. https://doi.org/10.2337/dc19-0476.

Reduced Hospitalizations and Amputations in Patients with Diabetic Foot Ulcers Treated with Cyclical Pressurized Topical Wound Oxygen Therapy: Real-World Outcomes; Jessica Izhakoff Yellin, et al; Advances in Wound Care 2022; http://doi.org/10.1089/wound.2021.0118

About AOTI

AOTI is a privately-owned company based in Oceanside, California USA and Galway, Ireland that provides innovative solutions to resolve severe and chronic wounds worldwide. Our mission is to help all people with chronic conditions get back to living their lives to the fullest. We do this by enhancing access to care, improving quality of life and advancing health equity. 
Our products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. Our patented Topical Wound Oxygen (TWO2) at home therapy is clinically proven to deliver Sustained Wound Healing that reduces both Amputations and Hospitalizations, So Life Can Get Back to Normal.

For more information see: www.aotinc.net

Contact:
Dr. Mike Griffiths
CEO & President
360322@email4pr.com
(760) 672 1920

SOURCE AOTI Inc.

Telehealth technology utilized at Signature HealthCARE

GLASGOW — Residents at Signature HealthCARE of Glasgow can avoid trips to a doctor’s office or to the hospital for treatment of some medical conditions thanks to telehealth technology through YourDoc2U.

 

With telehealth technology, health care providers can talk face-to-face with residents, as well as the staff at the nursing facility via computer screen that sits atop a cart enabling it to be moved from location to location as needed.

 

Psychiatric and wound care evaluations are the medical services available to the nursing facility residents through telehealth technology.

 

“If we identify a need with any of our elders, we call the primary physician and ask for a consult with telewound,” said Kim Poynter, director of nursing at Signature HealthCare of Glasgow. “It’s all online. They have nurse practitioners and physicians available. If it’s an emergency situation, like if we have an elder who is having a crisis and needs psych services, we either call in or get online and make an appointment. They are available 24/7.” read more

Key risk factors for diabetic foot reinfections uncovered in study

by Claire Kowalick, 

Texas has one of the highest rates of diabetes in the country, with more than 2.7 million Texans diagnosed with the condition. About one in six people in San Antonio have type 2 diabetes, and a third of residents are prediabetic, according to the American Diabetes Association.

Type 2 diabetes is a chronic condition in which the body cannot produce enough insulin or use insulin properly and, if left uncontrolled, can lead to high blood sugar, heart disease and kidney failure. It also predisposes people to foot ulcers, of which almost 50% become infected, subsequently leading to hospitalization and potentially amputation of part of the foot or a lower limb … full article

related:

Texas has one of the highest rates of diabetes in the country, with more than 2.7 million Texans diagnosed with the condition. This epidemic has significant implications for healthcare systems, particularly in the management of complications like diabetic foot ulcers (DFUs). In San Antonio, where approximately one in six residents has type 2 diabetes and a third of the population is prediabetic, the risk of developing DFUs is alarmingly high.

Diabetic foot ulcers result from a combination of neuropathy, poor circulation, and impaired immune response, all of which are common in individuals with long-standing diabetes. Without proper intervention, these ulcers can progress to severe infections, leading to hospitalizations, amputations, and increased mortality rates. Given the high prevalence of diabetes in Texas, hospitals and wound care centers face mounting challenges in treating and preventing these wounds effectively.

The economic burden of DFUs is also substantial. Studies indicate that treating a single DFU can cost tens of thousands of dollars, with the total cost of diabetic foot care in the U.S. exceeding billions annually. In areas like San Antonio, where diabetes rates are disproportionately high, local healthcare facilities must prioritize specialized wound care services, early detection, and preventive measures such as total contact casting (TCC) to offload pressure from wounds and enhance healing.

Community-wide initiatives are essential to combat this growing crisis. Increasing awareness about proper foot care, expanding access to podiatric and wound care specialists, and implementing preventive strategies—such as routine screenings for neuropathy and peripheral artery disease (PAD)—can significantly reduce the incidence and severity of DFUs. Additionally, addressing social determinants of health, such as limited access to quality healthcare, lower socioeconomic status, and dietary challenges, is crucial in mitigating the long-term consequences of diabetes-related foot complications.

As Texas continues to grapple with rising diabetes rates, proactive intervention and innovative wound care solutions will be key in preventing DFUs and improving patient outcomes.

A Compendium of Perspectives on Diabetes: A Challenge for Sustainable Health in the Modern Era

Diabetes is a chronic illness. Hyperglycemia is the characteristic of this disorder. Diabetes is a global crisis which affects the economy and health of all nations. Over the last decades, the number of individuals living with diabetes has significantly increased worldwide. Asia is a key epicenter of the emerging diabetes epidemic, with China and India the two nations having the highest number of diabetic people. Economic development, modernization, unhealthy diet, population aging, and sedentary lifestyles are the major factors responsible for the increasing diabetes epidemic. Diabetes is associated with several complications, and cardiovascular disease is the most important cause of morbidity and mortality among people with diabetes. These life-threatening problems can be prevented or delayed by proper management of diabetes. Lifestyle modification is an important factor to decrease the diabetes risk. The frequency of diabetic complications will rise if there is a lack of cost-effective and sustainable interventions. Hence, prevention of diabetes and its complications such as diabetic retinopathy and cardiovascular disease … read more

Urgo Medical announces NICE recommendation

     of UrgoStart for diabetic and venous ulcers

The UK’s National Institute of Health and Care Excellence (NICE) has published new guidance recommending UrgoStart wound dressings (Urgo Medical) for treatment of diabetic foot ulcers and venous leg ulcers. In a press release, Urgo Medical states that use of the wound dressing could prevent more than 3,000 diabetes-related amputations … The conclusion of the NICE medical technology guidance is that UrgoStart is associated with increased wound healing compared with non-interactive dressings and could result in fewer ulcer-related amputations. The committee recognised that the treatment is also associated with significant cost savings for the UK National Health Service (NHS) and improved quality of life for patients … read more

Spend a Minute, Save a Life

Inlow’s 60-Second Diabetic Foot Screen

 

Boulton states that “throughout our medical training, we are taught how to manage patients who present with symptoms, which usually leads to a clinical examination, a diagnosis, and a treatment and management plan. However, virtually no time is spent on teaching how to manage patients who have no symptoms because they have lost the ability to feel pain; that is, they have peripheral neuropathy.”1 Clinical experience and the literature1 have shown us that the lack of symptoms Boulton referred to in those with or at risk for diabetic foot complications can have devastating effects on the person, their family and health systems. As clinicians, we have the opportunity, and the obligation, to step in and fill the gap left when peripheral neuropathy is present, or potentially present, in any of our patients. The key is a simple, quick procedure: foot screening … read more

Reflections on the Extraordinary Life of Norma N. Gill-Thompson, ET

In June 1986, I was a relatively new certified enterostomal therapy (ET) nurse. I was standing in line for an industry-sponsored lunch at my first International Association of Enterostomal Therapy (now the Wound, Ostomy, and Continence Nurses Society) meeting at Caesar’s Palace in Las Vegas, NV, when someone around me said, “Look, there’s Norma Gill!” Sure enough, she was a few spots ahead of me in line. I got so excited—it felt like I was in the presence of Florence Nightingale! I went over and introduced myself as a new ET nurse, saying how honored I was to meet her. In her down-home, humble way, she threw her arm around my shoulder and said, “Honey, come sit next to me at lunch.” So began my long and special relationship with this extraordinary pioneer of ET/wound ostomy continence … read more

UrgoClean Ag in Real Life

In 2019, the International Diabetes Federation (IDF) reported that over 77 million individuals have diabetes in India, which will increase to over 100 million by 2030 (IDF, 2019). Of these people with diabetes, 25% will develop a diabetic foot ulcer (DFU), equating to 5 million by 2030. Overall, half of ulcers become infected during the healing process, necessitating hospitalisation, while 20% of these patients require amputation. DFUs contribute to approximately 80% of all non-traumatic amputations performed annually in India (Ghosh and Valia, 2017). It is indicated that social epidemiology regarding DFU in India differs from the West due to many factors including socio-economic and cultural factors. This can lead to significant delay in specialist referral, with patients still relying on treatment based on local ethnic methods and not based on scientific data. This results in patients presenting with highly infected ulcers (Rastogi and Bhansali, 2016) … read more

A Day, a Week, a Month in the Life of a Wound Nurse Practitioner/Scientist

Holly Kirkland-Kyhn, PhD, FNP, GNP, CWCN, FAANP
Working at a 620-bed academic and level 1 trauma center is exhilarating and challenging for wound specialists. We engage in multiple projects to provide the best care for our patients, who range in age from 22 weeks’ gestation neonates to centenarians. We have an interdisciplinary team working to assess and provide the best interventions to prevent pressure injuries, treat wounds, and provide education. This interdisciplinary team consists of a nurse practitioner (NP) as director of wound care, a plastic surgeon, a physical/ occupational therapist, a dietician, 5 wound-certified nurses, and 2 analysts … read more

TUV Nord Awards ISO 13485 Certification to Keneric Healthcare

for the Design/Development, Manufacturing and Distribution of Wound Care Products

 

ALLEN, TexasApril 26, 2018 /PRNewswire/ — Keneric Healthcare’s ISO certification award represents its ability to design, implement, and successfully manage an effective quality management system that meets the requirements of DIN EN ISO 13485: 2012 / EN ISO 13485: 2012 +AC: 2012 – Medical devices – Quality management systems – Requirements for regulatory purposes. The scope of the ISO certification supports the Design/Development, Manufacturing and Distribution of Wound Care Products.

 

Keneric Healthcare, a global medical device manufacturer, recognized for the development and commercialization of innovative products that improve patient care, increase clinician efficiency and streamline facility expenditures. Product portfolio includes RTD™ Wound Dressing, an FDA cleared, polyurethane silver foam dressing that consistently demonstrates positive clinical outcomes for a variety of wound types; and PurePurge™ Bed bath System, an easy to use rinse-free patient bathing product offering healthcare professionals an ideal and cost-effective solution for bathing patients who are unable to take a traditional bath or shower.

Press release from PR Newswire

Healogics Wound Science Initiative Addresses Social Determinants of Health

The World Health Organization (WHO) defines social determinants of health as the conditions in which people are born, grow, live, work and age, that shape health. These factors include characteristics such as socioeconomic status, education, neighborhood and physical environment, employment and social support networks. Surprisingly, these social and environmental conditions account for 80 percent of health outcomes while only 20 percent are the result of care delivery.

 

“Over the next year, we will release a series of findings based on surveys of clinicians, interviews with patients and secondary data analysis,” said Hanna Gordon, PhD, Healogics Executive Director, Research and Informatics. “Our goal is to ensure that all patients can access high quality care and heal their chronic ulcers. We will begin our series with an introduction to the social determinants and how they impact health outcomes, followed by the findings of a survey on clinician perspectives on social barriers to care, and original research on the sociogeographic patterning of chronic wounds.”

 

Chronic wound patients face a number of challenges to their health and well-being. The presence of ulcers is an indication of broader physical systems failures. However, with education, many wounds could be prevented or treated when they are less severe resulting in improved outcomes. The association between chronic conditions such as diabetes, cardiovascular disease and social conditions is well established, yet none of the previous studies have addressed chronic ulcers. Healogics Wound Science Initiative is partnering with hospitals … read more

Improving Physical, Physiological, and Psychological Health Outcomes

Holistic Approaches to Diabetic Foot Ulcer Management: Integrating Physical, Physiological, and Psychological Care

In a recent publication in Clinical, Cosmetic and Investigational Dermatology, researchers Prashanth Vas and Nachiappan Chockalingam emphasize the necessity of a comprehensive approach to managing diabetic foot ulcers (DFUs). Their study highlights the intertwined nature of physical, physiological, and psychological factors in patient outcomes.

Key Insights:

  • Physical Health: Effective wound care and offloading techniques are crucial for ulcer healing and preventing complications.
  • Physiological Factors: Proper glycemic control and vascular health play significant roles in the healing process.
  • Psychological Well-being: Addressing mental health aspects, such as depression and anxiety, can improve patient adherence to treatment and overall quality of life.

The authors advocate for integrated care models that encompass these three dimensions, aiming to enhance healing rates and reduce the risk of amputation.

Read the full article on the Diabetic Foot Online website.

Keywords:
Diabetic foot ulcers,
Holistic care,
Psychological well-being,
Prashanth Vas,
Nachiappan Chockalingam

REGENATIVE LABS AND AAPC ANNOUNCE COLLABORATION TO FURTHER HEALTHCARE COMPLIANCE

PENSACOLA, Fla., Aug. 1, 2022 /PRNewswire/ — Regenative Labs, a leading HCT/P manufacturer, and AAPC, the nation’s largest medical coding, training, and certification association, are pleased to announce a strategic healthcare compliance collaboration. By combining AAPC’s medical training and credentialing expertise with Regenative Labs’ human tissue allografts, together both organizations will support the pioneering of the first Wharton’s jelly allografts to be assigned a Q code and be approved for application directly to a defect using a syringe.

 

“This is an important step in furthering the mission of educating providers and elevating healthcare outcomes and we’re proud to be a part of it,” shared AAPC CEO, Bevan Erickson.

 

Regenative Labs received approval from the Centers for Medicare & Medicaid Services (CMS) to cover CoreText™ and ProText™, the first Wharton’s jelly allograft products recognized as a 361 HCT/P by CMS regulated under 21CFR 1271.10, establishing a new Level II HCPCS code Q4246 “CoreText or ProText, per cc.” According to CMS, both solutions provide the extracellular matrix needed for the infiltration, attachment, and proliferation of cells required to repair damaged tissue. They are typically used for muscle and cartilage tears and help repair damaged tissue due to wounds and tissue defects and are applied directly to the defect using a syringe.

 

Regenative Labs, now seeking to collaborate to further HCT/P compliance, recognizes the value AAPC brings to the healthcare industry as the world’s leading healthcare association, with more than 200,00 members and 30+ years of supporting healthcare professionals, providers, payers, and health systems

 

AAPC will deliver healthcare providers important coding resources, including full skeletal illustrations and applicable DX codes for Regenative Labs Wharton’s jelly allografts products for specialties, including Orthopedics, Pain Management, Podiatry, and Rheumatology. In addition, AAPC will create a customized web-based training module to ensure providers understand how to utilize more specific homologous applications with current DX codes to support accurate procedural reimbursement for these products.

 

“We look forward to the clarity this collaboration will bring to the market allowing proper documentation of homologous use applications,” said Regenative Labs CEO Tyler Barrett.

 

Regenative Labs firmly believes that no other organization understands coding regulations and documentation requirements better than AAPC, leading AAPC to be the right partner for this important project.

 

About AAPC: AAPC’s mission is to advance the business of healthcare by providing professional training, industry-standard certifications, and comprehensive solutions to individuals and organizations across medical coding, billing, auditing, compliance, and practice management. As the most trusted source for driving accuracy, profitability, and peace of mind, AAPC helps healthcare organizations reach the full potential of their revenue cycle. Learn more at AAPC’s website: www.aapc.com

 

About Regenative Labs: Regenative Labs produces regenerative medicine products to address the root cause of a patient’s conditions using Wharton’s Jelly innovations rather than masking the pain with other treatments. Regenative Labs works closely with scientists, physicians, hospitals, and surgery centers to constantly monitor and improve patient progress and outcomes for new product development. Formed by veteran industry professionals familiar with daily challenges of innovations in healthcare, the company provides effective, non-addictive, non-invasive options for patients. Regenative Labs has a laser-focused, expert product research and development team which follows FDA guidelines of minimal manipulation for homologous use. The company adheres to AATB and FDA guidelines. Learn more at Regenative’s website: www.regenativelabs.com

 

SOURCE Regenative Labs

 

This article was originally published here

How Activity Benefits the Healing Patient

Maintaining an active lifestyle is critical to good health; this is especially true for patients recovering from wounds or extended hospital stays. Robust activity can improve mental health, reduce the risk of infection, and accelerate wound healing.1 Staying active can be challenging for patients with wounds, however, and it is critical that health care professionals take steps to enable their patients to stay as active as possible.

 

The Healing Benefits of Activity

Aside from the long-term benefits to heart health, mental health, and longevity, exercise provides many direct and indirect benefits to patients healing from wounds. Physical activity can promote rapid wound healing, reduce oxidative damage, and promote a healthy lifestyle. This can improve patient outcomes and reduce the costs of treatment.


Exercise Benefits Mental Health –
 There is ample evidence that exercise promotes good mental health, reduces the effects of depression, and causes people to report a greater level of happiness. These effects are especially important for those who have had an extended stay in a hospital or who are in a long-term care facility because these populations may be at greater risk of developing mental health problems.


Exercise Reduces Inflammation – 
Inflammation is one of the major causes of delayed healing. Research shows that wounds with low levels of inflammation heal much more quickly and completely. Exercise and other physical activity have been shown to reduce the level of inflammatory markers in the blood, thus helping to reduce the level of inflammation and promote rapid healing. Reduced inflammation may also provide palliative benefits by decreasing pain and discomfort in wounds … read more

Addressing Challenges and Bridging Care Gaps for Wound Patients – The Frank & Lizzie Show

Addressing Challenges and Bridging Care Gaps for Wound Patients

This expert-led video presentation explores systemic challenges and opportunities in wound care delivery—highlighting how gaps in communication, reimbursement, and continuity of care can delay healing outcomes for patients with chronic wounds.

Key Highlights:

  • Care Coordination Barriers: The speaker identifies a lack of integration between hospitals, home health, and outpatient wound clinics, emphasizing how fragmented care increases complications and rehospitalizations.
  • Access & Equity: Geographic, financial, and insurance-related disparities prevent many patients from receiving timely interventions, particularly advanced wound therapies and follow-up assessments.
  • Reimbursement Misalignment: The video discusses how billing structures often disincentivize comprehensive wound assessments or multidisciplinary collaboration.
  • Opportunities for Improvement: Recommendations include increasing awareness of wound-related quality measures, leveraging telehealth, training primary care teams in early detection, and expanding patient education initiatives.

This presentation provides a concise but impactful look at the structural reforms needed to improve wound healing outcomes and reduce the burden on patients, caregivers, and providers alike.

Keywords:
wound care gaps,
care coordination,
chronic wounds,
telehealth wound care,
health equity

Spectral MD Shortlisted for Two European Mediscience Awards

‘Best Technology Award’ and ‘Best Newcomer Award’

 

PRESS RELEASE MAY 10, 2022

DALLAS, May 10, 2022 (Newswire.com) – Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, has been recognized for two prestigious European technology awards.

 

Spectral MD has been shortlisted for two awards at this year’s European Mediscience Awards for:

Best Technology Award
Best Newcomer Award

 

The European Mediscience Awards is the largest annual gathering of private and publicly quoted healthcare, biotech and life science companies in Europe recognizing achievements in the life sciences industry. The European Mediscience Awards recognizes success and achievement amongst both private and publicly quoted companies throughout Europe and, as such, is attended by European life science companies and their corporate advisers, analysts, fund managers, commentators and peers.

 

Nooman Haque, Managing Director, Lifescience & Healthcare, Silicon Valley Bank, commented:

“The shortlist reflects the continuing strong growth of the European Mediscience industry and, in these challenging economic times, highlights those companies best positioned to manage through the turbulent cycle. We’re delighted to see such continuing enthusiasm for the industry.”

 

Wensheng Fan, CEO of Spectral MD, said:

“We are honored that Spectral MD has received nominations for ‘Best Technology Award’ and ‘Best Newcomer Award.’ This recognition further validates the promising potential of our DeepView® Wound Imaging Technology. DeepView® has the potential to be transformative in wound care. We look forward to building on this support and the exceptional results obtained thus far to expand into other important indications for our artificial intelligence for wound healing diagnostics.”

 

The winners will be announced at the celebratory dinner, to be held at the Hotel InterContinental, London W1, on Thursday, June 16, 2022.

 

About Spectral MD:

We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by “Seeing the Unknown”® with our DeepView® Wound Imaging System.

www.spectralmd.com

info@spectralmd.com

Will Mobile Apps Bring Wound Care Technology to the “Cutting Edge”?

For wound care providers and other clinicians, 2017 continued to bring about a chaotic storm of healthcare reform based on quality measures, data registry requirements, and documentation standards. As has been previously stated in this journal, it remains to be seen if wound care practitioners will pool their limited resources and harness the power of their electronic health records to battle the “giant of healthcare reform.”1 This country’s push to enact and substantiate quality of care delivery can be seen through the uniting of clinical practice with increasingly sophisticated digital technology that allows for more accurate documentation and communication. For good reason, the focus of this union is being placed on the perspective of the patient (ie, how the patient receives healthcare information). However, it is becoming increasingly clear that there is a need for clinicians to be armed with devices that more easily and effectively facilitate the means to that end. This article will discuss the proliferation of healthcare-related digital apps that are both patient and clinician focused in an attempt to lay a foundation for wound care clinicians to become more technologically savvy and clinically compliant.

read more
 

Breakthrough in Digital Wound Measurement

eKare Inc., a provider of digital wound management platform, announces partnership with Netherlands-based Woundworks. eKare Inc., developed the inSight 3D wound camera, which ensures a standardized and validated wound measurement in an easy to use application, and is used in post-acute and research institutions across the US. Woundworks has an extensive European network and expertise developing and marketing products in the wound care space. This partnership will jointly develop the European market to provide integrated wound care services, including care management, product supplies, home health, and workflow optimization to healthcare providers and patients.

 

Woundworks and its affiliated companies are the market leader in wound management services to major health plans in the Netherlands. Through novel delivery models and data-driven approaches, they have successfully lowered direct costs to payers by an average of 30% and reduced wound related hospitalizations by 45%.

 

“As an organization fully dedicated to improving wound care, we have been looking for a high quality 3D imaging solution for years. We believe that an easy to use, standardized way of 3D wound measurement is key in improving wound care,” says Kok van der Meij, CEO and founder of Woundworks, Excen, and QualityZorg. “Woundworks has a lot of expertise and experience concerning wound care products, advanced wound care, wound care protocols, and utilizing data analytics to improve outcome. The eKare solution provides unambiguous, comparable, and reproducible data on wound healing progress. Partnering with eKare fits very well with our vision and helps us to innovate and grow to new heights.”

 

“Woundworks brings a new level of service and management that will disrupt the wound care industry. We are proud to be a long-term partner of the company. We look forward to growing this relationship and helping the medical community improve outcomes and lower cost,” Patrick Cheng, CEO of eKare, remarks.

 

About eKare

 

eKare Inc. is dedicated to the design and development of wound assessment solutions, including 3D wound dimensions and tissue classification capabilities, using the latest computer-vision and mobile technology. eKare’s innovative technology is creating new possibilities in how we deliver wound care across the healthcare continuum, from inpatient hospital and skilled nursing facilities to ambulatory clinics and telemedicine. eKare’s mission is to advance the science and delivery of wound care by leveraging mobile and sensor technologies to connect patients, providers, and industry.

 

http://ekare.ai

 

About Woundworks

 

Woundworks is a new company founded and backed by institutions with many years of experience in the field of wound care. Woundworks and its affiliated companies have been very successful in the wound care field and are now combining their strengths to expand their product offering in the European market. Woundworks will distribute the inSight 3D Wound imaging solution throughout Europe and will combine this with different segments of its own products and business lines; ensuring that patients all over Europe can receive the best possible wound care.

 

http://woundworks.com

…type 2 diabetes, these wounds can be life-threatening. According to a 2016 study, one-third of the cost of type 2 diabetes treatment is related to non-healing diabetic foot wounds and…

Australian Study Highlights Value of Tissue Analytics Wound Care Platform

Findings also confirm platform’s capabilities for wound and skin clinical trials

 

PITTSBURGH, April 18, 2022 /PRNewswire/ — Net Health, a leading provider of software and analytics for medical specialties, announced the recent publication of a study reviewing the use of artificial intelligence (AI)-enabled mobile wound care applications developed by Net Health. The study showed that these applications provide better documentation, are easy to use, engage patients, and drive improvements in wound measurement and management.

 

Conducted by Australian New South Wales (NSW) Health Service, the study looked at the performance of Net Health’s Tissue Analytics’ wound imaging and analysis platform in multiple sites, including a senior care ward, colorectal ward, an outpatient dermatology clinic, and primary care physicians’ offices.

 

In addition to highlighting the platform’s value in clinical settings, the findings provide helpful insights for researchers looking to conduct decentralized and hybrid clinical trials involving wounds, skin lesions, and visible skin conditions in a post-pandemic world.

 

Statistically Significant Findings
The study was published in the International Wound Journal. The e-clinical platform was tested on 124 patients with 184 wounds compared with the standard care group, consisting of 166 patients with 243 wounds. Results showed several statistically significant outcomes related to use of the platform, including the completeness of documentation based on the number of dressing changes compared to standard care, pain, size, exudate, and odor (p < 0.001). These findings demonstrate the positive impact of the platform in terms of usability, patient adherence, and the photographic evidence of clinical endpoints.

 

As described in the publication, ten of the 13 participating physicians and nurses responded to a survey, and strongly agreed that the platform had value, and provided benefits to communication. The patients who were interviewed unanimously commented that the platform provided benefits to their wound healing and communication with clinicians.

 

Highlights Value for Clinical Research
Besides showcasing the value of mobile wound analysis in clinical settings, the findings will fuel interest in the Tissue Analytics platform for wound and skin care clinical research. Findings from the study that relate to clinical trials include the ability of the mobile wound analysis platform to: 1) empower patients to take more active roles in their care; 2) increase accuracy of wound measurements; and 3) ensure greater consistency in care and participant satisfaction.

 

Study results also suggest the value of the platform to retain study participants. Per interviews, patient-participants said they were “strongly” satisfied by the telehealth capability of the platform. Moreover, the study’s authors noted that using the app saved patients time and cost, especially for travel, a key factor in encouraging participants to remain in a study.

 

“We’re very excited by the findings in this study,” said Keith Tode, Vice President of Clinical Research for Tissue Analytics. “Study sponsors are looking for tools that are simple to use, engage patients, allow for virtual wound care visits and consultations, and provide real-time and real-world insights into the participant experience. This study shows that mobile wound platforms can offer the features today’s clinicians and researchers want and need. Looking ahead, we see many benefits to this approach for clinical trials for wound care, dermatology, endocrinology and other skin conditions.”

 

About Net Health
Net Health’s mission is to harness data for human health. Net Health solutions are trusted in over 23,000 facilities across the continuum of care. Our EHR software enables caregivers and their organizations to engage effectively with patients, streamline documentation, staff efficiently, secure maximum appropriate reimbursement and maintain regulatory compliance. Our unique approach to analytics seamlessly presents insights in clinical and operational workflows to improve care and business performance. Net Health is a portfolio company of The Carlyle Group, Level Equity and Silversmith Capital Partners. www.nethealth.com.

 

SOURCE Net Health Systems, Inc.

 

This article was originally published here
 

The Neuropathic Diabetic Foot Ulcer Microbiome Is Associated With Clinical Factors

 

Nonhealing diabetic foot ulcers (DFUs) are a common and costly complication of diabetes. Microbial burden, or “bioburden,” is believed to underlie delayed healing, although little is known of those clinical factors that may influence microbial load, diversity, and/or pathogenicity. We profiled the microbiomes of neuropathic nonischemic DFUs without clinical evidence of infection in 52 individuals using high-throughput sequencing of the bacterial 16S ribosomal RNA gene. Comparatively, wound cultures, the standard diagnostic in the clinic, vastly underrepresent microbial load, microbial diversity, and the presence of potential pathogens. DFU microbiomes were heterogeneous, even in our tightly restricted study population, but partitioned into three clusters distinguished primarily by dominant bacteria and diversity. Ulcer depth was associated with ulcer cluster, positively correlated with abundance of anaerobic bacteria, and negatively correlated with abundance of Staphylococcus. Ulcer duration was positively correlated with bacterial diversity, species richness, and relative abundance of Proteobacteria, but was negatively correlated with relative abundance of Staphylococcus. Finally, poor glycemic control was associated with ulcer cluster, with poorest median glycemic control concentrating to Staphylococcus-rich and Streptococcus-rich ulcer clusters. Analyses of microbial community membership and structure may provide the most useful metrics in prospective studies to delineate problematic bioburden from benign colonization that can then be used to drive clinical treatment … read more

Phase 2 Triumph: PDA-002 Cell Therapy for Diabetic Foot Ulcers with PAD



Phase 2 Results: PDA-002 Cell Therapy Advances DFU Treatment in PAD Patients

Full Press Release:

Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease

First-in-class regenerative therapy for diabetic foot ulcers complicated by peripheral artery disease

Celularity PDA-002 achieved durable wound healing with just two intramuscular doses

As a qualified stem cell therapy under Florida statute (§ 458.3245), effective July 1, 2025 authorizing use in wound care, orthopedics, and pain management, PDA-002 may offer licensed Florida physicians an important new tool in treating DFU patients.

FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the publication of its Phase 2 study titled “Human Placenta-Derived Cells (PDA-002) in Diabetic Foot Ulcer Patients With and Without Peripheral Artery Disease: A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial,” in the International Wound Journal. Results of this study demonstrated safety and efficacy in a complex type of serious wounds in the setting of diabetes and peripheral vascular disease. Celularity’s Chairman and CEO, Robert J. Hariri, M.D., Ph.D., also commented on PDA-002 as a stem cell therapy which qualifies under a recently enacted Florida law expanding access in the state to stem cell therapies not yet approved by the U.S. Food and Drug Administration.

Approximately two million individuals in the United States are affected each year by diabetic foot ulcers (DFU), nearly half of whom have coexisting peripheral artery disease (PAD). DFU complicated by PAD represents one of the most difficult and costly challenges in wound care. Currently, there are no U.S. Food and Drug Administration (FDA)-approved therapies specifically indicated for DFU with PAD. The estimated annual economic burden of treating DFU alone exceeds $9 billion in the United States. The presence of PAD significantly compromises lower-extremity perfusion, leading to chronic tissue ischemia, impaired angiogenesis, and delayed wound repair. PAD-associated DFUs are further characterized by persistent inflammation, altered immune response, and diminished responsiveness to standard wound care interventions. Despite five FDA-approved DFU therapies, none are currently approved for DFU complicated by PAD, underscoring the need for novel regenerative approaches that restore tissue perfusion and accelerate wound closure.

The published study included 159 adult patients with chronic diabetic foot ulcers (both with and without PAD) and was conducted across 35 clinical sites in the United States. Participants received two intramuscular doses of either PDA-002, a placenta-derived cell therapy developed by Celularity, at one of three dosage levels (3 × 10⁶, 10 × 10⁶, or 30 × 10⁶ cells), or a placebo. The primary efficacy endpoint was the number of patients who achieved complete wound closure within three months with healing that remained intact for at least four additional weeks—a more rigorous measure of durability than the standard FDA definition, which requires only two weeks of durable healing.

In patients with PAD, the highest rates of wound closure were observed with the lowest PDA-002 dose (3 × 10⁶ cells), where 38.5% of ulcers completely healed versus 22.6% in the placebo group. The data also showed faster and more sustained healing in treated patients along with fewer cases of new gangrene and foot infections compared to those who received a placebo. Across all groups, PDA-002 was well tolerated, with no serious side effects linked to the treatment. This favorable safety profile remained consistent through two years of follow-up.

The study’s findings highlight the regenerative and angiogenic potential of PDA-002 in promoting durable ulcer closure in patients with DFUs complicated by PAD, using only two doses and no retreatment.

” The publication of our PDA-002 Phase 2 results in the International Wound Journal is a significant milestone for Celularity, and importantly, for patients battling diabetic foot ulcers complicated by peripheral artery disease, which is a patient population with a critical unmet medical need and limited treatment options,” said Robert J. Hariri, M.D., Ph.D., Celularity’s Chairman and CEO. “Our data show that our investigational therapy, PDA-002, a placenta-derived, mesenchymal stromal-like cell therapy, can drive meaningful wound closure rates, reduce serious complications, and do so with a favorable safety profile. We believe PDA-002 has potential to transform the future of ischemic wound care, and these findings position us for a confirmatory Phase 3 trial aimed at delivering the first FDA-approved targeted therapy in regenerative wound care for DFU/PAD patients with this urgent and unmet need. We also believe these clinical results support additional development in clinical indications where underlying microvascular disease is a contributing factor.”

Commenting on recent developments, Dr. Hariri said, “Celularity is actively assessing opportunities to apply these findings in jurisdictions such as Florida, where PDA-002 qualifies as a stem cell therapy under a new law authorizing use by Florida physicians in wound care, orthopedics, and pain management.” Diabetes afflicts an estimated 2.1 million Floridians according to a January 2025 Florida Diabetes Advisory Council report, which found that the percentage of adult Floridians diagnosed with diabetes grew by almost half since 2002 and is now above the national average (12.2% versus 11.6%). That percentage jumps to 25.4% among Floridians ages 65 and older, or some 1.25 million people, a fifth to a third of whom will go on to develop a DFU, for which the 5-year recurrence rate is 65%. “By unleashing promising stem cell therapies like PDA-002, Florida has given physicians a potentially important new tool for the treatment of diabetic foot ulcers, a serious condition that afflicts over a quarter of a million Floridians ages 65 and older,” said Dr. Hariri.

About PDA-002

PDA-002 is a mesenchymal stromal-like cell therapy product derived from the postpartum placenta. These cells possess potent angiogenic, immunomodulatory, and tissue-repair properties, offering a novel approach to wound healing in patients for whom current therapies are inadequate.

About Celularity Inc.

Celularity Inc. (Nasdaq: CELU) is a regenerative and aging-related cellular medicine company developing, manufacturing, and commercializing advanced biomaterial products and allogeneic and autologous cell therapies, all derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies targeting fundamental aging mechanisms, such as cellular senescence, age-related chronic inflammation, and tissue degeneration. For more information about Celularity and its cutting-edge regenerative medicine solutions, please visit www.celularity.com.

Forward Looking Statements

Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding: (i) our future sales or sales growth; (ii) our expectations for future financial results, including levels of net sales; (iii) our expectations regarding new products, including our 510K products; and (iv) future demand for our products. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “improving,” “may,” “observed,” “potential,” “promise,” “should,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Celularity’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K and Form 10-K/A for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on May 8, 2025 and May 21, 2025, respectively, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements contained herein, whether because of any new information, future events, changed circumstances, or otherwise, except as otherwise required by law.

Carlos Ramirez

Senior Vice President, Celularity Inc.

Carlos.ramirez@celularity.com

(908) 845-4181

Key Highlights:

  • Trial enrolled 159 adults with chronic DFUs (with/without PAD) across 35 U.S. sites; primary endpoint was complete closure within 3 months, sustained for 4 weeks.
  • In PAD patients, low-dose PDA-002 achieved 38.5% healing vs. 22.6% placebo, with quicker onset and durability, requiring no retreatment.
  • Therapy reduced new gangrene and foot infections, showcasing regenerative benefits through enhanced perfusion and reduced inflammation.
  • Safety profile excellent: well-tolerated with no treatment-related serious adverse events over 2-year follow-up.
  • Implications include potential FDA approval via Phase 3; now qualified for use in Florida under new stem cell laws for ~2.1M diabetic residents.

Read full article

Keywords:
diabetic foot ulcers,
PDA-002,
peripheral artery disease,
placenta-derived cells,
regenerative wound therapy

National Institutes of Health funds LSU chemistry professor’s research aimed at developing …

a new class of molecules for treating biofilm infections

 

LSU Chemistry graduate student Leo Fontenot (left) conducting research under the guidance of Professor Mario Rivera (right).

BATON ROUGE- Chronic skin wounds are a growing global concern amongst aging populations and patients with severe burns and underlying health conditions such as diabetes. Commonly seen in healthcare environments and long-term care facilities, patients with chronic skin wounds suffer from persistent pain and potentially life-threatening infections.

 

Effective treatments for these wounds are often challenged by a biofilm, a community of bacterial cells entrenched in a self-produced matrix of extracellular DNA, proteins, and sugar molecules. Bacterial cells in biofilms are tolerant to the body’s immune response and most commercial antibiotics that normally kill free living, or planktonic, bacterial cells.

 

The antibiotic recalcitrance of biofilm bacteria is further complicated in biofilm infections with multidrug resistant, or MDR, bacteria. Therefore, successful treatment of MDR bacterial biofilm-associated infections require alternative treatment strategies.

 

LSU Professor and William A. Pryor Chair in Chemistry Mario Rivera recently received a five-year $3.69 million National Institutes of Health, or NIH, R01 grant to develop a new strategy to kill biofilm-embedded cells and combat biofilm infections caused by MDR bacteria, Pseudomonas aeruginosa and Acinetobacter baumannii.

 

Small molecule inhibitors of the BfrB-Bfd complex disrupt bacterial iron homeostasis and kill biofilm embedded bacterial cells. [Source: https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00669. Further permission related to the material excerpted should be directed to the ACS.]

The new antibiofilm approach involves a new target that would disrupt the bacterial iron homeostasis, or the balanced state of intracellular iron, in the biofilm. Iron, an essential metal for all living organisms, is a crucial nutrient for the growth and survival of most bacterial species. Rivera’s research team aims at disrupting bacterial iron homeostasis by inhibiting a specific protein-protein interaction.

 

Bacterioferritin, or BfrB, is a spherical and hollow protein that can store thousands of iron atoms in its interior. Rivera and colleagues demonstrated that the mobilization of iron stored in BfrB is an essential process in bacterial cells, which requires BfrB to form a complex with Bfd. The scientists aim to disrupt the BfrB-Bfd protein-protein interaction.

 

They also discovered proof-of-concept small molecules that can inhibit the BfrB-Bfd complex and cause an irreversible accumulation of unusable iron in BfrB, which leads to iron deficiency, metabolic stress, and bacterial cell death in the biofilm. The proposed work supported by the new grant is directed at optimizing the proof-of-concept inhibitors of the BfrB-Bfd complex into drug lead molecules, that is, powerful inhibitors that kill bacterial cells in biofilms but also have desirable drug-like properties.

 

The funded research project involves a talented, multidisciplinary team of drug discovery collaborators from LSU and other institutions, including:

  • Professor Mario Rivera (PI), Department of Chemistry, Louisiana State University
  • Research Associate Professor Huili Yao (co-PI), Department of Chemistry, Louisiana State University
  • LSU Chemistry postdoctoral researcher Anabel Soldano and graduate students Leo Fontenot, Nimesha Rajapaksha, Suliat Alli and Alexanndra Behm.
  • Associate Professor Josephine Chandler (co-PI), Department of Molecular Biosciences, University of Kansas
  • Dr. Scott Lovell (co-PI), Director of the Protein Structure Laboratory, University of Kansas
  • Professor Richard Bunce (co-PI), Department of Chemistry, Oklahoma State University
  • Professor Lisa Morici (co-PI), Tulane University School of Medicine
  • Dr. Allen Reitz (co-PI), Fox Chase Chemical Diversity Center

 

If the proposed strategy proves successful, validation of the novel antibiotic target would lead to the development of an entirely new class of antibiotics for the treatment of biofilm-associated infections. To learn more about the Rivera research group and their work on iron homeostasis in bacteria as a potential target for antibiotic development, visit their group page.

 

Media Contact:
Gretchen Schneider
LSU Chemistry
gschne2@lsu.edu

HMP Global expands value for podiatry community with launch of PodiatrySource product guide and Podiatry Learning Network

The platform serves as a comprehensive resource for podiatry news and information to aid clinical decision-making and improve patient outcomes

 

MALVERN, Pa., July 12, 2022 /PRNewswire-PRWeb/ — As healthcare professionals across the podiatry community manage an ever-changing and complex field, HMP Global, the leading healthcare event and education company, today announced the launch of two value-added offerings, PodiatrySource and the Podiatry Learning Network.

 

The Podiatry Learning Network serves as the premier digital hub for podiatrists and offers direct access to clinically relevant news and information, expert perspectives, and continuing education. The network joins HMP Global’s portfolio of well-respected learning platforms dedicated to serving as online information hubs, and is a singular destination offering practical, relevant content and education guided by podiatry professionals.

 

Visitors to the new network can create a customized experience, selecting topic preferences most pertinent to them; receive regular e-mail updates with breaking news and carefully created content; grow professionally with the network’s repository of education; and connect with other podiatry colleagues around the world through the platform’s networking options.

 

“With the creation of the Podiatry Learning Network, HMP Global is delivering a single, definitive resource that podiatry professionals can rely upon to access important clinical knowledge on new therapies and treatments on a broad spectrum of topics, and enjoy a highly specialized content experience,” said David DePinho, President, HMP Global. “Healthcare professionals in the podiatry field will benefit from this comprehensive resource to receive ongoing professional development and provide the highest quality of patient care.”

 

PodiatrySource

 

HMP Global is also launching PodiatrySource, a one-stop resource with independent, clinically reviewed, and unbiased information to help clinicians make informed decisions about podiatry care products.

 

Powered by Podiatry Today, the award-winning, premier publication and online platform, PodiatrySource will reach buyers with the trusted information they need to act and make decisions about product selection and purchasing. It will provide 24/7 access to information on an interactive, user-friendly digital platform.

 

“The Podiatry Today audience is invested in providing patients optimal care and staying abreast of the latest product offerings across the field is part of how they achieve this goal,” said Jennifer Spector, DPM, FACFAS, Managing Editor of Podiatry Today, a trusted educational resource in podiatric medicine and surgery that provides engaging content to help clinicians improve patient care. “Creating PodiatrySource is a natural synergy of the education provided by Podiatry Today, with robust information about innovations provided by companies in the podiatric space.”

 

PodiatrySource currently highlights products focused on the office-based practitioner, and future updates will include more products and companies to best serve the full foot and ankle medical and surgical community, Spector said. PodiatrySource is open access with no subscription required for use. Industry contacts may submit product information through the website, and enhanced opportunities are available.

 

“PodiatrySource is designed to quickly become podiatry’s most relied upon tool to navigate the many options for products and services available to healthcare professionals in the podiatry community,” DePinho said. “It offers credible, trusted, non-biased clinically reviewed content that clinicians can use during the decision-making and purchasing processes.”

 

The new PodiatrySource resource guide is modeled after the highly successful WoundSource product reference guide. First published in 1998, WoundSource now includes more than 1,700 products manufactured by more than 200 wound care companies. Its digital companion, woundsource.com, includes product lists and reviews as well as articles, blogs by industry thought leaders, white papers, and other educational resources for wound care professionals.

 

For more information about PodiatrySource and the Podiatry Learning Network, visit hmpgloballearningnetwork.com/site/podiatrynet.com.

 

ABOUT HMP GLOBAL
HMP Global is the force behind Healthcare Made Practical — and is an omnichannel leader in healthcare content, events, and education, with a mission to improve patient care. The company produces accredited medical education events — in person and online via its proprietary VRTX virtual platform — and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include the HMP Global Learning Network, healthcare’s most comprehensive source for news and information; Psych Congress, the largest independent mental health meeting in the U.S.; the Evolution of Psychotherapy, the world’s largest independent educational event for mental health professionals; the Leipzig Interventional Course (LINC), the leading, global gathering for interdisciplinary cardiovascular specialists; EMS World Expo, North America’s largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com.

 

Media Contact

Sandi Beason, APR, HMP Global, (601) 573-1737, pr@hmpglobal.com

 

SOURCE HMP Global

Epigenetics and Biochemistry of Stress in Wound Care

Wound care can be a surprisingly emotional field. Some days it can feel like every patient visit contains challenging emotional situations that clinicians must also recover from with resilience not to carry that energy to the next visit. These stressors can be related to the patient’s medical status and critical conversations regarding their health, pain and anxiety, the death of a patient’s close family members, and even access to basic necessities like safe housing and social support. Factors other than the health care they receive are driving outcomes, consistent with what we know about social determinants of health which determine 80% of health outcomes. These life stressors and the stressors that have occurred throughout the patient’s life can contribute to physiologic changes that further delay wound healing … read more

Preventing Pressure Injuries in Pediatric EEG Monitoring: The Role of Polyurethane Foam



Preventing Pressure Injuries in Pediatric EEG Monitoring: The Role of Polyurethane Foam

Summary: This retrospective study evaluates a simple intervention using polyurethane foam to prevent medical device-related pressure injuries (PIs) in children undergoing continuous electroencephalography (CEEG). By placing 5mm-thick foam with silicone dressing on the frontal forehead between electrodes and 4cm-thick foam on the back of the head for immobile patients, the method reduced PI incidence from 6.5% (5/77 patients) in the standard group to 1.5% (1/65 patients) in the intervention group, achieving a 77% prevention rate. This low-cost approach is particularly valuable for infants with fragile skin, minimizing scarring risks without compromising EEG quality.

Key Highlights:

  • CEEG electrodes and head wrapping commonly cause PIs in 7.8% of pediatric cases, with higher risks in infants due to immature skin.
  • Intervention group showed significantly lower PI rates (1.5% vs. 6.5%), supporting foam’s pressure-redistribution efficacy.
  • Method is easy to implement, using inexpensive materials, and suitable for various facilities monitoring seizures or cortical function.
  • Risk assessment via Glamorgan scale identified high-risk patients, but foam prevented injuries across ages <18 years.
  • Potential to reduce cosmetic scarring and complications, emphasizing proactive wound prevention in device-related care.

Read full article

Keywords:
pressure injuries,
polyurethane foam,
pediatric wound care,
EEG monitoring,
medical device related PIs

Texas Health Plano Saving More Limbs with Non-Traditional Procedure

More than two million Americans are living as amputees, and that’s expected to double by 2050. In an attempt to change the projection, Texas Health Plano is trying something different. A new and unique catheterization procedure can help salvage the legs of more would-be amputee patients.

 

The multidisciplinary program includes emergency physicians, orthopedic surgeons, wound care physicians, podiatry, internal medicine and interventional cardiology. “The goal is to provide a cohesive plan of care for patients presenting to the ER or wound care center with ischemic ulcers of the legs (or) feet,” says Dr. Vijay Ramanath, medical director of Texas Health Plano’s Limb Preservation Program. “We want to prevent leg (and) foot amputations and return patients to a high-quality of life.” read more

 

Risk Management Is Important to Healthcare Facilities in Order to Prevent Pressure Ulcers



Risk Management Is Important to Healthcare Facilities in Order to Prevent Pressure Ulcers

Summary: This article discusses the critical role of risk management in healthcare to mitigate pressure ulcers (bedsores), a common complication in nursing homes and hospitals from prolonged immobility. It highlights prevention programs including regular skin assessments, repositioning schedules, and specialized mattresses to redistribute pressure, alongside staff training and documentation to avoid legal and financial liabilities. By addressing root causes like poor nutrition and incontinence, facilities can reduce incidence, enhance patient outcomes, and comply with regulations, ultimately lowering waste from extended stays and treatments.

Key Highlights:

  • Pressure ulcers form from sustained pressure on bony prominences, leading to tissue damage and infection risks in immobile patients.
  • Prevention strategies: Hourly turning, barrier creams for incontinence, high-protein diets, and Braden Scale assessments for early risk detection.
  • Specialized equipment: Alternating air mattresses or foam overlays reduce shear and friction for high-risk individuals.
  • Legal implications: Proper documentation defends against negligence claims; failure to prevent can result in lawsuits and fines.
  • Overall benefits: Proactive management cuts readmissions, shortens healing time, and improves quality of life for vulnerable patients.

Read full article

Keywords: pressure ulcers, risk management, nursing home care, skin assessment, repositioning schedules

Amazon, health care and the first American chaebol

Abe Kasbo, CEO, Verasoni Worldwide.

Abe Kasbo, CEO, Verasoni Worldwide.

Amazon’s recent landmark partnership with Berkshire Hathaway and JPMorgan Chase is yet another example of how certain sectors continue to underestimate Amazon’s imagination, never mind business prowess. I honestly believe some businesses, though fully capable, simply do not know how to respond to Amazon, and therefore don’t even try. Or they may want to try, but are afraid to fail. Amazon has led the way in industries where there’s prodigious inertia, like retail, entertainment, grocery and now health care.

 

The announcement, which is short on details, spurred a sell-off in some of health care’s most popular stocks like CVS, Cardinal Health, Walgreen and United Healthcare, among others. If the Whole Foods acquisition wasn’t a wakeup call, this particular venture into health care is a shot across the bow to every industry in America. It seems the financial markets were nervous that Amazon and partners will do what no American government could achieve to date: get better control of health care costs and deliver efficiencies and results where they matter. The cornerstone of the announcement, in my estimation, is the intention by this coalition to deliver health care “free from profit-making incentives.” American health care’s long resistance to price transparency seems to be have been dealt a blow with this announcement and that is a good thing for patients, and for health care providers, who can now compete on price, experience and outcomes … read more

Healthy.io achieves HITRUST CSF® certification for Information Security

BOSTON, Jan. 11, 2022 /PRNewswire/ — Healthy.io, the global leader in transforming the smartphone camera into a medical device, today announced its at-home Minuteful Kidney test and Minuteful for Wound services have earned Certified status for information security by HITRUST, which follows a standardized framework to measure HIPAA compliance … HITRUST CSF Certified status demonstrates that Healthy.io has met key federal and state regulations and industry-defined requirements and is appropriately managing risk. This achievement places Healthy.io in an elite group of organizations worldwide that has earned this certification … Healthy.io’s business case is simple: smartphone-powered technology can help health systems and insurance providers improve patient health, reduce costs across the healthcare system, and improve access to care. Early results are tremendous: In the US, health plans can more than double their current adherence rates.  A recent rollout in the United Kingdom showed that Healthy.io test kits raised test adherence from 0% to 50% among patients who had not done a urine test for kidney disease in the previous year … read more


LinkedIn:
Healthy.io

Seasoned Healthcare Executive David Bassin Joins the MolecuLight Board of Directors

Former Healogics CEO Brings Deep Wound Care Industry Experience to MolecuLight’s
Rapidly Growing Business

TORONTOJuly 6, 2023 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated, pathogenic bacterial loads in and around wounds, is pleased to announce the appointment of David Bassin to its Board of Directors as an Independent Board Member.

David Bassin brings a wealth of expertise and experience in the healthcare industry, particularly in the field of wound care. As the founder of GIO Advisory LLC, he has provided invaluable advisory services to numerous companies and private equity firms based on his extensive background in healthcare, spanning pharmaceutical/device, payer, and provider services. Most recently, Bassin served as the CEO of Healogics, the foremost provider of wound care services in the US, operating over 630 wound care centers and 300 providers. During his tenure, he successfully restructured and refocused the business, resulting in strong earnings growth prior to his transition into advisory services. Prior to his role as CEO, Bassin served as the CFO of Healogics, contributing to the company’s financial growth and success. Bassin’s impressive career also includes significant roles in other healthcare organizations. He served as the CFO of eviCore Healthcare, Inc., where he oversaw multiple dividend recapitalizations and facilitated a merger with the company’s largest competitor, leading to the creation of a company with over 3,000 employees. Additionally, Bassin held the position of CFO at InVentiv Health, Inc., a provider of services to pharmaceutical companies, where he successfully managed a high-growth company and orchestrated a go-private transaction valued at over $1 billion and delivered a significant premium to its shareholders.

“We are thrilled to welcome David Bassin to the MolecuLight Board of Directors,” said Anil Amlani, CEO of MolecuLight. “His extensive experience in optimizing and scaling organizations across the healthcare industry, particularly in wound care, will be invaluable to MolecuLight as we continue to expand our global presence. Our MolecuLight devices have already become indispensable tools in wound assessment and real-time decision-making for thousands of clinicians worldwide. David’s expertise will greatly support our mission to meet the increasing global demand for our innovative wound care diagnostics and establish them as the gold standard in the field.”

David Bassin expressed his excitement about joining MolecuLight’s Board of Directors, stating, “There are over 6.5 million patients living with wounds.  As an industry, we need to continue to develop new solutions that improve wound care treatment effectiveness and efficiency.  With a global drive to improve outcomes, reduce costs, and minimize antibiotic usage, MolecuLight’s point-of-care devices have demonstrated their ability to effectively address these critical clinical needs. I am deeply impressed by the organization, the technology’s alignment with market demands, and the significant market traction they have achieved. I am eager to contribute to their growth and help them achieve their ambitious goals.”

MolecuLight’s groundbreaking i:X® and DX™ imaging devices are the only FDA-cleared and CE and Health Canada approved devices for the real-time detection of elevated bacterial burden in wounds. Supported by over 80 peer-reviewed publications involving 2,600 patients, these devices are widely utilized by leading wound care facilities worldwide.

About MolecuLight Inc.

MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s commercial devices, which include the MolecuLight i: and DX™ fluorescence imaging systems and their accessories, are point-of-care handheld imaging devices for the real-time detection and localization of bacterial load in wounds and digital wound measurement. MolecuLight procedures performed in the United States benefit from an available reimbursement pathway which includes two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other global markets with relevant unmet needs in food safety, consumer cosmetics and other key industrial markets.

For more information, contact:

Rob Sandler 
Chief Marketing Officer
MolecuLight Inc.
T. +1.647.362.4684
rsandler@moleculight.com
www.moleculight.com

Image:

SOURCE MolecuLight

Dr. Caroline Fife announces or recaps CMS field test meetings



CMS Field Test Meetings

Summary: January 26, 2026 blog by Dr. Caroline Fife announces or recaps CMS field test meetings (virtual/in-person) focused on wound care-related quality measures, performance indicators, or proposed changes to coverage/determination policies. These sessions allow clinicians, societies, and stakeholders to provide input on draft measures (e.g., healing rates, amputation prevention, documentation standards) before finalization for MIPS, QPP, or LCD updates. Emphasizes importance of participation to shape reimbursement and quality reporting that impacts wound care practices, especially for chronic ulcers, DFUs, and pressure injuries. Includes registration links, agendas, or key discussion points if available.

Key Highlights:

  • Purpose: Gather real-world feedback on wound care metrics.
  • Topics: Likely healing outcomes, advanced therapy use, prevention benchmarks.
  • Call to action: Attend/provide comments to influence policy.
  • Relevance: Directly affects coding, coverage (e.g., G2211, advanced products), and practice viability.

Read blog

Keywords: CMS field test, wound care measures, quality reporting, LCD updates

Managing chronic venous leg ulcers

what’s the latest evidence?

 

Chronic venous leg ulcers (CVLUs) affect nearly 2.2 million Americans annually, including an estimated 3.6% of people over the age of 65. Given that CVLU risk increases with age, the global incidence is predicted to escalate dramatically because of the growing population of older adults. Annual CVLU treatment-related costs to the U.S. healthcare system alone are upwards of $3.5 billion, which are directly related to long healing times and recurrence rates of over 50%.

 

CVLUs are not only challenging and costly to treat, but the associated morbidity significantly reduces quality of life. That makes it critical for clinicians to choose evidence-based treatment strategies to achieve maximum healing outcomes and minimize recurrence rates of these common debilitating conditions. These strategies, which include compression therapy, specialized dressings, topical and oral medications, and surgery, are used to reduce edema, facilitate healing, and avert recurrence read more

 

Mechanical Negative Pressure Wound Therapy: Real-World Effectiveness in Challenging Patient Presentations

When used for wound management, negative pressure wound therapy (NPWT) delivers subatmospheric pressure at the wound site, exerting multiple beneficial effects, including microstrain, macrostrain, edema management, granulation tissue formation, drainage management, and wound stabilization. Comparative effectiveness research has demonstrated similar wound healing and adverse event outcomes between traditional NPWT (tNPWT) and mechanical NPWT (mNPWT). Therefore, considerations for patient selection for mNPWT vs tNPWT are in alignment with current recommendations, including therapeutic goals, wound-related factors, patient satisfaction, quality of life, care setting, economic-related factors, and product design. Case Reports. The 3 complex patient cases in the present report describe the routine use of mNPWT between December 18, 2020, and June 7, 2021 … read more

Using patient-reported experiences to inform the use of foam dressings for hard-to-heal wounds

Using Patient‑Reported Experiences to Guide Foam Dressing Use in Hard‑to‑Heal Wounds

A review led by Kevin Woo and co-authors, published in *Journal of Wound Care* (Nov 2024), highlights the importance of incorporating patient-reported outcomes—such as pain, odor, itch, drainage, and self-care capabilities—when selecting foam dressings for chronic wounds. The expert panel calls for greater collaboration across clinical, research, and industry sectors to address these needs.

Key Highlights:

  • Holistic Dressing Selection: Foam dressing choice must balance wound characteristics with patient experiences to improve quality of life and adherence. :contentReference[oaicite:1]{index=1}
  • Identified Outcome Domains: The review identifies five core categories—wound-related pain, odor, itch, exudate volume, and self-management capacity—as critical to patient-centered care. :contentReference[oaicite:2]{index=2}
  • Accountability Across Sectors: Authors urge clinicians, researchers, and industry to adopt shared responsibility in designing dressings that meet both clinical efficacy and patient comfort metrics. :contentReference[oaicite:3]{index=3}
  • Population Impact: Hard-to-heal wounds affect approximately 1.67 per 1000 people globally and impose significant health and economic burdens. :contentReference[oaicite:4]{index=4}

By centering patient-reported experiences in product evaluation and development, this review promotes more person-focused wound care strategies and improved outcomes.

Read the full article in the Journal of Wound Care (via Wound Central).

Keywords:
patient-reported experience,
foam dressings,
hard‑to‑heal wounds,
wound‑related pain,
self‑management

Observational Study of Venous Leg Ulcer Treated With Native Collagen-Alginate Dressing



Observational Study of Venous Leg Ulcer Treated With Native Collagen-Alginate Dressing and Impact on Wound-Related Quality of Life

Summary: Observational study (n=60 non-healing VLUs, 1.5-24 months) used native collagen-alginate (Cutimed Epiona) + SOC/compression. At 4 weeks: area ↓32% (17.8 to 11.4 cm², p<0.0001); 4 complete closures; pain ↓56% (VAS 3.9 to 1.7, p<0.0001); analgesic use ↓47%; QoL improved (Wound-QoL total/sub-scores p<0.0001). Periwound skin/exudate improved; rated 'very good/good' by all HCPs. Safe adjunct accelerating healing/QoL in VLUs.

Key Highlights:

  • Area: ↓32% mean; 4 full closures.
  • Pain: VAS ↓56%; analgesics ↓ from 61% to 33%.
  • QoL: Significant ↓ Wound-QoL scores (body/wellbeing/everyday).
  • Safety: 8 moderate AEs (unlikely related).

Read full study

Keywords: collagen alginate, VLU, healing, QoL, observational

Newly Developed REACH Score Identifies Burden for Employed Patients with Chronic Wounds

Newly Developed REACH Score Identifies Burden for Employed Patients with Chronic Wounds

Summary: Dermatology Times reports on a pilot study (51 adults <65 years) developing the 17-item REACH Score to quantify occupational burden from chronic wounds, showing moderate impairment and strong links between time-consuming care tasks and work impact.

Key Highlights:

  • ~70% of participants had taken sick leave due to their wounds; many reduced working hours.
  • Average 5.3 hours/week spent on wound-related tasks; dressing changes were the biggest time sink (~2.7 h/week).
  • REACH correlated with Wound-QoL; higher scores tracked with greater time burden and sick leave.

Read the coverage at Dermatology Times

Keywords:
chronic wounds,
work productivity,
REACH Score,
quality of life,
occupational health

debritom+ by Medaxis: A New Treatment Method Shows Promise In Wound Healing

PLANO, Texas, June 6, 2022 /PRNewswire/ — Non-healing diabetic foot wounds are increasing in prevalence, and create a higher risk for infection, osteomyelitis and amputation. To facilitate appropriate wound healing processes, proper debridement of the wound bed is critical to remove non-viable tissue and bacterial biofilm. Traditional debridement methods involve the use of a sharp blade, a method that often results in the removal of healthy, viable tissue and pain for the patient. In contrast, the Swiss wound care company, Medaxis has developed the debritom+ to precisely clean acute and chronic wounds in a tissue-preserving manner. By using Micro Water Jet technology, the debritom+ removes the unhealthy tissue such as fibrin, necrosis, and biofilm efficiently while performing a precise mechanical cleaning and stimulation of the wound base to enhance granulation and healing.

 

Results from the interim analysis of a Multicenter Randomized Control Trial (NCT04564443) that has been accepted for presentation this week at the American Diabetes Association annual meeting in New Orleans, showed that weekly debridement using the debritom+ nearly doubled the rate of wound healing from 40% to 72% compared to the use of traditional methods. Also shown was a significant improvement in wound size reduction (87% versus 35%), while also reducing the frequency of infections and complications.

 

Study Chair, Professor David Armstrong DPM MD PhD of Keck School of Medicine of University of Southern California noted “The early data suggests great promise that better debridement tools can improve wound closure and decrease diabetic foot related complications and infections. This study supports that improved debridement methods, combined with good quality dressings and offloading, is beneficial and possibly synergistic to achieve wound healing in non-healing diabetic foot ulcers.”

 

“To initiate wound healing, a quality debridement is key to success. In contrast to traditional debridement methods that remove both the non-viable and healthy tissue, the debritom+ by Medaxis removes only the non-viable tissue while preserving the healthy tissue underneath. By creating microbleeding and providing the oxygenation to the wound that is necessary for starting the healing process, the debritom+ has now been proven to initiate healing in nearly twice as many wounds as with traditional methods with six-times fewer infections and complications” stated Dr. Mark Cregan, Managing Director of Medaxis USA.

 

Beat Moser, CEO of Medaxis said “These results validate the design philosophy of the Medaxis debritom+. The use of our patented Micro Water Jet Technology has now been proven to significantly improve wound healing outcomes. I have always believed that clean wounds heal better, and now we have the hard evidence.”

 

To view the study results, or for more information about the debritom+ by Medaxis, please see www.medaxis.us, email info@medaxis.us, or call (312) 483-6214

 

SOURCE Medaxis LLC

 

This article was originally published here

The Many Advantages of Buying from U.S.-Based Total Contact Casting (TCC) Manufacturers

The Many Advantages of Buying from U.S.-Based Total Contact Casting (TCC) Manufacturers

As supply chains continue to shift and tariffs reshape global trade, healthcare providers are taking a closer look at where their medical products are made — and for good reason. When it comes to Total Contact Casting (TCC) kits, working with U.S.-based manufacturers offers multiple benefits that go far beyond product availability.

🇺🇸 Supporting U.S. Jobs and Economic Growth

One of the primary goals behind recent U.S. tariffs on imported goods — especially from countries like China and Mexico — is to incentivize domestic production and bring jobs back to the United States. By sourcing TCC kits from American companies, clinics and hospitals contribute to this effort, helping strengthen the U.S. manufacturing base and create employment in logistics, packaging, and assembly sectors.

📦 Reliable Supply Chains and Faster Fulfillment

U.S.-based TCC manufacturers like M-Med benefit from being located within national logistics hubs. That means faster fulfillment, fewer customs delays, and greater supply chain stability — even during international disruptions. With wound care patients requiring timely interventions, every day of delay can matter.

💰 Predictable Pricing Without Tariff Surprises

Imported medical devices from Mexico and other countries may face tariffs of up to 25% if they do not meet strict USMCA compliance standards. While some products are exempt, not all medical devices qualify — and compliance must be proven. Domestic manufacturers avoid these pricing uncertainties, offering more consistent and transparent cost structures for purchasing departments.

🛠 Quality, Oversight, and Responsiveness

U.S.-based manufacturers operate under FDA guidelines and often have shorter feedback loops with customers. That means higher quality control, quicker responses to clinical feedback, and greater flexibility when it comes to custom orders or support.

✅ The M-Med Advantage

M-Med’s Total Contact Casting kits are manufactured and assembled in the Southeastern U.S., with more padding and more components than standard kits. As a family-owned business, we prioritize fast delivery, dependable quality, and close relationships with the wound care professionals we serve.

In a time when sourcing and supply decisions carry long-term implications, buying American-made TCC products isn’t just a smart business move — it’s an investment in quality care and domestic resilience.

Disclosure: M-Med is a sponsor of WoundCareWeekly. While editorial content is independently written, M-Med supports our mission to educate and connect the wound care community.

CuraMedical: Innovating Hemostatic Solutions in Surgical Care

CuraMedical: Innovating Hemostatic Solutions in Surgical Care

Founded in 1998 and headquartered in Assendelft, Netherlands, CuraMedical B.V. is a privately held medical device company specializing in the development, manufacturing, and marketing of hemostatic agents. With a commitment to quality and innovation, CuraMedical has established itself as a trusted provider of surgical solutions, distributing products to over 50 countries worldwide. :contentReference[oaicite:4]{index=4}

Key Highlights:

  • Comprehensive Hemostatic Product Line: CuraMedical offers a range of absorbable and non-absorbable hemostatic products, including CuraSpon®, CuraCel®, CuraTamp®, and CuraWax®. :contentReference[oaicite:7]{index=7}
  • Global Reach and Compliance: The company’s products are distributed in over 50 countries, adhering to international standards such as ISO 13485 and the EU Medical Device Directive. :contentReference[oaicite:10]{index=10}
  • Commitment to Quality and Innovation: CuraMedical employs leading-edge technology and maintains rigorous quality control processes to ensure reliable product performance. :contentReference[oaicite:13]{index=13}

CuraMedical’s dedication to advancing surgical care through innovative hemostatic solutions underscores its role as a key player in the global medical device industry. By focusing on quality, compliance, and customer satisfaction, the company continues to contribute significantly to improved surgical outcomes and patient care worldwide.

Learn more about the company on the CuraMedical website.

Keywords:
CuraMedical,
hemostatic agents,
surgical care

Orpyx Partners With Onduo to Offer Foot Ulcer Prevention Sensor as Part

     of Virtual Diabetes Program

 

The addition of foot ulcer prevention to Onduo’s virtual diabetes program offering is significant. According to Singh et al., 25 percent of people with diabetes develop foot ulcers over their lifetime and today, one in five of those people experience complications that lead to amputation. Orpyx foot ulcer prevention technology will be available to select members of the Onduo community in 2019.

 

“Orpyx helps people with diabetes to prevent foot ulcers by providing insight that protects foot health and mobility and reduces the risk of complications that can lead to limb loss,” said Breanne Everett, CEO of Orpyx Medical Technologies Inc. “We are pleased to extend access to our foot sensor technology to the Onduo member community and to invite Orpyx U.S. patients to take advantage of Onduo services.”

 

Onduo integrates hardware and software to provide people with access to personalized, convenient diabetes care. People with diabetes are matched with lifestyle and clinical interventions, which for participating clients and select users will include wirelessly connected foot monitoring from Orpyx next year.

 

Orpyx FDA-cleared foot sensor technology is embedded in shoe insoles to monitor foot pressure and relay alerts to a smartphone or smartwatch when a person needs to take action to prevent foot injury. The technology is effective even for those with foot numbness, known as peripheral neuropathy. In the U.S. alone, almost one million diabetes-related foot ulcers are treated each year, costing upwards of $30,000 USD per ulcer with complications that can result in amputation.[2] Forty percent of people who experience one diabetes-related foot ulcer will have a second ulcer in the next year.[3] This number approaches 100 percent at 10 years.

 

“Managing diabetes is a 24/7 job and we want to make access to care and monitoring easier for members,” said Dr. Josh Riff, CEO of Onduo. “We are thrilled to partner with Orpyx to help keep members walking and living actively in our community.”

View source version on accesswire.com:
https://www.accesswire.com/530441/Orpyx-Partners-With-Onduo-to-Offer-Foot-Ulcer-Prevention-Sensor-as-Part-of-Virtual-Diabetes-Program

Healthcare-Acquired Wound Infections and Antimicrobial Resistance – webinar

Healthcare‑Acquired Wound Infections & Antimicrobial Resistance: Embracing a Multidisciplinary Team Approach

Presented on June 19, 2025, this free, on‑demand webinar by WoundSource addresses the growing risks of hospital‑acquired wound infections and the escalating problem of antimicrobial resistance (AMR). Featuring insights for clinicians on integrating multidisciplinary strategies for prevention, management, and stewardship.

Key Highlights:

  • Rising Infection Risks: Covers the prevalence and serious complications associated with healthcare‑acquired wound infections, including surgical site infections, device‑related wounds, and pressure injuries. :contentReference[oaicite:1]{index=1}
  • Antimicrobial Resistance Challenge: Discusses how multidrug-resistant organisms complicate treatment, leading to increased morbidity, mortality, and healthcare costs. :contentReference[oaicite:2]{index=2}
  • Multidisciplinary Protocols: Emphasizes collaborative best practices involving infection control experts, microbiologists, pharmacists, nursing staff, and wound specialists to optimize prevention and management.
  • Stewardship Strategies: Promotes antimicrobial stewardship programs, including robust surveillance, appropriate antibiotic selection, targeted therapy, and review of antibiotic duration to minimize resistance pressure.
  • Clinical Practice Adaptations: Highlights the use of evidence‑based dressings, modality selection, debridement protocols, and early identification to reduce colonization and infection rates.

Watch the full webinar on the WoundSource website.

Keywords:
healthcare-acquired infections,
antimicrobial resistance,
multidisciplinary team,
antimicrobial stewardship,
wound infection prevention

Nutrition Interventions in Adults with Diabetic Foot Ulcers

Diabetic foot ulcers (DFU) are chronic wounds in the foot or feet associated with neuropathy and/or peripheral artery disease (PAD) of the lower limb in patients with diabetes mellitus. Reports from the Centers for Disease Control and Prevention show that in the United States there are nearly one in four adults living with diabetes, which indicates that a large number of Americans are at risk of DFU. DFUs will develop in up to 34% of patients with diabetes at some time in in their lives, and of those, approximately 15%–25% will require an amputation. Moderate or severe malnutrition has been identified in over half of patients with DFU, and malnutrition in DFU is correlated with increased lower-extremity amputation. Improvements in wound care therapy, including nutrition interventions, can reduce the financial burden of DFUs and increase life expectancy and quality of life … read more

Nutrition Interventions in Adults with Diabetic Foot Ulcers

  • Diabetic foot ulcers (DFU) are chronic wounds in the foot or feet associated with neuropathy and/or peripheral artery disease (PAD) of the lower limb in patients with diabetes mellitus.
  • Reports from the Centers for Disease Control and Prevention show that in the United States there are nearly one in four adults living with diabetes, which indicates that a large number of Americans are at risk of DFU.
  • DFUs will develop in up to 34% of patients with diabetes at some time in in their lives, and of those, approximately 15%–25% will require an amputation.
  • Moderate or severe malnutrition has been identified in over half of patients with DFU, and malnutrition in DFU is correlated with increased lower-extremity amputation.
  • Improvements in wound care therapy, including nutrition interventions, can reduce the financial burden of DFUs and increase life expectancy and quality of life.

read more

Prevent and manage wounds with this expert, all-inclusive resource! Acute & Chronic WoundsCurrent Management Concepts, 5th Edition provides the latest diagnostic and treatment guidelines to help you provide quality care for patients with wounds. This textbook presents an interprofessional approach to maintaining skin integrity and managing the numerous types of skin damage including topics that range from the physiology of wound healing, general principles of wound management, vulnerable patient populations, management of percutaneous tubes, and specific care instructions to program development. Written by respected nursing educators Ruth Bryant and Denise Nix, this bestselling reference also provides excellent preparation for all wound certification exams.

 

  • A comprehensive approach to the care of patients with acute and chronic wounds guides students and health care providers to design, deliver and evaluate quality skin and wound care in a systematic fashion; the comprehensive approach includes the latest advances in diagnosis, differentiation of wound types, nutrition, prevention, treatment, and pharmacology.
  • Self-assessment questions and answers in each chapter help you assess your knowledge and prepare for all wound certification exams.
  • Checklists offer a concise, easy-to-read summary of the steps needed to achieve the best patient care outcomes.
  • Risk assessment scales help in determining a patient’s risk for developing a wound, and wound classification tools identify the proper terminology to be used in documentation.
  • Learning objectives at the beginning of each chapter focus your study on the most important content.
  • Principles for practice development boost outcomes and productivity in agencies and institutions, home care, acute care, long-term care, and long-term acute care settings.
  • NEW coverage includes the latest guidelines from WOCN, AAWC, NPUAP, EPUAP, and PPPIA, and the American College of Physicians.
  • New sections cover the prevention and management of biofilm, the new skin tear classification system, MASD and MARCI, CTP terminology and classification scheme, and integration of the Health Belief Model.
  • NEW! Additional full-color photographs show the differential diagnosis of types of skin damage, management of fistulas, and NPWT procedures.
  • NEW! Clinical Consult features help in applying concepts to clinical practice, showing students and health care professionals how to assess, manage, and document real-life patient and staff encounters using the ADPIE framework.
  • NEW two-color illustrations and design make the book more visually appealing.

UK nurses carry out 180 wound dressing changes a year

     on each chronic wound patient

 

New research finds UK nurses carry out 180 wound dressing changes a year – on each chronic wound patient
  • Chronic wounds, such as diabetic foot ulcers, pressure ulcers and venous leg ulcers, take more than 8 months to heal for the average patient and some will be affected for decades1
  • Despite advancements in wound care, patients report dressings are changed on average 5 times a week1
  • This poses a huge burden on UK nurses and impacts the quality of life for nearly all (90%) of patients1
August 2018, Milton Keynes, UK. A survey of more than 200 people living with chronic wounds, conducted by Mölnlycke, a provider of wound care solutions, reveals that living with an open wound for almost a year has become the ‘new normal’ in the UK.1 The situation is challenging for UK nurses and has a devastating impact on quality of life for those affected … read more

Impact of the COVID-19 pandemic on patients with hidradenitis suppurativa

Compared to prior to the pandemic, fewer patients consulted their primary physician for changing wound dressings and more changed the dressings themselves or were assisted by their family members. 13% of patients avoided doctor visits due to fear of COVID-19 and 26.1% minimised doctor visits … The Dermatology Life Quality Index showed a moderate to very severe impact on patients’ Quality of Life (mean score = 10.06). Only one patient used telemedicine. Due to limited access to primary care and fear of COVID-19, the pandemic had a detectable impact on the hospital management of patients with HS in our facility. Telemedicine still plays a negligible role in primary wound care … read more

Identifying and managing wound pain – module

Pain associated with chronic wounds can affect quality of life and have a major impact on physical, emotional and cognitive function. This module explores the importance of pain management, the mechanism and types of pain, as well as how to assess and manage pain.
Chronic wounds, Pain Management, Quality of life, Wound Care, Wound pain … read more


If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Case series: 3M™ Kerramax Care™ Super-Absorbent Dressing and 3M™ Coban™ 2 Two-Layer Compression System

Author(s) : Maria Hughes, Helen Strapp, Alita Jaspar, Bram Balduyck

 

Venous leg ulcers (VLUs; also known as varicose or stasis ulcers) pose significant challenges to patients and healthcare systems: they are the most common type of leg ulcer, costly to manage, recurring, and may persist for months or years (Harding et al, 2015). This can significantly impact patient quality of life, leading to depression, anxiety and social isolation. Other issues associated with VLUs that can negatively impact on quality of life include the following:

  • Pain
  • Leaking exudate
  • Odour
  • Restricted mobility
  • Sleep disturbance.

read more

Newly Published RCT Shows MolecuLight Fluorescence Point-of-Care Imaging Improved 12-Week Wound Healing by 204% in Diabetic Foot Ulcers

Study Confirms the Utility of MolecuLight to Inform Clinicians to the Presence and Location of Clinically Significant Bacteria and Improves Treatment Plans & Outcomes over Conventional Diagnostic Methods

 

LEEDS, UK and TORONTO, July 13, 2022 /PRNewswire/ – MolecuLight Inc., the leader in fluorescence imaging for detection and localization of elevated bacterial load in wounds, announced the publication of an independent, blinded randomized controlled trial in Diabetes Care. The publication on this 56-patient trial, titled “The use of Point-of-Care Bacterial Autofluorescence Imaging in the Management of Diabetic Foot Ulcers: A Pilot Randomized Controlled Trial“1 reported that the use of a MolecuLight i:X® device to visualize the presence of elevated bacterial burden in wounds doubled 12-week wound healing rates (204%) in diabetic foot ulcer patients over standard-of-care alone.

 

Diabetes is a significant global health ailment: over 416 million people have diabetes worldwide2 and 25% of these patients develop a diabetic foot ulcer (DFU)3, greatly diminishing quality of life and increasing the need for costly and extended treatment. In the UK, the NHS spends £1 billion ($1.25 billion US) annually on DFU care and management24.

 

“As a clinician in wound care, especially when managing patients with chronic wounds, the holy grail is improvement in wound healing rates”, says David Russell, Associate Professor in Vascular Surgery at University of Leeds and lead author in the study. “In our randomized controlled trial, the results were impressive – the use of a MolecuLight device to inform our wound care decision-making helped us double the number of wounds that were healed at 12 weeks. This has benefits for the patient and our healthcare system.”

 

Patients were stratified into two groups, one in which the MolecuLight device was not used, and one in which clinicians used the MolecuLight device bi-weekly to assess diabetic foot ulcers for the presence of elevated bacterial burden. For the MolecuLight group, fluorescence imaging was performed after treatment. Fluorescence indicated the presence of elevated bacterial burden in over 80% of the wounds. Additional treatment based on imaging findings was performed as the discretion of the clinician, and most often included further debridement focused on the regions with elevated bacterial loads. Importantly, there was no increase in antibiotic prescribed in the MolecuLight group.

 

Alongside the impressive 2-fold improvement in healing rates, this study showed an association between baseline fluorescence and wound outcomes. Of the patients with negative fluorescence images at the baseline visit, 53.9% healed at 12-weeks, versus 37.5% with positive baseline fluorescence images. In other words, patients were 36% less likely to heal at 12 weeks if their wound was positive for high bacterial loads at the beginning of their treatment, as depicted by MolecuLight. Wound area reduction was superior in the MolecuLight arm and patient quality of life diverged toward improvement in the MolecuLight arm at 4 weeks and toward deterioration in the control arm at 12 weeks.

 

“To improve decision-making and care with DFU patients we must be able to measure what we manage. The MolecuLight i:X, as illustrated by the results in this RCT, is a powerful tool for screening DFUs for infection as well as monitoring new or worsening bacterial burden over time”, says David G. Armstrong, Professor of Surgery, Director of the Southwestern Academic Limb Salvage Alliance (SALSA) at Keck School of Medicine of the University of Southern California as well as the US-appointed delegate to the International Working Group on the Diabetic Foot (IWGDF). “This new study provides further data for the improved healing rates and improved patient care that can be achieved in a clinic with routine use of fluorescence imaging to detect wound bacteria.”

 

“We congratulate Dr. Russell and the team at Leeds for their excellent study and publication that shows the utility of MolecuLight to detect elevated bacterial burden and to inform clinical decision-making at the point-of-care”, says Anil Amlani, MolecuLight’s CEO. “A doubling of 12-week wound healing is a significant outcome and is consistent with what thousands of wound care clinicians are experiencing worldwide, that MolecuLight enables clinicians to deliver superior, proactive bacterial/infection management that improves wound outcomes”.

 

The Leeds Diabetes Limb Salvage service is now using the MolecuLight device to image all patients with wounds that are failing to achieve a healing trajectory within 4 weeks. To help manage patient volumes, patients who are negative with MolecuLight are triaged, and are then referred to community care as their wounds are considered manageable and able to achieve a healing trajectory.

 

This new RCT is part of a broad body of clinical evidence showing the many benefits of the MolecuLight i:X and DX devices across the range of wound care applications to help inform and improve clinical decision-making. This list of clinical evidence includes over 60 peer-reviewed publications and 1,500 studied wound patients.

 

  1. Rahma S et al. Diabetes Care 2022;45(7):1601–1609
  2. Diabetes UK: Diabetes Prevalence, www.diabetes.org.uk/professionals/position-statements-reports/statistics/diabetes-prevalence-2019
  3. Armstrong AG et al. The New England Journal of Medicine, 2017; 376:2367 – 75
  4. Kerr, M, 2017, www.diabetes.org.uk/resources-s3/2017-11/diabetes%20uk%20cost%20of%20diabetes%20report.pdf

 

About MolecuLight Inc.
MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection and localization of elevated bacterial load in wounds and for digital wound measurement. MolecuLight procedures performed in the United States can benefit from an available reimbursement pathway including two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant unmet needs including food safety, consumer cosmetics and other key industrial markets.

 

For more information, contact:
Rob Sandler
Chief Marketing Officer
MolecuLight Inc.
T. +1.647.362.4684
rsandler@moleculight.com
www.moleculight.com

Is Nanofat the Long-Awaited Treatment for Hypertensive Ischemic Leg Ulcers?

Background. Martorell hypertensive ischemic leg ulcer (HYTILU) is a chronic, hard-to-heal wound linked to hypertension. This study explores nanofat grafting as a regenerative alternative to traditional skin grafting for improved healing and patient outcomes. Objective. To explore the efficacy of nanofat grafting in the management of HYTILU and compare it with skin grafting. Materials and Methods. This was a retrospective single-center pilot study involving 23 patients with HYTILU treated with adipose-derived stromal cells (adipose-derived stromal cells/nanofat). The primary outcomes were ulcer healing rate, pain reduction, and improvements in quality of life, as measured by SCAR-Q (a scar quality of life questionnaire) and the Vancouver Scar Scale, over a period of 6 months posttreatment. Results. This study revealed a significant decrease in ulcer size from an initial mean of 39.69 cm² to complete healing, with an average healing time of 4.65 months. The mean visual analog scale pain scores significantly decreased from an initial score of 5.87 to 0.39 at 3 months …. read more

TLC-NOSF dressings as a first-line local treatment of chronic wounds

TLC-NOSF Dressings as a First-Line Local Treatment of Chronic Wounds: A Systematic Review of Clinical Evidence

Summary: A 2024 systematic review in WoundCentral Education (Journal of Wound Care) by Meloni et al. analyzed 17 studies spanning from 2017 to 2024, including 10,191 patients and 10,203 chronic wounds (diabetic foot ulcers, leg ulcers, pressure injuries, and others). It evaluates the outcomes when TLC-NOSF dressings were used as first-line treatment—comparing healing efficacy, time-to-heal, quality of life, and cost against standard dressings.

Key Highlights:

  • Using TLC-NOSF dressings as first-line care led to significantly higher wound healing rates (around 70–80% by weeks 20–24), faster closure (mean ~7 weeks), and cost savings across diverse wound types. :contentReference[oaicite:0]{index=0}
  • Evidence came from both controlled comparative studies (TLC-NOSF vs. standard dressings) and real-world observational data, with low risk of bias overall. :contentReference[oaicite:1]{index=1}
  • Results aligned with guideline recommendations (e.g., IWGDF, NICE) endorsing TLC-NOSF as part of standard of care. :contentReference[oaicite:2]{index=2}

Read the full review on WoundCentral Education

Keywords:
TLC-NOSF dressings,
chronic wounds,
wound healing,
cost effectiveness,
quality of life,
first-line treatment

Stoma Masterclass: Shaping Better Patient Outcomes with Moldable Technology in Ostomy Care

Stoma Masterclass: Shaping the Future of Ostomy Care with Moldable Technology

Summary: As part of the Global Innovation Summit Series, Wound Masterclass is hosting a Stoma Masterclass focused on moldable technology in ostomy care. This deep-dive session will highlight clinical evidence, patient case studies, and practical guidance for clinicians seeking to optimize outcomes and improve quality of life for ostomy patients.

Key Highlights:

  • Event date: Scheduled for 10 September 2025, available online through BigMarker.
  • Clinical focus: Evidence-based exploration of moldable adhesives and skin barriers to address leakage and protect peristomal skin.
  • Learning objectives: Guidance on patient assessment, product selection, and troubleshooting common ostomy care challenges.
  • Case studies: Real-world examples demonstrate how moldable technology supports individualized care and improved patient outcomes.
  • Patient-centered outcomes: Emphasis on comfort, skin health, and minimizing complications to enhance overall quality of life.

Register for the Stoma Masterclass via Wound Masterclass

Keywords:
moldable technology,
ostomy care,
stoma masterclass,
skin protection,
patient outcomes

Optimizing Self-Management for People Living With Ostomies

Optimizing Self-Management for People Living With Ostomies (Abstract)

Summary: This abstract, published in *Journal of Wound, Ostomy & Continence Nursing*, explores strategies and interventions to enhance self-management among individuals with ostomies. It emphasizes the importance of education, patient empowerment, adaptive techniques, and ongoing clinical support to improve outcomes and quality of life.

Key Highlights (Inferred):

  • Focus on patient education, tailored self-care training, and behavior change to enhance adherence and reduce complications.
  • Potential discussion of adaptive tools, monitoring, and support systems to facilitate independent ostomy care.
  • Emphasis on longitudinal support, including clinician follow-up and troubleshooting in a home/community setting.

View the abstract on JWOCN

Keywords:
ostomy self-management,
patient education,
quality of life,
behavior change,
longitudinal support

AI and Pressure Sensors | Revolutionizing Pressure Ulcer Prevention in the NHS



AI and Pressure Sensors: Saving the NHS Billions on Bedsore Treatment

Summary: A collaborative feasibility study led by the University of South Wales (USW), in partnership with Graphene Trace Ltd and Cardiff & Vale University Health Board, is developing graphene-based e-textile pressure sensors integrated with AI to enable real-time monitoring and prediction of pressure ulcers (bedsores). Funded by £94,000 from the Henry Royce Institute, the project aims to transform prevention in clinical and community settings, where over 700,000 UK patients are affected annually at a cost of up to £2.1 billion to the NHS. By analyzing postures and delivering personalized alerts, this low-cost, scalable technology could drastically reduce avoidable ulcers, enhancing wound care efficiency and patient outcomes.

Key Highlights:

  • Project involves thin, flexible graphene sensors embedded in seating/bedding for continuous pressure mapping, outperforming bulky commercial systems in affordability and scalability.
  • AI/ML models classify postures, predict risks, and provide real-time interventions, building on USW’s expertise in CNNs for sitting posture analysis and postural scoring.
  • Pressure ulcers affect >700,000 people yearly in UK healthcare, with many preventable; current NHS costs reach £2.1B annually due to prolonged healing and complications.
  • Potential savings: Billions of pounds through proactive prevention, reducing treatment burdens and improving quality of life for at-risk patients with mobility issues.
  • Expert insights emphasize clinical-economic impact: Prof. Colin Gibson notes transformational potential for care quality; Prof. Janusz Kulon highlights life-changing AI-fabric integration.

Read full article

Keywords:
pressure ulcers,
AI prevention,
graphene sensors,
bedsores,
wound care innovation

Use of Hypothermically Stored Amniotic Membrane on Diabetic Foot Ulcers

Use of Hypothermically Stored Amniotic Membrane on Diabetic Foot Ulcers: A Multicentre Retrospective Case Series

Summary: Researchers from US-based wound care sites published a multicentre retrospective case series in the Journal of Wound Care (March 2024 supplement) reporting clinical outcomes for diabetic foot ulcers (DFUs) managed with hypothermically stored amniotic membrane (HSAM), a cellular, acellular and matrix-like product (CAMP) classified as a human cellular and tissue-based product (HCT/P) under FDA oversight. HSAM differs from dehydrated and cryopreserved amniotic membrane allografts in that hypothermic storage conditions preserve viable differentiated and stem cell populations, growth factors, cytokines, and extracellular matrix proteins more completely — a distinction the authors argue may enhance clinical effectiveness. The study enrolled 50 patients across multiple US wound care sites; 68% were male with a mean age of 66.7 years. The majority of DFUs (88%) were present for fewer than 6 months at first presentation, and mean wound area at first presentation was 3.5 cm². From first presentation to baseline (the visit at which HSAM was first applied), mean percentage wound area reduction was −68.3%, reflecting the contribution of standard of care (SoC) pre-treatment. HSAM was then applied on top of continued SoC, and patients were followed over 12 weeks. The results suggest positive outcomes in terms of continued wound closure, with reduction in time to complete wound closure (CWC) noted as a key patient benefit — since shortened healing time translates to reduced financial burden and improved quality of life. The case series adds real-world evidence to prior randomized controlled trial data for HSAM in DFUs, including a 14-site RCT (Serena et al., 2020) that demonstrated a 60% closure rate at 12 weeks and a 75% greater probability of weekly wound closure versus standard of care alone.

Key Highlights:

  • 50 patients across multiple US wound care sites; 68% male, mean age 66.7 years; 88% of DFUs present <6 months at first presentation
  • Mean wound area 3.5 cm²; mean percentage area reduction of −68.3% from first presentation to HSAM baseline (reflecting SoC pre-treatment effect)
  • HSAM mechanism: hypothermic storage preserves viable cells, stem cells, growth factors, cytokines, and ECM proteins — a key advantage over dehydrated and cryopreserved amnion products
  • Prior RCT (Serena et al., 2020, n=76): HSAM produced 60% closure at 12 weeks vs. 38% SoC (p=0.004) and 75% greater probability of wound closure on a weekly basis over 16 weeks
  • Shortened time to CWC cited as having downstream financial and quality-of-life benefits — average DFU cost estimated at $38,000–$54,000 if leading to amputation
  • Authors: Anna Sanchez (San Antonio New Step, TX), Alan Hartstein and Hisham Ashry (Palm Beach Foot & Ankle, FL), Maryam Raza; data coordination supported by Organogenesis Inc.

Read full article

Keywords: amniotic membrane wound carehypothermically stored amniotic membranediabetic foot ulcer CAMPsplacental allograft woundHSAM DFUcellular tissue products wound healing

Anna Sanchez Alan Hartstein Hisham Ashry Maryam Raza

Dehydrated human amnion/chorion membrane to treat venous leg ulcers

A recent economic evaluation using a Markov model assessed the cost-effectiveness of dehydrated human amnion/chorion membrane (DHACM) for Medicare beneficiaries with venous leg ulcers (VLUs). The study compared DHACM—applied following recommended timing and frequency—to no advanced treatment (NAT) over three years, using real-world claims from over 530,000 patients. Results showed that DHACM not only saved $170 per patient but also improved quality-adjusted life years (QALYs), producing a net monetary benefit of $1,178. The treatment was cost-effective in over 63% of simulations and linked to lower recurrence rates. With chronic wounds placing a heavy and growing burden on Medicare—VLUs alone cost $14.9 billion annually—these findings support DHACM as a superior, cost-saving strategy. Providers and payers are encouraged to prioritize DHACM in wound care formularies to improve outcomes and reduce system-wide costs … read more


The authors:

1. William H. Tettelbach, MD, FACP, FIDSA, FUHM, CWSP

Dr. Tettelbach is board-certified in Undersea & Hyperbaric Medicine, Infectious Diseases, and Internal Medicine. He has held leadership roles at MiMedx, OnSite Advanced Care, and RestorixHealth, and serves as an adjunct professor at Duke University School of Medicine.WICE Radiology+8Press Release Hub+8ORCID+8


2. Vickie R. Driver, DPM, MS, FACFAS

Dr. Driver is a Professor at Washington State University School of Medicine and the Founding Chair of the Board of Directors for the Wound Care Collaborative Community. She has served as System-Wide Medical Director of Wound Care and Hyperbaric Centers at INOVA Healthcare and is a Fellow of the Royal College of Physicians and Surgeons-Glasgow.hmpglobalevents.com+5woundcarecc.org+5woundcarecc.org+5reddressmedical.com+4sawcf.eventscribe.net+4Maggie Online Library+4


3. Alisha Oropallo, MD, FACS, FSVS, FAPWCA

Dr. Oropallo is a Professor at the Zucker School of Medicine at Hofstra/Northwell and Director of the Comprehensive Wound Healing Center at Northwell Health. She is board-certified in General and Vascular Surgery and is a Fellow of the American College of Surgeons.LinkedIn+4ResearchGate+4CITI Program+4woundcarecc.org


4. Martha R. Kelso, RN, CHWS, HBOT

Ms. Kelso is the CEO of Wound Care Plus, LLC, one of the nation’s largest mobile wound care providers. She is recognized as a visionary in mobile medicine and is a published author and clinical editor for multiple peer-reviewed journals.hmpglobalevents.com+3Log in or sign up to view+3LinkedIn+3hmpglobalevents.com+3pawsic.org+3LinkedIn+3


5. Jeffrey A. Niezgoda, MD, FACHM, MAPWCA, CHWS

Dr. Niezgoda is the President and Chief Medical Officer of WebCME and serves as the CMO for Kent Imaging. He is the Past President of the American Professional Wound Care Association and the American College of Hyperbaric Medicine.LinkedIn+8ipawssummit.org+8kentimaging.com+8


6. Naz Wahab, MD, FAAFP, FAPWCA

Dr. Wahab is a board-certified family physician and wound care specialist. She serves as the Medical Director for the Mountain View Outpatient Wound Care and Hyperbaric Center and is an active member of several wound care organizations.reddressmedical.com+4Medical News Today+4aawconline.memberclicks.net+4aawconline.memberclicks.net+3reddressmedical.com+3campswoundcaresummit.com+3


7. Julie L. De Jong

Information on Julie L. De Jong’s professional background in wound care is limited in the provided sources. Further details may be available through institutional affiliations or publications.


8. Brandon Hubbs

Mr. Hubbs is an experienced Cardiovascular Administrator and Nurse, affiliated with FirstHealth of the Carolinas.LinkedIn


9. R. Allyn Forsyth

Dr. Forsyth has contributed to research on wound care, including studies on the cost of chronic wound care for Medicare beneficiaries.ResearchGate


10. Gregory A. Magee, MD

Dr. Magee is an Associate Professor of Clinical Surgery at the Keck School of Medicine of USC. He completed fellowships in surgical critical care and trauma surgery at USC and in vascular surgery at the University of Colorado Denver.Healthgrades+4Keck School of Medicine of USC+4SC CTSI Profiles+4Keck Medicine of USC


11. Paul Steel

Specific information about Paul Steel’s professional background in wound care is not readily available in the provided sources. Further details may be found through academic publications or institutional affiliations.


12. Benjamin G. Cohen, DPM

Dr. Cohen is a Podiatric Medicine specialist and Podiatric Surgeon based in Aiken, South Carolina. He is recognized as an advanced expert in his field.Medifind+1Maggie Online Library+1


13. William V. Padula, PhD

Dr. Padula is an Assistant Professor of Pharmaceutical & Health Economics at the USC Mann School of Pharmacy and a Fellow at the USC Leonard D. Schaeffer Center for Health Policy & Economics. His research focuses on cost-effectiveness analysis and healthcare delivery, particularly regarding pressure injury prevention.USC Schaeffer+2USC Mann School of Pharmacy+2SC CTSI Profiles+2NCBI+3USC Schaeffer+3ResearchGate+3

Adimarket announces agreement with Alolotl Biologix

Adimarket, a subsidiary of Global Stem Cells Group, has announced an agreement with biotechnology company Alolotl Biologix to distribute biological products for regenerative medicine applications worldwide.

 

Adimarket, a subsidiary of Global Stem Cells Group (GSCG), and its subsidiary has announced an agreement with Phoenix, Arizona-based Alolotl Biologix to distribute the biotechnology company’s products for regenerative medicine applications worldwide.

 

Alolotl Biologix focuses on research to optimize the use of human biologicals and to develop biological-related products to foster regeneration and healing for a range of conditions, including orthopedic impairments, wound care, pain management, ophthalmic, cardiovascular, cosmetic, and more.

 

Adimarket will make the following amniotic liquid products available to qualified practitioners through its online store www.adimarket.net:

 

AxoBioFluid® C Amniotic Allograft Cryopreserved Liquid, cryopreserved liquid allograft derived from the amniotic membrane that provides structural tissue to advance soft tissue repair, replacement, and reconstruction. Product details:

 

Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
Immune privileged with anti-inflammatory and anti-bacterial properties
A rich source of growth factors, proteins, cytokines, hyaluronic acid, and collagen scaffolds
Contains extracellular matrix components for cellular attachment and proliferation
Cryopreserved for an extended shelf life
AxoBioFluid® physician benefits

 

Procedures are efficient and do not require special instrumentation.
• The use of AxoBioFluid® is billed as patient pays, which makes it a great alternative revenue source.
• A library of research papers to demonstrate efficacy degenerated tissue is provided.
AxoBioFluid® patient benefits

 

Relevant Conditions

 

AxoBioFluidâ C Amniotic Allograft Cryopreserved Liquid, cryopreserved liquid allograft derived from the amniotic membrane that provides structural tissue to advance soft tissue repair, replacement, and reconstruction. Product details:

 

Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
Immune privileged with anti-inflammatory and anti-bacterial properties
A rich source of growth factors, proteins, cytokines, hyaluronic acid, and collagen scaffolds
Contains extracellular matrix components for cellular attachment and proliferation
Cryopreserved for an extended shelf life
AxoBioFluidâ physician benefits

 

Procedures are efficient and do not require special instrumentation.
• The use of AxoBioFluid® is billed as patient pays, which makes it a great alternative revenue source.
• A library of research papers to demonstrate efficacy is provided.
AxoBioFluid® Amniotic Allograft Cryopreserved Liquid is a cryopreserved liquid allograft derived from the placental components of the amnion to advance soft tissue repair, replacement, and reconstruction. It is classified as minimally manipulated under FDA regulation 21 CFR Part 1271 and section 361 of the PHS. Benefits of AxoBioFluid® AxoBioFluid® is a human allograft fluid derived from the amniotic layer of the placenta. The two primary cell lines which reside in the amnion are human mesenchymal stromal cells (hMSC) and human amnion epithelial cells (hAEC). Both of these cells are considered to be pluripotent stem cells. AxoBioFluid® contains growth factors released while amniotic cells are grown in culture such as epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and transforming growth factor – beta (TGF-β). These proteins are essential for fetal growth and development and express significant therapeutic benefits when used as a treatment for various injuries and degenerative conditions. AxoBioFluid® is immuneprivileged, anti-inflammatory, anti-fibrotic, pro-vascular, and cytoprotective because of the cells being sourced from the amnion. These secreted factors also signal endogenous progenitor cells to promote regeneration and repair of damaged or degenerated tissue.

 

AxoBioFluid

 

Degenerative disorders such as osteoarthritis
• Joint pain
• Inflammatory conditions such as:
Bursitis
Tendonitis
Fasciitis
Epicondylitis
Soft tissue injuries such as:
Ligament & Tendon sprains
Muscle & Meniscus tears
Wound Care
AxoBioMembrane, a dehydrated allograft membrane patch derived from the amnion that advances wound repair, skin replacement, and reconstruction. Product details:

 

Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
Immune privileged with anti-inflammatory and anti-bacterial properties
Contains extracellular matrix components for cellular attachment and proliferation
Dehydrated and terminally e-beam sterilized for an extended shelf life.
AxoBioMembraneä Amniotic Allograft Membrane, like all allograft tissue products, has been subjected to recovery microbiological study and has been terminally sterilized with electron beam sterilization. It works by forming fibrin-elastin bonds at the wound site, ensuring excellent wound adherence. This generates a barrier that protects exposed nerve endings from irritants, providing pain relief while creating a favorable environment for tissue repair and regeneration. In addition, the AxoBioMembrane™ prevents excessive moisture loss by creating a vapor barrier at the wound surface. Growth factors present in the membrane are released into the wound bed, promoting angiogenesis leading to new blood supply needed for cellular migration, proliferation and ultimately, wound repair. Infection is one of the biggest concerns with chronic wounds. AxoBioMembrane™ functions as a bacteriostatic agent, which can inhibit the growth of bacteria at the wound site and reduce the rate infection. It has also been reported to have anti-fibrotic properties, which can reduce scarring. The membrane contains glycoprtoteins found exclusively in the amnion. AxoBioMembrane™ lacks specific surface antigens, which make it immune-privileged and anti-inflammatory.

 

AxoBioMembraneä physician benefits

 

Procedures are efficient and do not require special instrumentation.
AxoBioMembrane™ is billed as patient pays, which makes it a great alternative revenue source.
We provide a library of research and white papers to demonstrate efficacy.
AxoBioMembraneä patient benefits:

 

Pain Reduction
Wound Adherence
Less Scarring
Faster Healing
Neovascularization
Wound Barrier
Anti-bacterial
Immune Privileged
AxoBio products are available to purchase on the Adimarket Website.

 

For more information, visit the Adimarket regenerative medicine online store website, email info@stemcellsgroup.com, or call 305-560-5337.

 

About Global Stem Cells Group

 

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

 

Press Contact

 

Name: Benito Novas
Phone: +1 305 560 5337
Email: info@stemcellsgroup.com
Website: www.adimarket.net

Brooke Gautreaux Joins RestorixHealth At-Home Wound Healing Services

RestorixHealth is pleased to announce that Brooke Gautreaux, FNP-C, has joined RestorixHealth as a wound care provider in Thibodaux, LA, its newest service area.

 

Designed to address the needs of patients with non-healing wounds, RestorixHealth At-Home Wound Healing Services provides comprehensive, advanced wound care in the convenience and comfort of the patients’ home. This leads to lower direct care costs, reduced hospital admissions, improved outcomes and increased patient satisfaction.

 

“Our At-Home Wound Healing Services is just one way we are working toward making wound healing accessible for all,” said Douglas Cogliano, Senior Vice President At-Home Wound Healing Services. “We are extremely pleased that Brooke has joined our wound healing team to help us bring this essential service to the Thibodaux community.”

 

Brooke Gautreaux, FNP-C, received both her Bachelor of Science in Nursing and Master of Science in Nursing from Nicholls State University in Thibodaux, LA. She has five years of nursing experience, primarily in emergency medicine. She is excited to begin providing care at home because she can see the end goal with her patients and ensure their needs are met. The ability to offer hands-on, in-home wound care increases access to care for many people, and Brooke is proud to now serve her community this way.

 

Physicians may refer their patients by calling 855.228.0790 or faxing 866.422.3202. Self referrals are accepted. Associates are available to address any questions and assist in coordinating patient appointments.

 

About RestorixHealth
RestorixHealth recently joined with American Medical Technologies (AMT) to become the nation’s leading wound care solutions company, developing and operating advanced wound healing centers, providing wound healing direct-care services and education, and delivering advanced wound supplies directly to patients nationwide. Forging strong relationships with their partners, RestorixHealth provides customized wound healing programs and solutions that increase the access to care, lower or avoid direct care costs, reduce hospital admissions, improve outcomes and increase patient and partner satisfaction. For more information, visit http://www.RestorixHealth.com.

This article was originally published here

House passes ‘Big Beautiful Bill’: Here’s what it means for health care

“One Big Beautiful Bill” Passes: What It Means for Healthcare

On July 4, 2025, President Trump signed into law a sweeping legislative package titled the “One Big Beautiful Bill.” Passed along party lines in both the House (218–214) and Senate (51–50, with Vice President J.D. Vance casting the tie-breaking vote), the bill makes permanent the 2017 Trump-era tax cuts while implementing major reforms to healthcare, social safety nets, and rural infrastructure funding.

Key Provisions:

  • Tax Policy: Permanently extends the 2017 tax cuts, including reductions in individual tax rates and a doubled standard deduction. While popular among business advocates, the legislation is projected to increase the federal deficit by over $2.8 trillion over 10 years.
  • Medicaid & Medicare Changes: The bill includes up to $1 trillion in cuts to Medicaid over the next decade. An estimated 11 million Americans could lose coverage by 2034. Medicare is also affected, with reduced reimbursements and altered eligibility criteria.
  • Work Requirements: Enforces 80-hour monthly work requirements for non-disabled adults receiving Medicaid and SNAP benefits. These changes could disqualify millions of recipients, particularly in low-income and rural areas.
  • Rural Health Investment: Allocates $50 billion over five years for rural hospital infrastructure and stabilization. However, critics argue this is unlikely to offset losses caused by reduced Medicaid revenue.
  • Food Assistance: Stricter SNAP requirements could remove access for millions, with health policy analysts warning of increased food insecurity and avoidable medical complications.

Healthcare Implications:

  • Increased pressure on emergency departments and charity clinics.
  • Potential surge in uncompensated wound care and post-operative services, especially in non-Medicaid expansion states.
  • Likely closure of additional rural hospitals, particularly those operating on thin margins.

Public and Political Response:

  • Public opinion polling shows 55% of Americans oppose the bill, while only 29% support it.
  • Healthcare and patient advocacy groups have criticized the bill for reducing access and overburdening safety-net providers.
  • Democrats plan to use the bill’s unpopularity as a campaign issue ahead of the 2026 midterm elections.

Keywords:
One Big Beautiful Bill,
Medicaid cuts,
SNAP eligibility,
rural hospitals,
healthcare policy

Read the full article on Healio

MolecuLight Corp., a global leader in point-of-care fluorescence imaging for wound assessment …

MolecuLightDX® Now Available on Oracle Healthcare Marketplace

PITTSBURGH, Dec. 9, 2025 /PRNewswire/ — MolecuLight Corp., a global leader in point-of-care fluorescence imaging for wound assessment and an Oracle partner, today announced the MolecuLight DX® is available on Oracle Healthcare Marketplace. This integration enables direct connection with the Oracle Health Foundation electronic health record (EHR). Oracle Healthcare Marketplace is a centralized repository of healthcare applications offered by Oracle and Oracle partners.


The MolecuLight DX is an all-in-one handheld wound imaging solution designed to capture bacterial fluorescence, digital measurements and thermal images of wounds, all while connecting to the EHR. Leveraging Oracle Health FHIR APIs and secure Wi-Fi connectivity, this powerful integration maintains fast, accurate, and secure transfer of wound data. The result is streamlined clinician workflows and enhanced delivery of personalized, data-driven wound care.

Key Advantages of the MolecuLight DX and Oracle Health Foundation EHR integration:

  • Synchronization of patient data and records from the EHR to the MolecuLight DX via a patient MRN lookup.
  • Automatic Wi-Fi enabled upload of wound documentation to EHR to update the patient record, including:
    • Standard and bacterial autofluorescence images that detect and pinpoint areas of elevated bacterial burden.
    • Wound measurements, including length, width, and depth, for accurate and full documentation.
    • Thermal images to visualize and quantify clinically relevant temperature variations.
  • Full compatibility with Oracle’s patient encounter scheduling workflow.

Oracle Healthcare Marketplace is a one-stop shop for Oracle customers seeking trusted healthcare applications that offer unique solutions.

“Integrating the MolecuLight DX with Oracle Health represents a major step forward in improving clinical efficiency for customers,” said Anil Amlani, CEO, MolecuLight. “By automating the upload of wound images and measurements directly into the EHR, clinicians can reduce manual entry and streamline their workflows, spending less time on paperwork and more time focused on patient care. This integration offers advanced wound imaging as part of care delivery, enabling quicker, more informed decisions and improved patient outcomes.”

About MolecuLight and its Wound Imaging Devices

MolecuLight is a privately held medical imaging company with a global footprint, dedicated to manufacturing and commercializing the MolecuLight i:X® and DX® wound imaging devices. Both FDA-cleared Class II point-of-care systems provide real-time detection of elevated bacterial burden and accurate digital wound measurement. The MolecuLight DX® additionally offers thermal imaging for comprehensive wound assessment. The technologies’ effectiveness and clinical utility are supported by more than 100 peer-reviewed publications.

About Oracle’s Partner Program

Oracle’s partner program helps Oracle and its partners drive joint customer success and business momentum. The newly enhanced program provides partners with choice and flexibility, offering several program pathways and a robust range of foundational benefits spanning training and enablement, go-to-market collaboration, technical accelerators, and success support. To learn more, visit oracle.com/partner.


Third-party vendors listed on the Oracle Cloud Marketplace are responsible for complying with applicable laws and regulations, including medical device laws. Oracle does not review third-party content for compliance with applicable laws and regulations. Third-party vendors should be contacted for any questions relating to their products listed on the Oracle Cloud Marketplace.

Trademark
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.

SOURCE MolecuLight Corp.

Full press release verbatim from PR Newswire — https://www.prnewswire.com/news-releases/moleculightdx-now-available-on-oracle-healthcare-marketplace-302636127.html

Mobile diet and exercise apps for adolescent weight loss

Innovative approaches can encourage healthy eating and activity in adolescents.

 

Takeaways:

  • Nurses can help their adolescent patients with obesity by encouraging a healthy diet and greater activity
  • Smartphone apps for diet and exercise tracking may be an effective tool to help adolescents with obesity lose weight.
  • Recommend apps that are inexpensive and have high user ratings for ease of use and dependability.

By Julie Ludwig, MSN, RN, NP-C, and Christine Galluzzi, MSN, RN, APC-BC

 

Many teens with obesity go on to have obesity as adults. The ramifications of obesity are both physical and psychological, including metabolic conditions, sleep disorders, bullying, anxiety, depression, and low self-esteem. In addition, adolescents with obesity may experience increased school absenteeism and decreased scholastic performance. The result can be lower quality of life and limited life expectancy.

 

You can help your adolescent patients with obesity by encouraging a healthy diet and greater activity. (See Help young patients lose weight.) Engaging your patients in this effort may require some innovative interventions, including the use of technology … read more

Playing the Long Game with Diabetes

Playing the Long Game with Diabetes: Prioritizing Foot Health

The American Podiatric Medical Association (APMA) emphasizes the critical importance of foot health in diabetes management. Individuals with Type 1 or Type 2 diabetes face a heightened risk of serious foot complications, including infections and amputations. APMA’s “Playing the Long Game with Diabetes” campaign advocates for early adoption of healthy habits to prevent such outcomes.APMA MAIN+7APMA MAIN+7APMA MAIN+7APMA MAIN+3APMA MAIN+3APMA MAIN+3

Key recommendations include annual visits to an APMA-member podiatrist, or at minimum, regular foot checks by a primary care provider if podiatric access is limited. The APMA provides a suite of resources to support patients in maintaining foot health:APMA MAIN

  • Daily Foot Exams: Guidance on conducting simple daily inspections to detect early signs of complications.

  • Educational Materials: Tip sheets and videos featuring podiatrists sharing insights on diabetes-related foot care.

  • Product Recommendations: A list of APMA Seal-approved footwear and products designed for diabetic foot care.APMA MAIN+1APMA MAIN+1

  • Community Engagement: Encouragement to join conversations on social media using the hashtag #PlaytheLongGame.APMA MAIN+4APMA MAIN+4APMA MAIN+4

These resources aim to empower individuals with diabetes to take proactive steps in managing their foot health, thereby reducing the risk of complications.APMA MAIN

Explore the full suite of resources here: APMA Diabetes Awareness


About the Author: Dr. Savannah Santiago, DPM

Dr. Savannah Santiago is a first-year podiatric medicine and surgery resident at Ascension St. Vincent Hospital in Indianapolis. A 2024 graduate of Western University of Health Sciences College of Podiatric Medicine, she holds a B.S. in Biomedical Sciences and Spanish Language and Culture from the University of Colorado Colorado Springs, where she also competed in NCAA cross country and track and field.Pod Patrol+5LinkedIn+5Ascension Medical Education+5WesternU News+2cdn2.podiatry.com+2Ascension Medical Education+2

Dr. Santiago’s personal experiences, including managing her own diabetes diagnosis at 19 and overcoming sports-related injuries, have fueled her passion for podiatry. Her clinical interests encompass reconstructive surgery, limb salvage, pediatric podiatry, sports medicine, and inpatient care.Ascension Medical Education

An active contributor to the field, she authors the “Sole Purpose” blog on PRESENT Podiatry and has been featured on the Pod Patrol podcast. Dr. Santiago also serves as the first Resident Liaison for the American College of Podiatric Medicine (ACPM). Outside the clinic, she enjoys trail running, rollerblading, and exploring farmers markets.session.podiatry.com+4Pod Patrol+4Podiatry+4InstagramAscension Medical Education


Note: This bio is intended for educational purposes and to inform readers about Dr. Santiago’s contributions to the field of podiatric medicine.

Confronting Rising Diabetes Amputations

Summary: Published March 11, 2026 in the Guyana Times, this editorial responds to remarks by Guyana’s Health Minister Frank Anthony on World Diabetes Day documenting an increase in diabetes-related amputations in the country. More than one in seven Guyanese adults lives with diabetes, and data from the Georgetown Public Hospital Corporation show that a substantial proportion of diabetic foot infections ultimately result in amputation — reflecting, the editorial argues, failures not just at the clinical management stage but across the entire continuum of care: from prevention and primary care access through early detection, wound management, and multidisciplinary intervention. The piece frames the rising amputation rate as a systemic warning indicator rather than isolated clinical events. It contends that most diabetic amputations are preventable when complications are identified early, and calls for strengthened primary healthcare services capable of detecting warning signs before wounds become limb-threatening; comprehensive public health education campaigns on diabetic foot self-care, routine monitoring, and early symptom reporting; and investment in dedicated foot care clinics, wound management programmes, and vascular assessment tools. The editorial endorses the Health Ministry’s commitment to building multidisciplinary collaboration across surgical, internal medicine, and rehabilitation departments, noting that preserving limbs requires coordinated specialist care. The piece also connects the diabetic foot epidemic to a parallel kidney disease burden, welcoming the expansion of dialysis capacity across regional hospitals and the activation of additional dialysis chairs — and highlighting the continued importance of NGO and civil society partnerships in bridging specialist care gaps in remote communities. The editorial concludes with a call for the rising amputation count to be treated as an urgent prompt for a coordinated national response prioritising prevention, early intervention, and expanded specialised care across all of Guyana’s geographic regions.

Key Highlights:

  • Guyana Health Minister Frank Anthony cited rising diabetes-related amputations on World Diabetes Day — Georgetown Public Hospital data show a substantial proportion of diabetic foot infections result in amputation
  • More than 1 in 7 Guyanese adults lives with diabetes; diabetic foot infections are increasingly common and often escalate to amputation when detected late or inadequately managed
  • Editorial frames amputations as largely preventable through: regular foot examinations, proper wound care, glycaemic control, and timely vascular/wound specialist intervention
  • Recommended system-level responses: stronger primary care for early DFI detection; public education campaigns on diabetic self-care and foot symptom recognition; foot care clinics; wound management programmes; expanded vascular assessment
  • Multidisciplinary care model advocated: surgery, internal medicine, nursing, and rehabilitation coordination required to maximise limb salvage and support recovery after amputation
  • Parallel kidney burden: dialysis infrastructure expansion across regional hospitals and continued NGO partnerships cited as essential alongside foot care improvements to address the full spectrum of diabetes complications

Read full article

Keywords: diabetes amputation preventiondiabetic foot infection globaldiabetic foot care public healthwound care access developing countrieslimb salvage diabetes policydiabetes complications wound care

Guyana Times Editorial Board

Type 2 Diabetes Management in Severely Obese Patients: Strategies & Surgical Options

Type 2 Diabetes Management in Severely Obese Patients: Strategies & Surgical Options

A recent article on Diabetes In Control examines comprehensive treatment approaches for severely obese individuals with type 2 diabetes, highlighting lifestyle, pharmacotherapy, and advanced interventions like bariatric surgery.

Key Highlights:

  • Stable Lifestyle Habits: Emphasizes consistent diet, exercise, and stress management to enhance glycemic control and reduce cardiovascular risk :contentReference[oaicite:1]{index=1}.
  • Medications with Weight Benefits: GLP‑1 receptor agonists (e.g., semaglutide, tirzepatide) effectively improve glycemia and support weight loss; metformin remains the first-line therapy with favorable weight-neutral or weight-reducing effects :contentReference[oaicite:2]{index=2}.
  • Bariatric & Metabolic Surgery: For those with BMI ≥ 35 kg/m², procedures like sleeve gastrectomy, gastric bypass, and ileal interposition show substantial reductions in HbA1c—often leading to diabetes remission—and increased life expectancy :contentReference[oaicite:3]{index=3}.
  • Integrated Care Approach: The most effective management combines multidisciplinary support—nutrition, physical therapy, psychological care—with pharmacologic agents and, when needed, surgical interventions.

This article reinforces that managing type 2 diabetes in obese patients demands a personalized and progressive strategy—starting with lifestyle optimization, advancing to weight-friendly medications, and considering metabolic surgery for eligible individuals when conservative methods do not achieve control.

Source: Diabetes In Control (June 2025)

Keywords: type 2 diabetes, obesity, GLP‑1 agonists, bariatric surgery, weight management

Read the full article on Diabetes In Control

Peer-Reviewed Study Demonstrates Increased Cost-Effectiveness of MIMEDX

Dehydrated Human Amnion Chorion Membrane (DHACM) in Lower Extremity Diabetic Ulcer (LEDU) Treatment Compared to Standard of Care
Use of MIMEDX PURION® Processed DHACM Provided Improved Clinical Benefits, Shorter Average Length of Treatment and Increased Quality-Adjusted Life Years
MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the publication of a peer-reviewed study in the Journal of Wound Care evaluating the cost-effectiveness of the Company’s PURION® processed dehydrated human amnion/chorion membrane (DHACM) allografts (EPIFIX®) compared with standard of care for treating lower extremity diabetic ulcers (LEDUs), including diabetic foot ulcers (DFUs).

The study analyzed a retrospective cohort (2015-2019) of 10.9 million Medicare patients diagnosed with diabetes, 1.2 million of whom had a LEDU, and tracked outcomes such as amputations and healthcare utilization. Findings across propensity-matched cohorts demonstrated that the timely use of DHACM resulted in a significant reduction in long-term healthcare related costs, driven by the associated improved clinical benefits indicated by patients receiving DHACM, compared to those receiving standard of care, or receiving no advanced treatment (NAT) … read more

The other costs of pressure ulcers

The Hidden Human & Financial Toll of Pressure Ulcers

Pressure ulcers remain one of the most costly chronic wounds—financially and emotionally. In the US, hospital-acquired pressure injuries (HAPIs) cost over $26.8 billion annually, with Stage 3–4 ulcers disproportionately responsible. In England, the NHS spends approximately £3.8 million per day treating these injuries. Each non-healing ulcer can incur up to £374 per day in treatment costs.

Key Highlights:

  • Health System Strain: Repairing full-thickness ulcers delays rehabilitation by preventing patients from participating in essential therapy. It also burdens staff and hospital budgets.
  • Patient Suffering & Quality of Life: Patients describe ulcer pain as burning and sharp during dressing changes, along with unpleasant odour from anaerobic infection—which can lead to social isolation.
  • Serious Complications: Pressure ulcer–related sepsis causes approximately 60,000 deaths per year in the US and 37,000 in the UK.

This article underscores that preventing pressure ulcers isn’t just a cost-saving measure—it directly improves patient wellbeing and survival. Implementing robust prevention, early detection, and treatment protocols should be a high priority for healthcare systems.

Read the full article on the Wounds International website.

Keywords:
pressure ulcers,
healthcare costs,
patient wellbeing,
sepsis,
prevention

Diabetic Foot Ulcer Clinical Validation Study Initiated

Validation study to assess up to 200 adult subjects with participation from leading U.S. principal investigators.

 

DALLAS, June 14, 2022 (Newswire.com) – Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces the start of its clinical validation study to support the development of its Diabetic Foot Ulcer (“DFU”) application for the DeepView® Wound Imaging System. The proprietary technology combines multi-spectral imaging and Artificial Intelligence (AI) to provide clinicians with an immediate healing assessment for DFU, which enables clinicians to provide a more accurate and timely diagnosis for therapeutic intervention.

 

The study will collect data from up to 200 adult subjects across seven potential clinical sites to further develop DeepView®’s AI algorithm. Patient enrollment for the validation study began this month and is expected to complete in November 2022.

 

Building upon promising results from the clinical training study, where the current diagnostic accuracy is 81%, the data collected from the validation study will be used to bolster the Company’s existing clinical database of DFU images and physiologic information to train and improve the DeepView® AI algorithm. Additionally, the validation study will collect data from a broader population set of up to 200 subjects to increase geographic and ethnic variability. Importantly, data collected will support the Company as it prepares FDA and CE mark submissions for DeepView®’s DFU indication, planned in 2023.

 

Participating investigators include: Dr. Alisha Oropallo, MD, Director of Comprehensive Wound Healing Center at Northwell Health; Dr. Brock Liden, DPM, Podiatry Specialist at Circleville Foot & Ankle Center, LLC; and Dr. Babajide Ogunllana, DPM, West Houston Foot and Ankle Center. Additional clinical sites are being evaluated and will be incorporated into the validation study in the near future.

 

Dr. Alisha Oropallo, M.D., FACS, FSVS, Director of Comprehensive Wound Healing Center at Northwell Health and National Principal Investigator for the study, commented: “For patients with diabetes, foot ulcers can impact their quality of life and lead to complicated infections and potential amputation. I look forward to participating in this study as DeepView® has significant potential to improve the current standard of care, resulting in faster application of advanced therapy, better wound healing and reduced overall hospital visits and utilization.”

 

Mary Regan, Ph.D., VP of Clinical Affairs at Spectral MD, said: “We are very pleased to have initiated the Clinical Validation Study, the next critical step towards the completion of development for the DFU application for DeepView® Wound Imaging System. To obtain robust clinical data, the Spectral MD team has selected leading wound care providers to advance and develop our DeepView® Wound Imaging technology. I look forward to working with all participating clinical sites to ensure high-quality data and clinical engagement.”

 

About Spectral MD:

We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by “Seeing the Unknown”® with our DeepView®Wound Imaging System.

 

www.spectralmd.com

 

info@spectralmd.com

 

This article was originally published here

The Important Role Nurse Practitioners Play in Wound Care

Laura Swoboda, DNP, APRN, FNP-C, FNP-BC, CWOCN-AP

 

Nurse practitioners (NPs) are valuable members within the field of wound management. As licensed, independent clinicians, NPs practice autonomously and coordinate with other health care professionals and individuals. Half a century of research definitively demonstrates that NPs provide high-quality health care services across a person’s lifetime and in diverse settings. Nurse practitioners receive graduate-level education, with master’s or doctoral degrees, and possess the knowledge and clinical competency to provide health care beyond their initial registered nurse preparation. As providers that blend clinical expertise in diagnosing and treating acute and chronic health conditions, emphasizing disease prevention, health management, and patient education … read more

Wound care awareness

One in four families has a member with a chronic wound. For this reason, it is crucial for us as wound care experts to educate patients, caregivers and other health care providers about chronic wounds and advanced wound care treatment options … Nearly 7 million people in the U.S. are living with a chronic wound, and the number is expected to grow over the next decade. A chronic wound can be painful, dangerous and scary for patients and drastically affect people by diminishing their overall quality of life and potentially decreasing life expectancy if left untreated …They are also dangerous and damaging to our health care industry. The cost associated with chronic wounds is more than $50 billion annually, and this affects 14.5% of Medicare beneficiaries each year … continue

Evaluation of Wound Healing and Antibacterial Activities of Solvent Fractions

of 80% Methanol Leaf Extract of Brucea antidysenterica J.F. Mill (Simaroubaceae)

 

A wound is defined as damage or disruption to the normal anatomical structure and function of a living tissue. This ranges from a simple disruption in the epithelial integrity of the skin to deeper subcutaneous tissue involvement and also damage to other structures, like muscle and bone.2 Wounds can arise from physical, chemical, thermal, microbial, or immunological damage to a tissue or can be the result of a disease process like diabetes mellitus.

 

Wounds have considerable humanistic and economic burdens, both at individual and societal levels. A wound deters individual quality of life and productivity; and is associated with major economic burdens on the health care system. The current situation worldwide estimate of people with chronic wounds rises to 6 million each year. In developed countries, 1–2% of individuals in a population acquire a chronic wound during their lifetime.5 Globally, the economic burden of chronic wound is estimated to be nearly 2–4% of the health budgets.

 

Wound healing is the complex and dynamic process of restoring the structure and function of damaged tissues. It follows coordinated interactions between diverse immunological and biological systems. The interaction involves a cascade of ordered and precisely regulated steps and events, which are divided into four overlapping but distinct phases, ie, the hemostasis/coagulation phase, the inflammation phase, the proliferation phase, and the remodelling phase … read more

Digital Health Service for Diabetic Foot Ulcer Risk Stratification



Digital Health Service for Diabetic Foot Ulcer Risk Stratification: Usability Evaluation

Summary: Researchers developed and evaluated a digital health service designed to stratify risk of diabetic foot ulcers (DFU) and support preventive self-care. The platform integrates patient-reported data, education, and risk scoring. Usability testing showed strong user acceptance, ease of use, and potential to strengthen preventive efforts in high-risk diabetes populations, addressing the global need for scalable DFU prevention tools.

Key Highlights:

  • Digital tool combining risk assessment with patient education and monitoring
  • High usability scores from both patients and healthcare providers
  • Supports early identification and timely preventive interventions
  • Addresses lifetime DFU risk (up to 34%) through accessible technology

Read full open-access article

Keywords: DFU risk stratification, digital health DFU, diabetic foot prevention

Latest Clinical Evidence Presented at SAWC 2021 Illustrates the Significant Clinical Utility of the MolecuLight Point-of-Care …

Imaging Platform
7 Clinical Posters and Presentations Highlight the Breadth of Clinical Benefits
of the MolecuLight Device for Wound Care Applications

TORONTO and LAS VEGASOct. 28, 2021 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces the presentation of 7 clinical posters and presentations at the Symposium of Wound Care (SAWC) Fall 2021, held from October 29 – 31, 2021 in Las Vegas, Nevada. SAWC is one of the largest multidisciplinary meetings of wound care professionals.

“We are thrilled to have so many customers presenting their impressive clinical findings at this year’s SAWC Fall conference”, says Anil Amlani, MolecuLight’s CEO. “The clinical topics being presented span the wound care continuum, from improved wound assessment and treatment planning, to monitoring of wound cleaning and debridement efficacy, and the resulting improvement in wound healing rates. Presenters will also describe detection and treatment of wound-related cellulitis, and findings from the recently published Delphi consensus-based guidelines for the use of the MolecuLight platform. The outcomes presented in these studies illustrate the significant clinical improvements to wound care provided to clinicians by the MolecuLight i:X“.

A submission on MolecuLight by Dr. Charles A. Andersen was one of the top scoring abstracts out of more than 200 submissions. This is the fifth consecutive SAWC meeting at which an abstract on improved patient care achieved through use of the MolecuLight i:X has received this honour.

The 5 clinical posters and 2 presentations featuring the MolecuLight i:X from SAWC Fall 2021 are as follows:

Poster #CR-005
12-Week RCT Evaluating Impact of Routine Fluorescence Imaging of Bacteria on DFU Healing Rates
Alisha Oropallo, MD¹, Scott Gawlik DPM¹, Dean Vayser, MD²
¹Northwell Comprehensive Wound Health Center and Hyperbarics, Lake Success NY,
²ILD Research Centre, San Diego, CA
 Download poster

Poster #CR-006
Cleansing Techniques for Wound Hygiene: Which Are Most Effective?
Alisha Oropallo, MD1Amit Rao MD1Jai Joshi1
1Northwell Comprehensive Wound Health Center and Hyperbarics, Lake Success NY 
 Download poster

Poster #LR-025
Detection of bacterial fluorescence from in vivo wound biofilms using a point-of-care
fluorescence imaging device
Andrea J. Lopez1Laura M. Jones2, Landrye Reynolds1Rachel C. Diaz1Isaiah K. George1William Little1Derek Fleming3,4Anna D’souza2Kendra Rumbaugh3Allie Clinton Smith1Monique Y. Rennie2
1Department of Honors Studies, Texas Tech UniversityLubbock TX, USA; 2MolecuLight Inc. Toronto, ON Canada3Department of Surgery, Texas Tech University Health Sciences Center4Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA 
 Download poster

Poster #CR-020
Are Semi-quantitative Clinical Cultures Inadequate? Comparison to Quantitative Analysis of 1053 Bacterial Isolates from 350 Wounds
Thomas E. Serena1Phil Bowler2Gregory Schultz3Anna D’souza4Monique Rennie4
1
SerenaGroup Research Foundation, Cambridge MA USA; 2Phil Bowler Consulting, Warrington UK3Department of Obstetrics and Gynecology, University of Florida, FL, USA; 4MolecuLight Inc. Toronto 
 Download poster

Poster #PI-003
Guidelines for point-of-care fluorescence imaging for detection of wound bacterial burden based on Delphi consensus
Charles A. Andersen¹, Alisha R. Oropallo², Raymond Abdo³, Jenny Hurlow⁴, Martha R Kelso⁵, M. Mark Melin⁶ and Thomas E. Serena⁷
1Madigan Army Medical Center, Renton WA2. Zucker School of Medicine Hofstra/Northwell, Hempstead, NY3St. Louis Foot & Ankle LLC, St. Louis MO4Consultant Wound Care Practitioner, Memphis TN5Wound Care Plus LLC, Blue Springs MO6M Health Fairview, Edina MN7SerenaGroup Research Foundation, Cambridge MA
 
 Download poster

Oral Presentation & Poster #PI-002
Diagnosis and Treatment of the Invasive Extension of Bacteria (Cellulitis) from Chronic Wounds Utilizing Point-of-Care Fluorescence Imaging
Charles Andersen¹, Katherine McLeod¹, Rowena Steffan¹
¹Vascular/Endovascular/Limb Preservation Surgery Service, Madigan Army Medical Center, Joint base Lewis-McChord, WA USA
 Download poster

Podium Presentation
Innovation Spotlight: Shining a Light on Bold Ideas in Wound Care
Charles Andersen¹
¹Vascular/Endovascular/Limb Preservation Surgery Service, Madigan Army Medical Center, Joint base Lewis-McChord, WA USA

In additional to the clinical posters and presentations at SAWC (Symposium on Advanced Wound Care) Fall 2021, the recently launched MolecuLightDX will be available for demonstration in the MolecuLight booth #439 in the Exhibit Hall at Caesars Palace in Las Vegas, Nevada.

About MolecuLight Inc.

MolecuLight Inc., a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i: and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection of wounds containing elevated bacterial burden (when used with clinical signs and symptoms) and for digital wound measurement. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant, unmet needs including food safety, consumer cosmetics and other key industrial markets.

Download for Image:

SOURCE MolecuLight

Related Links

www.moleculight.com

What Do Medical Records Reveal About the Effectiveness of Care for Diabetic Foot Health?

Medical records are frequently the source of clinical data used in research of the diabetic foot. However, due to variations in the records, problems can result in collecting and using the data for such research … Worldwide, there are vast differences in the type of medical record, the quality of the medical record and how providers and or health systems manage the data it contains. Medical records can range from simple, handwritten notes that often include some short cuts or abbreviations, to sophisticated electronic health records. The issues of who collects the data and how it is documented will ultimately influence how it can be harvested, manipulated, and used in research … read more

Molnlycke Health Care Expands Wound Care Manufacturing Facility



Molnlycke Health Care Expands Wound Care Manufacturing Facility

Summary: Molnlycke Health Care is investing $135 million to expand its Brunswick, Maine facility, increasing U.S. wound care production capacity with completion targeted for late 2026 or early 2027. The upgrade features advanced U.S.-sourced machinery, renewable energy (wind/solar), and streamlined logistics for sustainability. Over five years, it will create ~10% more jobs (local contractors/suppliers) and faster delivery of products like advanced dressings for chronic wounds, pressure ulcers, and surgical sites. CEO Zlatko Rihter emphasizes resilience and patient access, while GM Chris Biddle highlights community partnerships.

Key Highlights:

  • Investment scope: $135M for expansion; boosts production of wound care solutions amid rising demand.
  • Sustainability: Integrates wind/solar power; reduces carbon footprint through efficient logistics.
  • Job creation: 10% workforce growth in Maine; engages local economy with suppliers and contractors.
  • Product impact: Enhances supply of dressings for chronic wounds, supporting faster, smarter care.
  • Quotes: Rihter: “A bold step… to deliver high-quality solutions sustainably.” Biddle: “A win for Molnlycke, community, and patients.”

Read full article

Keywords: Molnlycke expansion, wound care manufacturing, advanced dressings, sustainable production, chronic wound supply

Podimetrics Announces Expansion of Leadership Team with Four New Strategic Growth Hires

Longtime Congresswoman and former President and CEO of the Better Medicare Alliance, Allyson Schwartz, also joins Podimetrics’ Advisory Board

 

SOMERVILLE, Mass., May 12, 2022 /PRNewswire/ — Podimetrics, creator of the FDA-cleared SmartMat™ and integrated clinical care services that can help save the limbs and lives of complex patients with diabetes, today announced four new leadership hires aimed at helping the company scale and support even more health plans and providers serving patients living with complex diabetes: Matthew Scalo as Chief Financial Officer, Kyle Bray as Chief Operating Officer, Kim Nguyen as Vice President of Financial Planning and Analysis, and Elizabeth Hogan Hamacher as Vice President of Clinical Services and Support. Podimetrics also added a new member to their advisory board, Allyson Schwartz, a long-time Congresswoman and also the former President and CEO of the Better Medicare Alliance.

 

These key hires and advisory board appointment follow Podimetrics’ recent announcement of their Series C. The company also experienced unprecedented growth in 2021, including doubling the patients under management with the Veterans Health Administration; doubling revenue for the third year in a row; and also doubling the size of the Podimetrics team. Dr. Jon Bloom, CEO and co-founder of Podimetrics, shared the following insights on the company’s growth trajectory for the year ahead: “We are in high-growth mode, and these leadership hires and the appointment of Allyson Schwartz to Podimetrics’ advisory board reinforce our focus on helping even more at-risk, underserved patients avoid the unnecessary health toll and financial burden associated with amputations resulting from complex diabetes.”

 

In just the first quarter of 2022, Podimetrics rounded out their leadership team with a series of strategic new hires that position the company for strong growth in the year ahead:

 

  • Matthew Scalo, Chief Financial Officer — With nearly two decades of experience spanning banking and financial services, he most recently served as the senior vice president of finance at Cancer Treatment Centers of America;
  • Elizabeth Hogan Hamacher, Vice President of Clinical Services and Support — A registered nurse with more than 12 years of clinical operations experience, she most recently served as senior director of clinical operations at ConsumerMedical; and
  • Kim Nguyen, Vice President of Financial Planning and Analysis — With more than a decade of experience, she most recently served as associate vice president for financial planning and analysis for vRad (Virtual Radiologic).

 

The company’s latest addition to their advisory board, Allyson Schwartz, also brings unprecedented experience in healthcare, as well as policy. As a former member of the House of Representatives and former President and CEO of the Better Medicare Alliance, she is a nationally recognized leader on healthcare issues and was also instrumental in the passage of the Affordable Care Act. Schwartz shared the following insights about joining the advisory board at Podimetrics: “Podimetrics serves some of our nation’s most vulnerable patients — patients who have been ignored for far too long. It’s an honor to join their advisory board. The research and innovation they are leading will help drive a new preventive and proven approach to helping reduce amputations in patients living with complex diabetes.”

 

Podimetrics invented the SmartMat, which has already been used by thousands of patients through partnerships with leading risk-based healthcare providers and regional and national health plans. The SmartMat is the only easy-to-use, at-home mat that a patient steps on for only 20 seconds per day. The mat detects temperature changes in the foot, which are often a precursor to diabetic foot ulcers (DFUs). Patient temperature data from the SmartMat is then remotely monitored by Podimetrics’ in-house nurse support team. If the data from the mat is indicative of potential health issues, Podimetrics’ nursing team swiftly connects both with the patient and the patients’ provider.

 

For more information on Podimetrics and how its SmartMat and clinical care services can help prevent diabetic foot ulcers and improve patient outcomes, please visit Podimetrics.com.

 

About Podimetrics

Podimetrics is the creator of the FDA-cleared SmartMat™ and integrated clinical care services that can help save the limbs and lives of complex diabetic patients. Through partnerships with regional and national health plans and at-risk providers, such as the Veterans Health Administration, Podimetrics has helped prevent amputations associated with complex diabetes. By combining cutting-edge technology with best-in-class clinical care services, Podimetrics earns high engagement rates from patients and allows clinicians to save limbs, lives, and money — all while keeping vulnerable populations healthy in their own homes. For more information, visit Podimetrics.com or follow us on LinkedIn and Twitter.

Contact: press@Podimetrics.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/podimetrics-announces-expansion-of-leadership-team-with-four-new-strategic-growth-hires-301545591.html

Corstrata to Launch Next Gen Virtual Wound Clinic Powered by Citus Health

Corstrata, a provider of digital healthcare IT solutions and services for wound prevention and care management, announced today a partnership with Citus Health, a digital health solutions provider for the post-acute care industry, to power its next-generation virtual clinic. Corstrata will leverage Citus Health’s state-of-the-art patient and provider engagement platform to enable enhanced remote access to wound and ostomy care experts for wound and ostomy patients everywhere … Corstrata will utilize the Citus Health platform to serve its wound and ostomy customers, provider customers, and Diabetic Foot Ulcer Prevention members. Citus provides a versatile, leading-edge, patient and provider engagement architecture for enhanced care coordination and communication to improve clinical and financial outcomes. The Corstrata branded app powered by Citus Health will integrate key technologies, including wound image capture, video, patient engagement, and with the flexibility of the platform, streamline the capability to add third-party IoT data sources in the future … read more

Study to Explore the Impact of Simulating Extreme Obesity on Health Care Professionals ….

Extremely obese patients pose significant challenges for those who strive to provide care. The prevalence and consequences of weight bias and stigma in health care have been well documented, but research on how to reduce weight bias and stigma is limited. To assess the impact of simulating obesity on the attitudes and perceptions of health professionals toward extreme obesity, a qualitative study involving 6 registered nurses and 1 registered physiotherapist was conducted between November 2015 and May 2016.

 

Health professionals who had regular contact with persons with obesity were recruited through poster advertisement in 1 hospital and 2 universities. Participants completed a demographic survey that included their physical measurements (height, weight, and waist circumference). They then wore a suit simulating the shape and size of a person with extreme obesity for approximately 2 hours and engaged in activities such as taking public transport or visiting a café. Audiotaped, semistructured interviews were conducted before and after the suit exercise and transcribed verbatim for conventional content analysis that identified 3 main categories: 1) insights into the physical challenges facing people with extreme obesity; 2) awareness of social consequences for people with extreme obesity; and 3) changes in participants’ attitudes toward people with extreme obesity. Following the exercise, personal attitudes were found to be less judgmental and more empathetic. Using a simulation suit may increase awareness among health professionals regarding issues facing persons with obesity and may be a positive influence on diffusing weight stigma and bias in health care settings, particularly in the area of wound prevention … read more

Net Health Expands Predictive Analytics Resources for Wound Care Providers

Clinical and operational innovations better predict non-healing wounds and missed appointments

 

Further expanding its analytics capabilities and leadership position within the wound care marketplace, Net Health, a provider of specialty electronic health systems and advanced healthcare analytics, today announced the addition of two new predictive analytics resources to improve clinical and operational outcomes for wound care providers … The new Pressure Injury Deterioration Risk Indicator is built into Tissue Analytics, Net Health’s AI-powered wound imaging and analysis solution, which was recently granted breakthrough device status by the Food and Drug Administration (FDA). The Missed Visit Prediction Indicator is available in Net Health® Wound Care, one of the nation’s most widely used electronic health record (EHR) platforms for wound care. Both features are embedded in automated workflow processes and alert providers when risk is detected, enabling providers to intervene in real-time … read more

Paediatric skin health and wound healing study day

Upcoming Event: Paediatric Skin Health and Wound Healing Study Day

The Society of Tissue Viability is hosting a comprehensive virtual study day on paediatric skin health and wound healing, scheduled for June 17, 2025, from 9:30 AM to 4:00 PM. This free event is designed for healthcare professionals involved in paediatric care, including children’s nurses, paediatric specialist nurses, tissue viability nurses, allied health professionals, GPs, and nursing students. :contentReference[oaicite:3]{index=3}:contentReference[oaicite:4]{index=4}

Key Highlights:

  • Patient and Family Perspectives: Aarron and Jacqueline Higgins will share their experiences of managing a child’s chronic wound, providing valuable insights into the challenges faced by families. :contentReference[oaicite:7]{index=7}
  • Holistic Wound Assessment: Rachel Allaway, Tissue Viability Clinical Nurse Specialist at Great Ormond Street Hospital, will discuss comprehensive approaches to wound assessment in children. :contentReference[oaicite:10]{index=10}
  • Managing Hypergranulation: Jansy Williams, Lead Paediatric Tissue Viability Specialist at Alder Hey Children’s NHS Foundation Trust, will present problem-solving strategies for hypergranulation in paediatric wounds. :contentReference[oaicite:13]{index=13}
  • Nutrition’s Role in Healing: Natalie Yerlett, Interim Head of Dietetics at Great Ormond Street Hospital, will explore the impact of nutrition on wound healing processes. :contentReference[oaicite:16]{index=16}
  • Antimicrobial Stewardship: Claire Gardiner, Paediatric Tissue Viability CNS at the Royal Hospital for Children in Glasgow, will address responsible antimicrobial use in paediatric wound care. :contentReference[oaicite:19]{index=19}
  • Pressure Ulcer Prevention: Judith Kay and Sophie Whitecroft from Great Ormond Street Hospital will discuss the importance of seating, posture, and equipment selection in preventing and managing pressure ulcers in children. :contentReference[oaicite:22]{index=22}

This study day offers up to five hours of participatory learning, contributing to NMC revalidation requirements. Attendees will also benefit from industry presentations by organizations such as Flen Health, Pressure Care Management, Mediq, and Medstrom, providing insights into the latest products and innovations in paediatric wound care. :contentReference[oaicite:25]{index=25}:contentReference[oaicite:26]{index=26}

For more information and to register, visit the Society of Tissue Viability website.

Keywords:
paediatric wound care,
skin health,
hypergranulation,
nutrition and wound healing,
antimicrobial stewardship,
pressure ulcer prevention

Net Health NEXT 2026 Sets the Stage for AI-Powered, Human-Centered Care



Net Health NEXT 2026 Sets the Stage for AI-Powered, Human-Centered Care

Summary:** Net Health’s NEXT 2026 conference (March 4-6, Nashville) spotlights AI integration in wound care, with roadmaps for DFU management, rehab therapy, and occupational health. Sessions cover AI-driven EHRs for faster documentation, predictive analytics for ulcer prevention, and human-centered design to enhance clinician efficiency. Over 30 years of expertise inform the event, featuring keynotes like CTO Raj Grover on AI roadmaps and workshops on performance metrics, aiming to streamline care and reduce administrative burdens in chronic wound treatment.

Key Highlights:

  • Theme: AI for human-centered care; sessions on wound, rehab, and occupational health EHRs.
  • Roadmaps: DFU analytics for risk prediction; AI for therapy outcomes and compliance.
  • Keynotes: CTO Raj Grover on innovation; workshops/case studies for practical implementation.
  • Impact: Reduces admin time 30%; improves accuracy in ulcer assessment.
  • Date/Location: March 4-6, 2026, Nashville; registration open.

Read full article

Keywords: AI wound care, Net Health conference, DFU management, EHR innovation, rehab therapy

Game-Changing Alliance: Adia Labs and Axia Women’s Health



Game-Changing Alliance: Adia Labs and Axia Women’s Health

Summary:** Adia Nutrition Inc. announced a strategic alliance with Axia Women’s Health to integrate insurance-billable wound care products into Adia’s expanding network of Med clinics, specializing in orthopedic, pain management, and diabetic wound repair. The partnership leverages AdiaLabs’ lab division for advanced testing and therapies, aiming to address chronic wounds in women’s health while pursuing Nasdaq uplisting. With 13M U.S. diabetics at risk for ulcers, the collaboration enhances access to regenerative treatments and nutrition-focused care.

Key Highlights:

  • Partnership Focus: Wound care products for diabetic ulcers in Adia Med clinics.
  • Expansion: Nationwide growth with Axia for women’s health integration.
  • AdiaLabs: Billable diagnostics for personalized wound therapies.
  • Impact: Targets 50% infected DFUs; improves outcomes via nutrition/repair.
  • Financial: $5M+ funding; Nasdaq uplisting by 2026.

Read full article

Keywords: Adia Nutrition, Axia Women’s Health, wound care partnership, diabetic repair, insurance billable

Factors associated with foot ulcer self-management behaviors

     among hospitalized patients with diabetes

 

In this cross-sectional design, researchers have identified self-management behaviors related to pre-hospitalized diabetes-related foot ulcers (DFUs) and examined the factors associated with these behaviors. A survey questionnaire was given to 199 hospitalized patients with DFU at a medical center in Northern Taiwan from June 2015 to June 2016. According to findings, 62.8% of participants never monitored their blood glucose level when they had foot ulcers, and 63.8% did not seek treatment for their wounds when their wounds were not painful. Data reported that DFU self-management behaviors were not enough. Following the control of demographic and medical variables, multiple stepwise regression analysis showed that the following 8 significant variables were related to DFU self-management behaviors: two DFU self-management barrier beliefs, foot self-care behavior, no treatment for diabetes, poor financial status, employment, knowledge regarding the warning signs of DFU deterioration, and number of DFU hospitalizations. They concluded that some modifiable factors and high-risk groups have been identified for inadequate DFU self-management behavior.

Read the full article on Journal of Clinical Nursing

Is it a Pressure Injury?

     Factors to Consider When Determining Wound Etiology

 

As specialists in wound, continence and ostomy care, we are forever in a role of wearing many hats. We are educators to patients, staff, and providers… we are patient advocates and supporters of our bedside nurses… we are liaisons in many aspects of care and help to coordinate care and services for our patient population. We are often referred to as the specialist and are called upon when there is a patient with a wound, skin, ostomy, or continence concern. Our peers trust us, and it is important that we possess the knowledge and skills to share with others when determining etiology and treatment of wounds and skin issues.

 

Determining Wound Etiology
An issue we are often faced with as skin specialists is determining the etiology of wounds and skin concerns. When determining the etiology of wounds, it is important to look at the entire picture…and, when doing so, understand that many variables can and do make wounds better or worse, but there is usually an isolated variable that caused the wound.

 

Medical Device-Related Pressure Injuries
Some things to keep in mind: Pressure injuries are usually round, can appear punched out, may be partial- or full-thickness, may have slough or necrotic tissue, and are usually over a bony prominence. In terms of shape, pressure injuries related to devices usually take the shape of that device (think of a linear, fluid-filled blister from Foley catheter tubing on the thigh… a stage 2 medical device-related pressure injury, or a purple or discolored, non-blanchable area on the lip from an endotracheal tube… a mucosal pressure injury). Other devices that may be responsible for pressure injuries are prosthetic devices … read more

Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes

Patients with type 2 diabetes who took liraglutide were at a lower risk for foot amputation, according to a study recently published in Diabetes Care.

 

Researchers completed a post hoc analysis on data collected during the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial to determine the effect of liraglutide on rates of diabetes-related foot ulcers in patients who were also at high risk for cardiovascular events. Patients in the LEADER study were randomly assigned to either an intervention arm (n=4668), receiving 1.8 mg of liraglutide a day, or a control arm (n=4672), receiving a placebo. The study continued for 5 years with an average follow-up time of 3.8 years. A diabetes-related foot ulcer was specified as a medical event of special interest, and all complications related to the ulcer were documented.

read more

Organogenesis Inc. Announces Support of American Diabetes Association

Organogenesis will support initiatives to educate about diabetic foot ulcers, the leading cause of diabetes-related amputations

 

CANTON, Mass.June 21, 2018 /PRNewswire/ — Organogenesis Inc. – a leading regenerative medicine company committed to empowering healing – today announced it is a proud supporter of the American Diabetes Association (ADA). Organogenesis will support the production of an ADA scientific compendium focused on the latest scientific evidence related to the treatment of  diabetic foot ulcers (DFUs), the leading cause of diabetes-related amputations in the United States.

Organogenesis will also host a corporate symposium, “Innovations in Diabetic Wound Healing,”  at the ADA’s 78thScientific Sessions, held June 22-26 in Orlando, FL, and exhibit during the meeting trade show at Booth #616.

 

“As a global regenerative medicine company driven by a shared mission to empower healing, we work to provide opportunities for patients and health care professionals to learn more about state-of-the-art approaches to treat diabetic foot ulcers,” said Gary S. Gillheeney, Sr., President and CEO of Organogenesis. “We are happy to support the ADA and its work to help Americans living with diabetes.”

Read full press release

Expanding horizons to upskill wound practice and research

With our horizons limited by Covid-related travel restrictions, it is more important than ever to experience and learn about our multicultural world through reading about wound-related research and practice in other jurisdictions and countries. Two such articles provide this important international insight and are included in this issue of the journal. The first by Obilor and colleagues describes the assessment of nurses’ knowledge, attitude and competence in wound assessment in a tertiary healthcare facility in southwest Nigeria. Here they found that many of the nurses surveyed were lacking in wound assessment competence, suggesting an important continuing need for education and skills development. The second internationally focused paper, by Yigit and Tas, describes the demography and injuries related to chemical burns in the southeastern Anatolia region of Turkey. The burn centre at the core of this study serves 10 million people in Diyarbakir and the surrounding 300km and is the only centre with an intensive care unit in southeast Turkey, a very different experience from what we would see in an Australian context … read more

Unravelling the cardio-renal-metabolic-foot connection

Unravelling the Cardio-Renal-Metabolic-Foot Connection in People with Diabetes-Related Foot Ulceration: A Narrative Review

A recent narrative review published in Cardiovascular Diabetology explores the interconnectedness of cardiovascular, renal, metabolic, and foot complications in individuals with diabetes-related foot ulceration (DFU). The authors propose a “cardio-renal-metabolic-foot” framework, highlighting shared pathophysiological mechanisms that link DFU with cardiovascular and renal diseases.

The review emphasizes that systemic inflammation and infection associated with DFU may contribute to the development and progression of cardiovascular and renal conditions. Conversely, existing cardiovascular and renal diseases can exacerbate the risk and severity of DFU, indicating a bidirectional relationship. The authors advocate for a holistic, multidisciplinary approach to managing DFU, incorporating early screening and management of cardiovascular and kidney diseases.

Emerging therapies, such as sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and non-steroidal mineralocorticoid receptor antagonists, have shown promise in improving cardiovascular and renal outcomes in people with type 2 diabetes. While dedicated research in DFU populations is needed, these therapies could potentially address multiple aspects of the cardio-renal-metabolic-foot connection.

Read the full article on the Cardiovascular Diabetology website.

Keywords:
Diabetes-related foot ulceration,
Cardio-renal-metabolic connection,
Systemic inflammation,
Multidisciplinary care,
SGLT2 inhibitors,
GLP-1 receptor agonists,
Mineralocorticoid receptor antagonists

Note: The above synopsis is based on the article’s abstract and available information. For a comprehensive understanding, please refer to the full article.

PREVENTION AND MANAGEMENT OF PERIWOUND SKIN COMPLICATIONS

ISTAP Best Practice Recommendations for Prevention and Management of Periwound Skin Complications

The International Skin Tear Advisory Panel (ISTAP) has published comprehensive guidelines to enhance the prevention and management of periwound skin complications. These recommendations emphasize the significance of periwound skin health in promoting effective wound healing and reducing associated complications. Read the full document.

Key Highlights:

  • Definition of Periwound: The periwound is identified as the area surrounding a wound that may be affected by wound-related factors and/or underlying pathology.
  • Risks of Periwound Damage: Complications such as maceration, skin stripping, and medical adhesive-related skin injury (MARSI) can delay healing, increase infection risk, and elevate treatment costs.
  • Assessment Protocols: Regular evaluation of the periwound area should be integrated into wound assessments, focusing on skin integrity, moisture levels, and signs of infection or inflammation.
  • Management Strategies: Effective approaches include managing exudate to prevent moisture-associated skin damage (MASD), using appropriate dressings, and employing gentle cleansing techniques with pH-balanced solutions.
  • Infection Control: Implementing antimicrobial stewardship principles is crucial to prevent and manage infections without contributing to antimicrobial resistance.
  • Education and Training: Ongoing education for healthcare professionals and caregivers is essential to ensure best practices in periwound care are understood and applied consistently.

These guidelines serve as a valuable resource for clinicians aiming to improve patient outcomes through diligent periwound care.

Read the full document on the Wounds International website.

Keywords:
periwound skin care,
moisture-associated skin damage,
medical adhesive-related skin injury,
wound assessment,
antimicrobial stewardship

Hyperbaric Oxygen Accelerates Healing Assessed by Thermal Imaging & Planimetry

Hyperbaric Oxygen Accelerates Healing Assessed by Thermal Imaging & Planimetry

A 2019 clinical study from Poland evaluated 142 patients with chronic leg ulcers—caused by venous insufficiency or diabetic foot syndrome—undergoing 30 sessions of hyperbaric oxygen therapy (HBOT). Healing progress was monitored using both computerized planimetry and thermal imaging. :contentReference[oaicite:1]{index=1}

Key Highlights:

  • Digital Measurements: Computerized planimetry showed significant reductions in wound surface area and perimeter following HBOT across both ulcer types. :contentReference[oaicite:2]{index=2}
  • Thermal Imaging Insights: Thermographic scans detected inflammation-related temperature differences, which narrowed significantly after treatment (ΔT between ulcer center and periwound dropped from 0.9 °C to 0.3 °C). :contentReference[oaicite:3]{index=3}
  • Correlated Monitoring: Thermal and planimetric data were strongly correlated, though they measured different aspects—metabolic activity versus structural size. :contentReference[oaicite:4]{index=4}
  • Clinical Value: Combining thermal imaging and planimetry offers a non-invasive, objective way to track both physical and physiological healing responses to HBOT.

These findings support HBOT’s effectiveness in chronic wound care and highlight the potential of combined imaging methods to enhance diagnostic accuracy and treatment monitoring.

Read the full study on PubMed Central.

Keywords:
hyperbaric oxygen therapy,
thermal imaging,
planimetry,
chronic leg ulcer,
venous insufficiency

Unveiling Precision Medicine: Transforming Healthcare with Tailored Treatments

Unveiling Precision Medicine: Transforming Healthcare with Tailored Treatments

Summary: This article by David Blivin (President & CEO, Cottonwood Technology Fund) discusses how precision medicine is transforming healthcare by customizing diagnostics and therapies based on individual genetics, lifestyle, and environment—moving from a one-size-fits-all model to targeted interventions.

Key Highlights:

  • Definition & promise: Precision medicine aims to provide “the right drug to the right patient in the right dose at the right time.”
  • Successful fields: Oncology has led the way with targeted therapies based on biomarkers and genomics.
  • Expanding domains: The article explores opportunities in cardiology, infectious disease, and immunology as precision approaches extend beyond cancer.
  • Emerging tools: Biomarkers, AI, long-read sequencing, and novel molecular platforms like circular RNAs are highlighted as next-generation levers for personalization.
  • Challenges: Barriers include cost, data integration, clinical translation, regulatory pathways, and equitable access.

Read the full article on Medical Tech Outlook

Keywords:
David Blivin,
precision medicine,
personalized therapy,
biomarkers,
circular RNAs,
genomics,
biomedical innovation

Foot Health Awareness: Hyperbaric Oxygen Therapy’s Critical Role In Limb Preservation

CūtisCare Shares How HBOT is Impacting Limb Preservation

 

BOCA RATON, Fla., April 5, 2022 /PRNewswire/ — CūtisCare USA, a leading provider of wound care management services to hospitals and physicians, is raising awareness through its Hyperbaric Aware initiative of the successes we have seen with limb preservation when hyperbaric oxygen therapy, HBOT, is a part of a treatment plan. Diabetes is a complex disease to treat and manage. However, we are starting to see amputation rates decline when HBOT is incorporated into the treatment plan for those with chronic wounds. Research shows that the vast majority of non-traumatic amputations to the lower extremity are preventable, making the need for diversification in treatment plans stronger than ever before.

 

When administered correctly, pressurized oxygen helps speed cell repair and form new blood vessels from just one treatment. Repeated exposure gives a lifeline to ischemic tissue and promotes the healing process of chronic wounds, specifically those suffering from diabetic foot ulcers.

 

There are approximately 200 non-traumatic lower-limb amputations performed each day in the United States associated with diabetes. These patients often experience restrictions to the supply of blood needed to support healthy tissue due to restricted circulation. As a result, amputation was far too often the only option for seriously infected wounds that were unresponsive to treatment.

 

Experts in the field are incorporating hyperbarics as an adjunct therapy. Dr. Louis Pilati, MD, Kettering Medical Center Network and CutisCare Medical Advisor Board physician, recommends the use of HBOT for patients suffering from diabetic foot wounds and has become an advocate for HBOT after seeing the results firsthand. “Use of hyperbaric oxygen in treating these patients has been shown to reduce the risk of major amputation. These patients are complicated and require a team approach. This should include vascular surgery, foot and ankle surgeons, and infectious disease specialists along with the wound care and hyperbaric medicine team.”

 

There is hope for this vulnerable patient population. Healthcare systems that have established dedicated healthcare clinics that are using HBOT are showing significant reductions in amputation rates. CūtisCare offers hospitals customized management solutions to begin providing next-level care for their patients. Committed to the growth and success of each hospital or physician practice. Visit cutiscare.com to access more information regarding the benefits of hyperbaric oxygen therapy, or even to find a CutisCare Wound Care Center of Excellence.

 

About CūtisCare

Headquartered in Boca Raton, Florida, CūtisCare works with hospitals, academic medical centers, hospital systems, and physicians to design customized outpatient and office-based wound care and hyperbaric oxygen (HBOT) solutions. With more than 25 years of management experience, a commitment to research, and driven by ethics and a culture of compliance, CūtisCare collaborates with its partners to reach and heal people with chronic wounds.

 

For more information, visit https://cutiscareusa.com or CutisCare LLC | LinkedIn.

 

Media Contact: Kelly Caceres, (904) 446-0708, kcaceres@cutiscareusa.com

Current challenges and opportunities in wound care

3 CNOs weigh in

 

Wound care costs the U.S. healthcare system an estimated $50 billion annually. The large fiscal burden suggests wound care may be an overlooked target for quality improvement and cost reduction initiatives, according to Jacksonville, Fla.-based Healogics, the nation’s largest provider of advanced wound care services.

 

More than 30 million diabetics and 28.4 million individuals with heart disease reside in the U.S. Both morbidities represent public health epidemics and carry a heightened risk for chronic wound development. Approximately 6.7 million Americans are afflicted with chronic, non-healing wounds. This figure does not account for wounds attributable to conditions such as necrotizing fasciitis and surgical wounds related to the operating room. The Healogics team asserts that these numbers suggest America is experiencing a chronic wound epidemic.

 

On April 11, at Becker’s Hospital Review 9th Annual Meeting in Chicago, Arti Masturzo, MD, executive vice president of clinical innovation with Healogics, led a group of hospital leaders in a discussion on current challenges and opportunities related to wound care … read more

Demystifying Pressure Injury Staging



Demystifying Pressure Injury Staging

Summary: This on-demand webinar (free registration) breaks down the standardized staging system for pressure injuries per NPIAP/EPUAP/PPPIA guidelines. Covers definitions and clinical features of Stage 1 (non-blanchable erythema), Stage 2 (partial-thickness loss), Stage 3 (full-thickness loss to fascia), Stage 4 (exposed bone/muscle/tendon), Unstageable (obscured base), Deep Tissue Pressure Injury (persistent non-blanchable deep red/maroon/purple), Mucosal Membrane Pressure Injury, and Medical Device-Related Pressure Injury. Includes visual examples, differential diagnosis (e.g., vs. Kennedy Terminal Ulcer), prevention strategies (risk assessment, offloading, nutrition), and accurate documentation/coding implications for reimbursement and quality metrics. Ideal for nurses, wound specialists, and educators to improve consistency in assessment and reporting.

Key Highlights:

  • Stages: Detailed visuals and criteria for each category.
  • Special types: Device-related, mucosal, DTI evolution.
  • Best practices: Early intervention, photography for tracking, interdisciplinary communication.
  • Relevance: Enhances accuracy in pressure injury prevention programs; reduces misclassification risks.

Register/View webinar

Keywords: pressure injury staging, NPIAP guidelines, deep tissue injury, pressure ulcer staging

Skin Conditions Frequently Found in Obese Patient Populations

The Centers for Disease Control and Prevention state that in the United States, “…thirty eight percent of adults, and that seventeen percent of children and teens are obese.” It is imperative that the term obesity be differentiated from overweight. Obesity refers to higher than normal body fat, whereas overweight is in reference to an individual weighing more than the standard for height and weight. Although both terms mean that a person’s weight is greater than what is considered healthy for his or her height, obesity has higher negative health-related consequences.

 

Health care professionals are challenged to manage increasingly complex health issues related to obesity, including complex skin conditions. The increase in stored fat associated with obesity can contribute to a variety of changes in skin physiology and is implicated in a range of dermatologic conditions.2 The skin’s ability to manage transepidermal water loss is altered in the obese population. With increased fat stores the transepidermal water loss is increased, resulting in dryness and delayed skin repair. Additionally, sebaceous channels are blocked, leading to an increase in oils and resulting in acne.2 The thick layers of subcutaneous fat in obese individuals may contribute to profuse sweating (hyperhidrosis) when overheated or with activities. Hyperhidrosis can set the stage for profuse skin damage. Moisture trapped in skin folds coupled with friction as body folds rub together … read more

The Effect of COVID-19 on Diabetic Foot Ulcer Surgery at a Safety Net Hospital

COVID‑19’s Impact on Diabetic Foot Ulcer Surgeries at a Safety‑Net Hospital

A newly published case series examines how the COVID‑19 pandemic disrupted diabetic foot ulcer (DFU) surgical care at a major safety‑net hospital. The retrospective study evaluated ulcer-related surgeries over a five-year period (March 2018–February 2023), spanning pre-pandemic, pandemic onset, and recovery phases.

Key Findings:

  • Surgical Volume Trends: Of the 1,858 total DFU-related surgeries reviewed, 723 occurred pre-pandemic, 368 during the initial pandemic year (March 2020–February 2021), and 767 during the two years that followed.
  • Sharp Decline in Outpatient Access: The onset of COVID‑19 brought immediate restrictions on in-person visits and elective procedures, causing a steep drop in clinic access and early-stage DFU care.
  • Shift Toward Major Amputations: While minor surgical procedures (e.g., debridement, exostectomy) initially fell, major amputations either remained steady or increased—reflecting more advanced disease upon presentation.
  • Lasting Disruption: Even two years after reopening, clinic visit volumes remained below pre-COVID levels, underscoring persistent barriers in care continuity for vulnerable patients.
  • Clinical Implications: Delayed care during the pandemic likely contributed to higher rates of severe complications and limb loss. The authors emphasize the importance of preserving access to wound care services during future healthcare system disruptions.

This study illustrates the critical relationship between timely DFU care and surgical outcomes. The ripple effects of the pandemic continue to inform how healthcare systems should prioritize access and care delivery during public health emergencies.

Keywords:
COVID‑19 and DFU,
safety‑net hospital,
limb salvage,
amputation rates,
healthcare access

Read the full article on HMP Global Learning Network

Solsys Medical’s TheraSkin Regenerative Wound Healing

     Product Chosen to be a Part of Healogics New iSupply(SM) Program

 

NEWPORT NEWS, Va.Sept. 10, 2018 /PRNewswire/ — Solsys Medical, LLC (“Solsys”) (formerly known and doing business as Soluble Systems, LLC) (“Solsys Medical”), which markets TheraSkin®, a cellular and tissue-based product for regenerative wound healing, announced today that it has partnered with Healogics, the nations largest provider of advanced chronic wound care services, to be a part of the new Healogics iSupply program, offering TheraSkin to Healogics facilities. Through the partnership with Healogics, Solsys furthers its mission to improve quality outcomes while reducing the total cost of care.  TheraSkin is a living human split-thickness skin allograft that is cryopreserved to preserve living cells and growth factors while maintaining a mature native human dermal architecture.  The versatility in applications and sizes of TheraSkin reduces product waste and helps to drive operational efficiencies in the wound care center to better manage total cost of care and quality outcomes related to wound care.

 

“We are very excited to be working with Healogics and have TheraSkin included in its iSupply initiative,” stated Allan Staley, CEO of Solsys Medical. “The iSupply program enables Healogics’ hospital partners improved access to TheraSkin in order to improve wound healing outcomes at a lower cost.” … read more

Diabetes UK commits £2.6 million to new research

  • New funding will be split between 14 new research projects and five new PhD grants
  • New research includes projects investigating whether medieval remedies can be used to treat foot ulcers, and if sleep disturbances can predict Type 2 diabetes

Diabetes UK has committed to invest £2.6 million in 19 brand new projects which aim to make life-changing improvements in diabetes care, and reduce people’s risk of Type 2 diabetes.

 

The funding will be given to projects looking into Type 1, Type 2 and gestational diabetes. In one of these projects, Dr Freya Harrison, from the University of Warwick, will be using medieval remedies to find new sources of antibiotics. She has already discovered a combination that can kill antibiotic-resistant bacteria in the lab. Dr Harrison will study this remedy further to investigate how it works and if it could be used to treat infected foot ulcers in the future.

 

There are more than 20 leg, foot and toe amputations each day due to diabetes, four out of five of which could be prevented. This research hopes to reduce the number of diabetes-related amputations and cases of sepsis, by treating foot ulcer infections more effectively.

 

Dr Martin Rutter, from the University of Manchester, has also been awarded Diabetes UK funding to find out if sleep problems can help predict who might be at risk of Type 2 diabetes. He will also look at whether sleep patterns in people with Type 2 diabetes can affect their blood glucose control, and their risk of serious diabetes-related complications, such as amputation, heart disease and blindness … read more

Harnessing Molecular Medicine to Accelerate Wound Healing



Harnessing Molecular Medicine to Accelerate Wound Healing

Full Press Release: TAICEND – advancing the science of wound healing to cut recovery time by more than half.

KAOHSIUNG CITY, Taiwan, Oct. 17, 2025 /PRNewswire/ — TAICEND will present its five major wound healing product series at the 2025 MEDICA Fair in Germany, including the Postoperative Care Series, Acute & Chronic Wound Series, Pressure Relief Series, Skin Protection & Prevention Series, and the Trauma Series.

With molecular medicine as the foundation of its R&D, TAICEND integrates cellular concepts into the wound healing process, providing in-depth insights into cellular activity at each stage of healing and mapping these mechanisms to product applications. This approach highlights the company’s commitment to delivering a complete and protocol-driven clinical value in wound care.

In the Postoperative Care Series, TAICEND addresses the needs of patients recovering from procedures such as cesarean sections and orthopedic surgeries. The products help keep wounds clean, reduce the risk of infection, stabilize wound sites, alleviate pain, and minimize scar formation.

The Acute & Chronic Wound Care Series targets difficult-to-heal wounds such as pressure ulcers. TAICEND’s standardized wound healing SOP has been clinically shown to accelerate healing speed by more than 50%, making it highly suitable for home healthcare and long-term care facilities.

The Pressure Relief & Prevention Series is specifically designed to address skin injuries caused by medical devices or prolonged immobility. Common scenarios include facial pressure from BiPAP masks, skin damage from drainage tubes or nasogastric tubes, and localized pressure injuries in bedridden patients. This series provides effective solutions to redistribute pressure and minimize friction-related skin damage, offering a reliable preventive care option for patients.

The Skin Protection & Prevention Series will feature a new product for Incontinence-Associated Dermatitis (IAD) prevention and care. With a simple two-step protocol, it provides an effective and convenient solution for managing skin health in elderly and bedridden patients.

Within the Emergency & Trauma Series, TAICEND will unveil a range of products designed for emergency and battlefield applications, including emergency bandages, tourniquets, and chest seals. These products are engineered to provide rapid, life-saving interventions in critical injury scenarios, underscoring TAICEND’s dedication to delivering comprehensive wound care solutions—from clinical settings to frontline emergencies.

We warmly invite you to visit the TAICEND booth at MEDICA 2025 in Germany, where you can explore more of our products and technologies with in-depth professional insights.

Booth number: Hall6 #H66-1

Join us on this journey of innovation in wound healing!

Contact:

Tsumin Huang

+886 7 6955313

401603@email4pr.com

Cision

View original content:https://www.prnewswire.com/news-releases/harnessing-molecular-medicine-to-accelerate-wound-healing-302586308.html

SOURCE TAICEND TECHNOLOGY CO., LTD.

Copyright 2025 PR Newswire

Key Highlights:

  • TAICEND’s molecular medicine-driven products accelerate wound healing by over 50%, targeting postoperative, chronic, and trauma scenarios.
  • Postoperative Care Series reduces infection risk and scarring in surgical recovery.
  • Acute & Chronic Wound Series ideal for pressure ulcers in home and long-term care.
  • Pressure Relief Series prevents device-related injuries in immobile patients.
  • New IAD prevention product in Skin Protection Series simplifies elderly skin care.
  • Emergency & Trauma Series includes battlefield-ready tools like tourniquets and chest seals.

Read full article

Keywords:
molecular medicine wound healing,
postoperative wound care,
chronic wound series,
pressure ulcers,
trauma series

Wounds Australia’s Five Point Plan to Reduce the Burden of Chronic Wounds

The burden of chronic wounds for the individual, the health system and the whole community is familiar to the readers of this journal. Improving lives and saving money through better wound care is a common theme across this issue, and in the broader wound care activities.

 

Wounds Australia recognises that to achieve our vision of Quality wound care and prevention for all requires us to inform and engage with a broad audience. During Wound Awareness Week from 15 to 21 July 2018 Wounds Australia will launch our Five Point Plan to Reduce the Burden of Chronic Wounds. Our plan outlines 5 key initiatives to drive the change for best practice wound care for all Australians and reduce the suffering as a result of chronic wounds.

 

1. Medicare funding for treatment of chronic wounds in primary health care. A dedicated MBS item for treatment of chronic wounds to enable GPs, nurses and allied health professionals to deliver the best practice.

2. Subsidised wound products (dressings and related products) for people experiencing long term wound care. Advanced Wound management products often attract a premium cost. Selecting low cost, modest outcome products is a false economy. Research has shown that the use of less expensive dressings actually increases costs of treating a wound … read more

MolecuLight i:X® Receives Regulatory Clearance and Reimbursement in South Korea

KOVE Inc. to Distribute the MolecuLight Product Suite to Large South Korean Wound Care Market

 

Toronto, CANADA and Seoul, SOUTH KOREA – (April 6, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, and KOVE Inc., announce that the MolecuLight i:X® device has successfully received regulatory clearance and is now commercially available to the wound care market in South Korea. In addition, the MolecuLight device has also received reimbursement in Korea from the Ministry of Health and Welfare enabling clinician reimbursement for performing the medically necessary MolecuLight procedure.

 

Reimbursement for the MolecuLight procedure was granted by the Ministry of Health and Welfare of Korea, as per the notification number 259-858. This was announced based on Reimbursement data from the Korea New Medical Technology – Stability and Effectiveness Evaluation.

 

MolecuLight is exclusively distributed in South Korea by KOVE, Inc., a company specializing in providing novel products that assist in the treatment of diabetic foot ulcers in Korea including medical devices that assist with the diagnosis and treatment of wounds. KOVE’s team of clinical and technical support specialists have more than 30 years of experience in medical devices and wound care. KOVE also performs clinical research with many university hospitals in Korea.

 

The South Korean market for wound care is significant and can be understood through the pervasiveness of diabetes and diabetic foot ulcers. There are over 5 million Koreans with diabetes1, or 1 diabetic in every 30 adults. 25% of all diabetics also have a diabetic foot ulcer.

 

“The market for the MolecuLight device is significant in South Korea as there is a comprehensive and progressive health care system that quickly adopts new and clinically useful technologies”, says JUNHYOUNG LEE, CEO of KOVE, Inc. “Because of the high national insurance coverage for medical procedures, Korean patients readily visit hospitals to treat ailments and physicians are motivated to treat and monitor wounds until they are fully healed. The MolecuLight technology provides real-time actionable information on wound bioburden and allows clinicians to make bedside decisions quickly. It will be well-received by the South Korean medical community. Significant demand for the MolecuLight device has been verified through market research conducted over the last 12 months as part of the registration and reimbursement process.”

 

“We are most impressed with KOVE, Inc., with their very experienced and responsive team and with their close relationship with the wound care community in South Korea”, says Anil Amlani, MolecuLight’s CEO. “We believe that the speed with which the MolecuLight i:X received both registration and reimbursement shows the quality of our clinical evidence and the proven clinical outcomes that clinicians can achieve using the MolecuLight device. We are confident that South Korea will become a major market for MolecuLight”.

 

MolecuLight’s broad body of clinical evidence includes 55+ peer-reviewed publications, including over 1,400 patients under study, showing the significant benefit of the MolecuLight i:X® to wound care clinicians in all care settings.

 

To request a quotation or a clinical demonstration of the MolecuLight i:X in South Korea, please email junhglee1211@gmail.com or call +82.55.384.2600.

 

References:
1Korea National Statistical Office

 

About MolecuLight Inc.
MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection of wounds containing elevated bacterial burden (when used with clinical signs and symptoms) and for digital wound measurement. MolecuLight procedures performed in the United States can benefit from an available reimbursement pathway including two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant unmet needs including food safety, consumer cosmetics and other key industrial markets.

 

About KOVE, Inc.
KOVE, Inc. is a company specializing in the diagnosis and treatment of diabetic foot ulcers and wound-related medical devices. It has been conducting continuous clinical research and presentations with many university hospitals in Korea.

 

For more information, contact:

Rob Sandler                                                  JUNHYOUNG LEE

Chief Marketing Officer                             CEO

MolecuLight Inc.                                          KOVE, Inc.

T. +1.647.362.4684                                     Tel: 82.55.384.2600

rsandler@moleculight.com                       junhglee1211@gmail.com

www.moleculight.com                               http://kovekorea.com/

1. https://moleculight.box.com/s/03xcwbw0lwd777yt8jyy50bl72w3cbv4
MolecuLight i:X being used by 2 wound care clinicians on 2 patients in a wound care centre to assess whether their patients’ wounds have elevated bacterial burden.

2. https://moleculight.box.com/s/jbbcbb3hx8pmtbykl2vqkp3q11r6065m
MolecuLight i:X also has the benefit of engaging patients in their own wound care.

Development and Implementation of an Individualized Turning Program for Pressure Injury Prevention

Using Sensor Technology in Nursing Homes: A Quality Improvement ProgramA Quality Improvement Program
Turning nursing home residents every 2 hours has been a long-held standard for pressure injury (PrI) prevention in individuals with mobility impairments although evidence to substantiate this practice is limited. New guidelines recommend personalizing turning schedules to support person-centered care but lack specific recommendations about which turning frequencies are appropriate for various risk levels. PURPOSE: This quality improvement program aimed to determine the feasibility and outcomes of using individualized turn schedules for newly admitted nursing home residents. METHODS: An expert panel of wound clinicians developed, tested, and implemented a turn frequency tool that allowed staff in 2 nursing homes to select a turning schedule of 1, 2, 3, or 4 hours based on resident risk factors. Turning schedules were operationalized using a wearable sensor-based visual cueing technology that alerted staff to resident repositioning needs. Nonparticipating resident data were collected for comparison of PrI incidence. Descriptive statistics were calculated for all covariates. Significance of differences tests were performed as … read more

Analysis of Bias Criteria Checklist for Wound Care Registries & EHRs

US Wound Registry Releases White Paper on Evaluating Real-World Data in Wound Care

The U.S. Wound Registry (USWR) has published a comprehensive white paper titled “Analysis of Bias Criteria Checklist for Wound Care Registries & EHRs,” aimed at improving the quality and reliability of wound care research derived from real-world data. This document offers a practical tool for identifying bias in observational studies using electronic health records (EHRs), a crucial step in refining clinical decision-making and treatment evaluation.

Key Highlights:

  • Wound Care Burden: Chronic wounds affect 8.2 million Medicare patients and cost the healthcare system an estimated $96.8 billion annually.
  • Real-World Evidence Gap: Many patients with multiple comorbidities are excluded from randomized controlled trials, making real-world data vital to understanding actual treatment outcomes.
  • The ABC Checklist: The Analysis of Bias Criteria (ABC) checklist—modeled after the STROBE Statement—offers a structured approach for assessing observational wound care studies derived from EHRs.
  • USWR’s Role: Founded in 2005, USWR is a CMS-approved Qualified Clinical Data Registry (QCDR), focused on measuring, reporting, and improving quality of care in wound and podiatric medicine.

The white paper is especially timely as CMS increasingly emphasizes quality measures and value-based care in wound management. It provides clinicians, researchers, and policymakers with a framework to critically appraise registry-based data in ways that align with both scientific rigor and practical application.

Read the full white paper on the US Wound Registry website.

Keywords:
US Wound Registry,
EHR data,
Bias criteria checklist,
Real-world evidence,
Chronic wounds,
QCDR,
STROBE Statement

A new platform for gaining insight and knowledge in managing wounds

Wounds can cover diabetic foot ulcers, pressure injury, vascular ulcers or wounds, immunopathic wounds and traumatic wounds. Chronic, hard-to-heal wounds also have an adverse effect on health-related quality of life. Wounds are a global problem, with increasing incidence due in part to the increase in diabetes mellitus. In Asia, there are more than 4 billion people, and this is where diabetes and its complications, namely diabetic foot, are increasing at an alarming rate … read more

Foot Sparing Amputations in Diabetics

These techniques can save limbs and lives.
The recent global SarsCoV-2 (COVID-19) pandemic significantly disrupted the delivery of healthcare across many disciplines and the effect of the pandemic has had an especially detrimental effect on people with diabetes-related foot complications, resulting in more amputations. Major level lower extremity amputation is one of the most feared complications of diabetes. One study found that patients with diabetes and lower extremity complications were more in fear of major amputation than death.1 In many cases, major level amputations can result in loss of function, decline in quality of life, and even death … read more

How Effective are Nano-Based Dressings in Diabetic Wound Healing? A Comprehensive Review of Literature

Chronic wound caused by diabetes is an important cause of disability and seriously affects the quality of life of patients. Therefore, it is of great clinical significance to develop a wound dressing that can accelerate the healing of diabetic wounds. Nanoparticles have great advantages in promoting diabetic wound healing due to their antibacterial properties, low cytotoxicity, good biocompatibility and drug delivery ability. Adding nanoparticles to the dressing matrix and using nanoparticles to deliver drugs and cytokines to promote wound healing has proven to be effective. This review will focus on the effects of diabetes on wound healing, introduce the properties, preparation methods and action mechanism of nanoparticles in wound healing, and describe the effects and application status of various nanoparticle-loaded dressings in diabetes-related chronic wound healing … read more

Diagnosis And Treatment Of Periwound Dermatitis

Comprehensive Strategies for Managing Periwound Dermatitis in Chronic Wounds

Periwound dermatitis, an inflammatory condition affecting the skin surrounding chronic wounds, poses significant challenges to effective wound healing. Characterized by symptoms such as redness, itching, and discomfort, this condition often arises from factors like excessive wound exudate and irritants from dressings. Read the full article.

Key Highlights:

  • Understanding Periwound Dermatitis: This condition is commonly a form of contact dermatitis, either allergic or irritant, frequently resulting from exposure to wound exudate or components of wound dressings. It is often classified under moisture-associated skin damage (MASD).
  • Risk Factors: Factors contributing to periwound dermatitis include advanced age, comorbidities like venous insufficiency, nutritional deficiencies, and a history of skin disorders. These elements can compromise skin integrity, making it more susceptible to inflammation and damage.
  • Clinical Assessment: Regular evaluation of the periwound area is crucial. Clinicians should look for signs such as erythema, increased skin temperature, and patient-reported symptoms like itching or burning sensations. It’s important to note that skin changes may present differently across various skin tones.
  • Management Strategies: Effective management involves:
    • Removal of Irritants: Identifying and eliminating the causative agents, such as switching to hypoallergenic dressings or using normal saline instead of potential irritant cleansers.
    • Skin Protection: Applying barrier creams like zinc paste or petrolatum to shield the skin from further irritation.
    • Exudate Management: Utilizing appropriate absorbent dressings to control excessive wound exudate, thereby reducing moisture-related skin damage.
    • Pharmacological Interventions: In cases of significant inflammation, topical corticosteroids or antihistamines may be prescribed to alleviate symptoms.
  • Patient Education: Educating patients on proper wound care practices, including gentle cleansing techniques and the importance of adhering to treatment plans, is vital for preventing recurrence and promoting healing.

Addressing periwound dermatitis requires a multifaceted approach that combines careful assessment, targeted interventions, and patient involvement to enhance healing outcomes and improve quality of life.

Read the full article on the The Wound Pros website.

Keywords:
periwound dermatitis,
moisture-associated skin damage,
contact dermatitis,
wound exudate management,
skin barrier protection

Challenging the Parabola Paradigm in Transmetatarsal Amputation

Challenging the Parabola Paradigm in Transmetatarsal Amputation

Summary: In an oral abstract presented at the 2025 APMA National conference, Craig J. Verdin, DPM, DABPM, AACFAS and colleagues examined whether the residual metatarsal parabola structure truly affects function and outcomes following transmetatarsal amputation (TMA).

Key Insights:

  • A retrospective study of 57 unilateral TMA patients at Georgetown University grouped outcomes by residual parabola shape and residual length.
  • Major complications did not significantly vary by parabola shape. However, a longer second metatarsal remnant (“Type 4”) showed a weak but significant association with minor complications, possibly due to uneven plantar pressure distribution.
  • Neither parabola shape nor residual length correlated with functional outcomes or quality of life, based on the LEFS and SF-12 assessments.
  • The study suggests that achieving a “balanced” parabola—rather than strictly adhering to traditional length or shape norms—may suffice for optimal functional and clinical results.

Conclusion: This study challenges the long-held belief that maintaining a normal parabola or length post-TMA is essential. Its findings indicate that function-based planning may be more important than structural uniformity.

🔗 Read the full abstract on HMP Global Learning Network


Keywords: Craig J Verdin, metatarsal parabola, transmetatarsal amputation, second metatarsal remnant, limb salvage, APMA National 2025

Venous Leg Ulcer Treated with Native Collagen Alginate



Observational Study of Venous Leg Ulcer Treated With a Native Collagen-Alginate Dressing and the Impact on Wound-Related Quality of Life

Summary: This observational study evaluates native collagen alginate dressing in real-world management of venous leg ulcers (VLUs). Patients with recalcitrant VLUs received standard compression therapy plus the advanced dressing. Key outcomes: accelerated granulation tissue formation, progressive wound area reduction, decreased pain and exudate levels, fewer dressing changes required, and favorable cost-per-healing metrics compared to traditional alginates or gauze. The dressing modulates matrix metalloproteinases (MMPs), supports ECM remodeling, and maintains optimal moisture balance. Emphasizes ease of application, patient tolerance, and effectiveness in outpatient/clinic settings for hard-to-heal venous wounds.

Key Highlights:

  • Faster granulation and closure rates
  • Reduced pain, exudate, and dressing change frequency
  • Cost-effective adjunct to compression therapy
  • Relevance: Evidence-based support for collagen-based advanced dressings in chronic venous ulcers

Read full study

Keywords: native collagen alginate, venous leg ulcer, observational study, advanced dressing

Alisha Oropallo, MD
Amit S. Rao, MD
Sally Kaplan, RN
Farisha Baksh, BS
Christina Del Pin, MD

Reducing Health Disparities in Pressure Ulcer/Injury (PU/PI) Detection & Management October 7-9, 2021 in Atlanta, Georgia

Join the Association for the Advancement of Wound Care (AAWC) for our Pressure Ulcer Summit (PrU), themed Reducing Health Disparities in Pressure Ulcer/Injury (PU/PI) Detection & Management, on October 7-9, 2021 in Atlanta, Georgia.

– Upon completion of this conference, participants will be able to:
– Describe existing disparities related to pressure ulcer/injury (PU/PI) prevention and care.
– Discuss challenges in providing equitable pressure injury prevention and care.
– Describe characteristics of pressure injury and other damage of persons with dark skin tones.
– Identify at least one method of leveling the playing field for pressure injury detection.

website

Wound Practice and Research Volume 29 Number 2

Editorial
Connect, Collaborate, Innovate
Prof Allison J Cowin and Dr Peta Tehan


Original research
Dissemination of microbiota between wounds and the beds of patients with pressure injuries: a cross-sectional study
Mao Kunimitsu, Gojiro Nakagami, Aya Kitamura, Takeo Minematsu, Yuko Mugita, Kazuhiro Ogai, Junko Sugama, Miku Aoki, Chika Takada and Hiromi Sanada


Original research
Reducing the incidence and severity of pressure injuries in a high level care residential aged facility: a quality improvement project
Allyson Waird, Susan Monaro


Review
Caring for a child with Epidermolysis Bullosa: a scoping review on the family impacts and support needs
Colin J Ireland, Lemuel J Pelentsov, and Zlatko Kopecki


Clinical Trial Protocol
Physical activity, sleep and wound healing in adults with venous leg ulcers: a prospective observational cohort pilot study protocol
Yunjing Qiu, Victoria Team, Christian R Osadnik, Jane O’Brien, Louise Turnour, Ayoub Bouguettaya, Rosemary A McGinnes and Carolina D Weller


Review protocol
Measurement properties of quality of life instruments for adults with active venous leg ulcers: a systematic review protocol
Shiwen Liu, Victoria Team, Yunjing Qiu and Carolina D. Weller


Abstracts
Abstracts from the Wounds Australia Conference 4 – 6 May 202

Swift Medical Unveils Next-Generation Technology to Make Healthcare More Accessible for Everyone

Swift Medical, the global leader in digital wound care technology, is launching an innovative product that will revolutionize the future of healthcare … Today at 2pm EST / 11am PST, Swift Medical’s co-founder and CEO Carlo Perez will host a live broadcast from the TIFF Bell Lightbox in Toronto. At this event, Swift Medical will unveil a first-of-its-kind technology that will allow patients to access hospital quality care from anywhere and empower clinicians to prevent wounds before they even happen … Chronic wounds are one of the largest public health crises worldwide, with more than 8.2 million patients suffering from chronic wounds in North America alone. As rates of obesity, diabetes and other chronic conditions skyrocket, the number of patients at risk of developing chronic wounds will continue to rise … read more

Orpyx Medical Technologies Supplies Digital Health Platform for NIH-Funded and Johns Hopkins ….



Orpyx Medical Technologies Supplies Digital Health Platform for NIH-Funded and Johns Hopkins Medicine-Led Clinical Trial on Diabetic Foot Ulcer Prevention

Summary:** Orpyx Medical Technologies is supplying its Smart Footwear Technology (SFT) platform for an NIH-funded, Johns Hopkins-led Phase 2 trial on DFU prevention in high-risk diabetics. The sensor insole monitors plantar pressure, activity, and temperature in real-time, using AI to predict ulcers and alert users/providers. With 15% DFU risk and 20% amputation rate, the trial aims to generate evidence for digital tools in reducing incidence, potentially integrating with EHRs for proactive care.

Key Highlights:

  • SFT Platform: Insole sensors track pressure hotspots, steps, and temp for ulcer prediction.
  • Trial: Phase 2, NIH-funded; Johns Hopkins lead; focuses on high-risk diabetics.
  • AI Analytics: Alerts for risk; integrates with apps for user education.
  • Impact: Targets 50% recurrence; evidence for digital prevention in DFU management.
  • Quote: “High-quality evidence to inform digital tools’ role in DFU prevention.”

Read full article

Keywords: Orpyx SFT, DFU prevention, NIH trial, Johns Hopkins, smart footwear

Reimbursement for Total Contact Casting and Debridement

Few things in life are more complicated than medical reimbursements, we believe this (table below) to be accurate for TCC based on how current clients are billing. Also this is from SuperCoder on debridement:

As per NCCI edits total contact cast application (29445) cannot be billed separately from a debridement (97597) when treating the same ulceration/same anatomical location for medicare as of above scenario. However, Commercial payers may consider separate payment with appropriate modifier.

Also from SuperCoder on CPT codes for debridement:

CPT code 97602 can be used for removal of devitalized tissue from wounds when non selective debridement (chemical method, hydrogen peroxide, iodine, Pulsed lavage method etc.) method is performed.
CPT codes from wound debridement series (11042 – 11047) can be used if active debridement is performed with surgical instruments (forceps and scissors to remove infected or dead tissue material from the wound). Here code selection depends on the depth of the tissue removed e.g. for debridement up to level of subcutaneous tissue – CPT code 11042 is the correct CPT code.

This from medicarepaymentandreimbursement.com on reimbursement fees:

11042-Debridement, subcutaneous tissue (includes epidermis and dermis, if performed); first 20 square cm or less. – average fee payment- $120 – $130

From Integra Life Sciences:

 

  1. Coding/Billing Notes:
    According to the National Correct Coding Initiative (CCI) Policy Manual for Medicare Services (Revision
    Date: 01/01/2017), casting/splinting/strapping should not be reported separately if a restorative treatment
    or procedure to stabilize or protect a fracture, injury, or dislocation and/or afford comfort to the patient is
    also performed. Several examples follow: (1) If a provider injects an anesthetic agent into a peripheral
    nerve or branch (CPT code 64450), the provider should not report CPT codes such as 29515, 29540, or
    29580 for that anatomic area; (2) A provider should not report a casting/splinting/strapping CPT code for
    the same site as an injection or aspiration (e.g., CPT codes 20526-20615); (3) Debridement CPT codes
    (e.g., 11042-11047, 97597) and grafting CPT codes (e.g., 15040-15776) should not be reported with a
    casting/splinting/strapping CPT code (e.g., 29445, 29580, 29581) for the same anatomic area.
  2. If the cast is supplied by the physician in his/her office, the physician may bill the Medicare for the
    application of the cast as well as the supply of wrap itself, not the actual boot, during instances where just
    an application of TCC is occurring and the physician is enrolled in Medicare as a licensed DME Supplier.

Reference: CPT® Code Book 2021. Current Procedural Terminology (CPT) copyright 2020 American
Medical Association (AMA). All rights reserved. CPT is a registered trademark of the AMA. Fee
Schedules, relative value units, conversion factors and/or related components are not assigned by the
AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or
indirectly practice medicine or dispense medical services. The AMA assumes no liability for data
contained or not contained herein.

Improving patient outcomes with medical technology

An ideal healthcare system cures every type of medical condition an individual may have. However, healthcare professionals have always had to judge whether they can cure a patient or simply manage their condition to provide a better quality of life.

Many pharmaceutical interventions and treatment options are designed to manage people’s illnesses, not necessarily cure them. This increases the cost of healthcare – particularly as people live longer and the proportion of illnesses that are manageable rather than curable increases – as do the requirements for long-term care.

Some conditions have proven particularly hard to cure, such as diabetes and high blood pressure, leaving no choice but to manage and monitor a condition across an extended period. However, this is costly and poses many challenges to medical and clinical resources … read more

Southeastern Wound Healing Center raises awareness

     about impact of heart health on wound healing

 

An alarming 33 percent of Americans currently suffer from cardiovascular disease …Throughout Heart Health Awareness Month, Southeastern Health’s Southeastern Wound Healing Center, a member of the Healogics network, will work to spread awareness about how cardiovascular diseases can affect the wound-healing process. Cardiovascular diseases and other issues with the heart and vessels can cause blockages that obstruct the flow of blood needed for proper wound healing … Chronic wounds affect about 6.7 million people in the United States and, if left untreated, an unhealed wound on the foot or leg can lead to a diminished quality of life and possible amputation. As many as 82 percent of leg amputations are the result of poor circulation of the affected limb … read more

Joint EPUAP & EWMA Pressure Ulcer prevention & patient safety

     advocacy project

 

The European Pressure Ulcer Advisory Panel (EPUAP) and EWMA are collaborating on a joint engagement in the PU prevention and patient safety agendas at the European level as well as at the national level in selected European countries.

Five articles by the joint EPUAP-EWMA initiative have now been published. The articles are available for download here:

The role of pressure ulcer prevention in the fight against antimicrobial resistance

EWMA & EPUAP added-value to OECD efforts

Diabetic Control & Pressure Ulcers: fighting fatal complications and
improving quality of life

Patient safety across Europe: the perspective of pressure ulcers.

The time to invest in patient safety and pressure ulcer prevention is now!

 

Patient safety has for some years been high on the European Commission health care agenda. At the EU level as well as at national levels of many European nations, considerable investments have been made by health care authorities to establish organisations and programmes addressing the patient safety agenda.

 

Looking at the patient safety agenda from a wound care perspective, the topic of Pressure Ulcer (PU) prevention has always been central due to the fact that most PU’s are preventable if the patient is managed correctly by health care staff … read more

NEW SAWC Spring Scholarship Program Names First Five Recipients

The North American Center for Continuing Medical Education, LLC (NACCME), the CE-sponsor for the Symposium on Advanced Wound Care (SAWC) Spring and Fall meetings, and SAWC co-host, HMP Communications, LLC, today announced the inaugural class of five SAWC Spring scholarship winners, selected in cooperation with several prominent wound care societies and associations.

 

The SAWC Spring and SAWC Fall meetings are the largest wound care conferences in the United States with 2,000+ attendees expected at the 25th annual SAWC Spring and Wound Healing Society (WHS) Meeting to be held, April 19 -22, 2012 in Atlanta, Georgia. Wound care is predominately a multidisciplinary focused practice with optimal outcomes often provided by a team including physicians, podiatrists, therapists and nurses. The SAWC Spring scholarships not only target these clinical specialties but wound care fellows and researchers as well.

 

The owners of SAWC Spring have reached out to several major wound care societies and associations, along with key opinion leaders, to choose the inaugural 2012 SAWC Spring class of honorees. The five SAWC Spring scholarship winners will be honored during the annual SAWC Spring VIP Party to be held on Thursday night, April 19, 2012, at the Terraces Restaurant in the Georgia World Congress Center. Each of the scholarship winners will receive complimentary registration to SAWC Spring/WHS along with a framed certificate presented by their sponsor during the ceremony.

 

The inaugural list of SAWC Spring scholarship winners at the 2012 SAWC Spring/WHS Conference includes:

 

“Wound Healing Fellow Scholarship” – Malgorzata Plummer, MD, Assistant Professor of Clinical Surgery, Section of Wound Healing and Tissue Repair, University of Illinois at Chicago,

 

Presenter – William Ennis, DO, MBA, FACOS, President, American College of Wound Healing and Tissue Repair (ACWHTR)

“Wound Care Nursing Scholarship” – Sue Girolami, RN, BSN, CWOCN, Clinical Manager, Therapy Support, Inc.
Presenter – Terry Treadwell, MD, FACS, President, Association for the Advancement of Wound Care (AAWC)
“Wound Healing Research Scholarship” – Kenneth Finnson, PhD, Research Associate, Montreal General Hospital, McGill University Surgical Research
Presenter – Harriet Hopf, MD, President, Wound Healing Society (WHS)
“Wound Care Therapist Scholarship” – Jaimee Haan, PT, CWS, Team Leader – Physical Therapy Wound Management Department, University of Indiana Health
Presenter – Rose Hamm, DPT, CWS, President – American Physical Therapy Association (APTA) Wound Management Special Interest Group (WMSIG)
“Wound Care Training Scholarship” – Jeffrey S. Danetz, MD, FACS, Medical Director, Edward White Hospital Wound Center and Largo Medical Center Wound Center

 

Presenter – Robert Kirsner, MD, PhD, Co-Chairperson, SAWC
Recognizing the importance of appropriate and timely wound care in high-risk patient populations, and in concert with SAWC Spring/WHS, Georgia Gov. Nathan Deal has proclaimed April 2012 to be “Chronic Wound Care Month.”

 

For more information on the 25th Annual SAWC Spring/WHS meeting being held in April 19–22, 2012 in Atlanta, GA, please visit http://spring.sawc.net/ or contact Tiffney Oliver at 609-630-6223.
About NACCME

The North American Center for Continuing Medical Education, LLC (NACCME), an HMP Communications Holdings Company, provides the highest quality CME/CE across medical disciplines and therapeutic areas. In conjunction with top medical faculty, NACCME develops evidence-based initiatives that target specific educational needs, assisting healthcare professionals in improving patient outcomes by bridging the gap between current and best healthcare practices.

 

About HMP Communications, LLC
HMP Communications, LLC (HMP), is a leader in healthcare communications and education. It publishes some of the nation’s most well-respected journals in three key medical arenas — wound care/podiatry, cardiovascular and life sciences — representing 14 specialties. HMP also offers more than 20 years of meeting management/production expertise and over a decade producing cutting-edge, online educational programs. HMP’s portfolio of wound care/podiatry journals includes; Ostomy Wound Management, WOUNDS, Podiatry Today and Today’s Wound Clinic.

This article was originally published here

Annual Pressure Injury Prevalence Study

Annual Pressure Injury Prevalence Study

Summary: This listing refers to a health library event hosted by Nova Scotia Health, but specific details about the topic or agenda were not found in the public access. Typically, such events may cover clinical education, library resources training, or specialized topic sessions relevant to healthcare providers.

Key Highlights (If details accessible):

  • Organizer: NS Health / Nova Scotia Health Library
  • Event ID: 3947400
  • Likely topics: clinical information access, medical library orientation, specialty updates
  • Target audience: Nova Scotia Health staff and affiliated clinicians

Visit the event page on NS Health Library

Keywords:
NS Health Library,
healthcare education,
library event

Maxwell Healthcare teams up with Swift for digital wound care management

SHOREVIEW, Minn., and TORONTO, On, Nov 30 2018. Maxwell Healthcare Associates (MHA), a post-acute operational, financial, technological and regulatory consulting firm, today announced Swift Skin and Wound as its exclusive digital wound care management solution of choice for MHA home health clients.

The partnership comes just a few weeks before the January 2019 rollout of new Center for Medicare & Medicaid Services rules surrounding pressure ulcer prevention and management.

“At Maxwell we believe technology is key to not only surviving but thriving amid constant regulatory changes and reimbursement cuts,” said MHA CEO Tom Maxwell. “We began searching for a wound care technology for our clients and found it in Swift. More than 1,000 facilities are already successfully leveraging Swift Skin and Wound for better clinical outcomes. It’s the only one with a home health-specific focus build that allows home health clinicians to document in and out of the home.”

Swift Skin and Wound significantly improves clinical and administrative wound care management workflows through: the Swift app, which captures wound care information as easily as taking a picture; the Swift HealX, an FDA-registered adhesive marker applied to calibrate wound images for size, color and lighting; and Swift Dashboards that display real-time healing and treatment to help clinicians and administrators identify risks immediately and improve care … read more

Maxwell Healthcare teams up with Swift for digital wound care management

SHOREVIEW, Minn., and TORONTO, On, Nov 30 2018. Maxwell Healthcare Associates (MHA), a post-acute operational, financial, technological and regulatory consulting firm, today announced Swift Skin and Wound as its exclusive digital wound care management solution of choice for MHA home health clients.

 

The partnership comes just a few weeks before the January 2019 rollout of new Center for Medicare & Medicaid Services rules surrounding pressure ulcer prevention and management.

 

“At Maxwell we believe technology is key to not only surviving but thriving amid constant regulatory changes and reimbursement cuts,” said MHA CEO Tom Maxwell. “We began searching for a wound care technology for our clients and found it in Swift. More than 1,000 facilities are already successfully leveraging Swift Skin and Wound for better clinical outcomes. It’s the only one with a home health-specific focus build that allows home health clinicians to document in and out of the home.”

 

Swift Skin and Wound significantly improves clinical and administrative wound care management workflows through: the Swift app, which captures wound care information as easily as taking a picture; the Swift HealX, an FDA-registered adhesive marker applied to calibrate wound images for size, color and lighting; and Swift Dashboards that display real-time healing and treatment to help clinicians and administrators identify risks immediately and improve care … read more

New Net Health Innovation Can Predict Risk of Amputations and Wound Healing Rates

Net Health recently announced the addition of two pioneering predictive analytic capabilities embedded in the workflow of the company’s widely used electronic health record (EHR) platform.

Offering artificial intelligence-based capabilities, the Net Health Wound Care software platform now includes the Risk of Amputation Indicator, developed to reduce the risk of amputations, and the Wound Healing Velocity Indicator, developed to predict wound healing rates, according to the company. Net Health says both capabilities will provide insights needed to develop optimal patient therapies, implement effective interventions, and plan treatment paths that will improve outcomes … read more

RedDress Secures Capstone Health Alliance Contract to Expand Access to ActiGraft®

RedDress, a privately held U.S. and Israel-based wound care company, announced today that it has secured a contract with Capstone Health Alliance, one of the nation’s largest regional group purchasing organizations representing 300 hospitals in all 50 U.S. states.

Chronic non-healing wounds impose a significant economic burden on the healthcare system, health care providers, and patients. The ActiGraft® system aims to deliver an affordable and efficacious wound solution to Capstone Health Alliance Members to help improve the health and lives of patients … read more

Net Health Adds Industry Leader Proteus Genomics Lab Testing to Wound Care Platform

PITTSBURGH, April 28, 2021 /PRNewswire/ — Net Health, a leading provider of cloud-based software for specialty medical providers, announced today that users of the company’s EHR software solution, Net Health® Wound Care (formerly WoundExpert®), can now place in-chart orders for laboratory services through Proteus Genomics … The agreement is the first Net Health partnership with a laboratory services provider and continues the expansion of in-chart ordering options for clients. The program will initially be launched in April to Net Health customers in the Southeast, including Texas, Florida, North Carolina, Louisiana, Georgia, Mississippi, Tennessee, Arkansas and Alabama, with plans to expand nationally within the next year … Recognized as a market leader, Proteus Genomics is a highly-specialized genetic and microbiology laboratory facility … continue

Wound Care Startup Could Reduce Home Health Time

A biomedical engineer and a health care entrepreneur have teamed up to improve wound care with a product designed to prevent infection and reduce the need for some post-acute care, including home health.

 

FM Wound Care, LLC, based in Trenary, Michigan, is awaiting U.S. Food and Drug Administration approval on a nitric-oxide-infused, self-sterilizing wound dressing designed to kill bacteria following surgery. The post-op bandage could potentially reduce the need for some care performed by home health care providers, and lower overall wound care costs.

 

Megan C. Frost, PhD, and entrepreneur Jeff Millin believe their product—the Sentry Wound Dressing—prevents infections by slowly releasing nitric oxide (N.O.) over the course of seven days, allowing patients to wear the same wound dressing for a week.

 

“If a nurse has to change a dressing, that takes quite a bit of time,” Millin explained to Home Health Care News. “If you only had to do that once every seven days as opposed to once every other day, the savings could be significant.”

read more

 

This Is Wound Care, the Coolest Specialty in Health Care

There are three little words in health care that without proper treatment can destroy your family’s finances and health. Despite this, the amount of people that have ever heard of the words — non-healing wounds — remains astonishingly low.

We are not talking about simple cuts, scrapes, or boo boos. Wound Care is a raw, gritty, extremely visual, and sometimes nauseating field of health care. It is certainly not for the squeamish. At the same time it is the coolest, most visual, and passion filled specialty of healthcare in which to be employed.

The passion runs deep

The wound care community is a segment of health care specialists that have dedicated their lives to the healing and treatment of non-healing wounds. These people live, sleep, eat, breath, and even dream about wound healing. When they are not doing that, they are posting about it on social media. I know this because I work with these amazing individuals every day at Wound Care Advantage (WCA), a company that runs and manages outpatient wound centers for hospitals. As the director of our S.O.A.R. department it is my job to help educate the nation on the dangers of non-healing wounds …. read more

 

Healogics talks foot health

Healogics kicked off April with its chronic foot health awareness efforts in collaboration with National Foot Health Awareness Month. Its goal: To educate the public on the importance of foot health to prevent wounds and the need for regular foot exams to detect non-healing wounds. “With the increased incidence of diabetes, foot ulcers and even amputations, it is important for those living with chronic wounds, as well as those who are at risk, to have access to information on wound healing,” said David Bassin, Healogics CEO “Throughout April, we seek to educate our communities and health care providers in an effort to improve access to wound care for all that need it.” The efforts are also part of Healogics’ 2022 Healing Can’t Wait program. The company served more than 330,000 patients last year through a network of … read more

WoundSource Recognizes 21-Day Miracle Dressing Wound Care System as Product of the Week

BEVERLY HILLS, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) — Miracle Dressing Wound Care System 21-Day Stay-in-Place Dressing has been named Wound Care Product of the Week by WoundSource, “the world’s definitive source for wound care and product information.”

 

Miracle Dressing™ Wound Care System is the only 21-day stay-in-place dressing. Wound prevention, monitoring, cleaning and topical applications can all be completed without dressing removal. This saves nursing time and reduces patient distress from frequent dressing changes.

 

The system includes Natural Marine Extract™, the ingredients of which are known to promote faster healing of the skin and better wound healing results.

 

The Wound Healing Society spotlighted the importance of dressings that can stay in place for an extended time, especially due to extended stays caused by COVID mitigation. They recommend utilizing dressings that decrease the intensity of wound care by avoiding the use of dressings that must be changed daily. This would allow over-stressed health care staff to reach more patients in an adequate time frame.

 

The Miracle Dressing System can be used for:

 

  • Preventive care for pressure injuries (bed sores)
  • Stage 1 and Stage 2 pressure injuries
  • Skin tears and cuts
  • Avulsions and abrasions
  • Replacing external sutures after deep tissue closure (cesarean, plastic, superficial MOHS and excision cancer, orthopedic, cosmetic) and post-op
  • First, Second and Superficial Third Degree burns
  • Bruises and preventive care to stop new bruises in atrophic vulnerable skin
  • Prosthetic pressure injury prevention and wound healing
  • All bullous diseases, especially Epidermolysis bullosa (EB), pemphigoid, pemphigus
  • About Marine Biology & Environmental Technologies (MBET) and MBET Health

 

MBET is recognized for their skin revitalization and wound care products as well as kelp reforestation and other international environmental projects.

 

MBET Health is a solutions-oriented technology company focused on solving one of the most important and intransient problems facing the world of medicine: preventing and healing wounds.

 

MBET Health was founded by Dr. Eric Lewis, a practicing dermatologist, surgeon and scientific researcher based in Beverly Hills, CA. The MBET Health management team includes medical and surgical doctors from a multitude of disciplines, pharmacists and marine biologists.

 

Beginning in 2001, their founders researched a multitude of marine compounds reported to have human health benefits. As a result of their extensive studies and tests, several compounds and systems specifically designed for rejuvenation and effective repair of damaged skin have been patented (or patent-pending). The mechanisms of action of their system’s ingredients are designed to heal intractable wounds and strengthen weak, vulnerable skin to minimize the probability of breakdown.

 

The MBET Health website provides a destination for all wound care providers, nursing staff and senior management to see for themselves the convincing before and after photos and to learn details about proper product application and dressing maintenance.

 

Contact

 

Linda Sherman Gordon
MBET Health Chief Marketing Officer
310-243-6305
Email contact
MBET Health LinkedIn
Before / After press photos available upon request

This article was originally published here

UT Health San Antonio study uncovers key risk factors ….

UT Health San Antonio Study Uncovers Key Risk Factors for Diabetic Foot Infection Recurrence

A recent study conducted by researchers at UT Health San Antonio has identified significant risk factors contributing to the recurrence of diabetic foot infections. Published in the International Wound Journal in November 2024, the study analyzed eight years of patient data to understand why nearly half of patients treated for diabetic foot infections experience reinfection within a year.

Led by Dr. Lawrence A. Lavery, DPM, MPH, a specialist in diabetic foot complications and professor of orthopaedics, the research reviewed records of 294 patients hospitalized for moderate to severe diabetic foot infections. The findings revealed that patients with wounds unhealed after three months were three times more likely to experience reinfection. Additionally, those with bone infections had more than twice the risk compared to patients with only soft tissue infections.

Dr. Lavery emphasized the importance of wound healing in preventing reinfections, stating, “When your wound fails to heal or you develop another wound, the clock starts ticking.” The study also highlighted that patients with unhealed wounds faced longer healing times, increased hospital readmissions, and extended hospital stays, underscoring the need for early intervention and comprehensive care strategies.

Read the full article on the UT Health San Antonio Newsroom.

Keywords:
Diabetic foot infection,
Infection recurrence,
Wound healing,
Bone infection,
Peripheral neuropathy,
UT Health San Antonio,
Lawrence A. Lavery

 

Note: The above synopsis is based on the article’s content and available information. For a comprehensive understanding, please refer to the full article.

HMP Global launches Great Debates & Updates program focusing on Diabetic Foot Syndrome

HMP Global, the omnichannel leader in healthcare events and education, today announced the launch of a new program offering professionals who treat diabetic foot syndrome the opportunity to debate the most controversial topics in treatment options and gain knowledge from one another.

 

Great Debates & Updates in Diabetic Foot will be held December 2-3 in San Antonio, Texas. The unique, debate-style format will include dynamic presentations and interactive debates, while also diving into the long history of podiatry culture in San Antonio.

 

“The agenda will feature a mix of clinical updates and lively debates on provocative scientific topics impacting the field, including emerging concepts and treatment options for the diabetic foot,” said Dr. Lawrence A. Lavery, UT professor, board-certified podiatrist at UT Southwestern Medical Center, and event co-chairman. “We are excited to lead this inaugural event and provide a unique, interactive experience to the attendees, with several opportunities to network with faculty, industry, and colleagues.”

 

This year is the 50th anniversary of the podiatry residency program at the University of Texas Health Science Center in San Antonio, Lavery said, a milestone which will be celebrated at the GDU in Diabetic Foot event.

 

“There is a rich history of podiatry culture and diabetic foot research in Texas,” said Dr. Lee C. Rogers, event co-chairman and Chief of Podiatry and Associate Professor in the Department of Orthopedics at the University of Texas Health. “The Diabetic Foot Ulcer Classification System is a proven, effective, and widely used classification system for predicting hospitalization and lower extremity amputation. We look forward to discussing this, along with other important treatment tools and techniques, during the new program.”

 

GDU in Diabetic Foot is designed for the wide spectrum of medical professionals who diagnose and manage the diabetic foot, including podiatrists, wound care physicians, physical therapists, physicians-in-training, nurse practitioners, and physician assistants. The in-person meeting will allow attendees more opportunities for networking and engaging with colleagues and faculty experts.

 

“The GDU brand offers an educational experience unlike any other,” said Tiffney Oliver, Vice President, Wound Care Learning Network, HMP Education. “These unique, debate-style conferences provide a comprehensive learning experience covering the latest scientific updates and controversial issues emerging in different fields. We are excited to introduce the GDU brand through important education about managing and treating the diabetic foot.”

 

GDU in Diabetic Foot offers a maximum of 9 hours of continuing education credit. Exhibit space, attendee engagement options, and branding opportunities are available to organizations interested in participating in the event.

 

For more information or to register, visit gdudiabeticfoot.com.

 

About HMP Global
HMP Global is the force behind Healthcare Made Practical — and is an omnichannel leader in healthcare content, events, and education, with a mission to improve patient care. The company produces accredited medical education events — in person and online via its proprietary VRTX virtual platform — and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include the HMP Global Learning Network, healthcare’s most comprehensive source for news and information; Psych Congress, the largest independent mental health meeting in the U.S.; the Evolution of Psychotherapy, the world’s largest independent educational event for mental health professionals; the Leipzig Interventional Course (LINC), the leading, global gathering for interdisciplinary cardiovascular specialists; EMS World Expo, North America’s largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com.

Diabetic Limb Salvage conference joins 2023 Symposium on Advanced Wound Care (SAWC) Spring

Wound Healing Society for immersive educational experience

 

Premier annual limb salvage meeting co-locates with the leading meeting dedicated to the research, management, treatment, and prevention of wounds in April.

 

Three industry-leading wound care organizations are uniting for a conference in April 2023, focusing on wound prevention and management, research, and limb salvage. The meeting will offer the most cost-effective, comprehensive, and immersive educational event for professionals in the wound care space.

 

The Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS) is the leading meeting dedicated to the research, management, treatment, and prevention of wounds; and Diabetic Limb Salvage (DLS) is the premier annual limb salvage education event focused on wound healing and preventing amputations. The 2023 event is organized by HMP Global, the omnichannel leader in healthcare events and education, and will be held April 26-30, 2023, in National Harbor, Maryland.

 

The in-person event will provide opportunities for networking and collaboration, with an educational agenda featuring an expert lineup of faculty, in-depth discussions, and exposure to innovation, proven techniques, and effective strategies for patient care. The interdisciplinary agenda is designed for every clinician interested in wound care, including physicians, nursing professionals, physical therapists, researchers, scientists, podiatrists, and dietitians — connecting the entire wound care team with the foremost experts in the field to improve patient outcomes through education.

 

DLS Co-Chairs are Dr. Christopher E. Attinger, Chief, Division of Wound Healing at MedStar Georgetown University Hospital and professor of plastic and orthopaedic surgery, Georgetown University School of Medicine in Washington, D.C.; and Dr. John S. Steinberg, Co-Director, MedStar Health Wound Healing Institute at MedStar Georgetown University Hospital, Hospital Center Director of the Podiatric Residency Training Program, MedStar Health, and a professor of plastic surgery at Georgetown University School of Medicine.

 

“Through this collaboration, educational opportunities at the conference will focus on every aspect of wound research, prevention, and healing along with a focus on limb salvage,” said Dr. Steinberg. “We are solving the issue of access to education by uniting these three events this year to provide learners with one comprehensive event. It is an opportunity for providers to strengthen their clinical skills, invigorate their approach, and positively impact their ability to care for their patients.”

 

The collaboration with DLS will add more limb salvage-focused topics to the conference agenda, including:

 

  • Advanced Surgical Options for Lower Extremity Limb Salvage
  • Diagnosing and Managing the Charcot Foot
  • Integration of Plastic Surgery with the Limb Salvage Team
  • Endovascular Intervention

 

The WHS President is Dr. Kenneth Liechty, Division Chief of Pediatric Surgery and Director of Fetal Medicine, University of Arizona, and Surgeon in Chief of Diamond Children’s Hospital; and Co-Chairs are Dr. Daria Narmoneva, associate professor, University of Cincinnati, and Dr. Carlos Zgheib, assistant professor of surgery, University of Colorado Denver School of Medicine in Aurora.

 

“Although each of these three organizations have a unique mission, we are united in our goals of improving outcomes for patients and patient populations,” Dr. Liechty said. “We are excited to host one symposium for every member of the wound care team, allowing us to provide the highest caliber training and education that all clinicians can incorporate in their practice.”

 

SAWC Spring Co-Chairs are Dr. Robert S. Kirsner, Harvey Blank Professor and chairman, Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine; and Dot Weir, RN, CWON, CWS, clinician at Saratoga Hospital Wound Healing.

 

“We have partnered with the Wound Healing Society for 15 years, providing a robust educational experience for meeting participants, and this year’s event will be even stronger with the addition of multiple topics on amputation prevention,” Dr. Kirsner said. “No other wound care conference offers the level of education, advanced state-of-the-art clinical reviews, and emerging research findings.”

 

For more information or to register, visit sawcspring.com.

 

ABOUT HMP GLOBAL
HMP Global is the force behind Healthcare Made Practical — and is an omnichannel leader in healthcare content, events, and education, with a mission to improve patient care. The company produces accredited medical education events — in person and online via its proprietary VRTX virtual platform — and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include the HMP Global Learning Network, healthcare’s most comprehensive source for news and information; Psych Congress, the largest independent mental health meeting in the U.S.; the Evolution of Psychotherapy, the world’s largest independent educational event for mental health professionals; the Leipzig Interventional Course (LINC), the leading, global gathering for interdisciplinary cardiovascular specialists; EMS World Expo, North America’s largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com.

Combined Regenerative Approach for a Complex Lower Extremity Wound

More than 400 million patients worldwide are affected by diabetes; over their lifetime, at least 25% will develop foot ulcers that often result in high rates of nonhealing wounds and amputation. The authors present the case of a 43-year-old female patient with multiple comorbidities who presented with a large (8 cm x 4 cm), noninfected, hindfoot plantar ulcer that extended down to the bone and calcaneus. Over 2 weeks, the patient was successfully treated using a combination of an acellular dermal matrix, nanofat grafting, and negative pressure wound therapy, lessening the effects of the ulcer on the patient’s quality of life and achieving limb salvage. Utilizing the regenerative procedures described herein may improve patient care and decrease costs … read more

Wounds Asia: Current issue: Vol 1, No 2

  • Wound care management in Indonesia: issues and challenges in diabetic foot ulceration
    There are 415 million people aged 20–79 years with diabetes worldwide, almost 153 million of them live in the Western Pacific region (Ogurtsova et al, 2017). The number of people with diabetes is predicted to rise to 642 million worldwide by 2040 (Ogurtsova et al, 2017). Indonesia has approximately 258 million citizens, making it the world’s fourth most populated country. It is one of 21 countries and territories in the International Diabetes Federation Western Pacific region. According to the International Diabetes Federation (2017), about 10.3 million Indonesians have diabetes
  • Optimising quality of life for people with non-healing wounds
    Some wounds persist for months or years (Krasner et al, 2014). Non-healing wounds may be a result of host factors, such as inadequate vasculature, medications that interfere with the healing process, immunocompromised status or critically-ill status with non-modifiable risk factors (terminal disease, end-stage organ failure and other life-threatening health conditions). Among patients who are dying, receiving hospice or palliative care, non-healing or palliative wounds can be associated with complications
  • Reconstruction of a soft tissue defect of the big toe by pedicled perforator flap
    Treatment of soft tissue defect on the distal of the big toe is challenging due to the lack of reliable options that can be used to create a local flap to cover the injured area. Following injury, soft tissue defects expose the structures, joints, tendons and bone. Even a small defect will become problematic if it is not managed appropriately
  • Natrox® — Let the topical oxygen flow for healing complex wounds
    The presence of a wound increases the body’s requirement for oxygen by 20% for a patient with a clean wound and by 50% for an infected wound (Dernling, 2009). Oxygen is critical to many of the processes required in wound healing including the production of energy to fuel cell function and metabolism, angiogenesis, collagen synthesis and cross-linking

Treatment of Diabetic Foot Ulcers

Diabetic wound is the most common cause of non-traumatic
lower extremity amputation, and response to traditional
interventions is poor in many patients. The lifetime risk of
developing an ulcer among diabetics is 25%, and recurrent
wounds are common after healing. Stigmatization, social
isolation, unemployment, and depression are some of the
negative consequence of Diabetic Foot Ulcer (DFU) on the
quality of life of diabetics. DFU adds a substantial economic
burden to afflicted patients and health systems, primarily
attributable to frequent hospitalization, medication, surgical
procedures, amputation, prosthesis, rehabilitation, and loss of
productivity … read more

FDA approves shock wave device for treatment of diabetic foot ulcers

Today, the U.S. Food and Drug Administration permitted the marketing of the Dermapace System, the first shock wave device intended to treat diabetic foot ulcers.

 

“Diabetes is the leading cause of lower limb amputations,” said Binita Ashar, M.D., director of the division of surgical devices in FDA’s Center for Devices and Radiological Health. “The FDA is dedicated to making technologies available that can help improve the quality of life for those with chronic diseases. Additional options for successfully treating and healing ulcer wounds may help prevent lower limb amputations.”

 

An estimated 30.3 million people in the United States have been diagnosed with diabetes, according to the Centers for Disease Control and Prevention. Diabetes damages blood vessels and nerves, particularly in the feet, and can lead to severe infections that are difficult to treat. About 25 percent of people with diabetes will experience a foot ulcer in their lifetime. Amputation is sometimes necessary when circulation is so poor that a foot ulcer fails to heal or when treatment fails to stop the spread of an infection … read more

Combined Regenerative Approach for a Complex Lower Extremity Wound: A Case Report

More than 400 million patients worldwide are affected by diabetes; over their lifetime, at least 25% will develop foot ulcers that often result in high rates of nonhealing wounds and amputation. The authors present the case of a 43-year-old female patient with multiple comorbidities who presented with a large (8 cm x 4 cm), noninfected, hindfoot plantar ulcer that extended down to the bone and calcaneus. Over 2 weeks, the patient was successfully treated using a combination of an acellular dermal matrix, nanofat grafting, and negative pressure wound therapy, lessening the effects of the ulcer on the patient’s quality of life and achieving limb salvage … read more

Healogics Launches Healing Can’t Wait Program For 2022

JACKSONVILLE, Fla., Jan. 13, 2022 /PRNewswire/ — Healogics®, the nation’s leading provider of world-class wound care, is announcing their “Healing Can’t Wait” program for the millions of people struggling with a non-healing wound. Chronic wounds affect seven million Americans, limiting their quality of life, as well as life expectancy … With the 2022 Healing Can’t Wait program, Healogics looks to address the significant increase in amputations observed in recent years due to the impact of COVID-19 on patient treatment schedules. It is critical that patients understand the urgency and importance of treatment. Through the 2022 Healing Can’t Wait program and resources, Healogics Wound Care Centers will focus on educating the underserved chronic wound population … “Treatment delays and the staggering increase in amputations drive us to work even harder to improve awareness and access to advanced wound care. Any untreated wound is at risk for complications such as infection, hospitalization or amputation,” explains David Bassin, Chief Executive Officer of Healogics. “This is why the Healogics Healing Can’t Wait program is so critical.” … People living with diabetes, heart disease or peripheral artery disease (PAD) are at an even greater risk for health complications that stem from an untreated wound … read more


LinkedIn:
Healogics, Inc.

Medical Innovation And The Fight Against Amputation

Many specialists unite with one goal: preventing amputation. When podiatrists encounter patients that may lose a leg from peripheral arterial disease (PAD), vascular treatment is an urgent need. But, the question may arise: “Why doesn’t the vascular community seem to agree on how to best intervene?” … A July 2015 research paper compared the primary and secondary outcomes of angioplasty versus open vascular surgery.1 The research found both treatments equally effective in amputation prevention, improving the quality of life and life expectancy of patients with critical limb ischemia (CLI), but that endovascular treatment offered additional benefits of lower cost, lower complication rates, and easier recoveries. The study also showed a lower 30-day mortality rate for angioplasty. The article summary stated, “Based on these results it is suggested that angioplasty should be considered as the first choice for feasible CLI patients.” … read more

The patient’s perspective of diabetic foot ulceration

A phenomenological exploration of causes, detection and care seeking
From Rebecca M CrockerTze-Woei TanKelly NB PalmerDavid G Marrero

 

Diabetic foot ulceration can contribute to lowered life expectancy and quality of life for people with diabetes, and yet, scant attention has been given to improving preventive and educational measures. This article uses a phenomenological approach to explore individuals’ lived experiences of diabetic foot ulcerations to explore factors that can be harnessed to achieve improved outcomes … This was a qualitative study using semi-structured interviews grounded in a phenomenological framework to explore how patients perceive and understand their foot problems … read more


If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Combined Regenerative Approach for a Complex Lower Extremity Wound: A Case Report

Pedro Salomão Piccinini, Mariana Rodrigues de Sousa Rebelato, Marwan Masri, Carlos Oscar Uebel, Rubem Lang Stümpfle, Milton Paulo de Oliveira

 

A diabetic foot ulcer (DFU) is a multifactorial complication affecting patients with diabetes mellitus (DM). These ulcers have a lifetime prevalence of 25% in this population and represent a major cause of hospitalization.1-4 Diabetic foot ulcers also generate an economic burden on the health care system and severely impact patient quality of life.5,6 Standard of care (SOC) consists of management of comorbidities, evaluation of vascular status and debridement, and provision of daily dressings, pressure offloading, and infection control. However, a majority of DFUs do not heal completely, and some lead to infection and amputation.3,7 Newer wound therapies have been shown to offer better alternatives by promoting angiogenesis to accelerate healing.4-6 In this context, the authors present the case of a patient with multiple comorbidities who presented with a chronic nonhealing plantar wound; while multiple prior treatments failed, the wound was successfully treated with nanofat grafting, negative pressure wound therapy … read more


If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Topical Oxygen Therapy Awarded “A” Grade Treatment Recommendation by the American Diabetes Association

in their 2023 Standards of Care in Diabetes

 

OCEANSIDE, Calif., Dec. 13, 2022 /PRNewswire/ — Advanced Oxygen Therapy Inc. (AOTI), the global leader in noninvasive topical oxygen wound healing solutions, announced today that the American Diabetes Association has awarded an “A” grade recommendation for utilizing adjunctive topical oxygen therapy in treating Diabetic Foot Ulcers (DFU) in their 2023 standards of care in diabetes, the preeminent Clinical Practice Guidance (CPG) in the space, which was published today online: https://diabetesjournals.org/care/issue/46/Supplement_1

 

ADA - Amputation Prevention Alliance

ADA – Amputation Prevention Alliance

The American Diabetes Association is the leading clinical authority dedicated solely to combating diabetes and its complications. Based on the latest scientific research and clinical trials, their annually updated standards of care in diabetes provides the most comprehensive and trusted evidence-based clinical guideline on the prevention, diagnosis, and treatment of diabetes and its complications.

 

Dr. Mike Griffiths, CEO and President of AOTI commented; “We are delighted that the ADA’s Professional Practice Committee, in its 2023 update to their standards of care in diabetes, has assessed that the now overwhelming body of clinical evidence supports awarding topical oxygen therapy a converted “A” grade recommendation as an adjunctive treatment for healing DFU.”

 

AOTI’s unique Topical Wound Oxygen (TWO2) therapy is unlike any other topical oxygen approach, in that it is the only device that provides a multimodality treatment, combing higher pressure oxygen delivery with non-contact cyclical compression and humidity, in a therapeutic applied by the patient at home. This patented approach has been demonstrated in numerous Randomized Controlled Trial (RCT) and Real World Evidence (RWE) studies to not only heal chronic wounds at a far higher rate, but perhaps more importantly, keep them closed longer term, thereby reducing unnecessary hospitalizations and amputations.1, 2

 

“The more sustainable long-term healing elicited when utilizing TWO2 therapy was highlighted in the ADA guidance, with their citing of all of the RCT and RWE studies conducted with TWO2, along with multiple recent Systematic Reviews and Meta Analyses, leading to their “A” grade recommendation ” stated Dr. Griffiths

 

1 Multinational, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy of Cyclical Topical Wound Oxygen (TWO2) Therapy in the Treatment of Chronic Diabetic Foot Ulcers; The TWO2 Study. Robert G. Frykberg et al, Diabetics Care 2020; 43:616-624. https://doi.org/10.2337/dc19-0476.

 

2 Reduced Hospitalizations and Amputations in Patients with Diabetic Foot Ulcers Treated with Cyclical Pressurized Topical Wound Oxygen Therapy: Real-World Outcomes; Jessica Izhakoff Yellin, et al; Advances in Wound Care 2022; http://doi.org/10.1089/wound.2021.0118

 

About AOTI
AOTI is a privately-owned company based in Oceanside, California USA and Galway, Ireland that provides innovative solutions to resolve severe and chronic wounds worldwide. Our products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. Our patented non-invasive Topical Wound Oxygen (TWO2) homecare therapy is clinically proven to deliver Sustained Wound Healing that reduces both Amputations and Hospitalizations, So Life Can Get Back to Normal.

 

For more information see: www.aotinc.net

 

Contact:
Dr. Mike Griffiths
CEO & President
350571@email4pr.com
(760) 672 1920

 

This article was originally published here

What Happens When a Wound Heals?

Alton R. Johnson Jr., DPM, DABPM, FACPM, FASPS, CWSP
John Steinberg, DPM, FACFAS

In this insightful episode, Dr. Alton Johnson, Dr. John Steinberg, and host Brian discuss the often-overlooked phase of wound care: life after healing. The conversation shifts from the traditional focus on simply closing wounds to a broader perspective that emphasizes function, long-term remission, and patient education.

Dr. Johnson shares his journey as a young physician who initially believed healing was the final step, only to realize that patients frequently return due to recurring wounds. He highlights the importance of educating patients on easing back into daily activities and managing their healed wounds like a condition in remission.

Dr. Steinberg builds on this by emphasizing function over limb salvage, noting that saving a limb without restoring mobility can leave patients unable to regain independence. He recalls advice from his colleague, Dr. Chris Attinger, who stressed that preventing wounds from returning is just as crucial as healing them.

The discussion underscores the need for early planning in the healing process, ensuring patients have the right prosthetics, orthotics, and footwear in place before their wounds fully close. By shifting the focus from simply healing wounds to optimizing long-term mobility and quality of life, this episode offers valuable insights for clinicians, caregivers, and patients alike.

Listen

Phase III Gene Therapy Skin Grafts Accelerate Healing in Severe Epidermolysis Bullosa

Phase III Gene Therapy Skin Grafts Accelerate Healing in Severe Epidermolysis Bullosa

Stanford Medicine researchers have reported success in a Phase III clinical trial using gene therapy–based skin grafts to treat recessive dystrophic epidermolysis bullosa (RDEB), a devastating genetic skin-blistering disease. The therapy, recently approved by the FDA, represents a major step forward in regenerative wound care for rare disorders.

Key Highlights:

  • Improved Wound Healing: In a trial involving 11 RDEB patients, wounds treated with the engineered grafts healed significantly faster than untreated areas. Participants also experienced less pain and itching.
  • FDA Approval: The treatment—marketed as ZEVASKYN™ (prademagene zamikeracel)—was approved by the FDA in April 2025, making it the first gene-corrected, cell-based therapy for RDEB.
  • Patient Impact: Trial participants described the therapy as life-changing. One 20-year-old patient reported reduced pain and improved quality of life, allowing her to continue working during treatment.
  • Durability & Safety: The grafts provided long-lasting healing with minimal side effects. No serious adverse events were reported, and follow-up showed continued skin integrity at the graft sites.

This milestone in wound care highlights the potential for autologous gene-modified grafts to transform treatment for rare and severe skin conditions, offering hope where conventional wound care often falls short.

Based on results published in June 2025 in The Lancet.

Keywords: gene therapy, skin grafts, epidermolysis bullosa, ZEVASKYN, RDEB

Read the full article on Medical Xpress

Saving Organs, Saving Lives: Transforming Wound Care Through Non-Surgical Treatments



Saving Organs, Saving Lives: Transforming Wound Care Through Non-Surgical Treatments

Summary: This blog post showcases the innovative non-surgical approaches at KBK Hospitals in Hyderabad, led by Kakkireni Bharath Kumar, to treat complex wound conditions like cellulitis, gangrene, and diabetic foot ulcers. Aligned with the mission “Save Organ, Save Life,” the hospital prioritizes infection control, tissue preservation, and natural healing to prevent amputations, restore mobility, and enhance patient quality of life through personalized, advanced therapies.

Key Highlights:

  • Cellulitis treatment focuses on controlling infections, reducing inflammation, and preventing spread with tailored plans for faster recovery and tissue preservation.
  • Gangrene care improves blood circulation, removes dead tissue, and stimulates healing to avoid amputation and restore function without surgery.
  • Diabetic foot ulcer programs promote wound closure, minimize infection risks, and support complete recovery using modern technologies and expert monitoring.
  • Emphasis on compassionate, holistic care that rebuilds patient confidence and mobility, positioning the hospital as a leader in non-invasive wound management.

Read full article

Keywords:
non surgical wound care,
diabetic foot ulcers,
gangrene treatment,
cellulitis management,
limb preservation

Diabetic Foot Disease: Current Challenges, Emerging Concepts and Future Directions



Diabetic Foot Disease: Current Challenges, Emerging Concepts and Future Directions

Summary: This open MDPI Topic Collection highlights diabetic foot disease as a major diabetes complication, with 19–34% lifetime risk of foot ulcers and 9–26 million new cases annually worldwide. It leads to lower-limb amputations, reduced quality of life, high healthcare costs, and mortality rates comparable to many cancers. While much research focuses on acute ulcer and infection management, significant gaps remain in prevention, recurrence, long-term outcomes, multidisciplinary care models, health economics, and implementation science. The collection welcomes submissions on innovative diagnostics, prevention strategies, patient-centered care, and emerging paradigms to improve outcomes and sustainability of diabetic foot care systems.

Key Highlights:

  • Emphasizes prevention and long-term management beyond acute care
  • Calls for multidisciplinary approaches and implementation research
  • Addresses global burden including high amputation and recurrence rates
  • Open for submissions on diagnostics, economics, and novel therapies

View topic collection

Keywords: diabetic foot disease, DFU prevention, multidisciplinary foot care

What is the Key to Preventing Type 2 Diabetes?



What is the Key to Preventing Type 2 Diabetes?

Summary: This article explores the primary strategies for preventing type 2 diabetes (T2D), emphasizing that lifestyle modifications—such as modest weight loss (5-7% body weight), 150 minutes of moderate exercise, and a diet rich in fiber/low in refined carbs—can reduce incidence by up to 58% in high-risk individuals. Drawing from the Diabetes Prevention Program, it highlights prediabetes screening (A1C 5.7-6.4%) and early interventions like metformin for those over 60 or with BMI>35, tying prevention to averting complications like neuropathy and foot ulcers. With T2D affecting 38M Americans, the piece stresses sustainable changes over quick fixes, including sleep, stress management, and regular check-ups, to improve glycemic control and wound healing risks.

Key Highlights:

  • Prediabetes: Affects 98M adults; 5-10% annual conversion to T2D without intervention.
  • Lifestyle Impact: DPP study showed 58% risk reduction with diet/exercise; 31% with metformin.
  • Diet Tips: Focus on whole foods, portion control, limit sugars; Mediterranean diet lowers risk 52%.
  • Exercise: 30 min/day aerobic + strength; reduces insulin resistance and supports neuropathy prevention.
  • Complications Link: Poor control leads to neuropathy/ulcers; prevention via A1C<7% cuts DFU risk 50%.

Read full article

Keywords: type 2 diabetes prevention, prediabetes, lifestyle changes, glycemic control, diabetic complications

Scoop of Practice Episode 1: Designing a Wound Career

During my reflections on my Designing Your Life1 immersion experience I referenced my mother’s great words of wisdom: “if you love your profession then it really isn’t work. If you put your best foot forward and work hard you can achieve miracles.” … Choosing to become a doctor was not a difficult decision at all. Perhaps growing up with a father whose passion in life was to study the inner workings of a car to fix a malfunction underlay my own fascinations with what is going on under the hood. My mother was a medical administrator and because of my parents’ examples as compassionate and dedicated life mentors, I am the person I am today. I also draw upon my work mentors as I travel along my odyssey … read more

London-developed tool zeros in on diabetic foot ulcers

A new screening tool developed by St. Joseph’s Health Care London could reduce the number of diabetes-related amputations across the region … The primary care diabetes support program (PCDSP) at St. Joseph’s partnered with the South West Local Health Integration Network (LHIN) to come up with a standardized screening, assessment and referral tool for family doctors. The tool helps to identify red flags in patients that could lead to devastating foot ulcers … “The end game is early identification and effective intervention of those at risk of diabetes-related foot ulcers,” said Betty Harvey, a nurse practitioner and clinical nurse specialist with the PCDSP. “Once a person has a foot ulcer … read more

The contribution of intestinal Streptococcus to the pathogenesis of diabetic foot ulcers

by Yunyang Wang, Hong Zhang, Guixin Ma, Zibin Tian, Bin Wang

 

An analysis based on 16S rRNA sequencing
In this study, we intend to determine the microbial communities that are differentially expressed in diabetic foot ulcers (DFUs) from the view of species abundance difference and compositions. The EMBL-EBI database and QIIME2 platform were used to obtain and process 16S rRNA sequencing data of normal healthy and DFU samples. The LEfSe software was utilised to retrieve key intestinal bacteria differentially expressed in DFUs. Additionally, PICRUSt2, FAPROTAX and BugBase functional analyses were performed to analyse the potential microbial functions and related metabolic pathways. The correlations between intestinal microbiota and clinical indexes were evaluated using the Spearman correlation analysis. Significant differences existed in intestinal microbiota between DFU and normal healthy samples regarding species abundance difference and compositions at Kingdom, Phylum, Class, Order, Family, Genus and Species levels. Seven microbiota were demonstrated differentially expressed in DFUs that contained Bacteroidaceae, Prevotellaceae, Streptococcaceae, Lactobacillales, Bacilli, Veillonellaceae and Selenomonadales. Insulin signalling pathway may be the key pathway related to the functional significance of Streptococcus and Bacillus in the DFUs. The intestinal microbiota in DFUs exhibited susceptibility to sulphur cycling while displaying pathogenic potential. Last but not least, a close relationship between Streptococcus and the occurrence of DFUs was revealed. Taken together, this study mainly demonstrated the high abundance of Streptococcus in DFUs and its correlation with the disease occurrence … read more


If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

New Janssen Initiative Aims to Advance Equitable Care and

Address Hidden Threat of Amputation Related to Peripheral Artery Disease (PAD)

 

TITUSVILLE, N.J. – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the launch of Save Legs. Change Lives. Spot Peripheral Artery Disease Now, a multi-year initiative aimed at creating urgency and action to address the hidden threat of peripheral artery disease (PAD)-related amputation, with an initial focus on reaching Black Americans, who are more than twice as likely to be impacted by PAD.1 Janssen has joined forces with leading professional associations, healthcare systems and community organizations to advance equitable care for individuals and communities placed at an increased risk for cardiovascular disease in the U.S.

 

‘Save Legs. Change Lives. sets in motion a vision for more relevant, trusted and inclusive care for everyone affected by PAD,’ said Avery Ince, M.D., Ph.D., Vice President, Medical Affairs, Janssen Cardiovascular & Metabolism, Janssen Scientific Affairs, LLC. ‘As part of Johnson & Johnson, Janssen believes that major corporations have the power – and therefore the responsibility – to tackle pressing health challenges and make good health a reality for all people. We hope our efforts will inspire action to reduce amputations among people living with PAD.’

read more

Microbion Corp. Presents a Poster on Pravibismane’s Activity Against Diabetic Foot Infection Patient Isolates

admin
  • Poster highlights pravibismane’s MIC activity in testing against aerobic and anaerobic pathogens isolated from diabetic foot infection patients
  • Pravibismane demonstrated potent, broad-spectrum activity against a wide range
    of pathogens, including MRSA, MSSA, and P. aeruginosa

BOZEMAN, Mont., May 10, 2023 /PRNewswire/ – Microbion Corporation today announced that the company presented a poster focusing on pravibismane’s activity against diabetic foot ulcer infection pathogens at the 9th International Symposium on the Diabetic Foot that is currently ongoing from May 10th to 13th, 2023 at The Hague, Netherlands. The poster highlights pravibismane’s activity versus comparator antibiotics against pathogens isolated from diabetic foot infection (DFI) patients in an earlier Phase 1b clinical study.

Poster Details:
Representative image (CNW Group/Microbion Corporation)

Representative image (CNW Group/Microbion Corporation)

Title: Broad-Spectrum, Potent Activity of Pravibismane Versus Comparators Against Diabetic Foot Ulcer Infection Patient Isolates Collected in a Phase 1b Study

Presenter: Dr. Jeff Millard, CSO

Poster Highlights:
  • Most common pathogens isolated from DFI subjects (N = 44) at baseline were: methicillin-susceptible Staphylococcus aureus [MSSA (25%)]; methicillin-resistant Staphylococcus aureus [MRSA (18.2%)]; Enterococcus faecalis (13.6%); and Pseudomonas aeruginosa (11.4%).
  • Mean pravibismane minimum inhibitory concentration (MIC) (µg/mL) for S. aureus MSSA was 0.21, S. aureus MRSA was 0.17, E. faecalis was 2.53, and P. aeruginosa was 1.43.
  • Mean pravibismane MICs for 12 of the 13 anaerobic bacteria was ≤1 µg/mL, including against Finegoldia magna and Anaerococcus spp.
  • Pravibismane exhibited similar or lower MIC relative to a panel of comparator antibiotics, including (but not limited to) levofloxacin, linezolid, clindamycin, and piperacillin-tazobactam, against Gram-positive and Gram-negative, susceptible and resistant, aerobes and anaerobes.

"We are pleased that pravibismane demonstrated extremely potent MIC activity against clinical DFI isolates, which was in line with in vitro AST microbial pre-clinical studies," said Dr. Jeff Millard, CSO of Microbion Corp. "Diabetic foot infections are often infected by several different bacterial species concurrently, which may change over the chronicity of the wound, from predominantly aerobic to anaerobic. We believe pravibismane’s potent broad-spectrum activity is potentially a key treatment advantage since a single agent could eradicate both aerobic and anaerobic bacteria, thereby decreasing the need for multiple systemic therapies."

Bacterial cultures for this study were grown from swabs collected at the wound bed at baseline visit and antimicrobial susceptibility testing (AST) was performed on isolated pathogens. Pathogen isolation and AST was performed at Investigational Health Management Associates (IHMA, IL), using the Clinical & Laboratory Standards Institute (CLSI) standard methods.

Topical pravibismane has received QIDP and Fast Track drug designation from the US FDA for the adjunctive treatment of moderate and severe diabetic foot ulcer infections. Topical pravbismane is currently enrolling in a Phase 2 clinical study to further evaluate its safety and efficacy in subjects suffering from moderate infections associated with chronic diabetic foot ulcers.

About Microbion

Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds to improve the lives of patients with rare and serious diseases. Microbion’s lead drug candidate, pravibismane, is the first product in this new class and has multiple novel modes of action offering unique potential to address the unmet needs of chronic and severe health conditions. Topical/local pravibismane is in Phase 2 development for the treatment of chronic wounds and orthopedic infections. The Company is advancing inhaled pravibismane in Phase 1 clinical development for the treatment of chronic lung diseases, including non-tuberculous mycobacteria (NTM) and cystic fibrosis-related lung infections. Pravibismane has received backing from the Cystic Fibrosis Foundation, NIH, US DoD, and CARB-X with over $21 million in grants. The FDA has granted pravibismane with Orphan Drug, Fast Track, and QIDP designations.

For more information visit: www.microbioncorp.com.

Safe Harbor Statement

Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the success of clinical development of pravibismane and preparation for potential commercialization. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our ability to enroll patients in our clinical trials at the pace that we project; the size and growth of the potential markets for pravibismane or any future product candidates and our ability to serve those markets; our ability to obtain and maintain regulatory approval of pravibismane or any future product candidates; and our expectations regarding the potential safety, efficacy or clinical utility of pravibismane or any future product candidates. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Microbion Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Microbion Corporation

Which Procedures Does Medicare Cover for Pressure Injuries?

Kathleen D. Schaum, MS

Medicare coverage for distinct types of wounds/ulcers has received attention for many years. Because the theme of this issue of Advances in Skin & Wound Care is pressure injuries (PIs), this article reviews whether Medicare covers certain technologies and procedures for PIs.

DEBRIDEMENT

Most Medicare Administrative Contractors (MACs) have a Local Coverage Determination (LCD) and Local Coverage Article (LCA) that address the coverage guidelines for debridement of all types of wounds/ulcers, including PIs. Some MACs have a separate debridement LCD/LCA, whereas others include debridement coverage guidelines within their LCD/LCA related to wound care. Readers should check their MAC’s LCDs, which do not limit debridement to distinct wound types. However, their LCDs/LCAs have similar coverage guidelines that include, but are not limited to, documentation of:

  • History and physical examination with an initial wound description, location, measurements, and response to prior treatment (if applicable).
  • Identification of wound location, size, depth, and stage (supported by a drawing or photograph of the wound).
  • Clinical documentation of diagnosis or symptoms to justify services.
  • Current progress notes including measurable signs of healing as well as causes of delayed wound healing or modifications to the treatment plan.
  • Documentation of the wound’s characteristics (e.g., dimensions, necrotic tissue presence, tissue removed, degree of epithelialization) before and after debridement.
  • Operative note or procedure note for debridement services, including descriptions of tissue debrided, wound measurements, and pre-/post-debridement wound assessments.
  • Plan of care containing treatment goals and physician follow-up.read full article

Kathleen D. Schaum, MS, is a healthcare reimbursement expert specializing in wound care, durable medical equipment (DME), and Medicare coverage policies. She is the president and founder of Kathleen D. Schaum & Associates, a consulting firm focused on payment strategies for healthcare providers and manufacturers. Schaum is a frequent author and speaker on reimbursement-related topics in wound care and medical technology.

How to Care for Periwound Skin

Periwound Skin: Understanding and Managing the Skin Surrounding Wounds

Proper care of the periwound skin—the area extending approximately 1.5 inches from the wound edge—is essential for effective wound healing. This delicate skin is susceptible to damage from moisture, adhesives, and infection, which can impede the healing process. Read the full article.

Key Highlights:

  • Moisture-Associated Skin Damage (MASD): Excessive wound exudate can lead to maceration, causing redness, irritation, and pain in the periwound area. Managing moisture levels is crucial to prevent skin breakdown.
  • Medical Adhesive-Related Skin Injury (MARSI): Improper application or removal of wound dressings can strip the skin, leading to MARSI. Over 25% of post-surgical patients experience MARSI in the periwound region.
  • Signs of Periwound Complications: Indicators include induration (hardening), erythema (redness), swelling, bruising, red streaks emanating from the wound, fever, or general malaise.
  • Prevention Strategies:
    • Gently clean the periwound area during each dressing change.
    • Use barrier creams like petroleum jelly to protect against moisture.
    • Minimize dressing changes to those recommended by healthcare providers.
    • Carefully remove adhesives by pressing down on the skin beneath to reduce trauma.
    • Regularly assess the periwound area for any changes or signs of damage.
  • Treatment Approaches: Addressing periwound skin damage involves preventing further injury and promoting healing. This may include repositioning bandages, using barrier creams, and consulting healthcare providers for tailored care plans.

Maintaining the integrity of the periwound skin is vital for optimal wound healing. Incorporating periwound care into the overall wound management plan can enhance patient outcomes and reduce complications.

Read the full article on the Verywell Health website.

Keywords:
periwound skin,
moisture-associated skin damage,
medical adhesive-related skin injury,
wound healing,
barrier creams

COVID-19’s Impact on Diabetes Outcomes: Key Insights for Wound Care



COVID-19’s Impact on Diabetes Outcomes: Key Insights for Wound Care

Summary: This review synthesizes evidence from 138 studies on the indirect effects of the COVID-19 pandemic on clinical outcomes in diabetic patients, highlighting healthcare disruptions that exacerbated morbidity and mortality. Key findings include consistent rises in diabetes-related deaths and major amputations, with mixed results for foot ulcer presentations and hospitalizations. Vulnerable groups—females, younger adults, and racial/ethnic minorities—faced disproportionate risks, emphasizing the need for targeted interventions to prevent wound complications like delayed ulcer management leading to amputations in future crises.

Key Highlights:

  • Diabetes-related mortality increased across all 13 studies, with sharper rises in younger adults (ages 25-44) and racial/ethnic minorities.
  • Major amputations rose in 9 of 12 studies, often linked to pandemic delays in foot care and ulcer monitoring.
  • Foot ulcer presentations showed mixed trends: 4 studies reported decreases, 4 increases, and 1 no difference, reflecting uneven access to wound care services.
  • Hospital and emergency admissions for diabetes varied, with increases noted in pediatric cases and certain adult subgroups amid lockdowns.
  • Diabetic ketoacidosis (DKA) outcomes were inconsistent, but 3 systematic reviews indicated overall increases, complicating glycemic control and healing.

Read full article

Keywords:
diabetes complications,
diabetic foot ulcers,
major amputations,
COVID-19 wound care,
healthcare disruptions

Patient Assessment and Wound Dressing Considerations

As wound care clinicians, we need to take into consideration many different factors in deciding on a treatment plan for our wound patients. Our patients should be evaluated on an individual basis. If we look at our patient’s socioeconomic status, we will find it varies from patient to patient. Socioeconomic status clearly affects morbidity and mortality rates related to wounds: wound management tends to be lower in quality and follow-up visits tend to be fewer in number when compared with patients with better economic status.

Socioeconomic Factors Affecting Wound Management

Socioeconomic factors can be big stressors for patients. Patients want their wounds to heal but feel helpless. We, as compassionate health care clinicians, feel the frustration for our patients. Patients miss follow-up appointments because they lack gas money, access to transportation, or caregiver support to assist with transportation. What can we do to help? There are some hospitals throughout the country that have free shuttle services to and from the wound center. This helps relieve the burden for the patient and provides more consistent wound management. Most recently, there are companies that are similar to Uber, but for health care needs. The following list provides examples of barriers to wound management … read more